insert into public.patient_type (id, title) values (1, 'Adult');
insert into public.patient_type (id, title) values (2, 'Pediatric');

insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (2, null, 1, null, null, 'Head & Neck Malignancies');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (4, null, 1, null, null, 'Thoracic');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (6, null, 1, null, null, 'Gynecologic Malignancy');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (7, null, 1, null, null, 'Urinary Tract');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (9, 9, 1, null, null, 'Biliary Tract Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (10, 9, 1, null, null, 'Hepatocellular Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (11, null, 1, null, null, 'Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (12, null, 1, null, null, 'Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (14, 4, 1, null, null, 'Thymoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (19, null, 2, null, null, 'Sarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (20, null, 2, null, null, 'Lymphoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (21, null, 2, null, null, 'Leukemias');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (23, 23, 1, null, null, 'Harmone-Refractory');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (24, 23, 1, null, null, 'Hormonal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (27, null, 1, null, null, 'Kaposi''s Sarcoma- AIDS Related');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (28, null, 1, null, null, 'Unknown Primary');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (29, 11, 1, null, null, 'AIDS-Related');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (30, 11, 1, null, null, 'Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (31, 11, 1, null, null, 'Non-Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (32, 12, 1, null, null, 'Acute Lymphocytic Leukemia (ALL)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (35, 12, 1, null, null, 'Chronic Myeloid Leukemia (CML)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (36, 12, 1, null, null, 'Hairy Cell Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (37, null, 1, null, null, 'Myeloma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (38, null, 2, null, null, 'CNS Tumors');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (39, null, 2, null, null, 'Neuroblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (40, null, 2, null, null, 'Retinoblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (41, null, 2, null, null, 'Hepatoblastoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (42, null, 2, null, null, 'Wilms'' Tumor');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (43, 19, 2, null, null, 'Osteosarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (44, 19, 2, null, null, 'Soft tissue and Bone');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (45, 20, 2, null, null, 'Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (46, 20, 2, null, null, 'Non-Hodgkin''s');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (47, 21, 2, null, null, 'Acute Lymphocytic Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (48, 21, 2, null, null, 'Acute Myeloid Leukemia');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (100, 7, 1, '378,378,378,379,379,380,378,380,379,381,382,383,384,385,386,387,388,389,390,390,391,392,391,392,393,392,383', null, 'Bladder Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (94, 3, 1, '646,647,648,649,650,651,651,652,653,653,654,655,656,657,658,659,660,661,662,663,664,665', null, 'Esophageal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (95, 3, 1, '644,645,717,644,718,719,720,721,722,723,724,725,727,727,728,729,730,731,732,733,734', null, 'Hepatobiliary');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (97, 4, 1, null, null, 'Non-Small Cell Lung Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (105, 13, 0, '416,416,416,416,417,417,416,417,417,417,418,416,418,416,417,418,416,418,417,419,419,418,416,417,416,416,417,417,427,417,427,419,427,419,427,417,419,428,428,417,428,417,419,428,429,428,429,427,429,418,428,429,429,419,428', null, 'Extensive Stage');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (113, 5, 0, null, null, 'BRCA Mutated ');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (13, 4, 1, null, null, 'Small Cell Lung Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (5, null, 1, '378,398,398,398,501,502,503,504,505,506,506,507,508,509,510,511,511,512,513,514,515,516,517,518,519,518,520,521,522,521', null, 'Breast Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (103, 7, 0, null, null, 'Penile Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (106, 97, 0, '455,455,455,456,455,456,455,456,456,457,457,458,457,458,457,458,458,455,458,458,457,457,458,457,458,457,457,457,459,459,460,457,457,460,457,460,460,457,460,458,461,458,461,462,461,462,461,462,462,463,457,463,460,463,463,464,463,464,455,464,465,465,456,465,458,457,460,461,461,462,463,463,464,465,464,459,455,456,466,466,456,466,467,458,467,467,467,468,468,467,468,469,462,469,468,469,469,469,458,457,460,462,464,464,463,467,455,455,463,460,463,470,470,470,470,470,468,470,457,458,459,459,458,461,469,467,465,463,465,462,468,470', null, 'Adenocarcinoma, Large Cell, NOS');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (22, 7, 1, null, null, 'Kidney Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (101, 7, 1, null, null, 'Prostate Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (102, 7, 1, null, null, 'Testicular Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (108, null, 1, null, null, 'Skin');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (104, 13, 0, '397,397,415,397,415,397,415,397,415,415,415,397,397,415,397,397', null, 'Limited Stage');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (15, 5, 1, '400,401,402,403,404,405,406,407,408,409,409,410,411,403,401,412,412,413,414,438,439,440,441,442,443,444,445,446,447,409,448,449,401,450,451,452,453,454,443', null, 'HER-2 Neu Negative');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (111, 108, 1, '587,587,587,587,588,588,587,588,588,588', null, 'Basal Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (17, 5, 1, '430,431,430,432,433,434,435,436,437', null, 'Hormonal Therapy');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (107, 97, 0, '471,471,471,472,471,472,471,473,473,473,474,474,472,472,473,474,475,475,476,475,476,475,476,476,477,477,471,477,478,478,479,479,480,481,479,480,478,480,480,479,482,482,483,483,481', null, 'Squamous Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (99, 6, 1, '559,560,561,562,562,563,564,565,566,567,568,569,570,571,572,573,574,575,574,576,577,578,579,580,581,582,583,584,585', null, 'Ovarian');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (18, 6, 1, '396,396,396,523,524,525,526,527,526,525,527,523,524,525,528,526,527,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543', null, 'Cervical');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (98, 6, 1, '544,545,546,547,548,549,550,551,552,553,554,555,556,557,558', null, 'Endometrial');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (16, 5, 1, '395,395,395,395,399,420,421,422,423,424,425,426,424,484,485,486,487,488,489,487,490,491,492,493,494,495,496,497,496,496,498,499,500,499', null, 'HER-2 Neu Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (109, 108, 1, null, null, 'Melanoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (110, 108, 1, null, null, 'Squamous Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (114, 5, 0, null, null, 'PIK3CA Mutated ');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (112, 108, 1, null, null, 'Merkel Cell Carcinoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (34, 12, 1, '586,586,587,586,586,586,586,586,586,586,586,586', null, 'Chronic Lymphocytic Leukemia (CLL)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (96, 3, 1, '699,700,701,702,703,704,703,705,706,707,708,709,709,710,711,712,713,714,715,716,715', null, 'Pancreatic');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (92, 3, 1, '666,667,668,669,674,675,676,677,678,679,680,681,682,683,683,684,685,686,687,688,689,690,691,692', null, 'Gastric');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (3, null, 1, null, null, 'Gastrointestinal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (93, 3, 1, '589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,726,735,736,737,738,739,740,741,742,743,744,745', null, 'Colorectal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (8, 3, 1, '693,694,695,696,697,698', null, 'Gastrointestinal Stromal Tumor (GIST)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (91, 3, 1, '394,394,635,636,637,638,639,640,641,640,639,642,643,642,643', null, 'Anal');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (33, 12, 1, '671,671,671,671,671,671,672,672,673,672,673', null, 'Acute Myeloid Leukemia (AML)');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (1, null, 1, '670,670,670', null, 'CNS Tumors');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (26, null, 1, '746,746', null, 'Sarcoma');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (119, null, 1, null, null, 'Adrenocortical Cancer');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (117, 12, 0, null, null, 'Myelodysplastic Syndrome');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (118, 97, 0, null, null, 'ROS1 Rearrangement Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (115, 97, 0, null, null, 'EGFR-1 Mutation Positive');
insert into public.cancer (id, parent_id, patient_type, regimen, sub_cancer_type, title) values (116, 97, 0, null, null, 'ALK Rearrangement Positive');


insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (1, 'Bevacizumab : Avastin', 'Bevacizumab/Irinotecan', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Bevacizumab/Irinotecan</b>', 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. $J Clin Oncol. 2007;25(30):4722-4279.$', null, '<b>Bevacizumab</b> 15 mg/kg IV<br> Repeat Every 21 Days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> with enzyme-inducing antiepileptic drugs, days 1, 8, 22, 29<br> <b>OR</b><br> <b>Irinotecan</b> 125 mg/m<sup>2</sup> with non-enzyme-including antiepileptic drugs, IV, days 1, 8, 22, 29<br> Repeat every 6 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (2, 'Lomustine : CCNU<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'PCV', '<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate-High', '<b>PCV</b>', 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. $Clin Cancer Res.2000;6(10):3878-3884.$', null, '<b>Procarbazine</b> 60 mg/m<sup>2</sup>/d PO, days 8-21<br> <b>Lomustine</b> 110 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, days 8, 29<br> Repeat every 6 weeks upto 7 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (3, 'Temozolomide : Temodar', 'Temozolomide+RT', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate for IV<br> <=75 mg/m<sup>2</sup> PO is minimal-low;<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', '<b>Temozolomide+RT</b>', 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.$N Engl J Med 2005; 352:987-996$', null, '<b>Temozolomide</b> 75 mg/m<sup>2</sup> daily along with radiation<br> <b>FOLLOWED 28 DAYS LATER BY</b><br><b>Temozolomide<sup>e</sup></b> 150 mg/m<sup>2</sup> daily for 5 days<br>Repeat every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (4, 'Carmustine : BCNU', 'BCNU (Carmustine)', '<b>Hepatic Impairment</b><ul><li>Carmustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carmustine:<br>If CrCl < 60 mL/min, do not use</li></ul>', 'High', '<b>BCNU (Carmustine)</b>', 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine. $Neurosurgery.2002;51(2):343-355; discussion 355-357.$', null, '<b>Carmustine</b> 200 mg/m<sup>2</sup> IV over 30-60 minutes<br> Repeat every 8 weeks ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (5, 'Bevacizumab : Avastin', 'Bevacizumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bevacizumab</b>', 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma. $J Clin Oncol. 2009;27(5):740-745.$                                                           Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas. $Cancer.2010;116(22):597-5305.$', null, '<b>Bevacizumab</b> 10 mg/kg IV<br> Repeat every 14 days on a 28-day cycle<br><b>OR</b><br><b>Bevacizumab</b> 15 mg/kg IV<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (6, 'Temozolomide : Temodar', 'Temozolomide', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate for IV<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', '<b>Temozolomide</b>', 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.$J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27$', null, '<b>Temozolomide</b> 150 mg/m<sup>2</sup> every day for 5 days per 28-day cycle<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (7, 'Carboplatin : Paraplatin<br>Cetuximab : Erbitux<br>Fluorouracil : 5-FU', 'Carboplatin/Fluorouracil/Cetuximab', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Moderate', '<b>Carboplatin/Fluorouracil/Cetuximab</b>', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', null, '<b>Carboplatin</b> AUC of 5, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1 <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (9, 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU', 'Cisplatin/Fluorouracil/Cetuximab', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin/Fluorouracil/Cetuximab</b>', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', null, '<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximuum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1. <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (138, 'Anastrozole : Arimidex', 'Anastrozole', '<b>Hepatic Impairment</b><ul><li>Anastrozole:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Anastrozole:<br>No dose reduction </li></ul>', 'N/A', '<b>Anastrozole</b>', 'Arimidex [package insert]. $Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.$', null, '<b>Anastrozole</b> 1 mg PO  once daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (11, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'CP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>CP</b>', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', null, '<b>Cisplatin</b> 75 mg/m<sup>2</sup>, day 1 and<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (14, 'Cisplatin : CDDP<br>Fluorouracil : 5-FU', '5-Fluorouracil + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>5-Fluorouracil + Cisplatin</b>', '$Kies MS, et al. Cancer 1987;60:2156-2160.$', null, '<b>5-Fluorouracil</b>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5<br><b>Cisplatin</b>100 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle on weeks 1, 5, 8, and 11.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (15, 'Cisplatin : CDDP', 'Irinotecan + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'High', '<b>Irinotecan + Cisplatin</b>', '$Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.$', null, '<b>Irinotecan</b>65 mg/m<sup>2</sup> IV weekly for 4 weeks<br><b>Cisplatin</b>30 mg/m<sup>2</sup> IV weekly for 4 weeks<br>Repeat cycle every 6 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (16, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'Paclitaxel + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>Paclitaxel + Cisplatin</b>', '$Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.$', null, '<b>Paclitaxel</b>200 mg/m<sup>2</sup> IV over 24 hours on day 1<br><b>Cisplatin</b>75 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 21 days. G-CSF support is recommended.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (17, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Capecitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Capecitabine + Oxaliplatin</b>', '$Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.$', null, '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (18, 'Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECF</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks.<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (714, '', 'Olaparib', '', '', '', '', 'METASTATIC', '<p><strong>Olaparib:&nbsp;</strong>300 mg PO twice daily</p>

<p>Continue therapy until evidence of disease progression. Patients must have germline <em>BRCA1/2&nbsp;</em>mutation and have received at least 16 weeks of platinum-based chemotherapy.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (10, 'Cisplatin : CDDP', 'Cisplatin + radiation', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Cisplatin + radiation</b>', 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma. $Cancer. 2009;115(11):2464-2471.$', null, '<p><strong>Cisplatin</strong> 100 mg/m2 IV, days 1,22, 43 concomitantly with radiation (For Laryngeal Preservation)</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (19, 'Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'EOF', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>EOF</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (20, 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECX', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECX</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid continuously<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (21, 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'EOX', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>EOX</b>', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', null, '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid times 21 days<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (22, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Paclitaxel</b>', '$Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.$', null, '<b>Paclitaxel</b>250 mg/m<sup>2</sup> IV over 24 hours on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (23, 'Cisplatin : CDDP<br>Docetaxel : Taxotere<br>Fluorouracil : 5-FU', 'DCF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>DCF</b>', 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. $J Clin Oncol. 2006;24(31):4991-4997$', null, '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1-3 hours, day 1<br> <b>Fluorouracil</b> 750 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (24, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'Docetaxel/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'High', '<b>Docetaxel/Cisplatin</b>', 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. $Ann Oncol. 2000;11(3):301-306$', null, '<b>Docetaxel</b> 85 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> Repeat every 21 days for a maximum of 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (25, 'Cisplatin : CDDP<br>Epirubicin : Ellence, various', 'ECF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>ECF</b>', 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. $Br J Cancer. 1999;80(1-2):269-272.$', null, '<b>Epirubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 200 mg/m<sup>2</sup>/d CIVI, for up to 6 months<br> Repeat every 21 days for a maximum of 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (720, '', 'Capecitabine + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (26, 'Etoposide : VP-16<br>Fluorouracil : 5-FU', 'ELF', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>ELF</b>', 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group. $J Clin Oncol. 2000;18(41):2648-2657$', null, '<b>Leucovorin calcium</b> 300 mg/m<sup>2</sup>/d IV over 10 minutes, <b>FOLLOWED BY</b><br> <b>Etoposide</b> 120 mg/m<sup>2</sup>/d IV over 50 minutes,<br> <b>THEN</b><br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV  bolus<br> Give all agents on days 1-3; repeat every 22 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (27, 'Fluorouracil : 5-FU', '5-FU/LV and Radiation', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV and Radiation</b>', 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. $N Engl J Med. 2001;345(10):725-730.$', null, '<b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days,<br> <b>FOLLOWED BY</b><br> <b>RT</b> 4,500 cGy (180cGy/d), 5 days a week for 5 weeks<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup>/d IV, on the first 4 and last 3 days of RT<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d, on the first 4 and last 3 days of RT,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days<br>repeat 28 days X 2 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (28, 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU<br>Trastuzumab : Herceptin', 'Trastuzumab + Cisplatin + Capecitabine or Fluorouracil', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High day 1, low for the remaining treatment days', '<b>Trastuzumab + Cisplatin + Capecitabine or Fluorouracil</b>', 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial. $Lancet. 2010;376(99742):687-697.$', null, '<b>Trastuzumab</b> 8 mg/kg IV, day 1 of the first cycle <b>THEN</b>  6 mg/kg IV, day 1<br><br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1. <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14 <br> Repeat  every 21 days<br> <b>OR</b><br> <b>Fluorouracil</b> 800 mg/m<sup>2</sup>/d CIVI for 5 days of each 3-week cycle<br> Repeat for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (31, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'GEMOX', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>GEMOX</b>', '$Taieb J, et al. Cancer 2003;98:2664-2670.$', null, '<b>Gemcitabine</b>1,000 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>100 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 2 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (32, 'Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4', '$Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).$', null, '<b>Oxaliplatin</b>85 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>400 mg/m<sup>2</sup> IV bolus, followed by 600 mg/m<sup>2</sup> IV continuous infusio for 22 hours on days 1 and 2<br><b>Leucovorin</b>200 mg/m<sup>2</sup> IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil<br>Repeat cycle every 2 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (33, 'Bevacizumab : Avastin<br>Erlotinib : Tarceva', 'Bevacizumab + Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Low', '<b>Bevacizumab + Erlotinib</b>', '$Thomas MB, et al. J Clin Oncol 2009;27:843-850.$', null, '<b>Bevacizumab</b>10 mg/kg IV on days 1 and 14<br><b>Erlotinib</b>150 mg PO daily<br>Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (34, 'Sorafenib : Nexavar', 'Sorafenib', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Low', '<b>Sorafenib</b>', '$Llovet J, et al. N Engl J Med 2008;359:378-390.$', null, '<b>Sorafenib</b>400 mg PO bid.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (35, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Doxorubicin</b>', '$Venook AP. J Clin Oncol 1994;12:1323-1334.$', null, '<b>Doxorubicin</b>20-30 mg/m<sup>2</sup> IV weekly<br>Repeat cycle every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (36, 'Cisplatin : CDDP', 'Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Cisplatin</b>', '$Okada S, et al. Oncology 1993;50:22-26.$', null, '<b>Cisplatin</b>80 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (37, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>Capecitabine</b>', '$Patt YZ, et al. Cancer 2004;101:578-586.$', null, '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br>Repeat cycle every 21 days. PO bid on days 1-14.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (38, 'Bevacizumab : Avastin', 'Bevacizumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bevacizumab</b>', '$Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.$', null, '<b>Bevacizumab</b>10 mg/kg IV on day 1<br>Repeat cycle every 14 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (39, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine + Cisplatin</b>', '$Thongprasert S, et al. Ann Oncol 2005;16:279-281$', null, '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV on Day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (40, 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various', 'Gemcitabine + Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine + Capecitabine</b>', '$Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO BID on Days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (41, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Gemcitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Gemcitabine + Oxaliplatin</b>', '$Andre T, et al. Ann Oncol 2004;15:1339-1343.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup> on Day 2<br> Repeat cycle every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (42, 'Cisplatin : CDDP', '5-Fluorouracil + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>5-Fluorouracil + Cisplatin</b>', '$Taieb J, et al. Ann Oncol 2002;13:1192-1196.$', null, '<b>5-FU</b> 400 mg/m<sup>2</sup> on Day 1<br> <b>FOLLOWED BY</b> 600 mg/m<sup>2</sup> continuous infusion over 22 hours on days 1 and 2<br> <b>Cisplatin</b> 50 mg /m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (43, 'Capecitabine : Xeloda<br>Cisplatin : CDDP', 'Capecitabine + Cisplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Capecitabine + Cisplatin</b>', '$Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.$', null, '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (44, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Capecitabine + Oxaliplatin', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Capecitabine + Oxaliplatin</b>', '$Nehis O, et al. Br J Cancer 2008;98:309-315.$', null, '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (45, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>Capecitabine</b>', '$Patt YZ, et al. Cancer 2004;101:578-586.$', null, '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (46, 'Docetaxel : Taxotere', 'Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>Docetaxel</b>', '$Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.$', null, '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (47, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine</b>', '$Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on days 1 and 8<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (139, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>Capecitabine</b>', 'Xeloda [package insert]. $San Francisco, CA: Genentech; 2011.$', null, '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14, <br>Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (244, '', 'Temsirolimus', '<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>', 'Low', '<b>Temsirolimus</b>', 'Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator''s choice therapy for the treatment or relapsed or refractory mantle cell lymphoma. $J Clin Oncol.2009; 27(23):3822-3829.$', null, '<b>Temsirolimus</b> 175 mg IV per week for 3 weeks<br> <b>FOLLOWED BY</b><br> <b>Temsirolimus</b> 75 mg IV weekly  ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (48, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFIRINOX', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFIRINOX</b>', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. $N Engl J Med. 2011;364(19):1817-1825.$', null, '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours <b>FOLLOWED BY Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours with the addition, after 30 minutes <b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes; <b>IMMEDIATELY FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>THEN</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> IV over 46 hours<br> Repeat cycle every 2 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (49, 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Capecitabine</b>', 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. $J Clin Oncol. 2007;25(16):221-2217.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (50, 'Erlotinib : Tarceva<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Erlotinib</b>', 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group. $J Clin Oncol. 2007;25(15):1960-1966.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> <b>Erlotinib</b> 100 <b>OR</b> 150 mg/d PO<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (51, 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'GEMOX', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>GEMOX</b>', 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. $J Clin Oncol. 2005;23(15):3509-3516.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>, day 1 as 100-minute infusion<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup>, day 2 as 2-hour infusion<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (52, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. $J Clin Oncol. 1997;15(6):2403-2413.$', null, '<b>Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (53, 'Cetuximab : Erbitux', 'Cetuximab/Irinotecan', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Cetuximab/Irinotecan</b>', 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. $N Engl J Med. 2004;351(4):337-345.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose,<b>THEN</b> 250 mg/m<sup>2</sup> IV every 7 days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV every 21 days<br> <b>OR</b> 180 mg/m<sup>2</sup> IV every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (54, '', '5-FU/LV (Mayo regimen)', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low ', '<b>5-FU/LV (Mayo regimen)</b>', 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma. $J Clin Oncol. 1989;7(10):1407-1418$', null, '<b>Fluorouracil</b> 370mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1-5<br> <b>FOLLOWING Leucovorin calcium</b> 200 mg/m<sup>2</sup>/d IV bolus, days 1-5<br> Repeat at 4 and 8 weeks, and every 5 weeks thereafter', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (55, 'Fluorouracil : 5-FU', '5-FU/LV (Roswell Park regimen)', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV (Roswell Park regimen)</b>', 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. $J Clin Oncol. 1989;7(10):1419-1426$<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma. $J Clin Oncol. 1987;5(10):1559-1565.$', null, '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (721, '', 'Capecitabine + Oxaliplatin', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (56, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU', '5-FU/LV + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU/LV + Bevacizumab</b>', 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer. $J Clin Oncol. 2005;23(16):3706-3712.$<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer. $J Clin Oncol. 2005;23(15):3502-3508$', null, '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks<br> <b>Bevacizumab</b> 5mg/kg IV<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (57, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FLOX', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FLOX</b>', 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. $J Clin Oncol. 2007;25(16):2198-2204.$', null, '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours, days 1, 15, 29<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV bolus 1 hour after the infusion begins, days 1, 8, 15, 22,    29, 36<br> Repeat every 8 weeks for 3 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (58, 'Fluorouracil : 5-FU', 'FOLFIRI', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI</b>', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. $J Clin Oncol. 2004;22(2):229-237$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (59, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU', 'FOLFIRI + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI + Bevacizumab</b>', 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. $J Clin Oncol. 2007;25(30):4779-4786.$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours, day 1<br> <b>Bevacizumab</b> 5 mg/kg IV, day 1<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (60, 'Cetuximab : Erbitux<br>Fluorouracil : 5-FU', 'FOLFIRI + Cetuximab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>FOLFIRI + Cetuximab</b>', 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. $J Clin Oncol. 2007;25:4000 (abstract).$', null, '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THERE AFTER</b> 250mg/m<sup>2</sup> IV weekly', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (61, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4</b>', 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.$http://jco.ascopubs.org/content/24/25/4085.abstract$', null, '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV AND <br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br><b>Day 2</b><br><b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (759, null, 'Dasatinib', '<p>None</p>', 'Low', null, null, null, '<p>100 mg po daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (62, 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4 + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4 + Bevacizumab</b>', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', null, '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV <b>AND</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours, <br><b>Bevacizumab</b> 5 mg/kg IV.<br><b>Day 2</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, day 2, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days <br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (63, 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'FOLFOX4 + panitumumab ', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>FOLFOX4 + panitumumab</b> ', 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. $J Clin Oncol. 2010;28(31):4697-4705.$', null, '<b>Panitumumab</b> 6 mg/kg IV over 60 minutes <br> <b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV, day 1<br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV on day 1<br> <b>FOLLOWED BY Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>FOLLOWED BY Fluorouracil</b> 600mg/m<sup>2</sup> IV infusion over 22 hours on days 1 and 2<br> Repeat cycle every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (66, '', 'XELIRI', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>XELIRI</b>', 'Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer. $Am J Clin Oncol. 2007;30(4):350-357$', null, '<b>Irinotecan</b> 250 mg/m<sup>2</sup> IV over 30-90 minutes, day 1<br> <b>Cappecitabine 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (67, 'Oxaliplatin : Eloxatin, Oxaliplatin, various', 'XELOX', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>XELOX</b>', 'Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer. $J Clin Oncol. 2004;22(11):2084-2091$', null, '<b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (68, 'Bevacizumab : Avastin<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'XELOX + Bevacizumab', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>XELOX + Bevacizumab</b>', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', null, ' <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br><b>Bevacizumab</b> 7.5 mg/kg IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (69, 'Capecitabine : Xeloda', 'Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>Capecitabine</b>', 'Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study. $J Clin Oncol. 2001;19(21):4097-4106$', null, '<b>Capecitabine</b> 1,000- 1,250 mg/m<sup>2</sup>/d PO bid, days 1-14, <b>FOLLOWED BY</b> 7 days rest<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (70, 'Cetuximab : Erbitux', 'Cetuximab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Cetuximab</b>', 'Erbitux [package insert]. $Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose over 120 minutes, <b>FOLLOWED BY</b> 250 mg/m<sup>2</sup> IV over 60 minutes<br> Repeat every 7 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (71, 'Fluorouracil : 5-FU', '5-FU', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Low', '<b>5-FU</b>', 'Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. $J Clin Oncol. 1990;8(2):313-318.$<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. $lEur J Cancer. 1996;32A(suppl 5):S18-S22.$', null, '<b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (151, 'Trastuzumab : Herceptin', 'Trastuzumab q3wk', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Trastuzumab q3wk</b>', 'Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1659-1672.$', null, '<b>Trastuzumab</b> 8 mg/kg IV over 90 minutes, day 1, then 6 mg/kg IV over 90 minutes<br> Repeat every 21 days for 1 year(adjuvant).', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (72, '', 'Irinotecan', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Irinotecan</b>', 'Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. $J Clin Oncol. 1997;15(1):251-260$<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. $J Clin Oncol. 1996;14(3):709-715.$<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. $Lancet. 1998;352(9138):1413-1418.$', null, '<b>Irinotecan</b> 125 mg/m<sup>2</sup>/d IV over 90 minutes, days 1,8, 15,22 <b>FOLLOWED BY</b> 2 weeks rest<br> Repeat every 6 weeks<br> <b>OR</b><br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV over 90 minutes<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (77, 'Imatinib : Gleevec', 'Imatinib', '<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>', 'Low', '<b>Imatinib</b>', 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. $J Clin Oncol. 2008;26(4):626-632$', null, '<b>Imatinib mesylate</b> 400-800 mg PO, daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (78, 'Nilotinib : Tasigna', 'Nilotinib', '<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>', 'Low', '<b>Nilotinib</b>', 'Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. $Eur J Cancer. 2009;45:2293-2297.$', null, '<b>Nilotinib</b> 400 mg PO bid', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (79, 'Sunitinib : Sutent', 'Sunitinib', '<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>', 'Low', '<b>Sunitinib</b>', 'Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial. $Lancet. 2006;368(9544):1329-1338.$', null, '<b>Sunitinib malate</b> 50 mg/d for 28 days, 14 days rest then repeat cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (80, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carbo-Tax', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carbo-Tax</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', null, '<b>Paclitaxel</b> 225mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose targeted by AUC of 6 mg/mL/min, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (81, 'Cisplatin : CDDP<br>Pemetrexed : Alimta', 'Cisplatin/Pemetrexed', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'High', '<b>Cisplatin/Pemetrexed</b>', 'Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. $J Clin Oncol. 2008;26(21):3543-3551.$', null, '<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Pemetrexed</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (82, 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Vinorelbine : Navelbine', 'Cisplatin/Vinorelbine/Cetuximab', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'High', '<b>Cisplatin/Vinorelbine/Cetuximab</b>', 'Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. $Lancet. 2009;373(9674):1525-1531.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THEN</b><br> 250 mg/m<sup>2</sup>/wk<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> <b>Vinorelbine</b> 25 mg/m<sup>2</sup> IV, days 1, 8<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (83, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'Docetaxel/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'High', '<b>Docetaxel/Cisplatin</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (152, 'Vinorelbine : Navelbine', 'Vinorelbine', '<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', '<b>Vinorelbine</b>', 'Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer. $J Clin Oncol. 1995;13(11):2722-2730.$', null, '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV<br> Repeat every 7 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (84, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. $J Clin Oncol. 1999;17(1):12-18.$', null, '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> /d IV,days 1,8,15<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days<br> <b>OR</b><br> <b>Gemcitabine</b> 1,250 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV over 60 minutes, day 1<br> Repeat every 21 days                                         ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (85, 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Docetaxel</b>', 'Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. $Lancet. 2001;357(9267):1478-1484.$', null, '<b>Gemcitabine</b> 1,100 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour, day 8<br>  Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (86, 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol', 'Gemcitabine/Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Paclitaxel</b>', 'Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. $J Clin Oncol. 2002;20(17):3578-3585.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (87, 'Gemcitabine : Gemzar, various<br>Vinorelbine : Navelbine', 'Gemcitabine/Vinorelbine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Vinorelbine</b>', 'Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. $J Clin Oncol. 2000;18(13):2529-2536.$<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer. $Chest. 2000;117(6):1583-1589.$<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. $Cancer. 2000;88(6):1353-1358.$', null, '<b>Gemcitabine</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 8<br> <b>Vinorelbine</b> 30 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 21 days<br> <b>OR</b><br> <b>Gemcitabine</b> 800-1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> <b>Vinorelbine</b> 20 mg/m<sup>2</sup>/d IV over 10-30 minutes, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (88, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'PC', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>PC</b>', 'Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer. $N Eng/J Med.2002;346(2);92-98.$<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975. $J Clin Oncol.2003;21(21):3909-3917.$                                                                                                                                                ', null, '<b>Paclitaxel</b> 135mg/m<sup>2</sup> over 24hours, day 1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours,day 1<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days   ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (89, 'Bevacizumab : Avastin<br>Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'PCB', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>PCB</b>', 'Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. $N Engl J Med. 2006;355(24):2542-2550.$', null, '<b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of IV ,day 1<br> <b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (189, 'Docetaxel : Taxotere<br>Prednisone : various', 'Docetaxel/Prednisone', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>Docetaxel/Prednisone</b>', 'Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. $N Engl J Med. 2004;351(15):1502-1512.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 5 mg PO bid, days 1-21<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (90, 'Cisplatin : CDDP<br>Vinorelbine : Navelbine', 'Vinorelbine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'High', '<b>Vinorelbine/Cisplatin</b>', 'Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial. $Lancet Oncol.2006:7(9):719-727.$ ', null, '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> <b>Cisplatin</b> 100mg/m<sup>2</sup> IV over 1 hour day 1.<br>Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (91, 'Crizotinib : Xalkori', 'Crizotinib', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate-High', '<b>Crizotinib</b>', 'Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer. $N engl J Med.2010;363(18):1693-1703.$<br> Xalkori [packages insert]. $New York, NY: Pfizer labs;2011.$', null, '<b>Crizotinib</b> 250 mg PO bid in 28-day cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (92, 'Docetaxel : Taxotere', 'Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>Docetaxel</b>', 'Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. $J Clin Oncol. 2000;18(10):2095-2103.$<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens. $J Clin Oncol. 2000;18(12):2354-2362.$', null, '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1hour.<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (93, 'Erlotinib : Tarceva', 'Erlotinib', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Low', '<b>Erlotinib</b>', 'Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21. $J Clin Oncol. 2008;26(14):2350-2357.$<br> Tarceva [packaga insert]. $Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010.$', null, '<b>Erlotinib</b> 150mg PO daily at least 1hour before <b>OR</b> 2 Hours after eating', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (94, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. $J Clin Oncol. 1999;17(7):2081-2085.$<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study. $Lung Cancer.2000;27(2):75-80.$', null, '<b>Gemcitabine</b> 1000 mg/m<sup>2</sup>/d IV over 30 minutes, day 1,8,15<br> <br>  Repeat every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (95, 'Pemetrexed : Alimta', 'Pemetrexed', '<b>Hepatic Impairment</b><ul><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'Low', '<b>Pemetrexed</b>', 'Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy. $J Clin Oncol. 2004;22(9):1589-1597.$', null, '<b>Pemetrexed</b> 500mg/m<sup>2</sup> IV over 10 minutes<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (96, 'Vinorelbine : Navelbine', 'Vinorelbine', '<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Low', '<b>Vinorelbine</b>', 'Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. $J Clin Oncol.1994;12(2):360-367.$', null, '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> Repeat every 7 days .', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (97, 'Carboplatin : Paraplatin', 'Carboplatin/Irinotecan', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Moderate', '<b>Carboplatin/Irinotecan</b>', 'Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. $J Clin Oncol. 2008:26(26):4261-4267.$', null, '<b>Carboplatin</b> AUC of 5 IV, day 1<br> <b>Irinotecan</b> 175mg/m<sup>2</sup> IV, day 1<br> Repeat every 21days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (98, 'Cisplatin : CDDP', 'Cisplatin + CPT-11', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin + CPT-11</b>', 'Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. $N Engl J Med. 2002;346(2):85-91.$', null, '<b>Cisplatin</b> 60mg/m<sup>2</sup>, day 1<br> <b>Irinotecan</b> 60mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (190, 'Flutamide : various', 'FL', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>FL</b>', 'Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? $Urology. 2000;55(3):391-396.$', null, '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (99, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'CAV', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>CAV</b>', '$Roth  BJ, et al. J Clin Oncol 1992;10:282-291.$', null, '<b>Cyclophosphamide</b>  1,000 mg/m<sup>2</sup>IV on day 1.  <br>                                              <b>Doxorubicin</b> 40 mg/m<sup>2</sup>IV on day 1.<br>                                                                <b>Vincristine</b> 1 mg/m<sup>2</sup>IV on day 1. (maximum, 2 mg) <br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (100, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carboplatin + Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carboplatin + Paclitaxel</b>', '$Neubauer M, et al. J Clin Oncol2004;22:1872-1877$', null, '<b>Carboplatin</b>AUC of 2, IV on days1,8, and 15.<br><b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV on days 1,8, and 15. Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (101, 'Carboplatin : Paraplatin<br>Etoposide : VP-16', 'EC', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>EC</b>', 'Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer. $Acta Oncal. 1994;33(8):921-924.$', null, '<b>Etoposide</b> 100mg/m<sup>2</sup>/d IV, days 1-3<br><b>Carboplatin</b> 450mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (102, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'EP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>EP</b>', 'Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. $J Clin Oncol.1994; 12(10):2022-2034.$', null, '<b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cisplatin</b> 80mg/m<sup>2</sup> IV, day 1 (Standard dose)<br> Repeat every 21 days <b>OR</b><br> <b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 27mg/m<sup>2</sup> IV, days 1-5(high dose)<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (103, 'Etoposide : VP-16', 'Etoposide', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Low', '<b>Etoposide</b>', 'Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer. $Semin Oncol. 1993;20(4):315-325.$', null, '<b>Etoposide</b> 160 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 28 days<br> <b>OR</b><br> <b>Etoposide</b> 50 mg PO bid for 14 days<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (104, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. $J Clin Oncol. 1995;13(6):1430-1435.$<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. $Am J Clin Oncol. 1999;22(5):517-522$<br>', null, '<b>Paclitaxel</b> 250 mg/m<sup>2</sup> IV over 24 hours<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (105, 'Topotecan : Hycamtin', 'Topotecan IV', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan IV</b>', 'Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. $J Clin Oncol.1997;15(5):2090-2096.$<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. $J Clin Oncol. 1999;17(2):658-667.$', null, '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (106, 'Topotecan : Hycamtin', 'Topotecan PO', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan PO</b>', 'Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. $J Clin Oncol. 2007;25(15):2086-2092.$ $Erratum in: J Clin Oncol. 2007;25(22):3387.$', null, '<b>Topotecan</b> 2.3 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (509, 'Ado-trastuzumab emtansine: Kadcyla', 'Ado-Trastuzumab Emtansine', '', 'Minimal', '', 'Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.', 'METASTATIC', '<p><strong>Ado-trastuzumab</strong>: 3.6mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (107, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various', 'CAP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>CAP</b>', 'Loehrer PJ, et al.$J Clin Oncol 1994;12:1164-1168.$', null, '<b>Cyclophosphamide</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Cisplatin</b> 500 mg/m<sub>2</sub> IV on day 1<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (108, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'Cisplatin + Etoposide', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>Cisplatin + Etoposide</b>', 'Giaccone G, et al.$J Clin Oncol 1996;14:814-820.$', null, '<b>Cisplatin</b> 60 mg/m<sub>2</sub> IV on day 1<br><b>Etoposide</b> 120 mg/m<sub>2</sub> IV on day 1 - 3<br>Repeat cycle every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (109, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'ADOC', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>ADOC</b>', 'Fornasiero A, et al.$Cancer 1991;68:30-33.$', null, '<b>Cisplatin</b> 50 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 40 mg/m<sub>2</sub> IV on day 1<br><b>Vincristine</b> 0.6 mg/m<sub>2</sub> IV on day 3<br><b>Cyclophosphamide</b> 700 mg/m<sub>2</sub> IV on day 4<br>Repeat cycle every 28 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (110, 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'VIP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>VIP</b>', 'Loehrer PJ, et al.$Cancer 2001;91:2010-2015.$', null, '<b>Etoposide(VP-I6)</b> 75 mg/m<sub>2</sub> IV on days 1-4<br><b>Ifosfamide</b> 1200 mg/m<sub>2</sub> IV on days 1-4<br><b>Cisplatin</b> 20 mg/m<sub>2</sub> IV on days 1-4<br><b>Mesna</b> 240 mg/m<sub>2</sub> IV before first ifosfamide dose, then 4 and 8 hours later on days 1-4<br>Repeat cycle every 21 days for a total of 4 cycles.G-CSF support at 5 micro grams/kg/day on days 5-15', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (111, 'Gemcitabine : Gemzar, various<br>Topotecan : Hycamtin', 'Gemcitabine + Topotecan', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Moderate', '<b>Gemcitabine + Topotecan</b>', 'William WN, et al.$Am J Clin Oncol 2009;32:15-19.$', null, '<b>Gemcitabine</b>1000 mg/m<sub>2</sub> IV on days 1,8, and 15.<br><b>Topotecan</b>0.75-1.5 mg/m<sub>2</sub> IV on days 1,8, and 15.<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (112, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carboplatin + Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carboplatin + Paclitaxel</b>', 'Lemma GL, et al.$ J Clin Oncol 2011;29:2060-2065.$', null, '<b>Carboplatin</b> AUC of 6, IV on day 1 <br><b>Paclitaxel</b>225 mg/m<sub>2</sub> IV on day 1<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (722, '', 'Gemcitabine + Nab-Paclitaxel', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (113, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various', 'AC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>AC</b>', 'Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15. $J Clin Oncol. 1990;8(9):1483-1496$', null, '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (115, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'AC  Paclitaxel/Trastuzumab', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High for AC,low for paclitaxel and/or tratuzumab', '<b>AC  Paclitaxel/Trastuzumab</b>', 'Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1673-1684.$ ', null, '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days for 4 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour, weekly X 12 <br> <b>Trastuzumab</b> (concurrently with paclitaxel) 4 mg/kg IV over 90 minutes, day 1<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly for 51 additional weeks     ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (116, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'AC  T (dose-dense)               ', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High for AC, low for paclitaxel  ', '<b>AC  T (dose-dense)</b>               ', 'Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741. $J Clin Oncol. 2003;21(8): 1431-1439$', null, '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of   each cycle<br><b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2<b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                                               ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (122, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Fluorouracil : 5-FU', 'CAF(oral)', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Moderate-High', '<b>CAF(oral)</b>', 'Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102. $J Clin Oncol. 2005;23(33):8313-8321.$', null, '<b>Cyclophosphamide</b> 100mg/m<sup>2</sup> PO, days 1-14<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV ,days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, days 1,8<br> Repeat every 28 days for 6 cycles      ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (123, 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various<br>Fluorouracil : 5-FU', 'FEC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>FEC</b>', 'Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. $J Clin Oncol. 1998;16(8):2651:2658.$<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment. $J Clin Oncol. 2000;18(7):3115-3124.$', null, '<b>Cyclophosphamide</b> 75 mg/m<sup>2</sup>/d PO, days 1-14<br> <b> Epirubicin</b> 60 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV, days 1,8<br> Repeat every 28 days for 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> IV, day 1<br> <b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (117, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various<br>Trastuzumab : Herceptin', 'AC  TH                                                  ', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High for AC, low for docetaxel and/or trastuzumab', '<b>AC  TH</b>                                                  ', 'Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial. $Ann Oncol. 2006; 17(3):381-390$', null, '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV, day1<br> Repeat every 21 days for 4 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV, day 1,<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly during docetaxel,<br> <b>FOLLOWED BY</b><br> 6 mg/kg IV every 21 days for 1 year                                                      ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (118, 'Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various', 'AT - Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>AT - Docetaxel</b>', 'Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial. $J Clin Oncol. 2003;21(6):968-975.$', null, '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over 15 minutes, day 1<br> <b>FOLLOWED 1 HOUR LATER BY</b><br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> day 1<br> Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (119, 'Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'AT - Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>AT - Paclitaxel</b>', 'Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. $J Clin Oncol. 2001;19(6):1707-1715$', null, '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over, day 1<br> <b>FOLLOWED 24 HOUR LATER BY</b><br> <b>Paclitaxel</b>  220 mg/m<sup>2</sup>,IV over 3 hours ,day 2<br> Repeat every 21 days for up to 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (120, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'A - T - C (dose-dense)', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate, low for paclitaxel', '<b>A - T - C (dose-dense)</b>', 'Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741. $J Clin Oncol. 2003;21(8):1431-1439$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV ,every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                  ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (121, 'Bevacizumab : Avastin<br>Paclitaxel : Taxol', 'Bevacizumab/Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Bevacizumab/Paclitaxel</b>', 'Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. $J Clin Oncol. 2003;3(6):421-422$', null, '<b>Bevacizumab</b> 10 mg/kg IV, days 1, 15<br> <b>Paclitaxel</b> 90 mg/m<sup>2</sup> IV over 1 hour, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (130, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'Sequential AC --> T', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High for AC, low for paclitaxel  ', '<b>Sequential AC --> T</b>', 'Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. $N Engl J Med. 2008;238(16):1663-1671.$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> over 5-15 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 7 days for 12 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (124, 'Cyclophosphamide : Cytoxan<br>Fluorouracil : 5-FU', 'CMF', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Moderate for IV, Moderate-High for PO', '<b>CMF</b>', 'Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study. $J Clin Oncol. 2000:18(17):3125-3134.$<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results.$ JAMA. 1995:273(7):542-547.$', null, '<b>Cyclophosphamide </b>100 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 28 days for up to 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 12 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (125, 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol', 'Gemcitabine/Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Gemcitabine/Paclitaxel</b>', 'Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. $J Clin Oncol. 2008;26(24):3950-3957.$', null, '<b>Gemcitabine 1,250 mg/m<sup>2</sup> IV over 30-60 minutes, days 1, 8<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours before gemcitabine, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (126, 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various', 'EC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>EC</b>', 'Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. $J Clin Oncol. 2001;19(12):3103-3110.$', null, '<b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 830 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (127, 'Capecitabine : Xeloda<br>Ixabepilone : Ixempra', 'Ixabepilone/Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Ixabepilone:<br>Monotherapy:  <br>                                                                                                 If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2<br>                                                                         If AST or ALT < 10 upper normal limit, and bilirubin < 1 upper normal limit, use 32 mg/m2  <br>                                                                                     If AST and ALT < 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2 <br>                                                                  If AST or ALT > 10 upper normal limit, or bilirubin > 3 upper normal limit, do not use <br>                                                                                                                                                                                   In combination with capecitabine:  <br>                                                             If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2 <br>                                                                        If AST or ALT > 2.5 upper normal limit, or bilirubin > 1 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Ixabepilone:<br>If CrCl > 30 mL/min, no dose reduction</li></ul>', 'Low', '<b>Ixabepilone/Capecitabine</b>', 'Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. $J Clin Oncol. 2007;25(33):5210-5217.$', null, '<b>Ixabepilone</b> 40 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days for up to 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (128, 'Capecitabine : Xeloda<br>Lapatinib : Tykerb', 'Lapatinib/Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li></ul>', 'Low', '<b>Lapatinib/Capecitabine</b>', 'Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. $N Engl J Med. 2006;355(26):2733-2743.$', null, '<b>Lapatinib</b> 1,250 mg PO 1 hour before breakfast, daily<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (129, 'Lapatinib : Tykerb<br>Letrozole : Femara', 'Lapatinib/Letrozole', '<b>Hepatic Impairment</b><ul><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>', 'Low', '<b>Lapatinib/Letrozole</b>', 'Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. $J Clin Oncol. 200927(33):5538-5546.$', null, '<b>Lapatinib</b> 1,500 mg PO, daily<br> <b>Letrozole</b> 2.5 mg PO, daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (131, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various', 'TAC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>TAC</b>', 'Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. $N Engl J Med. 2005;352(22):2303-2313.$', null, '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> as a 15-minute IV bolus, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> as a 1- to 5-minute IV bolus,<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (723, '', 'Capecitabine', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days. Dose may be reduced to 825-900 mg/m<sup>2</sup> PO twice daily on days 1-14.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (132, 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere', 'TC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>TC</b>', 'Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. $J Clin Oncol. 2006:24(34):5381-5387.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (133, 'Capecitabine : Xeloda<br>Docetaxel : Taxotere', 'X+T', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>X+T</b>', 'O''Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results. $J Clin Oncol. 2002;20(12):2812-2823.$', null, '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> as a 1-hour IV infusion, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (134, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere<br>Trastuzumab : Herceptin', 'TCH', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate for combination therapy, low for trastuzumab monotherapy', '<b>TCH</b>', 'Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). $J Clin Oncol. 2007;25:LBA 1008 (abstract).$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of 6 day 1 <br> Repeat every 21 days for 8 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV,<br> <b>FOLLOWED BY</b><br> <b>Trastuzumab</b> 2 mg/kg IV weekly during chemotherapy, <b>THEN</b> 6 mg/kg IV<br> Repeat every 21 days for 1 year', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (135, 'Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'TP', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>TP</b>', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', null, '<b>Trastuzumab</b> 4 mg/kg IV loading dose, day 1 <b>THEN</b> 2 mg/kg IV weekly, days 8, 15<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (136, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin', 'Trastuzumab/Paclitaxel/Carboplatin', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate (low for single-agent trastuzumab)', '<b>Trastuzumab/Paclitaxel/Carboplatin</b>', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', null, '<b>Trastuzumab</b> 4 mg/kg loading dose, day 1 of cycle 1, <b>THEN</b> 2 mg/kg weekly thereafter<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> <b>Carboplatin</b> AUC of 6, day 2<br> Repeat every 21 days for at least 6 cycles<br> <b>FOLLOWED BY Trastuzumab</b> 2 mg/kg weekly until disease progression.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (137, '', 'Abraxane', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Abraxane</b>', 'Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. $J Clin Oncol. 2005;23(31):7794-7803.$', null, '260 mg/m<sup>2</sup> IV over 30 minutes<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (140, 'Docetaxel : Taxotere', 'Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Low', '<b>Docetaxel</b>', 'Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. $J Clin Oncol. 1999;17(8):2341-2354.$<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. $J Clin Oncol. 1999;17(5):1413-1424.$<br> Taxotere [package insert]. $New York, NY: Sanofi-Aventis; 2010.$', null, '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 21 days <b>OR</b><br><b>Docetaxel</b>40 mg/m <sup>2</sup>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (141, 'Eribulin : Halaven', 'Eribulin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Eribulin</b>', 'Cortes J, O''Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. $Lancet. 2011;377(9769):914-923.$', null, '<b>Eribulin</b> 1.4 mg/m<sup>2</sup> IV over 2-5 minutes, days 1 and 8<br> Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (142, 'Exemestane : Aromasin, various', 'Exemestane', '<b>Hepatic Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul>', 'NA', '<b>Exemestane</b>', 'Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial. $J Clin Oncol. 2000;18(11):2234-2244.$<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. $J Clin Oncol. 2000;18(7):1399-1411.$<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. $N Engl J Med. 2004;350(11):1081-1092.$', null, '<b>Exemestane</b> 25 mg PO once daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (143, 'Fulvestrant : Faslodex', 'Fulvestrant', '<b>Hepatic Impairment</b><ul><li>Fulvestrant:<br>If SGOT, SGPT, bilirubin and alkaline phosphatase < 2 upper normal limit, no dose reduction<br>                                                                                If SGOT, SGPT, bilirubin and alkaline phosphatase > 2 upper normal limit, unknown </li></ul><b>Renal Impairment</b><ul><li>Fulvestrant:<br>No dose reduction </li></ul>', 'N/A', '<b>Fulvestrant</b>', 'Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.$J Clin Oncol. 2010 Oct 20;28(30):4594-600$', null, '<b>Fulvestrant</b> 500 mg IM loading dose on day 1,15, and 29 and then every 28 days. ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (144, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. $J Clin Oncol. 1995;13(11):2731-2736.$', null, '<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (145, 'Letrozole : Femara', 'Letrozole', '<b>Hepatic Impairment</b><ul><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>', 'NA', '<b>Letrozole</b>', 'Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate. $J Clin Oncol. 1998;16(2):453-461.$<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. $Cancer. 1997;80(2):218-224.$<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. $N Engl J Med. 2003;349(19): 1793-1802.$', null, '<b>Letrozole</b> 2.5 mg PO once daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (146, '', 'Megestrol', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Megestrol</b>', 'Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate. $J Clin Oncol. 2001;19(14):3357-3366.$', null, '<b>Megestrol</b> 40 mg PO, every 6 hours', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (147, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. $J Clin Oncol. 1995;13(10):2575-2581.$<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. $J Clin Oncol. 1999;17(11):3403-3411.$', null, '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (148, 'Tamoxifen : Nolvadex', 'Tamoxifen', '<b>Hepatic Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul>', 'N/A', '<b>Tamoxifen</b>', 'Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. $J Clin Oncol. 2011;29(13):1657-1663.$', null, '<b>Tamoxifen</b> 20-40 mg PO once daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (149, '', 'Toremifene', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Toremifene</b>', 'Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. $J Clin Oncol. 1995;13(10):2556-2566.$<br> Fareston [package insert]. $Memphis, TN: GTx, Inc,:2011.$', null, '<b>Toremefene</b> 60 mg/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (150, 'Trastuzumab : Herceptin', 'Trastuzumab qwk', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Trastuzumab qwk</b>', 'Herception [package insert]. $South San Francisco, CA: Genentech, Inc: 2010.$', null, '<b> Trastuzumab</b> 4 mg/kg IV loading dose over 90 minutes, <b>FOLLOWED BY</b> 2 mg/kg IV over 30 minutes, weekly', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (153, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere', 'Carbo-Docetaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>Carbo-Docetaxel</b>', 'Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. $J Natl Cancer Inst. 2004;96(22):1682-1691.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose AUC of 5 IV over 1 hour day 1<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (154, 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol', 'Carbo-Tax', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carbo-Tax</b>', 'Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', null, '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose AUC of 5 IV  day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (155, 'Carboplatin : Paraplatin', 'CD (Doxil/Carboplatin)', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>', 'Moderate', '<b>CD (Doxil/Carboplatin)</b>', 'Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase. $J Clin Oncol. 2010;28:3323-3329.$', null, '<b>Liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 1 <b>Carboplatin</b>AUC of 5 IV day 1<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (156, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'CT', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>CT</b>', 'McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. $N Engl J Med. 1996;334(1):1-6.$<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', null, '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (157, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various', 'GC', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>GC</b>', 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. $J Clin Oncol. 2006;24(29):4699-4707.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV, days 1, 8<br> <b>Carboplatin</b> AUC of 4, IV, day 1<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (158, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'Intraperitoneal CT', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>Intraperitoneal CT</b>', 'Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. $N Engl J Med. 2006;354(1):34-43.$', null, '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IP, day 2<br> <b>Paclitaxel</b> 60 mg/m<sup>2</sup> IP, day 8<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (159, 'Altretamine : Hexalen', 'Altretamine', '<b>Hepatic Impairment</b><ul><li>Altretamine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate-High', '<b>Altretamine</b>', 'Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. $Gynecol Oncol. 1998;69(3):226-229.$', null, '<b>Altretamine</b> 260 mg/m<sup>2</sup>/d PO in 4 divided doses for 14 days<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (160, 'Bevacizumab : Avastin', 'Bevacizumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bevacizumab</b>', 'Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. $J Clin Oncol. 2007;25(33):5165-5171.$', null, '<b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days until disease progression ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (161, 'Gemcitabine : Gemzar, various', 'Gemcitabine', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine</b>', 'Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'', 2'' difluorodeoxycytidine) in previously treated ovarian cancer patients. $J Natl Cancer Inst. 1994;86(20):1530-1533.$', null, '<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (191, 'Flutamide : various<br>Goserelin : Zoladex', 'FZ', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', '<b>FZ</b>', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610. $J Clin Oncol. 2009;26(4):585-591.$', null, '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ<br> Repeat every 28 days, beginning 8 weeks prior to Radiation theraupy for 4 cycles<br> <b>OR</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ 8 weeks prior to Radiation theraupy <b>AND</b><br> <b>Goserelin acetate implant</b> 10.8 mg SQ 4 weeks prior to Radiation theraupy', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (162, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', null, '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (163, '', 'Pegylated liposomal doxorubicin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Pegylated liposomal doxorubicin</b>', 'Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. $J Clin Oncol. 2000;18(17):3093-3100.$<br> Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP;2010.$', null, '<b>Pegylated liposomal doxorubicin</b> 50 mg/m<sup>2</sup> IV every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (164, 'Topotecan : Hycamtin', 'Topotecan', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Low', '<b>Topotecan</b>', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', null, '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (165, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'Cisplatin/Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin/Doxorubicin</b>', 'Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2006;24(1):36-44.$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV day 1<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1, cycles 1-7<br> Repeat every 21 days upto 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (166, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol', 'TAP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>TAP</b>', 'Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(11):2159-2166.$', null, '<b>Doxorubicin</b> 45 mg/m<sup>2</sup>, day 1<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>, day 1<br> <b>Paclitaxel</b> 160 mg/m<sup>2</sup> over 3 hours, day 2<br> <b>Filgrastim</b> 5 mcg/kg d SQ, days 3-12<br> <b>OR</b><br>Repeat every 21 days for a maximum of 7 cycles<br><b>PEG-Filgastrim</b>6 mg SQ on day 3.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (167, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Doxorubicin</b>', 'Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(19):3902-3908.$', null, '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV every 21 days (maximum cumulative dose, 500 mg/m<sup>2</sup>)<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (168, '', 'Medroxy-progesterone', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Medroxy-progesterone</b>', 'Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group. $J Clin Oncol. 1999;17(6):1736-1744.$', null, '<b>Medroxyprogesterone acetate</b> 200 mg/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (188, 'Docetaxel : Taxotere<br>Estramustine : Estracyte', 'Docetaxel/Estramustine', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Estramustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate-High', '<b>Docetaxel/Estramustine</b>', 'Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. $N Engl J Med. 2004;351(15):1513-1520.$', null, '<b>Docetaxel</b> 60 mg/m<sup>2</sup> IV, day 2<br><b>Estramustine</b> 280 mg PO tid, days 1-5<br> Repeat every 21 days until progression or to a maximum of 12 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (260, '', 'ATRA', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>ATRA</b>', 'Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. $Blood. 1995;85(10):2643-2653.$', null, '<b>All-trans-retinoic acid</b> (ATRA, tretinoin) 45 mg/m<sup>2</sup>/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (169, 'Cisplatin : CDDP<br>Fluorouracil : 5-FU', 'Cisplatin/Fluorouracil', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'High', '<b>Cisplatin/Fluorouracil</b>', 'Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. $N Engl J Med. 1999;340(15):1137-1143.$<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. $J Clin Oncol. 1999;17(5):1339-1348.$', null, '<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 4 hours, day 1, given within 16 hours of the first dose of RT<br> <b>Fluorouracil</b> 4,000 mg/m<sup>2</sup> CIVI over 96 hours, days 2-5<br> Repeat every 21 days for 3 cycles<br> <b>OR</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV, days 1, 29, given 4 hours before the first dose of RT<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d IV, days 2-5, 30-33', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (724, '', 'Pembrolizumab', '', '', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks. Used only in the setting of MSI/dMMR tumors.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (170, 'Cisplatin : CDDP<br>Paclitaxel : Taxol', 'C-P', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>C-P</b>', 'Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study. $J Clin Oncol. 2009;27(28):4649-4655.$', null, '<b>Cisplatin</b> 50 mg/m2 IV, day 1<br> <b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (171, 'Cisplatin : CDDP<br>Topotecan : Hycamtin', 'Cisplatin/Topotecan', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'High', '<b>Cisplatin/Topotecan</b>', 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. $J Clin Oncol. 2005;23(21):4626-4633.$', null, '<b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Topotecan</b> 0.75 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (172, 'Cisplatin : CDDP', 'Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Cisplatin</b>', 'Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. $N Engl J Med. 1999;340(15):1154-1161.$', null, '<b>Cisplatin</b> 40 mg/m<sup>2</sup> IV once per week during RT for up to 6', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (177, 'Sorafenib : Nexavar', 'Sorafenib', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Low', '<b>Sorafenib</b>', 'Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. $N Engl J Med. 2007;356(2):125-134.$', null, '<b>Sorafenib</b> 400 mg PO bid', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (178, 'Sunitinib : Sutent', 'Sunitinib', '<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>', 'Low', '<b>Sunitinib</b>', 'Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. $N Engl J Med. 2007;356(2):115-124$', null, '<b>Sunitinib malate</b> 50 mg PO daily for 28 days on<br> <b>FOLLOWED BY</b> 14 days off', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (179, '', 'Temsirolimus', '<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>', 'Low', '<b>Temsirolimus</b>', 'Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. $N Engl J Med. 2007;356(22):2271-2281.$', null, '<b>Temsirolimus</b> 25 mg IV over 30 minutes weekly', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (180, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Carboplatin', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Moderate', '<b>Gemcitabine/Carboplatin</b>', 'Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. $Cancer. 2006;106(2):297-303.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br> <b>Carboplatin</b> AUC of 5 IV over 1 hour, day 1<br> Repeat cycle every 21 days upto 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (181, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', null, '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1,8,15<br> <b>Cisplatin</b> 70mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (261, '', 'Arsenic', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>Arsenic</b>', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', null, '<b>Arsenic trioxide</b> 0.15 mg/kg/d IV for 25 doses up to 5 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (182, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'MVAC', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>MVAC</b>', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', null, '<b>Methotrexate</b> 30 mg/m<sup>2</sup>/d IV, days 1, 15, 22<br> <b>Vinblastine</b> 3 mg/m<sup>2</sup>/d IV, days 2, 15,22<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Cisplatin</b> 70 mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (347, 'Beleodaq', 'Belinostat', '', 'Minimal', '<b>Belinostat</b>', 'Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.$Br J Haematol. 2015 Mar;168(6):811-9.$', null, '<b>Belinostat</b> 1000 mg/m<sup>2</sup>  days 1-5, <br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (183, 'Bleomycin : Blenoxane<br>Cisplatin : CDDP<br>Etoposide : VP-16', 'BEP', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>BEP</b>', 'Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study. $J Clin Oncol. 1998;16(4):1287-1293.$', null, '<b>Bleomycin</b> 30 units IV bolus, weekly for 12 weeks<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 30-60 minutes,days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1-5<br> Repeat every 21 days for 4 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (184, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'EP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>EP</b>', 'Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. $J Clin Oncol. 1995;13(11):2700-2704.$', null, '<b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat after 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (185, 'Cisplatin : CDDP<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Paclitaxel : Taxol', 'TIP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'High', '<b>TIP</b>', 'Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. $J Oncol. 2005;23(27):6549-6555.$', null, '<b>Paclitaxel</b> 250 mg/m<sup>2</sup>/d CIVI over 24 hours, day 1<br> <b>Ifosfamide</b> 1,500 mg/m<sup>2</sup>/d IV over 1 hour, days 2-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes, days 2-5<br> <b>Mesna</b> 500 mg/m<sup>2</sup> IV before ifosfamide, and at 4 and 8 hours after ifosfamide daily, days 2-5<br> <b>Peg-Filgrastim</b> 6 mcg SQ, days 6<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (186, 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vinblastine : Velban', 'VIP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>VIP</b>', 'Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. $Ann Intern Med. 1988;109(7):540-546.$', null, '<b>Vinblastine</b> 0.11 mg/kg/d IV, days 1, 2<br> <b>OR</b><br> <b>Etoposide</b> 75 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>AND</b><br> <b>Infosfamide</b> 1,2000 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 20mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Mesna</b> 400 mg IV 15 minutes prior to ifosfamide, <b>THEN</b> 1,200 mg/d CIVI, days 1-5<br> Repeat every 21 days for 4 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (187, 'Cabazitaxel : Jevtana<br>Prednisone : various', 'Cabazitaxel', '<b>Hepatic Impairment</b><ul><li>Cabazitaxel:<br></li></ul><b>Renal Impairment</b><ul><li>Cabazitaxel:<br>Caution should be used in patients with severe renal impairment (creatinine clearence of <30 ml/hr)</li></ul>', 'Low', '<b>Cabazitaxel</b>', 'de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. $Lancet. 2010;376(9747):1147-1154.$', null, '<b>Cabazitaxel</b> 25 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 10 mg PO daily<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (245, '', 'Tositumomab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Tositumomab</b>', 'Bexxar [package insert]. $Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011.$', null, 'Dosimetric step: <b>Tositumomab</b> 450 mg IV over 60 minuutes<br> <b>I-131 tositumomab</b> (35 mg tositumomab containing 5.0 mCi I-131) IV over 20 minutes<br> Therapeutic step: <b>Tositumomab</b> 450mg infused over 60minutes<br> <b>I-131 tositumomab</b> (dose individualized for each patient based on results of dosemetric step)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (192, 'Mitoxantrone : Novantrone<br>Prednisone : various', 'Mitoxantrone/Prednisone', '<b>Hepatic Impairment</b><ul><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Low', '<b>Mitoxantrone/Prednisone</b>', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', null, '<b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 5 mg PO bid<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (262, 'Cytarabine : Ara-C', 'HiDAC', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>HiDAC</b>', 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B. $N Engl J Med. 1994;331(14):896-903.$', null, 'For patients <60 years of age:<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> CIVI over 3 hours, every 12 hours, days 1, 3, 5<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (193, 'Bicalutamide : Casodex<br>Goserelin : Zoladex', 'Bicalutamide/Leuprolide.  ', '<b>Hepatic Impairment</b><ul><li>Bicalutamide:<br>No dose reduction</li><li>Goserelin:<br>No dose reduction </li><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bicalutamide:<br>No dose reduction </li><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', 'Bicalutamide/Leuprolide.  ', 'Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. $Urology. 1995;45(5):745:752.$', null, '<b>Bicalutamide</b> 50 mg/d PO <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (194, 'Degarelix : Firmagon', 'Degarelix', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Degarelix</b>', 'Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. $BJU Int. 2008;102(11):1531-1538.$', null, '<b>Degarelix</b> 240 mg SQ <br> <b>FOLLOWED BY</b><br> 80 mg SQ<br> Repeat every 28 days for 13 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (195, 'Abaraterone : Zytiga', 'Abaraterone', '<b>Hepatic Impairment</b><ul><li>Abaraterone:<br>No dosage adjustment is necessary for patients with baseline mild hepatic impairment. <br>In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of ZYTIGA to 250 mg once daily. If elevations in ALT or AST >5X ULN or total bilirubin >3X ULN occur in patients with baseline moderate hepatic impairment, discontinue ZYTIGA treatment. <br> The safety of ZYTIGA in patients with baseline severe hepatic impairment has not been studied. These patients should not receive ZYTIGA. For patients who develop hepatotoxicity during treatment, interruption of treatment</li></ul><b>Renal Impairment</b><ul><li>Abaraterone:<br>No dose adjustment needed</li></ul>', 'Low', '<b>Abaraterone</b>', 'Ryan CJ, et al. "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy". $N. Engl. J. Med. 368 (2): 138–48.$', null, '<b>Abaraterone</b>1000 mg PO once daily on empty stomach<br> <b>Prednisone</b> 5 mg PO twice daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (198, 'Goserelin : Zoladex', 'Goserelin', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'N/A', '<b>Goserelin</b>', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. $Wilmington, DE: AstraZeneca; 2010.$  ', null, '<b>Goserelin acetae implant</b> 3.6 mg SQ every 28 days or 10.8 mg SQ every 12 weeks.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (199, '', 'Leuprolide', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Leuprolide</b>', 'Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers]. $North Chicago, IL: Abbot Laboratories; 2011.$', null, '<b>Leuprolide acetate depot</b> 7.5 mg IM every 28 days <br>22.5 mg IM every 3 months, <br><b>OR</b> <br>30 mg IM every 4 months', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (200, 'Nilutamide : Nilandron', 'Nilutamide', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Nilutamide:<br>No dose reduction</li></ul>', 'N/A', '<b>Nilutamide</b>', 'Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group. $J Urol. 1997;158(1):160-163.$', null, '<b>Nilutamide</b> 300 mg/d PO, days 1-30, <b>THEN</b> 150 mg/d PO, in combination with surgical castration; begin on same day or day after castration', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (201, 'Prednisone : various', 'Prednisone', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Prednisone</b>', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', null, '<b>Prednisone</b> 5 mg PO bid', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (202, 'Sipuleucel-T : Provenge', 'Sipuleucel-T', '<b>Hepatic Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul>', 'N/A', '<b>Sipuleucel-T</b>', 'Provenge [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', null, '<b>Sipuleucel-T</b> Administer 3 doses at 14-day intervals', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (203, '', 'Triptorelin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Triptorelin</b>', 'Trelstar [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', null, '<b>Triptorelin pamoate depot</b> 3.75 mg IM<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (205, 'Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'DI', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>DI</b>', 'Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. $J Clin Oncol. 1995;13(7):1537-1545.$', null, '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV bolus, day 1,<br> <b>FOLLOWED BY</b><br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> CIVI, day 1<br> <b>Mesna</b> 600 mg/m<sup>2</sup> IV bolus, before ifosfamide, FOLLOWED BY 2,500 mg/m<sup>2</sup> CIVI with ifosfamide, and 1,250 mg/m<sup>2</sup> IV over 12 hours following ifosfamide<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (263, 'Cytarabine : Ara-C', 'Cytarabine', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Cytarabine</b>', 'Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. $Blood. 2001;98(3):548-553.$', null, 'For patients >=60 years of age:<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days for 4 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (208, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex', 'Methotrexate/Cisplatin/Doxorubicin Ifosfamide', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25% <br>  If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If CrCl 30-60 mL/min, reduce dose by 50%    <br>                                                                  If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>Methotrexate/Cisplatin/Doxorubicin Ifosfamide</b>', 'Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. $J Clin Oncol. 2005;23(34):8845-8852.$', null, '<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV over 4 hours day 1<br> <b>WITH Leucovorin calcium</b> 8 mg/m<sup>2</sup> IV every 6 hours for 11 doses beginning 24 hours from the start of the Methotrexate infusion, days 1, 42 (preoperatively); days 133, 196, 238 (postoperatively)<br> <b>Cisplatin</b> 120 mg/m<sup>2</sup> CIVI over 48 hours, days 7-8, 49-50 (preoperatively); days 140-141, 203-204, 245-246 (postoperatively). <br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> CIVI over 24 hours, days 7, 49 (preoperatively); days 98, 161 (postoperatively). Doxorubicin was increased to 90 mg/m<sup>2</sup> IV over 24 hours for postoperative treatment courses<br> <b>Ifosfamide</b> 3,000 mg/m<sup>2</sup>/d CIVI for 5 days with equimolar doses of mesna, days 28-32, 70-74 (preooperatively); days 119-123, 182-186, 224-228 (postoperatively)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (209, 'Doxorubicin : Adriamycin, various', 'Doxorubicin', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Doxorubicin</b>', 'Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group. $Br J Cancer. 1998;78(12):1634-1639.$', null, '<b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (210, '', 'Interferon alfa-2b', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>Interferon alfa-2b</b>', 'Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome.$Ann Intern Med. 1984 May;100(5):671-6$', null, '<b>Interferon alfa-2b</b>  30 million IU/m<sup>2</sup> IM <b>OR</b> SQ 3 times per week<br>Repeat until disease progression ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (211, '', 'Liposomal daunorubicin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>Liposomal daunorubicin</b>', 'Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. $AM J Clin Oncol.2002;25(1): 57-59$', null, '<b>Liposomal daunorubicin</b> 40 mg/m<sup>2</sup> IV over 60 minutes<br>  Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (212, 'Paclitaxel : Taxol', 'Paclitaxel', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Low', '<b>Paclitaxel</b>', 'Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi''s Sarcoma.$http://jco.ascopubs.org/content/17/6/1876.full$', null, '<b>Paclitaxel</b>  135 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days<br><b>OR</b><br> <b>Paclitaxel<sup>a</sup></b> 100 mg/m<sup>2</sup> IV over 3 hours<br>Repeat every 14 days   ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (213, '', 'Pegylated liposomal doxorubicin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Pegylated liposomal doxorubicin</b>', 'Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.$Int J Nanomedicine. 2007 September; 2(3): 345–352.$', null, '<b>Pegylated liposomal doxorubicin</b> 20 mg/m<sup>2</sup> IV every 3 weeks as tolerated', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (242, 'Rituximab : Rituxan', 'Rituximab Maintenance', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Rituximab Maintenance</b>', 'van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin''s lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study. $ JClin Oncol. 2010;28(17):2853-2858.$', null, '<b>Rituximab</b> 375 mg/m<sup>2</sup>/d IV, day 1<br> Repeat every 90 days until relapse or maximum of 2 years', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (214, 'Carboplatin : Paraplatin<br>paclitaxel : Taxol', 'Carbo-Tax', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Carbo-Tax</b>', 'Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study. $J Clin Oncol. 2000; 18(17):3101-3107.$                                                      ', null, '<b>Carboplatin</b> AUC of 6 mg/ml/min IV over 30 minutes.<br><b>FOLLOWED  BY</b><br><b>Paclitaxel</b> 200mg/m<sup>2</sup>  IV over 3 hours, day 1<br><b> Filgrastim </b> 300 mcg/d SQ, days 5-12<br><b>OR</b> <br><b>PEG-Filgrastim</b>6 mg SQ on day 2.<br>Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (215, 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere', 'Docetaxel/Carboplatin', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate', '<b>Docetaxel/Carboplatin</b>', 'Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study. $Acta Oncol. 2008;47(6): 1148-1155.$', null, '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30 minutes, day1<br><b>Carboplatin</b> AUC of 5 mg/mL/min IV over 30 minutes, day 1<br>Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (216, 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various<br>paclitaxel : Taxol', 'Gemcitabine/Carboplatin/paclitaxel', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Gemcitabine/Carboplatin/paclitaxel</b>', 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.                ', null, '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup>  1V, days 1,8<br><b>Carboplatin</b> AUC of 5 IV, day 1<br><b>Paclitaxel</b> 200 mg/m2 IV over 1 hour, day 1<br>Repeat cycle every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (217, 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'High', '<b>Gemcitabine/Cisplatin</b>', 'Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01). $JClin Oncol. 2003;21(18):3479-3482.$', null, '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV, days 1 and 8<br><b>Cisplatin</b> 100mg/m<sup>2</sup> IV, day 1<br>Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (218, 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various', 'Gemcitabine/Docetaxel', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Low', '<b>Gemcitabine/Docetaxel</b>', 'Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. $Cancer. 2004; 100(6): 1257-1261.$', null, '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br><b>Docetaxel</b> 75 mg/m<sup>2</sup>  IV over 1 hour, day 8<br>Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (219, 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various', 'Oxaliplatin Capecitabine', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Moderate', '<b>Oxaliplatin Capecitabine</b>', 'Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. $Cancer. 2010; 116(10):2448-2454.$', null, '<b>Oxaliplatin</b> 130 mg/m<sup>2</sup>  IV, day 1<br><b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br>Repeat cycle every 21 days upto 6 cycles                                                 ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (220, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Paclitaxel : Taxol', 'Paclitaxel/Carboplatin/Etoposide', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', '<b>Paclitaxel/Carboplatin/Etoposide</b>', 'Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study. $J Clin Oncol. 2006;24(22):3548-3554.$', null, '<b>Paclitaxel</b>  200mg/m<sup>2</sup> IV over 1 hour, day 1,<br><b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose targeted by Calvert equation to AUC of 6 mg/mL/min IV, day 1<br><b>Etoposide</b> 50 mg/d PO alternated with 100mg/d PO, days 1-10<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (243, '', 'Romidepsin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Romidepsin</b>', 'Istodax [package insert]. $Summit , NJ: Celgene Corporation; 2011.$', null, '<b>Romidepsin</b> 14mg\m<sup>2</sup> IV on days 1,8,and 15.<br> Repeat every 28 days           ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (725, '', 'Gemcitabine', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (221, 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'ABVD', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>ABVD</b>', 'Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin''s disease after failure of MOPP: ABVD and B-CAVe. $Ann Intern Med. 1984;  101(4):440-446$.<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin''s disease. $J Clin Oncol. 1997; 15(11): 3338-3346$.     ', null, '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (222, 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'BEACOPP (Escalated)', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>BEACOPP (Escalated)</b>', 'Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin''s disease. $N Engl J Med. 2003;348(24):2386-2395$.', null, '<b>Bleomycin</b> 10 mg/m<sup>2</sup> IV, day8<br> <b>Etoposide</b> 200 mg/m<sup>2</sup> IV, days 1-3<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 8<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup> PO, days 1-7<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> IV, days 1-14<br> Repeat on day 22 for 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (223, 'Bleomycin : Blenoxane<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Vinblastine : Velban<br>Vincristine : Oncovin, VCR', 'Stanford V', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mechlorethamine:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>Stanford V</b>', 'Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin''s disease: a Preliminary report. $J Clin Oncol. 1995; 13(5):1080-1088$.', null, '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Mechlorethamine</b> 6 mg/m<sup>2</sup> IV,day1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup>/d IV, days 8, 22<br> <b>Bleomycin</b> 5 units per m<sup>2</sup> per day  IV, days 8,22<br> <b>Etoposide</b> 60mg/m<sup>2</sup>/d IV, days 15,16<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO every other day', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (224, 'Bendamustine : Treanda<br>Rituximab : Rituxan', 'BR', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Moderate', '<b>BR</b>', 'Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany). $Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405.$', null, '<b>Rituximab</b> 375mg/m<sup>2</sup> IV, day 1<br> <b>Bendamustine</b> 90 mg/m<sup>2</sup> IV, days 1, 2<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (225, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisolone : Flo-pred, various<br>Vincristine : Oncovin, VCR', 'CHOP', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CHOP</b>', 'Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin''s lymphomas. $ Eur J Cancer. 1995;31A(6):903-911$.', null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisolone</b> 50 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (240, '', 'Ibritumomab tiuxetan', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Ibritumomab tiuxetan</b>', 'Zevalin [package insert]. $San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010.$<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin''s lymphoma. $Crit Rev Oncol Hematol. 2001;39(1-2):181-194.$', null, '<b>Ibritumomab tiuxetan</b> is given in 2 steps:<br> Step 1: <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b> 5.0 mCi (1.6 mg total antibody dose) of <b>In- 111 ibrituximomab tiuxetan</b> administered as a 10-minute IV push<br> Step 2: (7-9 days after step 1): <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b><br> <b>Y-90 ibritumomab tiuxetan</b> 0.4 mCi/kg (maximum, 32 mCi) admistered as a 10-minute IV push               ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (226, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R - CHOP', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>R - CHOP</b>', 'Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. $N Engl J Med. 2002;346(4):235-242.$<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. $J Clin Oncol. 1999; 17(1):268-276$.', null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1 upto a maximum dose of 2mg<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (227, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CODOX-M/IVAC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CODOX-M/IVAC</b>', 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study. $Ann Oncol. 2002, 13(8): 1254-1274.$', null, '<u>Cycles 1 AND 3 (CODOX-M)</u><br> <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup>/d IV, days 2-5<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV up to a maximum dose of 2 mg, days 1,8 for cycle 1, days 1,8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 hour, day 10,          <b>THEN</b> 240 mg/m<sup>2</sup>/h CIVI for the next 23 hours<br> <b>Leucovorin calcium </b>192 mg/m<sup>2</sup> IV, starting at hour 36  <b>THEN</b> 12 mg/m<sup>2</sup> every 6 hours until Methotrexate level is <5*10<sup>-8</sup> M<br> <b>Filgrastim</b>5 mcg/kg/d SQ until ANC >1,000/mm<sup>3</sup><br> <b>Methotrexate</b> 12mg IT, day 15<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 16<br>                                                              <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1,3,5<br> <b>Methotrexate</b> 12 mg IT, day 12 Cycles 2 AND 4 (IVAC)<br> <b>Ifosfamide</b> 1,500mg/m<sup>2</sup> IV over 1 hour, days 1-5<br> <b>Mesna</b> 360 mg/m<sup>2</sup> IV over 1 hour <b>THEN</b> 360 mg/m<sup>2</sup> IV every 3 hours for a maximum of 7 doses  per 24 hour period, days 1-5<br> <b>Cytarabine</b>  2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1 and 2<br> <b>Methotrexate</b> 12 mg IT, day 5<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 6<br> <b>Filgrastim</b> 5 mcg/kg/d SQ until ANC > 1,000/mm<sup>3</sup>                                                  ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (228, 'Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R - CVP', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>R - CVP</b>', 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. $Blood, 105(4): 1417-1423.$<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma. $J Clin Oncol. 2008;26(28):4578-4589.$', null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> up to a maximum dose of 2 mg IV, day 1<br> <b>Prednisone</b> 40 mg PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for a maximum off 8 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (229, 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Dexamethasone : various', 'DHAP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', '<b>DHAP</b>', 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). $Blood. 1988;71(1):117-122.$', null, '<b>Dexamethasone</b> 40 mg/d PO or IV over 24 hours, days 1-4<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> CIVI, day 1<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 2 doses, day 2<br> Repeat every 21-28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (230, 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various', 'ESHAP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>ESHAP</b>', 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. $J Clin Oncol. 1994; 12(6): 1169-1176.$<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. $J Clin Oncol. 1995; 13(7): 1734-1741.$', null, '<b>Etoposide</b> 40 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2-3 hours,             day 5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>OR</b><br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-4<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2 hours, day 5, immediately following completion of cisplatin<br> Repeat every 21-28 days        ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (241, 'Pralatrexate : Folotyn', 'Pralatrexate', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Pralatrexate</b>', 'Folotyn [package insert]. $Westminster, CO: Allos Therapeutics Inc.; 2012.$', null, '<b>Pralatrexate</b> 30 mg/m<sup>2</sup> IV, weekly for 6 weeks<br> Repeat every 7 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (246, 'Vorinostat : Zolinza', 'Vorinostat', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Vorinostat</b>', 'Zolinza [package insert].', null, '<b>Vorinostat</b> 400mg PO daily with food', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (231, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Vincristine : Oncovin, VCR', 'Hyper-CVAD/MTX-Ara-C', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>Hyper-CVAD/MTX-Ara-C</b>', 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma. $J Clin Oncol. 1998; 16(12): 3803-3809$.', null, '<u>COURSE 1</u><br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> over 3 hours every 12 hours  for 6 doses , days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> over 48 hours after cyclophosphamide, days 4-5<br> <b>Vincristine</b> 2 mg administered 12 hours  after last cyclophosphamide dose, repeated on day 11<br> <b>Dexamethasone</b> 40 mg/d IV or PO,days 1-4,11-14<br> <b>Filgrastim</b> 5 mcg/kg IV or SQ beginning 24 hours after doxorubicin is complete.<br> <u>COURSE 2 <br>(BEGIN AFTER CLINICAL AND HEMATOLOGIC RECOVERY FROM COURSE 1)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus, day 1<br> <b>FOLLOWED BY</b><br> <b>Methotrexate</b> 800mg/m<sup>2</sup>over 24 hours day1 <b>Followed by</b><br><b>Cytarabine</b>3000 mg/m<sup>2</sup> IV every 12 hours for 4 doses, days 2-3 (dose reduced to 1,000 mg/m<sup>2</sup> in patients >60 years or with serum creatinine >1.5 mg/dL)<br> <b>Leucovorin calcium</b> 50 mg PO 24 hours after end of Methotrexate infusion<br> <b>FOLLOWED 6 HOURS LATER BY</b><br> <b>Leucovorin calcium</b> 15 mg PO every 6 hours for 8 doses (dose adjusted for Methotrexate concentration at 24 and 48 hours after completion of Methotrexate infusion)<br> <b>Filgrastim</b> 5mcg/kg IV or SQ begining 24 hours after cytarabine.<br> Repeat courses every 21 days.            ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (232, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR', 'R-EPOCH', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>R-EPOCH</b>', 'Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. $Ann Oncol. 2004; 15(3):511-516$.', null, '<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 65 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Vincristine</b> 0.5 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 5<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> Repeat every 21 days for 4 -6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (233, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Rituximab : Rituxan', 'RICE', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>RICE</b>', 'Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. $Blood. 2004; 103(10):3684-3688.$', null, '<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 every 14 days<br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> with mesna 5,000 mg/m<sup>2</sup> CIVI over 24 hours, day 4<br> <b>Carboplatin</b> AUC of 5 (maximum 800 mg) IV, day 4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 3-5<br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (234, 'Bendamustine : Treanda', 'Bendamustine', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Moderate', '<b>Bendamustine</b>', 'Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study. $Cancer. 2010,116(1):106-114 $.', null, '<b>Bendamustine</b> 120 mg/m<sup>2</sup> IV days 1 and 2<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (235, 'Bexarotene : Targretin', 'Bexarotene', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Bexarotene</b>', 'Targretin [package insert]. $Woodcliff Lake, NJ: Eisai Inc.; 2011.$', null, '<b>Bexarotene</b> 300 mg/m<sup>2</sup>/d PO with a meal', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (236, 'Bortezomib : Velcade', 'Bortezomib', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Low', '<b>Bortezomib</b>', 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study. $Ann Oncol. 2009;20(3):520-525.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1,4, 8, 11<br> Repeat every 21 days for up to 17 cycles.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (237, '', 'Brentuximab vedotin', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Brentuximab vedotin</b>', 'Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update. $Blood (ASH Annula Meeting Abstracts). 2011; 118:443.$<br> Adcetris [package insert]. $Bothell, WA: Seattle Genetics; 2011.$', null, '<b>Brentuximab</b> 1.8 mg/kg IV over 30 minutes,  day 1<br> Repeat every 21 days for upto 16 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (238, '', 'Denileukin diftitox', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Denileukin diftitox</b>', 'Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. $J Clin Oncol. 2001; 19(2):376-388.$', null, '<b>Denileukin diftitox</b> 9 <b>OR</b> 18 mcg/kg/d/IV over 15-60 minutes, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (239, 'Fludarabine : Fludara', 'Fludarabine', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>Fludarabine</b>', 'Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin''s lymphoma previously treated with an alkylating agent or alkylatic containing regimen. $J Clin Oncol. 2002;20(24):4649-4654.$', null, '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 10 minutes, days 1-5<br> Repeat every 28 days for up to 8 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (247, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'CDE', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>CDE</b>', 'Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491). $J Clin Oncol. 2004; 22(8): 1491-1500.$', null, '<b>Cyclophosphamide</b> 200mg/m<sup>2</sup>/d CIVI for 4 days<br><b>Doxorubicin</b> 12.5 mg/m<sup>2</sup>/d CIVI for 4 days<br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d CIVI for 4 days<br> Repeat every 28 days for a maximum of 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (248, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'CHOP', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CHOP</b>', 'Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. $Cancer. 2006; 106(7): 1560-1568.$ ', null, '<b>Cyclophosphamide</b> 750mg/m<sup>2</sup> IV, day 1<br> Doxorubicin 50 mg/m<sup>2</sup> IV, day 1<br><b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 100mg/m<sup>2</sup> PO, days 1-5<br> Repeat every 21 days.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (249, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CODOX-M/IVAC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CODOX-M/IVAC</b>', 'Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma. $Cancer. 2003;98(6): 1196-1205.$', null, '<u>CYCLES 1 and 3 (CODOX-M)</u><br>  <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 200 mg/m<sup>2</sup>/d IV, days 2-5<br>  <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 8 for cycle 1,days 1, 8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 h, day 10, <b>THEN</b> 240 mg/m2/h CIVI for the next 23 hours<br> <b>Leucovorin calcium</b> 50 mg IV q6h, begining 36 hours from the start of Methotrexate until Methotrexate level <0.05 mcM<br> <b>Filgrastim</b> beginning 24 h from the start of leucovorin until ANC>1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1, 3<br> <b>Methotrexate<b> 12 mg IT, day 15<br> <u>CYCLES 2 AND 4 (IVAC)</u><br> <b>Ifosofamide</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Mesna</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Etoposide</b> 60 mg/m<sup>2</sup> IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV q 12h, days 1 and 2<br> <b>Filgrastim</b> beginning 24 h after completion of chemotherapy until ANC >1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 15<br> Additional IT Treatment for CNS disease- positive patients:<br> Cycle 1: cytarabine 70 mg IT, days 1,3,5, and Methotrexate 12 mg IT, days 15,17<br> Cycle 3: cytarabine 70 mg IT, days 1,3, and Methotrexate 12 mg IT, day 15                                                                                                                                                               ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (250, 'Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'EPOCH Dose-adjusted ', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>EPOCH Dose-adjusted </b>', 'Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. $BLOOD.2003;101(12):4653-4659.$', null, '<b>Etoposide</b> 50 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Vincristine</b> 0.4 mg/m<sup>2</sup>/d /CIVI, days 1-4 (96 hours)<br> <b>Cyclophosphamide</b> <br>Cycle1: <br>375 mg/m<sup>2</sup> IV, day 5, if CD4+ cells >= 100/mm<sup>3</sup>; 187 mg/m<sup>2</sup> IV, day 5, if CD4+ cells<100/mm<sup>3</sup><br> After cycle 1: increase dose by 187 mg if nadir ANC > 500/mvL or platelets <25,000/mcL<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Filgrastim</b> 5 mcg/kg/d SQ, day 6, and until ANC >5,000/mcl<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (259, '', 'Arsenic', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>Arsenic</b>', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', null, '<b>Arsenic trioxide</b> 0.15 mg/kg IV, daily until remission, not to exceed 60 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (251, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Thioguanine : 6-TG<br>Vincristine : Oncovin, VCR', 'CALGB 8811', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CALGB 8811</b>', 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. $Blood. 1995;85(8):2025-2037.$', null, '<u>INDUCTION (COURSE 1:4 WEEKS)</u><br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day1 (800 mg/m<sup>2</sup> for patients >=60 years)<br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup> IV, days 1-3 (30 mg/m<sup>2</sup> for patients>=60 years)<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15, 22<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-21 (days 1-7 for patients >=60 years)<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 5, 8, 11, 15, 18, 22<br> <u>EARLY INTENSIFICATION (COURSE 2:4 WEEKS, REPEAT ONCE)</u><br> <b>Methotrexate</b> 15 mg IT, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 1-4, 8-11<br> <b>Vincristine</b> 2 mg IV, days 15, 22<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 15, 18, 22, 25<br> <u>CNS PROPHYLAXIS AND INTERIM MAINTENANCE (COURSE 3:12 WEEKS)</u><br> <b>Cranial RT</b> 2,400 cGy, days 1-12<br> <b>Methotrexate</b> 15 mg IT, days 1, 8, 15, 22, 29<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-70<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 36, 43, 50, 57, 64<br> <u>LATE INTENSIFICATION (COURSE 4:8 WEEKS)</u><br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, days 1, 8, 15<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15<br> <b>Dexamethasone</b> 10 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 29<br> <b>Thioguanine</b> 60 mg/m<sup>2</sup>/d PO, days 29-42<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 29-32, 36-39<br> <u>MAINTENANCE (COURSE 5:4 WEEKS, FOR 2 YEARS FROM DIAGNOSIS)</u><br> <b>Vincristine</b> 2 mg IV, day 1 of every 4 weeks<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5 of every 4 weeks<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 1, 8, 15, 22<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-28', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (252, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Mesna : Mesnex, various<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various<br>Vincristine : Oncovin, VCR', 'Hyper-CVAD', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>Hyper-CVAD</b>', 'Kantarjian HM, O''Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. $J Clin Oncol. 2000;18(3):547-561.$', null, '<u>ODD CYCLES (1, 3, 5, 7)</u><br>                            <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1-3<br> <b>Mesna</b> 600 mg/m<sup>2</sup>/d CIVI, days 1-3, ending 6 hours after cyclophosphamide completion<br> <b>Vincristine</b> 2 mg IV, days 4, 11<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Dexamethasone</b> 40 mg/d, days 1-4, 11-14<br> <b>Filgrastim</b> 5 mcg/kg bid SQ beginning 24 hours after doxorubicin completion <br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>EVEN CYCLES (2, 4, 6, 8)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV over 2 hours, day 1,<br> <b>FOLLOWED BY</b>  800 mg/m<sup>2</sup> IV over 24 hours<br> <b>Leucovorin calcium</b> 15 mg IV every 6 hours for 8 doses, beginning 24 hours after Methotrexate completion; adjust per Methotrexate level<br> <b>Cytarabine</b> 3 g/m<sup>2</sup> IV over 2 hours every 12 hours for 4 doses, days 2, 3<br> <b>Methylprednisolone</b> 50 mg IV bid, days 1-3<br> <b>Filgrastim</b> 6 mg/kg SQ beginning 24 hours after cytarabine completion<br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 2 of each cycle<br> <b>Cytarabine</b> 100 mg IT, day 8 of each cycle<br>4-16 cycles based on risk profile', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (253, '', 'Nelarabine', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Nelarabine</b>', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline;2011.$', null, '<b>Nelarabine</b> 1,500 mg/m<sup>2</sup>/d IV, days 1, 3 and 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (254, '', 'ATRA/Arsenic', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>ATRA/Arsenic</b>', 'Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. $Blood. 2006;107(9):3469-3473.$', null, '<b>All-trans-retinoic acid (ATRA)</b> 45 mg/m<sup>2</sup> PO in 2 divided doses daily<br> <b>Arsenic trioxide</b> 0.15 mg/kg/d IV over 1 hour, daily beginning day 10 and continued until <5% blasts and absence of promyelocytes', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (255, 'Idarubicin : Idamycin', 'ATRA/Idarubicin', '<b>Hepatic Impairment</b><ul><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li></ul>', 'Moderate', '<b>ATRA/Idarubicin</b>', 'Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group. $Blood. 2008;112(8):3130-3134.$', null, '<b>All-trans-retinoic acid</b> (ATRA) 45 mg/m<sup>2</sup> PO, daily<br> <b>Idarubicin</b> 12 mg/m<sup>2</sup> IV, on days 2, 4, 6, 8', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (256, 'Cytarabine : Ara-C<br>Etoposide : VP-16<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone', 'Idarubicin/Cytarabine/Etoposide', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Moderate', '<b>Idarubicin/Cytarabine/Etoposide</b>', 'Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10. $J Clin Oncol. 2009;32(10):5397-5403.$', null, '<b>Cytarabine</b> 25 mg/m<sup>2</sup> IV <b>FOLLOWED BY</b> 100 mg/m<sup>2</sup> CIVI, days 1-10<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-5<br> <b>Daunorubicin</b> 50 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Idarubicin</b> 10 mg/m<sup>2</sup> IV, days 1, 3, 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (257, 'Cytarabine : Ara-C<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone', '7 + 3', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Moderate', '<b>7 + 3</b>', 'Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. $Blood. 1987;69(5):1441-1449.$<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia. $Blood. 1992;79(2):313-319.$<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. $Cancer Chemother Pharmacol. 1991;28(6):480-483.$', null, '<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Idarubicin</b> 13 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup>/d IV, days 1-3', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (264, 'Bendamustine : Treanda<br>Rituximab : Rituxan', 'BR', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Moderate', '<b>BR</b>', 'Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). $J Clin Oncol. 2011;29(26)3559-3566.$', null, '<b>Bendamustine</b> 90 mg/m<sup>2</sup> IV on days 1 and 2<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV for the first cycle and 500 mg/m<sup>2</sup> for subsequent cycles<br> Repeat every 28 days for up to 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (265, 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara', 'FC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>FC</b>', 'Catovsky D, Richards S, Oscier D, et al. Assesmentof fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial. $Lancet. 2007; 370(9583):230-239.$', null, '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (266, 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara<br>Rituximab : Rituxan', 'FCR', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Moderate', '<b>FCR</b>', 'Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. $J Clin Oncol. 2010;28(10):1756-1765.$', null, '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 cycle 1<br> <b>FOLLOWED BY</b><br> <b>Rituximab</b> 500 mg/m<sup>2</sup> IV, day 1 cycles 2-6<br> Repeat every 28 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (267, 'Fludarabine : Fludara<br>Rituximab : Rituxan', 'FR', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>FR</b>', 'Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). $Blood. 2003;101(1):6-14$', null, '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 20-30 minutes, days 1-5<br> Repeat every 28 days for a total of 6 cycles<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV<br> Repeat every 7 days for 4 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (268, 'Cyclophosphamide : Cytoxan<br>Pentostatin : Nipent<br>Rituximab : Rituxan', 'PCR', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Pentostatin:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>PCR</b>', 'Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. $Blood. 2007;109(2):405-411.$', null, '<b>Pentostatin</b> 2 mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (269, 'Alemtuzumab : Campath', 'Alemtuzumab', '<b>Hepatic Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul>', 'Low', '<b>Alemtuzumab</b>', 'Campath [package insert]. $Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009.$', null, '<b>Alemtuzumab</b> 30 mg per day IV, 3 times per week, upto a maximum of 23 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (271, 'Chlorambucil : Leukeran', 'Chlorambucil', '<b>Hepatic Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul>', 'Low', '<b>Chlorambucil</b>', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', null, '<b>Chlorambucil</b> 0.4 mg/kg PO <br> Repeat therapy every 14 days, increase upto  0.8 mg/kg  if  tolerated', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (272, 'Fludarabine : Fludara', 'Fludarabine', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Low', '<b>Fludarabine</b>', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', null, '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes , days 1-5<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (775, null, 'Pembroluzumab', '
<ul><li>Pembrolizumab:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Pembrolizumab:&nbsp;200 mg </strong>IV on day 1</p><p>Repeat cycles every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (776, null, 'Nivolumab', '
<ul><li>Nivolumab:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Nivolumab:&nbsp;240 mg </strong>IV on day 1</p><p>Every 2 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (777, null, 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p><p>Docetaxel&nbsp;<br>If bilirubin &gt; upper normal limit, do not use<br>If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt;2.5 upper normal limit, do not use</p><p><strong>Renal Impairment</strong></p><ul><li>Docetaxel:<br>No dose reduction</li></ul>', 'moderate', null, null, null, '<p><strong>Docetaxel</strong> 100 mg/m2 IV over 1 hour, day1<br><br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (273, 'Ofatumumab : Arzerra', 'Ofatumumab', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Ofatumumab</b>', 'Arzerra [package insert]. <br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fluda-rabine-refractory chronic lymphocytic leukemia. $J Clin Oncol. 2010;28:1749-1755.$', null, '<b>Previously untreated CLL:</b><br>300 mg IV on Day 1 followed by 1,000 mg IV on Day 8 (Cycle 1)<br>1,000 mg IV on Day 1 subsequent 28-day cycles for a minimum of 3 cycles until best response or maximum of 12 cycles.<br><b>Refractory CLL:</b><br><b>Ofatumumab</b> 300 mg IV, initial dose,<br> <b>FOLLOWED 1 week later BY</b><br> <b>Ofatumumab</b> 2,000 mg IV, weekly dose for 7 weeks<br> Repeat every 28 days for 4 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (274, 'Dasatinib : Sprycel', 'Dasatinib', '<b>Hepatic Impairment</b><ul><li>Dasatinib:<br>Unknown. Metabolism mainly hepatic </li></ul><b>Renal Impairment</b><ul><li>Dasatinib:<br>Unknown. < 4% excreted by kidney </li></ul>', 'Low', '<b>Dasatinib</b>', 'Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia. $N Engl J Med. 2010;362(24):2260-2270.$', null, '<b>Dasatinib</b> 100 mg PO, daily (chronic phase)<br> <b>OR</b><br> <b>Dasatinib</b> 140 mg PO, daily (accelerated or blast phase)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (275, 'Imatinib : Gleevec', 'Imatinib', '<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>', 'Low', '<b>Imatinib</b>', 'Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.$N Engl J Med. 2001 Apr 5;344(14):1031-7.$', null, '<b>Imatinib mesylate</b> 400 mg PO daily <b>OR</b> 600 mg PO daily(accelarated phase / blast crisis) ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (276, 'Nilotinib : Tasigna', 'Nilotinib', '<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>', 'Low', '<b>Nilotinib</b>', 'Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.$Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17$', null, '<b>Nilotinib</b> 300 mg PO bid  (newly diagnosed)<br> <b>OR</b><br> <b>Nilotinib</b> 400 mg PO bid (resistant or intolerant chronic or accelerated phase)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (277, 'Cladribine : 2-CdA', 'Cladribine', '<b>Hepatic Impairment</b><ul><li>Cladribine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Cladribine</b>', 'Saven A, et al. $Blood 1992;79:1111-1120.$', null, '<b>Cladribine:</b>0.09 mg/kg/day IV continuous infusion on days 1 to 7 <br>Administer one cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (278, 'Pentostatin : Nipent', 'Pentostatin', '<b>Hepatic Impairment</b><ul><li>Pentostatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Pentostatin</b>', 'Cassileth PA, et al.$J Clin Oncol. 1991;9:243-246.$', null, '<b>Pentostatin:</b> 4 mg/m<sup>2</sup> IV on day 1 <br>Repeat cycle every 14 days for 6 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (280, 'Bortezomib : Velcade', 'Bortezomib/Doxil', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Low', '<b>Bortezomib/Doxil</b>', 'Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010.$<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. $J clin Oncol. 2007;25(25):3892.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Pegylated liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV over 1 hour, day 4<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (281, 'Bortezomib : Velcade<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various', 'Bortezomib/Doxorubicin/Dexamethasone', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Moderate', '<b>Bortezomib/Doxorubicin/Dexamethasone</b>', 'Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). $Blood. 2008;112(11):Abstract 653.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup> IV, bolus days 1-4<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, 17-20', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (282, 'Bortezomib : Velcade<br>Thalidomide : Thalomid', 'Bortezomib/Thalidomide/Dexamethasone (VTD)', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Low', '<b>Bortezomib/Thalidomide/Dexamethasone (VTD)</b>', 'Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. $Lancet. 2010;18;376(9758):2075-2085.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV bolus, days 1, 4, 8, and 11<br> <b>Thalidomide</b> 100 mg PO daily for 14 days and 200 mg daily thereafter<br> <b>Dexamethasone</b> 40 mg PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12; total of 320 mg per cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (283, 'Bortezomib : Velcade<br>Cyclophosphamide : Cytoxan<br>Dexamethasone : various', 'CyBorD', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate-High', '<b>CyBorD</b>', 'Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma. $Br J Haematol. 2011 [Epub ahead of print].$', null, '<b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> PO days 1, 8, 15, 22<br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV on days 1, 4, 8, and 11<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, and 17-20<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (342, 'Tagrisso', 'Osimertinib', '', 'Minimal', '<b>Osimertinib</b>', 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406. $', null, '<b>Osimertinib</b> 80 mg  PO daily<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (284, 'Cisplatin : CDDP<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Thalidomide : Thalomid', 'DT-PACE', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>DT-PACE</b>', 'Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. $J Clin Oncol. 2003;21(14):2732-2739.$', null, '<b>Dexamethasone</b> 40 mg PO, days 1-4<br> <b> Thalidomide</b> 400 mg/d PO<br> <b>Cisplatin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Etoposide</b> 40 mg/m<sup>2</sup>/d CIVI, days 1-4', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (286, 'Melphalan : Alkeran<br>Prednisone : various', 'Melphalan/Prednisone (MP)', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Low', '<b>Melphalan/Prednisone (MP)</b>', ' $Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152$', null, '<b>Melphalan</b> 8 - 10 mg per m<sup>2</sup>  on days 1 - 4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> days 1 - 4<br> Repeat cycle every 42 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (287, 'Melphalan : Alkeran<br>Prednisone : various', 'Melphalan/Prednisone/Talidomide (MPT)', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Low', '<b>Melphalan/Prednisone/Talidomide (MPT)</b>', ' $Palumbo A, et al. Lancet 2006;28:367-835.$', null, '<b>Melphalan</b> 0.25 mg/kg PO, daily for 5 days<br> <b>Prednisone</b> 1 mg/kg PO, daily for 5 days<br> Repeat every 28 days for 8 cycles<br> <b>Thalidomide 50 - 100 mg PO, daily ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (288, 'Bortezomib : Velcade<br>Dexamethasone : various<br>Lenalidomide : Revlimid', 'RVD', '<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>', 'Low', '<b>RVD</b>', 'Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. $Blood. 2010;116(5):679-686.$', null, '<b>Lenalidomide</b> 25 mg/d PO, days 1-14<br> <b> Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Dexamethasone</b> 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 (cycles 1-4)<br> Repeat every 21 days for 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (289, 'Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VAD', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>VAD</b>', 'Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. $Br J Haematol. 1999;105(1):127-130.$', null, '<b>Vincristine</b> 0.4 mg/d CIVI, days 1-4<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Dexamethasone</b> 40 mg/d PO, days 1-4, 9-12, 17-20<br> Repeat every 25 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (290, 'Bortezomib : Velcade<br>Melphalan : Alkeran<br>Prednisone : various', 'VMP', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Low', '<b>VMP</b>', 'San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. $Blood. 2007;110(11 pt 1): Abstract 78.$<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. $N Engl J Med. 2008;359(9):906-917.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11, 22, 25, 29, 32 cycles 1-4<br> <b>FOLLOWED BY</b><br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 8, 22, 29 cycles 5-9<br> <b>Melphalan</b> 9 mg/m<sup>2</sup> PO, days 1-4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> PO, days 1-4<br> Repeat every 6 weeks for 9 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (291, 'Bortezomib : Velcade', 'Bortezomib', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Low', '<b>Bortezomib</b>', 'Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. $N Engl J Med. 2003;348(26):2609-2617.$', null, '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1, 4, 8, 11<br> Repeat every 21 days ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (292, 'Dexamethasone : various', 'Dexamethasone', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'N/A', '<b>Dexamethasone</b>', 'Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. $Blood. 1992;80(4):887-890.$', null, '<b>Dexamethasone</b> 20 mg/m<sup>2</sup>/d PO, days 1-4, 9-12, 17-20<br> Repeat after 14-day rest period', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (293, 'Thalidomide : Thalomid', 'Thalidomide', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Thalidomide</b>', 'Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. $N Engl J Med. 1999;341(21):1565-1571.$ $ Erratum in N Engl J Med. 2000;342(5):364.$', null, '<b>Thalidomide</b> 200 mg/d PO at bedtime (increased dose every 2 weeks for 6 weeks up to a dose of 800 mg/d)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (294, 'Carfilzomib : Kyprolis', 'Carfilzomib', '<b>Hepatic Impairment</b><ul><li>Carfilzomib:<br>The safety, efficacy and pharmacokinetics of Carfilzomib have not been evaluated in patients with baseline hepatic impairment.<br> Patients with the following laboratory values were excluded from the KYPROLIS clinical trials: ALT/AST = 3 × upper limit of normal (ULN) and bilirubin = 2 × ULN</li></ul><b>Renal Impairment</b><ul><li>Carfilzomib:<br>No dose adjustment recommended</li></ul>', 'Low', '<b>Carfilzomib</b>', 'Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.$Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25$', null, '<b>Carfilzomib</b> 20 mg/m<sup>2</sup>, Days 1,2,8,9,15, and 16, followed by a 12 day rest period<br> Repeat cycle every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (295, 'Pomalidamide : Pomalyst', 'Pomalidamide', '<b>Hepatic Impairment</b><ul><li>Pomalidamide:<br>Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALTgreater than 3.0 x ULN.</li></ul><b>Renal Impairment</b><ul><li>Pomalidamide:<br>Avoid Pomalidamide in patients with a serum creatinine greater than 3.0 mg/dL.</li></ul>', 'Low', '<b>Pomalidamide</b>', 'Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.$Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14$', null, '<b>Pomalidamide</b>4 mg PO daily, from Day 1-21 <br>Repeat cycle every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (296, 'Cisplatin : CDDP<br>Etoposide : VP-16', 'CDDP/VP-16', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>CDDP/VP-16</b>', 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. $J Clin Oncol. 1990;8(2):330-336.$', null, '<b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 150 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 21 days for 4 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (297, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'COPE or "Baby Brain I"', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>COPE or "Baby Brain I"</b>', 'Duffner id, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. $N Engl J Med. 1993;328(24):1725-1731.', null, '<u>CYCLE A</u><br> <b>Vincristine</b> 0.065 mg/kg/d (maximum, 1.5 mg) IV, days 1, 8<br> <b>Cyclophosphamide</b> 65 mg/kg/d IV over 30 minutes, day 1<br> <u>CYCLE B</u><br> <b>Cisplatin</b> 4 mg/kg/d IV over 6 hours, day 1<br> <b>Etoposide</b> 6.5 mg/kg/d IV over 1 hour, days 3, 4<br> Regimens given in alternating 28-day cycles in the sequence AABAAB', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (298, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Vincristine : Oncovin, VCR', 'Vincristine/Cyclophosphamide/Cisplatin', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', 'Vincristine/Cyclophosphamide/Cisplatin', 'Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. $Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164.$<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma. $http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> Repeat every 6 weeks for 8 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (328, '', '6-MP/ MTX', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>6-MP/ MTX</b>', 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. $Blood. 2000;95(11):3310-3322.$', null, '<b>Mercaptopurine</b> 25 mg/m<sup>2</sup>/d PO, days 1-56<br> <b>Methotrexate</b> 5,000 mg/m<sup>2</sup> IV over 24 hours, days 8, 22, 36, 50<br> <b>Methotrexate</b> 12 mg/d IT (adjust dose for children<3 years), days 8, 22, 36, 50', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (343, 'Keytruda', 'Pembrolizumab', '', 'Minimal', '<b>Pembrolizumab</b>', 'Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. $N Engl J Med 2015; 372:2018-2028.$', null, '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (344, 'Imbruvica', 'ibrutinib', '', 'Minimal', '<b>ibrutinib</b>', 'Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.$N Engl J Med. 2013 Aug 8;369(6):507-16.$', null, '<b>Ibrutinib</b> 560 mg PO daily (for Mantle Cell Lymphoma)<br>420 mg PO daily for Waldenstrom''s <br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (345, 'Gilotrif', 'Afatinib', '', 'Minimal', '<b>Afatinib</b>', 'Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.$J Clin Oncol. 2013 Sep 20;31(27):3327-34.$', null, '<b>Afatinib</b> 40 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (299, 'Carboplatin : Paraplatin<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'Carbo/VP-16/Vincristine', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>Carbo/VP-16/Vincristine</b>', 'Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children''s Cancer Study Group PNET-3 study. $J Clin Oncol. 2003;21(8):1581-1591.$', null, '<u>CYCLES 1 AND 3 (3-WEEK CYCLES)</u><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Carboplatin</b> 500 mg/m<sup>2</sup> IV, days 1, 2<br><br> <u>CYCLES 2 AND 4 (3-WEEK CYCLES)</u><br> <b>Vincristine<sup>d</sup></b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Cyclophosphamide</b> 1,500 mg/m<sup>2</sup> IV, day 1<br> <b>Mesna</b> 750 mg/m<sup>2</sup> IV, 15 minutes before and 4 and 8 hours after cyclophosphamide', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (300, 'Lomustine : CCNU<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'POC', '<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>POC</b>', 'Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. $J Clin Oncol. 1995;13(1):112-123.$', null, '<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Lomustine</b> 100 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 1, 8, 15', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (301, 'Carboplatin : Paraplatin', 'Carboplatin', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>', 'High', '<b>Carboplatin</b>', 'Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. $J Clin Oncol. 2000;18(22):3819-3828.$', null, '<b>Carboplatin</b> 560 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (302, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'A<sub>1</sub>', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>A<sub>1</sub></b>', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', null, '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (303, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'A<sub>3</sub>', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>A<sub>3</sub></b>', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', null, '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (304, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'CAV + P/VP', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>CAV + P/VP</b>', 'Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. $J Clin Oncol. 1994;12(12):2607-2613.$', null, '<u>CAV (COURSES 1, 2, 4, 6)</u><br> <b>Cyclophosphamide</b> 70 mg/kg/d IV over 6 hours, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d CIVI for 72 hours<br><b>Vincristine</b>0.033mg/kg/d CIVI for 72 hours<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV bolus, day 9<br> <br><u>P/VP (COURSES 3, 5, 7)</u><br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV over 2 hours, days 1-3<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV over 1 hour, days 1-4', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (305, 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16', 'High-risk neuroblastoma', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>High-risk neuroblastoma</b>', 'Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. $N Engl J Med. 1999;341(16):1165-1173.$', null, '<b>Cisplatin</b> 60 mg/m<sup>2</sup> IV over 6 hours, day 0<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 2, 5<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 28 days for 5 cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (306, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR', 'Chemoreduction', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>Chemoreduction</b>', 'Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. $Arch Ophthalmol. 2003;121(7):979-984.$', null, '<b>Vincristine</b> 0.05 mg/kg (for age <12 months)<br> <b>OR</b> 1.5-2 mg/m<sup>2</sup> (for age >12 months)<br> <b>Carboplatin</b> 20 mg/kg (for age <12 months)<br> <b>OR 550-600 mg/m<sup>2</sup> (for age >12 months)<br> <b>Etoposide phosphate</b> 5 mg/kg (for age <12 months) or 150 mg/m2 (for age >12 months)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (307, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'CD', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>CD</b>', 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology. $J Clin Oncol. 2000;18(22):3819-3828.$', null, '<b>Cisplatin</b> 80 mg/m<sup>2</sup> CI over 24 hours (>1 year of age) <b>OR</b> 3 mg/kg (<1 year of age) IV over 6 hours with post-hydration fluid<br> <br>Doxorubicin</b> 30 mg/m<sup>2</sup>/d CIVI over 48 hours, days 2, 3<br> Administer 4 cycles before surgery, 2 cycles after surgery', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (308, 'Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VAD', '<b>Hepatic Impairment</b><ul><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Vincristine plus dactinomycin, high; vincristine plus doxorubicin, or doxorubicin-containing, moderate', '<b>VAD</b>', 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study. $J Clin Oncol. 1995; 13(1):124-133.$<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor. $Cancer. 1994;73(12):3081-3086.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 10 weeks, then every 3 weeks for 15 weeks<br> <b>Dactinomycin</b> 1.5 mg/m<sup>2</sup> IV every 6 weeks for 26 weeks<br> <b>ALTERNATING WITH</b><br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV every 6 weeks for 1 year (stage III)<br> <b>OR</b><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Dactinomycin</b> 15 mcg/kg/d IV, days 1-5 or 60 mcg/kg IV, day 1<br> Repeat every 6 weeks; if stage III or IV, add:<br> <b>Doxorubicin</b> 20 mg/m<sup>2</sup> IV, day 1, and RT', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (309, 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'IFoVP', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>IFoVP</b>', 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. $J Clin Oncol. 1987;5(8):1191-1198.$', null, '<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 1 hour, days 1-5<br> <b>Mesna</b> 2,880 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (329, '', 'MTX/6-MP', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>MTX/6-MP</b>', 'Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study. $J Clin Oncol. 1989;7(10):1539-1544.$', null, '<b>Methotrexate</b> 20 mg/m<sup>2</sup> IM weekly, weeks 25-130<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, weeks 25-130', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (346, 'Iressa', 'Gefitinib', '', 'Minimal', '<b>Gefitinib</b>', 'Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. $N Engl J Med. 2010 Jun 24;362(25):2380-8.$', null, '<b>Gefitinib</b> 250 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (310, 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various', 'MTX-CDDP/Adr', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li></ul>', 'High', '<b>MTX-CDDP/Adr</b>', 'Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. $Cancer Treat Rep. 1986;70(12):1431-1432.$', null, '<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV weekly for 2 weeks; escalate dose by 1,000 mg/m<sup>2</sup> in subsequent courses until peak level of 10-8 M is reached (reduce dose to 8,000 mg/m<sup>2</sup> IV for patients >12 years)<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup> IV every 3 hours for 8 doses beginning 16 hours after completion of methotrexate, <b>THEN</b> every 6 hours PO for 8 doses<br> <b>ALTERNATING WITH</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 15 of cycles 1-7,<br> <b>THEN</b> 120 mg/m<sup>2</sup> for cycles 8-10<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 15-17 of cycles 1-7', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (311, 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'VP/high-dose Ifos', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>VP/high-dose Ifos</b>', 'Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. $J Clin Oncol. 2002;20(2):426-433.', null, '<b>Etoposide</b> 100 mg/m<sup>2</sup> days 1-5<br> <b>Ifosfamide</b> 3,500 mg/m<sup>2</sup> days 1-5<br> <b>Mesna</b> 700 mg/m<sup>2</sup> over 4 hours, <b>THEN</b> mesna 700 mg/m<sup>2</sup> at hour 4, 7, 10, 13, days 1-5<br> <b>GCF</b> 5 mcg/kg/d begin day 6<br> Repeat in 3 weeks for a total of 2 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (312, 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex', 'ICE', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>ICE</b>', 'Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. $Semin Oncol. 1995;22(3 suppl 7):23-27.$', null, '<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4<br> <b>Carboplatin</b> 400 mg/m<sup>2</sup>/d IV over 1 hour, days 0, 1<br> <b>Etoposide 100 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (313, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'VCR/Cyclophosphamide', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>VCR/Cyclophosphamide</b>', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', null, '<b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (314, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Vincristine : Oncovin, VCR', 'P6', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>P6</b>', 'Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing''s family of tumors in children and young adults. $J Clin Oncol. 2003;21(18):3423-3430.$', null, '<u>CYCLES 1, 2, 3 AND 6</u><br> <b>Cyclophosphamide</b> 2,100 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup> CIVI, days 1-3<br> <b>Vincristine</b> 0.67 mg/m2 (maximum, 2 mg/cycle0 CIVI, days 1-3<br><br> <u>CYCLES 4, 5 AND 7</u><br> <b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (330, 'Cytarabine : Ara-C', 'CA', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'high', '<b>CA</b>', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', null, '<b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM 3 hours after last dose of cytarabine<br> Repeat 28 days after initial cycle or after recovery of blood counts, whichever is later', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (315, 'Cyclophosphamide : Cytoxan<br>Topotecan : Hycamtin', 'Topo/CTX', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'High', '<b>Topo/CTX</b>', 'Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncolgy Group study. $J Clin Oncol. 1998;16(3):945-952.$', null, '<b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>FOLLOWED BY</b><br> <b>Topotecan</b> 0.6-0.75 mg/m<sup>2</sup>/d IV as an escalating dose, days 1-5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (316, 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Vincristine : Oncovin, VCR', 'VAC', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>VAC</b>', 'Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. $J Clin Oncol. 2001;19(12):3091-3102.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 3 weeks<br> <b>Dactinomycin</b> 0.015 mg/kg/d (maximum, 0.5 mg/kg/d) IV for 5 days<br> <b>Cyclophosphamide</b> 2,200 mg/m<sup>2</sup> IV, day 1', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (317, 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban', 'ABVD', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'High', '<b>ABVD</b>', 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group. $J Clin Oncol. 1990;8(12):1971-1980.$', null, '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 14 days for 12 courses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (318, 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR', 'BEACOPP', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>BEACOPP</b>', 'Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin''s lymphoma: preliminary results from the Children''s Cancer Group Study Ccg-59704. $Ann Oncol. 2002;13(suppl 1):107-111.', null, '<b>Bleomycin</b> 10 units/m<sup>2</sup> IV, day 7<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 0-2<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 0<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 0<br> <b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 7<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup>/d PO, days 0-6<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 0-13<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (319, 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'CHOP', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>CHOP</b>', 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy. $N Engl J Med. 1990;322(17):1169-1174.$', null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 6 doses<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO for 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (331, 'Cytarabine : Ara-C', 'DA', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', '<b>DA</b>', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', null, '<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (320, 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR', 'SNCCL/B-ALL', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'High', '<b>SNCCL/B-ALL</b>', 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. $J Clin Oncol. 1996;14(4):1252-1261.$', null, '<u>INITIAL PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup>/d (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup>/d (maximum, 12 mg/d) IT, days 4, 11<br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV push every 12 hours for 6 doses, days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 4, 11<br> <b>ALTERNATING WITH</b><br><br> <u>SECONDARY PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup> (maximum, 50 mg) IT, day 1<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup> (maximum, 12 mg) IT, day 1<br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus,<br> <b>THEN</b> 800 mg/m<sup>2</sup> CIVI<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses, days 2, 3<br> <b>Leucovorin calcium</b> 30 mg/m<sup>2</sup> IV at hour 42, then 3 mg/m<sup>2</sup> IV at hours 54, 66, 78', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (321, 'Dexamethasone : various<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'VCR/Asparaginase/Dex/MTX', '<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate for MTX agent IT, minimal for others', '<b>VCR/Asparaginase/Dex/MTX</b>', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0,7, 14, 21<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses, starting on days 2-4<br> <b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO in 3 equal doses (was substituted for prednisone)<br> <b>Methotrexate</b> 8, 10, or 12 mg IT, age-adjusted, days 0, 14 (also days 7, 21 for patients with CNS disease at diagnosis)<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (322, 'Cytarabine : Ara-C<br>Prednisone : various<br>Vincristine : Oncovin, VCR', 'VCR/Prednisone/Pegaspargase/Cytarabine/MTX', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate for MTX agent IT, minimal for others', '<b>VCR/Prednisone/Pegaspargase/Cytarabine/MTX</b>', 'Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children''s Cancer Group Study. $Blood. 2002;99(6):1986-1994.$ $Erratum in: Blood. 2002; 100(6):1531.$', null, '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO, days 0-28, then 10-day taper<br> <b>Pegaspargase</b> 2,500 units/m<sup>2</sup> IM, day 3<br> <b>Cytarabine</b> 30, 50, or 70 mg IT, age-adjusted, day 0<br> <b>Methotrexate</b> 8, 10, <b>OR</b> 12 mg IT, age-adjusted, days 7, 28', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (323, '', 'Nelarabine', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Nelarabine</b>', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline; 2011.$', null, '<b>Nelarabine</b> 650 mg/m<sup>2</sup>/d IV, over 1 hour for 5 consecutive days<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (324, 'Dexamethasone : various<br>Vincristine : Oncovin, VCR', 'OD', '<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', '<b>OD</b>', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', null, '<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Methotrexate</b> 8-12 mg IT, age-adjusted dosing schedule', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (325, '', 'PVDA', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>PVDA</b>', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', null, '<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Daunorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Asparaginase</b> 5,000 units/m<sup>2</sup>/d IM, days 2, 5, 8, 12, 15, 19', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (326, 'Cytarabine : Ara-C<br>Hydrocortisone : various', 'TIT (CNS Prophylaxis)', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>TIT (CNS Prophylaxis)</b>', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', null, '<u>Regimen <%0B>Age 1y <%0B>Age 2y <%0B>Age>=3y</u><br> <b>Methotrexate</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Cytarabine</b> <%0B>20 mg <%0B>25 mg <%0B>30 mg<br> <b>Hydrocortisone</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Administer</b> IT on day 1, then at weeks 1, 2, 3, 6, 11, 16, 21, 26, 31, then every 12 weeks', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (327, '', 'IDMTX', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul>', 'Week 1, high; week 2, minimal', '<b>IDMTX</b>', 'Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 2000;18(6):1285-1294.$', null, '<u>WEEK 1</u><br> <b>Methotrexate</b> 1,000 mg/m<sup>2</sup> IV over 24 hours<br> <b>FOLLOWED BY</b><br> <b>Mercaptopurine</b> 1,000 mg/m<sup>2</sup> IV over 6 hours<br> <b>THEN</b> (48 hours after the start of Methotrexate)<br> <b>Leucovorin calcium</b> 5 mg/m<sup>2</sup> IV every 6 hours for at least 5 doses<br> <u>WEEK 2</u><br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> IM, day 1<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, days 1-7<br> Repeat 2-week cycle times 12', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (332, 'Cytarabine : Ara-C<br>Thioguanine : 6-TG', 'DAT', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', '<b>DAT</b>', 'Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 1991;9(4):572-580.$', null, '<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d IV, days 1-7<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d PO, days 1-7', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (333, 'Cytarabine : Ara-C<br>Dexamethasone : various<br>Etoposide : VP-16<br>Thioguanine : 6-TG', 'DCTER', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Moderate', '<b>DCTER</b>', 'Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children''s Cancer Group. $Blood. 1996;87(12):4979-4989.$', null, '<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d (if age < 3 yeras 0.2mg/kg/d) PO tid, days 0-4<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup>/d (if age < 3 yeras 6.7 mg/kg/d) CIVI, days 0-4<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) PO bid, days 0-4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) CIVI, days 0-4<br> <b>Daunorubicin</b> 20 mg/m<sup>2</sup>/d (if age < 3 yeras 0.67 mg/kg/d) CIVI, days 0-4<br> <b>Cytarabine</b> IT (age-based doses)<br> Doses in parentheses used for children <3 years of age', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (334, 'Azacitidine : Vidaza<br>Cytarabine : Ara-C<br>Etoposide : VP-16', 'HI-C DAZE', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'High', '<b>HI-C DAZE</b>', 'Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. $J Pediatr Hematol Oncol. 1995;17(3):185-197.$', null, '<b>Daunorubicin</b> 30 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup>/d IV every 12 hours, days 1-4<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 1-3, 6-8<br> <b>Azacitidine</b> 150 mg/m<sup>2</sup>/d IV, days 3-5, 8-10', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (335, '', 'MACE/consolidation', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>MACE/consolidation</b>', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', null, '<b>Amsacrine</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup> CIVI, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (336, '', 'MidAC', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Moderate', '<b>MidAC</b>', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', null, '<b>Mitoxantrone</b> 10 mg/m<sup>2</sup> IV (short infusion), days 1-5<br> <b>Cytarabine</b> 1,000 mg/m<sup>2</sup> IV (2-hour infusion), every 12 hours, days 1-3', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (337, 'Opdivo', 'Nivolumab', '', 'Minimal', '<b>Nivolumab</b>', 'Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. $Lancet Oncol. 2015 Mar;16(3):257-65.$', null, '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (338, 'Docetaxel:Taxotere<br> Ramicurimab:Cyramza', 'Docetaxel/Ramucirumab', '', 'Moderate', '<b>Docetaxel/Ramucirumab</b>', 'Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. $Lancet. 2014 Aug 23;384(9944):665-73.$', null, '<b>Docetaxel</b>75 mg/m <sup>2</sup>IV<br> Repeat Every 21 Days<br> <b>Ramucirumab</b> 10 mg/kg IV  <br> Repeat Every 21 days<br>Until disease pogression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (339, 'Alecensa', 'Alectinib', '', 'Minimal', '<b>Alectinib</b>', 'Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study. $ J Clin Oncol. 2015 Nov 23. pii: JCO639443. $', null, '<b>Alectinib</b> 600 mg PO BID<br>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (340, 'Zykadia', 'Ceritinib', '', 'Minimal', '<b>Ceritinib</b>', 'Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. $N Engl J Med. 2014 Mar 27;370(13):1189-97.$', null, '<b>Ceritinib</b> 750 mg  PO daily<br> ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (341, 'Necitumumab:Portrazza<br> Gemcitabine:Gemzar<br> Cisplatin<br>Various', 'Necitumumab/Gemcitabine/Cisplatin', '', 'Severe', '<b>Necitumumab<br>Gemcitabine<br>Cisplatin</b>', 'Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial. $Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.$', null, '<b>Necitumumab</b> 800 mg IV Day 1 and 8<br><b>Gemcitabine</b>1250 mg/m <sup>2</sup> IV<br><b>Cisplatin</b> 75 mg/m<sup>2</sup>IV<br>Repeat every 21 days<br>Continue Necitumumab until disease progression or intolerable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (348, 'Adcetris', 'Brentuximab Vedotin', '', 'Minimal', '<b>Brentuximab Vedotin</b>', 'Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin''s lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial. $Lancet. 2015 May 9;385(9980):1853-62. $', null, '<b>Bretuximab Vedotin</b> 1.8 mg/ kg<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (349, 'Idelalisib:Zydelig<br> Rituximab:Rituxan', 'Idelalisib/Rituximab', '', 'Minimal', '<b>Idelalisib/Rituximab</b>', 'Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. $N Engl J Med. 2014 Mar 13;370(11):997-1007.$', null, '<b>Idelalisib</b> 150 mg  po BID <br> Rituximab 375 mg/m<sup>2</sup> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (350, 'Imbruvica', 'Ibrutinib', '', 'Minimal', '<b>Ibrutinib</b>', 'Byrd JC, Brown JR, O''brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.$N Engl J Med. 2014 Jul 17;371(3):213-23.$', null, '<b>Ibrutinib</b> 420 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (351, 'Ofatumumab:Arzerra<br> Chlorambucil:Various', 'Ofatumumab/Chlorambucil', '', 'Minimal', '<b>Ofatumumab<br>Chlorambucil</b>', 'Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial. $Lancet. 2015 May 9;385(9980):1873-83. $', null, '<b>Ofatumumab</b> 300mg IV on Day 1 and 1000 mg on day 8, Cycle 1. Subsequent cycles 1000 mg IV on Day 1 only <br><b>Chlorambucil</b> PO 10 mg/m<sup>2</sup>, day 1 to 7. Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (352, 'Blincyto', 'Blinatumomab', '', 'Minimal', '<b>Blinatumomab</b>', '', null, '<b>Blinatumomab</b> 9  mcg/day on days 1-7, 28 mcg/day on days 8-28 of the first 42 day cycle<br>28 mcg/day on day1-28 in later cycles', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (353, 'Ixazomib:Ninlaro<br> Lenalidamide:Revlimid<br> Dexamethasone:Decadron', 'Ixazomib/Lenolidamide/Dexamethasone', '', 'Moderate', '<b>Ixazomib/Lenolidamide/Dexamethasone</b>', 'Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma . $Lancet Oncol. 2014 Dec;15(13):1503-12. $', null, '<b>Ixazomib</b> 4 mg PO  on days 1,8,15<br> <br> <b>Lenalidomide</b> 25mg PO on day 1 thru 21<br> <b>Dexamethasone</b> 40 mg PO, days 1,8,15,22<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (354, 'Darzalex', 'Daratumumab', '', 'Minimal ', '<b>Daratumumab</b>', 'Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. $N Engl J Med. 2015 Sep 24;373(13):1207-19.$', null, '<b>Daratumumab</b> 16 mg/kg  every 7 days x 8 weeks <br> every 14 days x 16 weeks<br>then every 4 weeks until disease progression', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (355, 'Opdivo', 'Nivolumab', '', 'Minimal', '<b>Nivolumab</b>', 'Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. $N Engl J Med. 2015 Nov 5;373(19):1803-13. $', null, '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (356, 'Inlyta', 'Axitinib', '', 'Minimal', '<b>Axitinib</b>', 'Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. $Lancet Oncol. 2013 May;14(6):552-62. $', null, '<b>Axitinib <br>5 mg po BID', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (357, 'Zelboraf', 'Vemurafinib', '', 'Minimal', '<b>Vemurafinib</b>', 'Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib. $N Engl J Med. 2012 Feb 23; 366(8): 707–714 .$', null, '<b>Vemurafenib</b> 960 mg po BID', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (358, 'Yervoy', 'Ipilumimab', '', 'Minimal', '<b>Ipilumimab</b>', 'Hodi FS, O''Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma. $N Engl J Med 2010; 363:711-723. $', null, '<b>Ipilumimab</b>  IV 3 mg/kg  every 3 weks upto 4 doses', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (359, 'Ipilumimab:Yeroy<br> Nivolumab:Opdivo', 'Ipilumimab/Nivolumab', '', 'Minimal', '<b>Ipilumimab/Nivolumab</b>', 'Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma. $N Engl J Med. 2015 May 21;372(21):2006-17. $', null, '<b>Ipilumimab</b> 3mg/kg  IV <br> Nivolumab </b> 1 mg/kg IV<br> every 3 weeks  x 4 cycles <br> followed by Nivolumab 3 mg/kg  every 3 weeks until disease progression on unaccceptable toxicity', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (360, 'Dabrafenib:Tafilnar<br> Trametinib:Mekinist', 'Dabrafenib/Trametinib', '', 'Minimal', '<b>Dabrafenib/Trametinib</b>', 'Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib. $ N Engl J Med. 2015 Jan 1;372(1):30-9.$', null, '<bDabrafenibt</b> 150 mg PO  BID <br> Trametinib</b>2 mg once daily ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (361, 'Cotellic', 'Cobimetinib/Vemurafenib', '', 'Minimal', '<b>Cobimetinib/Vemurafenib</b>', 'Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma. $N Engl J Med. 2014 Nov 13;371(20):1867-76. $', null, '<b>Cobimetinib</b> 60 mg once daily<br>Vemurafenib</b>960 mg twice a day from day1-21, on a 28 day cycle ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (362, 'Keytruda', 'Pembrolizumab', '', 'Minimal', '<b>Pembrolizumab</b>', 'Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma. $N Engl J Med 2015; 372:2521-2532. $', null, '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (363, 'Elotuzumab:Empliciti<br> Lenalidomide:Revlimid<br> Dexamethasone:Decadron, various', 'Elotuzumab/Lenalidomide/Dexamethasone', '', 'Minimal', '<b>Elotuzumab<br>Lenalidomide<br>Dexamethasone</b>', 'Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma .$ N Engl J Med. 2015 Aug 13;373(7):621-31. $', null, '<b>Elotuzumab</b> 10 mg/Kg IV  Weekly x2 and then Every 2 weeks<br> <b>Lenalidomide</b> 25 mg po daily  from day 1-21 (3 weeks)<br> <b>Dexamethasone </b> 8 mg IV prior to Elotuzumab infusion and then 28 mg orally, In weeks without Elotuzumab  40 mg PO every week', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (364, 'Lonsurf', 'Trifluridine/Tipiracil', '', 'Minimal', '<b>Trifluridine/Tipiracil</b>', 'Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.$ N Engl J Med. 2015 May 14;372(20):1909-19..$Lancet Oncol. 2014 Oct;15(11):1195-206. $', null, '<b>Trifluridine/Tipiracil</b>  35  mg/m<sup>2</sup>  PO twice daily days 1 through 5 and 8 through 12<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (365, 'Ramucirumab:Cyramza', 'Ramicirumab/FOLFIRI', '', 'Moderate', '<b>Ramicirumab/FOLFIRI</b>', 'Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. $ Lancet Oncol. 2015 May;16(5):499-508. $', null, '<b>Ramicirumab</b> 8 mg/kg IV <br> <b>Irinotecan  </b> 180 mg/m<sup>2</sup>  over 90 minutes <br> <b>Leucovorin</b> Calcium 400 mg/m<sup>2</sup> IV<br>FOLLOWED BY<br><b>Fluorouracil</b> 400 mg<sup>2</sup> IV<br> <b>Fluorouracil</b> 2,400 mg<sup>2</sup>  CIVI over 46 hours<br>Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (716, '', 'Capecitabine', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>May decrease dose to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy.</p>

<p>Repeat cycle every 21 days.</p>

<p>&nbsp;</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (366, 'Ramucirumab:Cyramza<br> Paclitaxel:Taxol', 'Ramucirumab/Paclitaxel', '', 'Moderate', '<b>Ramucirumab/Paclitaxel</b>', 'Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial. $Lancet Oncol. 2014 Oct;15(11):1224-35. $', null, '<b>Ramucirumab</b> 8 mg/kg IV  on days 1 and 15<br>  <b>Paclitaxel</b> 80 mg/m<sup>2</sup>  IV on days 1, 8, 15<br>Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (367, 'Cyramza', 'Ramucirumab', '', 'Minimal', '<b>Ramucirumab</b>', 'Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. $ Lancet. 2014 Jan 4;383(9911):31-9. $', null, '<b>Ramucirumab</b> 8 mg/kg IV  every 2 weeks<br>  ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (368, 'Liposomal Irinotecan:Onivyde', 'Irinotecan liposome/Fluorouracil/Leucovorin', '', 'Moderate', '<b>Irinotecan liposome<br>Fluorouracil<br>Leucovorin</b>', 'Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial. $ Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1. $', null, '<b>Irinotecan liposome</b> 70 mg/m<sup>2</sup> IV <br> <b>Fluorouracil</b> 2400 mg/m<sup>2</sup>  IV over 46 hours<br> <b>Leucovorin</b> 400mg/m<sup>2</sup> IV <br> Repeat every 14 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (369, 'nab-paclitaxel:Abraxane<br> Gemcitabine:Gemzar', 'nab-Paclitaxel/Gemcitabine', '', 'Moderate', '<b>nab-Paclitaxel/Gemcitabine</b>', 'Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. $ N Engl J Med. 2013 Oct 31;369(18):1691-703. $', null, '<b>nab-Paclitaxel</b> 125 mg/m<sup>2</sup> IV<br> <br> <b>Gemcitabine</b>  1000 mg/m<sup>2</sup>  days 1, 8, 15<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (370, 'Pablociclib:Ibrance<br> Letrozole:Femara', 'Pablociclib/Letrozole', '', 'Minimal', '<b>Pablociclib/Letrozole</b>', 'Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study. $Lancet Oncol. 2015 Jan;16(1):25-35. $', null, '<b>Pablociclib</b>125 mg PO  on days 1 through 21<br>  <b>Letrozole</b> 2.5 mg PO daily<br> Repeat every 28 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (371, 'Everolimus:Afinitor<br> Exemestane:Aromasin', 'Everolimus/Exemestane', '', 'Minimal', '<b>Everolimus/Exemestane</b>', 'Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2. $ Breast Cancer Res Treat. 2014 Feb;143(3):459-67. $', null, '<b>Everolimus</b> 10 mg PO daily <br>  <b>Exemestane</b> 25 mg PO daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (372, 'Pertuzumab:Perjeta<br> Trastuzumab:Herceptin<br> Docetaxel:Taxotere', 'Pertuzumab/Trastuzumab/Docetaxel', '', 'Moderate', '<b>Pertuzumab/Trastuzumab/Docetaxel</b>', 'Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. $ N Engl J Med. 2012 Jan 12;366(2):109-19. S', null, '<b>Pertuzuamb</b>840  mg IV loading dose followed by 420 mg <br><b>Docetaxel</b> 75 mg/m<sup>2</sup> IV<br> <b>Trastuzumab</b> 8 mg/kg loading dose followed by 6 mg/kg<br> Repeat every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (373, 'Kadcyla', 'ado-trastuzumab', '', 'Minimal', '<b>ado-trastuzumab</b>', 'Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. $ N Engl J Med. 2012 Nov 8;367(19):1783-91. $', null, '<b>ado-trastuzumab</b>3.6 mg/kg IV every 21 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (374, 'Bosulif', 'Bosutinib', '', 'Minimal', '<b>Bosutinib</b>', 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.$ J Clin Oncol.2012  October 30;(28):3486-3492. $', null, '<b>Bosutinib</b> 500 mg po daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (375, 'Iclusig', 'Ponatinib', '', 'Minimal', '<b>Ponatinib</b>', 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.$N Engl J Med.2013 Nov 7;369(19):1783-96. $', null, '<b>Ponatinib</b> 45 mg po daily', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (376, 'Synribo', 'Omacetaxine', '', 'Minimal', '<b>Omacetaxine</b>', 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.$Blood.2012 Sep;120(13):2573-2580.$', null, '<b>Omacetaxine</b> 1.25 mg<sup>2</sup>  SQ twice daily for 14 days on a 28 day cycle (Induction)<br>1.25 mg<sup>2</sup>  SQ twice daily for 7 days on a 28 day cycle (maintenance)', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (377, 'Obinutuzumab : Gazyva', 'Obinutuzumab/Chlorambucil', '', 'Minimal', '<b>Obinutuzumab/Chlorambucil</b>', 'Goede V, et. al. Obinutuzumab plus chlorambulcil in patients with CLL and coexisting conditions. $N Engl J Med. 2014 Mar 20;370(12):1101-10.$', null, '<b>Obinutuzumab/Chlorambucil</b><br><b>Cycle 1:</b><br>100 mg IV on day 1 and 900 mg IV on day 2, 1,000 mg on day 8 and 15<br><b>Cycle 2-6:</b><br>1,000 mg IV on day 1<br><b>Chlorambucil</b><br>0.5 mg/kg on Day 1 and 15 of each cycle', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (602, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX6)', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2&nbsp;</sup>IV continuous infusion for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (379, 'Gemcitabine (Gemzar), CIsplatin (Platinum) ', 'Gemcitabine and Cisplatin (split dosing)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Each cycle should not begin until the WBC is &ge;3000/microL and platelet count is &ge;100,000/microL.Gemcitabine should be withheld on day 8 and/or day 15 of the scheduled treatment if the WBC is &lt;2000/microL or the platelet count is &lt;50,000/microL.&nbsp;If the day 8 or 15 dose of gemcitabine is omitted, the treatment cycle may be shortened to 21 days.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Neurologic toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Nephrotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'severe', '', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7.', 'NEOADJUVANT', '<h4>Chemotherapy</h4>

<ul>
	<li>Cisplatin (Platinol)&nbsp;35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>
	<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>
</ul>

<p><strong>21-day cycle for 4 cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (381, 'Atezolizumab (Tecentriq)', 'Atezolizumab monotherapy', '<p>none</p>
', 'none', '', 'Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8.', 'METASTATIC', '<h4>Immunotherapy</h4>

<ul>
	<li>Atezolizumab (Tecentriq)&nbsp;1200 mg IV once on day 1</li>
</ul>

<p><strong>21-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (633, '', 'Binimetinib + Encorafenib + Cetuximab (BEC)', '', '', '', '', 'METASTATIC', '<p><strong>Binimetinib:&nbsp;</strong>45 mg PO twice daily</p>

<p><strong>Encorafenib:&nbsp;</strong>300 mg PO daily</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Continue treatment until disease progression. Use only for patients with&nbsp;<em>BRAF</em> V600E-mutant mCRC.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (378, 'Methotrexate (Otrexup; Rasuvo; Rheumatrex [DSC]; Trexall; Xatmep). Vinblastine (Vinblastine), Doxorubicin (Adriamycin), (Cisplatin (Platinum)', 'dose-dense MVAC (DDMVAC)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Delay treatment cycle until the WBC count is &gt;3000/mm<sup>3</sup>&nbsp;and platelet count is &gt;90,000 mm<sup>3</sup>. Methotrexate and doxorubicin doses should be reduced by 33% in patients who have a nadir WBC &lt;2000/mm<sup>3</sup>.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Neurologic toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Cisplatin therapy should be discontinued when neurologic symptoms are first observed.&nbsp;The manufacturer recommends a dose reduction of vinblastine by 1 mg/m<sup>2</sup>&nbsp;in patients with severe neurotoxicity.</li>
				<li>For severe paresthesias and/or constipation, the dose of vinblastine should be reduced by 50%.&nbsp;Vinblastine should be discontinued permanently if an adynamic ileus occurs.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Mucositis</strong></td>
			<td colspan="3">
			<ul>
				<li>Doses of methotrexate should be reduced by 33% in patients who develop grade 3 or grade 4 mucositis.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Cardiotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Discontinue doxorubicin in patients who develop signs/symptoms of cardiomyopathy.</li>
				<li>Monitor cumulative doxorubicin dose and reassess LVEF periodically during MVAC therapy as clinically indicated.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Renal dysfunction</strong></td>
			<td colspan="3">
			<ul>
				<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL or CrCl &gt;55 mL/min and/or BUN &lt;25 mg/dL.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'severe', '', 'Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12.', 'NEOADJUVANT', '<p>Variant 1: -- 3 or 4 cycles&nbsp;</p>

<h4>Chemotherapy</h4>

<ul>
	<li>Methotrexate (MTX)&nbsp;30 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1</li>
	<li>Vinblastine (Velban)&nbsp;3 mg/m<sup>2</sup>&nbsp;IV push once on day 2</li>
	<li>Doxorubicin (Adriamycin)&nbsp;30 mg/m<sup>2</sup>&nbsp;IV push once on day 2</li>
	<li>Cisplatin (Platinol)&nbsp;70 mg/m<sup>2</sup>&nbsp;IV in 1 liter normal saline once on day 2
	<ul>
		<li>Split dose could be used at physician discretion for patients with CrCl less than 60 mL/min/1.73m<sup>2</sup>: 35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 2</li>
	</ul>
	</li>
</ul>

<h4>Supportive medications</h4>

<ul>
	<li>Pegfilgrastim (Neulasta)&nbsp;6 mg SC once, 24 to 48 hours after completion of chemotherapy</li>
	<li>Antiemetics used often included&nbsp;Aprepitant (Emend),&nbsp;Ondansetron (Zofran), and&nbsp;Dexamethasone (Decadron)&nbsp;but were not specified by the trial.</li>
</ul>

<p><strong>14-day cycle for 3 or 4&nbsp;cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (380, 'Gemcitabine (Gemzar), Cisplatin (Platinum) ', 'Gemcitabine and Cisplatin (single-dose cisplatin)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Each cycle should not begin until the WBC is &ge;3000/microL and platelet count is &ge;100,000/microL.Gemcitabine should be withheld on day 8 and/or day 15 of the scheduled treatment if the WBC is &lt;2000/microL or the platelet count is &lt;50,000/microL.&nbsp;If the day 8 or 15 dose of gemcitabine is omitted, the treatment cycle may be shortened to 21 days.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Neurologic toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Nephrotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'severe', '', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7', 'NEOADJUVANT', '<h4>Chemotherapy</h4>

<ul>
	<li>Cisplatin (Platinol)&nbsp;35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>
	<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>
</ul>

<p><strong>21-day cycle for 4 cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (382, 'Pembrolizumab (Keytruda)', 'Pembrolizumab monotherapy', '', 'none', '', 'KEYNOTE-052: Balar AV, Castellano D, O''Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26.', 'METASTATIC', '<h4>Immunotherapy</h4>

<ul>
	<li>Pembrolizumab (Keytruda)&nbsp;200 mg IV once on day 1</li>
</ul>

<p><strong>21-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (383, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', 'Gemcitabine and Paclitaxel (14 day cycle)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li><strong>Do not administer</strong>&nbsp;paclitaxel and gemcitabine on day 1 of each new cycle unless ANC is &gt;1500/microL and platelet count is &gt;100,000/microL.&nbsp;For patients who develop neutropenic fever OR ANC &lt;500/microL for &gt;7 days or delay of next cycle by &gt;7 days or thrombocytopenia, withhold treatment until counts recover to an ANC of at least 1500/microL and platelet count of at least 100,000/microL on day 1, or to an ANC of at least 500/microL and platelet count of at least 50,000/microL on days 8 or 15 of the cycle.&nbsp;Upon resumption of therapy, reduce both drugs by 20 to 25% upon the first occurrence, an additional 20 to 25% on the second recurrence, and discontinue treatment for a third occurrence.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Sepsis</strong></td>
			<td colspan="3">
			<ul>
				<li>Sepsis has occurred in patients with or without neutropenia (risk factors are biliary obstruction or presence of a biliary stent). Initiate broad-spectrum antibiotics in the presence of fever, even if not neutropenic. Interrupt paclitaxel and gemcitabine until sepsis resolves and, if neutropenic, until neutrophils are at least 1500/microL, then resume at lower doses.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA; also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Peripheral neuropathy</strong></td>
			<td colspan="3">
			<ul>
				<li>For days 1,8, and 15: withhold paclitaxel for grade&nbsp;3 or 4 neuropathy.<span style="font-size:13.3333px"> </span>Resume paclitaxel at 20 to 25 percent reduced doses when peripheral neuropathy improves to grade&nbsp;&le;2 or completely resolves .&nbsp;Upon resumption of therapy, reduce paclitaxel by 20 to 25% for the first occurrence of grade 3 or 4 peripheral neuropathy, and an additional 20 to 25% for the second occurrence<sup>.&nbsp;</sup>Discontinue treatment for a third occurrence.&nbsp;For grade 2 peripheral neuropathy, decrease paclitaxel dose by 20 to 25%.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear gemcitabine dose recommendations in these patients.</li>
				<li>Reduced starting doses of paclitaxel are recommended for individuals with pre-existing moderate to severe hepatic impairment; the need for further dose adjustments in subsequent courses based upon ongoing hepatotoxicity should be based on individual tolerance and clinician judgment.</li>
				<li>One protocol recommends the following:&nbsp;on days 1, 8, and 15, for serum bilirubin elevations &ge;grade 2, withhold both drugs until toxicity resolves to grade &le;1; resume treatment at the same dose as before. If not resolved, discontinue therapy.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Pneumonitis has occurred with the use of paclitaxel in combination with gemcitabine. Permanently discontinue treatment with both agents.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Other toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>On days 1, 8, and 15: for grade 3 cutaneous toxicity, hold both drugs until recovered to &le;grade 2, and reduce paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.<span style="font-size:13.3333px"> </span>For grade 3 mucositis or diarrhea, withhold therapy until it&nbsp;improves to &le;grade 1, then resume with reduction of paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'moderate', '', 'Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Gemcitabine (Gemzar)&nbsp;2500 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1,&nbsp;<strong>given second</strong></li>
	<li>Paclitaxel (Taxol)&nbsp;150 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1,&nbsp;<strong>given first</strong></li>
</ul>

<p><strong>14-day cycle for 6 to 12 cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (384, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', 'Gemcitabine and Paclitaxel (21 day cycle)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li><strong>Do not administer</strong>&nbsp;paclitaxel and gemcitabine on day 1 of each new cycle unless ANC is &gt;1500/microL and platelet count is &gt;100,000/microL.&nbsp;For patients who develop neutropenic fever OR ANC &lt;500/microL for &gt;7 days or delay of next cycle by &gt;7 days or thrombocytopenia, withhold treatment until counts recover to an ANC of at least 1500/microL and platelet count of at least 100,000/microL on day 1, or to an ANC of at least 500/microL and platelet count of at least 50,000/microL on days 8 or 15 of the cycle.&nbsp;Upon resumption of therapy, reduce both drugs by 20 to 25% upon the first occurrence, an additional 20 to 25% on the second recurrence, and discontinue treatment for a third occurrence.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Sepsis</strong></td>
			<td colspan="3">
			<ul>
				<li>Sepsis has occurred in patients with or without neutropenia (risk factors are biliary obstruction or presence of a biliary stent). Initiate broad-spectrum antibiotics in the presence of fever, even if not neutropenic. Interrupt paclitaxel and gemcitabine until sepsis resolves and, if neutropenic, until neutrophils are at least 1500/microL, then resume at lower doses.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA; also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Peripheral neuropathy</strong></td>
			<td colspan="3">
			<ul>
				<li>For days 1,8, and 15: withhold paclitaxel for grade&nbsp;3 or 4 neuropathy.<span style="font-size:13.3333px"> </span>Resume paclitaxel at 20 to 25 percent reduced doses when peripheral neuropathy improves to grade&nbsp;&le;2 or completely resolves .&nbsp;Upon resumption of therapy, reduce paclitaxel by 20 to 25% for the first occurrence of grade 3 or 4 peripheral neuropathy, and an additional 20 to 25% for the second occurrence<sup>.&nbsp;</sup>Discontinue treatment for a third occurrence.&nbsp;For grade 2 peripheral neuropathy, decrease paclitaxel dose by 20 to 25%.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear gemcitabine dose recommendations in these patients.</li>
				<li>Reduced starting doses of paclitaxel are recommended for individuals with pre-existing moderate to severe hepatic impairment; the need for further dose adjustments in subsequent courses based upon ongoing hepatotoxicity should be based on individual tolerance and clinician judgment.</li>
				<li>One protocol recommends the following:&nbsp;on days 1, 8, and 15, for serum bilirubin elevations &ge;grade 2, withhold both drugs until toxicity resolves to grade &le;1; resume treatment at the same dose as before. If not resolved, discontinue therapy.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Pneumonitis has occurred with the use of paclitaxel in combination with gemcitabine. Permanently discontinue treatment with both agents.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Other toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>On days 1, 8, and 15: for grade 3 cutaneous toxicity, hold both drugs until recovered to &le;grade 2, and reduce paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.<span style="font-size:13.3333px"> </span>For grade 3 mucositis or diarrhea, withhold therapy until it&nbsp;improves to &le;grade 1, then resume with reduction of paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'moderate', '', 'Meluch AA, Greco FA, Burris HA 3rd, O''Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24.', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15</li>
	<li>Paclitaxel (Taxol)&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</li>
</ul>

<p><strong>21-day cycle for up to 6 cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (385, 'Nivolumab (Opdivo)', 'Nivolumab monotherapy', '<p>none</p>
', 'none', '', 'CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25.', 'METASTATIC', '<h4>Immunotherapy</h4>

<ul>
	<li>Nivolumab (Opdivo)&nbsp;3 mg/kg IV once on day 1
	<ul>
		<li><em>The FDA-approved dose which is listed in the package insert is 240 mg IV over 60 minutes once on day 1</em></li>
	</ul>
	</li>
</ul>

<p><strong>14-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (386, 'Paclitaxel (Taxol)', 'Paclitaxel monotherapy (21 day cycle)', '<table border="1" cellpadding="1" cellspacing="1" style="width:100%">
	<tbody>
		<tr>
			<td style="text-align:center">Hepatic Impairment</td>
			<td>
			<p>Transaminases &lt;10 times ULN and bilirubin level &le;1.25 times ULN: 175 mg/m<sup>2</sup></p>

			<p>Transaminases &lt;10 times ULN and bilirubin level 1.26 to 2 times ULN: 135 mg/m<sup>2</sup></p>

			<p>Transaminases &lt;10 times ULN and bilirubin level 2.01 to 5 times ULN: 90 mg/m<sup>2</sup></p>

			<p>Transaminases &ge;10 times ULN or bilirubin level &gt;5 times ULN: Avoid use</p>
			</td>
		</tr>
		<tr>
			<td style="text-align:center">Renal Impairement</td>
			<td style="text-align:center">none</td>
		</tr>
		<tr>
			<td style="text-align:center">Myelosuppression</td>
			<td>Courses of paclitaxel should not be repeated until the neutrophil count is &ge;1,500/mm<sup>3</sup>&nbsp;and the platelet count is &ge;100,000/mm<sup>3</sup>; reduce dosage by 20% for patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500/mm<sup>3</sup>&nbsp;for a week or longer)</td>
		</tr>
	</tbody>
</table>

<p>&nbsp;</p>

<p>&nbsp;</p>
', 'moderate', '', 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17', 'METASTATIC', '<p>&nbsp;</p>

<h4>Chemotherapy</h4>

<ul>
	<li>Paclitaxel (Taxol)&nbsp;175 mg/m<sup>2</sup>&nbsp;IV once on day 1</li>
</ul>

<p><strong>21-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (392, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', 'Carboplatin Gemcitabine (AUC 5/1250)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Chemotherapy should be delayed for one week if the ANC is &lt;1000/microL and/or the platelet count is &lt;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &lt;500/microL. A 50% dose reduction should be considered if the platelet nadir is &lt;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>
				<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Other nonhematologic toxicity<sup>&sect;</sup></strong></td>
			<td colspan="3">
			<ul>
				<li>Creatinine clearance should be &ge;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>
				<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'moderate', '', 'Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Carboplatin (Paraplatin)&nbsp;AUC 5 IV over 30 to 60 minutes once on day 2</li>
	<li>Gemcitabine (Gemzar)&nbsp;1250 mg/m<sup>2</sup>&nbsp;IV over 30 to 60 minutes once per day on days 1 &amp; 8</li>
</ul>

<p><strong>21-day cycle for up to 6 cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (634, '', 'Nivolumab + Ipilimumab', '', '', '', '', 'METASTATIC', '<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p>

<p><strong>Ipilimumab:&nbsp;</strong>1 mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days for 4 cycles and then treat with nivolumab at 3 mg/kg or 240 mg IV every 14 days until disease progression or toxicity.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (387, 'Docetaxel (Taxotere)', '', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Docetaxel should only be administered if the absolute neutrophil count is &gt;1500 cells/microL. Reduce docetaxel to 60 mg/m<sup>2</sup>&nbsp;for subsequent cycles for severe prolonged neutropenia (&lt;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &gt;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>&nbsp;Discontinue docetaxel if toxicity persists at the lower dose.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Hepatotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5 times the ULN.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'low', '', 'McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Docetaxel (Taxotere)&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</li>
</ul>

<p><strong>21-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (388, 'Durvalumab (Imfinzi)', 'Durvalumab Monotherapy', '<p>none</p>
', 'low', '', 'Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O''Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6.', 'METASTATIC', '<h4>Immunotherapy</h4>

<ul>
	<li>Durvalumab (Imfinzi)&nbsp;10 mg/kg IV over 60 minutes once on day 1</li>
</ul>

<p><strong>14-day cycle for up to 26 cycles (1 year)</strong>. Patients could receive another 12 months of treatment if they experienced disease progression, had not received other anticancer treatment, and did not meet criteria for discontinuation.</p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (389, 'Avelumab (Bavencio) ', 'Avelumab Monotherapy', '<p>none</p>
', 'low', '', 'Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.', 'METASTATIC', '<h4>Immunotherapy</h4>

<ul>
	<li>Avelumab (Bavencio)&nbsp;10 mg/kg IV over 60 minutes once on day 1</li>
</ul>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (390, 'Erdafitinib (Balversa)', 'Erdafitinib monotherapy', '<table border="1" cellpadding="1" cellspacing="1" style="width:100%">
	<tbody>
		<tr>
			<td>Renal Impairement</td>
			<td>none</td>
		</tr>
		<tr>
			<td>Hepatic Impairement</td>
			<td>none</td>
		</tr>
	</tbody>
</table>

<p><strong>Dose at the time of toxicity: 8 mg once daily.</strong></p>

<p>First dose reduction level: 6 mg once daily.</p>

<p>Second dose reduction level: 5 mg once daily.</p>

<p>Third dose reduction level: 4 mg once daily.</p>

<p>Discontinue if unable to tolerate 4 mg once daily.</p>

<p>&nbsp;</p>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%">
	<tbody>
		<tr>
			<td><em>Hyperphosphatemia:</em>&nbsp;<strong>Note:&nbsp;</strong>Restrict phosphate intake to 600 to 800 mg daily; if serum phosphate is &gt;7 mg/dL, consider initiating an oral phosphate binder until phosphate level is &lt;5.5 mg/dL.</td>
			<td>
			<p>Phosphate level 5.6 to 6.9 mg/dL: Continue erdafitinib at current dose.</p>

			<p>Phosphate level 7 to 9 mg/dL: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), reinitiate erdafitinib at the same dose. If hyperphosphatemia persisted for &gt;1 week, consider dose reduction.</p>

			<p>Phosphate level &gt;9 mg/dL: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), may reinitiate erdafitinib at the next lower dose level.</p>

			<p>Phosphate level &gt;10 mg/dL, or significant alteration in baseline renal function, or grade 3 hypercalcemia: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), may reinitiate erdafitinib at 2 dose levels lower.</p>
			</td>
		</tr>
		<tr>
			<td><em>Ocular toxicity (central serous retinopathy/retinal pigment epithelial detachment)</em></td>
			<td>
			<p>Grade 1 (asymptomatic; clinical or diagnostic observations only): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, reinitiate erdafitinib at the next lower dose level. If no recurrence for one month, may consider re-escalating the dose. If central serous retinopathy/retinal pigment epithelial detachment is stable for 2 consecutive eye exams (but not resolved), reinitiate erdafitinib at the next lower dose level.</p>

			<p>Grade 2 (visual acuity &ge;20/40 or &le;3 lines of decreased vision from baseline): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, may reinitiate erdafitinib at the next lower dose level.</p>

			<p>Grade 3 (visual acuity &lt;20/40 or &gt;3 lines of decreased vision from baseline): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, may reinitiate erdafitinib at 2 dose levels lower. If grade 3 toxicity recurs, consider permanent discontinuation.</p>

			<p>Grade 4 (visual acuity &le;20/200 in affected eye): Permanently discontinue erdafitinib.</p>

			<p>Dry eye symptoms: Administer dry eye prophylaxis (with ocular demulcents) as needed.</p>
			</td>
		</tr>
		<tr>
			<td><em>Other toxicity:</em></td>
			<td>
			<p>Grade 3: Interrupt erdafitinib therapy until improvement to grade 1 or baseline, then may reinitiate at the next lower dose level.</p>

			<p>Grade 4: Permanently discontinue erdafitinib.</p>
			</td>
		</tr>
	</tbody>
</table>

<p>&nbsp;</p>
', 'low', '', 'BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O''Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348.', 'METASTATIC', '<h4>Biomarker eligibility criteria</h4>

<ul>
	<li>Alterations: FGFR3 mutation, FGFR2 fusion, or FGFR3 fusion</li>
</ul>

<h4>Chemotherapy</h4>

<ul>
	<li>Erdafitinib (Balversa)&nbsp;8 mg PO once per day
	<ul>
		<li>If serum phosphorus level and tolerability are acceptable at days 14 to 21, increase to 9 mg PO once per day</li>
		<li>Additional dose adjustments per package insert</li>
	</ul>
	</li>
</ul>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (391, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', 'Carboplatin Gemcitabine (AUC4.5/1000)', '<table cellspacing="0">
	<tbody>
		<tr>
			<td><strong>Myelotoxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>Chemotherapy should be delayed for one week if the ANC is &lt;1000/microL and/or the platelet count is &lt;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &lt;500/microL. A 50% dose reduction should be considered if the platelet nadir is &lt;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>
				<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Thrombotic microangiopathy</strong></td>
			<td colspan="3">
			<ul>
				<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Pulmonary toxicity</strong></td>
			<td colspan="3">
			<ul>
				<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td><strong>Other nonhematologic toxicity<sup>&sect;</sup></strong></td>
			<td colspan="3">
			<ul>
				<li>Creatinine clearance should be &ge;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>
				<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles.</li>
			</ul>
			</td>
		</tr>
	</tbody>
</table>
', 'moderate', '', 'De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009 Nov 20;27(33):5634-9', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Carboplatin (Paraplatin)&nbsp;AUC 4.5 IV over 60 minutes once on day 1,&nbsp;<strong>given second</strong></li>
	<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8,&nbsp;<strong>given first</strong></li>
</ul>

<p><strong>21-day cycles</strong></p>

<p><em>Patients who achieved complete response were given two additional cycles of treatment.</em></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (708, '', 'Gemcitabine + Docetaxel + Capecitabine (GTX)', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;IV over 75 minutes on days 4 and 11</p>

<p><strong>Docetaxel:&nbsp;</strong>30 mg/m<sup>2</sup>&nbsp;IV on days 4 and 11</p>

<p><strong>Capecitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 3 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (393, 'Enfortumab vedotin (Padcev) ', 'Enfortumab vedoitin monotherapy', '<table align="center" border="1" cellpadding="1" cellspacing="1" style="width:100%">
	<tbody>
		<tr>
			<td style="text-align:center">Renal Impairment</td>
			<td style="text-align:center">none</td>
		</tr>
		<tr>
			<td style="text-align:center">Hepatic Impairment</td>
			<td style="text-align:center">none</td>
		</tr>
	</tbody>
</table>

<p>&nbsp;</p>

<table border="1">
	<thead>
		<tr>
			<th colspan="2">
			<p><strong>Recommended Enfortumab Vedotin Dosage Reduction Levels</strong></p>
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td>
			<p>Initial (usual) dose</p>
			</td>
			<td>
			<p>1.25 mg/kg up to a maximum of 125 mg</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>First dose reduction level</p>
			</td>
			<td>
			<p>1 mg/kg up to a maximum of 100 mg</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Second dose reduction level</p>
			</td>
			<td>
			<p>0.75 mg/kg up to a maximum of 75 mg</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Third dosage reduction level</p>
			</td>
			<td>
			<p>0.5 mg/kg up to a maximum of 50 mg</p>
			</td>
		</tr>
	</tbody>
</table>

<table border="1">
	<thead>
		<tr>
			<th colspan="3">
			<p><strong>Enfortumab Vedotin Dosage Adjustment for Toxicities</strong></p>
			</th>
		</tr>
		<tr>
			<th>
			<p><strong>Toxicity</strong></p>
			</th>
			<th>
			<p>Severity<sup>a</sup></p>
			</th>
			<th>
			<p>Enfortumab Vedotin Dose Modification</p>
			</th>
		</tr>
	</thead>
	<tfoot>
		<tr>
			<td colspan="3">
			<p><sup>a</sup>Grade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening.</p>
			</td>
		</tr>
	</tfoot>
	<tbody>
		<tr>
			<td rowspan="2">
			<p>Hematologic toxicities</p>
			</td>
			<td>
			<p>Grade 3, or grade 2 thrombocytopenia</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Grade 4</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until &le; grade 1, then reduce dose by 1 dose level or discontinue treatment.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Hyperglycemia</p>
			</td>
			<td>
			<p>Blood glucose &gt;250 mg/dL</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until elevated blood glucose has improved to &le;250 mg/dL, then resume treatment at the same dose level.</p>
			</td>
		</tr>
		<tr>
			<td rowspan="2">
			<p>Peripheral neuropathy</p>
			</td>
			<td>
			<p>Grade 2</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level (if first occurrence). For a recurrence, withhold until &le; grade 1, then resume treatment with the dose reduced by one dose level.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Grade 3 or higher</p>
			</td>
			<td>
			<p>Permanently discontinue enfortumab vedotin.</p>
			</td>
		</tr>
		<tr>
			<td rowspan="2">
			<p>Dermatologic toxicity (skin reactions)</p>
			</td>
			<td>
			<p>Grade 3 (severe)</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Grade 4 or recurrent grade 3</p>
			</td>
			<td>
			<p>Permanently discontinue enfortumab vedotin.</p>
			</td>
		</tr>
		<tr>
			<td rowspan="2">
			<p>Other nonhematologic toxicity</p>
			</td>
			<td>
			<p>Grade 3</p>
			</td>
			<td>
			<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p>Grade 4</p>
			</td>
			<td>
			<p>Permanently discontinue enfortumab vedotin.</p>
			</td>
		</tr>
	</tbody>
</table>
', 'moderate', '', 'Rosenberg JE, O''Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29. ', 'METASTATIC', '<h4>Chemotherapy</h4>

<ul>
	<li>Enfortumab vedotin (Padcev)&nbsp;1.25 mg/kg (maximum dose of 125 mg) IV over 30 minutes once per day on days 1, 8, 15</li>
</ul>

<p><strong>28-day cycles</strong></p>
', 100);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (628, '', 'FOLFIRI + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (114, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li>Docetaxel:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li>Doxorubicin:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li>Docetaxel:<br />
	No dose reduction</li>
	<li>Doxorubicin:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for docetaxel', '<b>AC/Docetaxel</b>', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', null, '<p><span style="font-family:Times New Roman,Times,serif"><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV, day 1<br />
<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles<br />
<br />
<strong>FOLLOWED BY</strong><br />
<br />
<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles</span></p>
', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (398, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li>Docetaxel:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li>Doxorubicin:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li>Docetaxel:<br />
	No dose reduction</li>
	<li>Doxorubicin:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 'NEOADJUVANT', '<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV, day 1<br />
<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles<br />
<br />
<strong>FOLLOWED BY</strong><br />
<br />
<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV, day 1<br />
Repeat every 21 days for 4 cycles</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (399, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Pertuzumab: Perjeta<br>Trastuzumab: Herceptin', 'TCHP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84.', 'NEOADJUVANT', '<p><strong>Docetaxel</strong>: 75mg/m<sup>2</sup>&nbsp;on day 1<br />
<strong>Carboplatin</strong>: AUC 6, IV on day 1<br />
<strong>Pertuzumab</strong>: 840mg IV loading dose on day 1 and then 420mg IV every 3 weeks<br />
<strong>Trastuzumab</strong>: 8mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks</p>

<p>Repeat every 21 days for 6 cycles.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (603, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX7)', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continous infusion on days 1 and 2 for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (493, 'Everolimus: Afinitor<br>Exemestane: Aromasin', 'Everolimus/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong><br />
	Mild (Child Pugh A): Decrease dose to 7.5 mg daily<br />
	Moderate (Child Pugh B): Decrease dose to 5 mg daily<br />
	Severe (Child Pugh C): Decrease dose to 2.5 mg daily</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'Minimal', '', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'METASTATIC', '<p><strong>Everolimus</strong>&nbsp;10mg PO daily<br />
<strong>Exemestane</strong> 25mg PO daily</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (410, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU<br>Docetaxel: Taxotere', 'FEC/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for FEC, low for docetaxel', '', 'Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71.', 'ADJUVANT', '<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />
<strong>Epirubicin</strong> 100 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 6&nbsp;cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 3 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (499, 'Abemaciclib: Verzenio<br>Anastrozole: Arimidex', 'Abemaciclib/Anastrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Abemaciclib</strong><br />
	Child-Pugh C: Reduce dosing frequency to once daily</li>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>
', 'Minimal', '', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'METASTATIC', '<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />
<strong>Anastrozole</strong>&nbsp;1mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (437, 'Everolimus: Afinitor<br>Exemestane: Aromasin', 'Everolimus/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong><br />
	Mild (Child Pugh A): Decrease dose to 7.5 mg daily<br />
	Moderate (Child Pugh B): Decrease dose to 5 mg daily<br />
	Severe (Child Pugh C): Decrease dose to 2.5 mg daily</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Everolimus</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'Minimal', '', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'ADJUVANT', '<p><strong>Everolimus</strong>&nbsp;10mg PO daily<br />
<strong>Exemestane</strong> 25mg PO daily</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (411, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for paclitaxel', '', 'Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (494, 'Palbociclib: Ibrance<br>Letrozole: Femara', 'Palbociclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Palbociclib</strong><br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt;10 mL/min, no dose reduction</li>
</ul>
', 'Minimal', '', 'Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.', 'METASTATIC', '<p><strong>Palbociclib</strong>&nbsp;125mg PO daily for 21 days<br />
<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>

<p>Repeat cycle every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (604, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (605, '', 'FOLFOXIRI', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>165 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (606, '', 'FOLFOXIRI + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>165 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (607, '', 'FOLFOXIRI + Panitumumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks&nbsp;</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (733, '', 'Pembrolizumab', '', '', '', '', '', '<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days. May also give 200 mg IV on day 1 every 3 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (734, '', 'Ramucirumab', '', '', '', '', '', '<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (400, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin', 'AC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (500, 'Abemaciclib: Verzenio<br>Letrozole: Femara', 'Abemaciclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Abemaciclib</strong><br />
	Child-Pugh C: Reduce dosing frequency to once daily</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt;10 mL/min, no dose reduction</li>
</ul>
', 'Minimal', '', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'METASTATIC', '<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />
<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (402, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (weekly) ', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>Cyclophosphamide:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li>Doxorubicin:<br />
	No dose reduction</li>
	<li>Paclitaxel:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for paclitaxel', '', 'Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>: 80mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 7&nbsp;days for 12&nbsp;cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (404, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel (weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 'ADJUVANT', '<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV on day 1<br />
<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.<br />
<br />
<strong>FOLLOWED BY</strong><br />
<br />
<strong>Docetaxel</strong>&nbsp;35&nbsp;mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 7&nbsp;days for 12&nbsp;cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (456, 'Pembrolizumab: Keytruda
Cisplatin: Platinol
Pemetrexed: Alimta', 'Pembrolizumab + Cisplatin + Pemetrexed', '<p><u><strong>Pembrolizumab</strong></u></p>

<p><strong>Renal Impairment:</strong></p>

<p><em>Prior&nbsp;to treatment initiation:</em>&nbsp;No dosage adjustment necessary.&nbsp;</p>

<p><em>During&nbsp;treatment:</em></p>

<ul>
	<li>
	<p>Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</p>
	</li>
	<li>
	<p>Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</p>
	</li>
</ul>

<p><strong>Hepatic Impairment:</strong></p>

<p><em>Prior to treatment initiation:</em>&nbsp;</p>

<ul>
	<li>No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</li>
	<li>No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</li>
</ul>

<p><em>During treatment:</em></p>

<ul>
	<li>
	<p>Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</p>

	<ul>
		<li>
		<p>Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</p>
		</li>
		<li>
		<p>Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</p>

		<ul>
			<li>
			<p>AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</p>
			</li>
			<li>
			<p>AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</p>
			</li>
			<li>
			<p>If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</p>
			</li>
		</ul>
		</li>
	</ul>
	</li>
</ul>

<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>

<p><u><strong>Pemetrexed</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span class="marker"><span style="background-color:white"><span style="color:#232323">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>
	</li>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>
	</li>
</ul>

<p><strong><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">Hepatic Impairment:&nbsp;</span></span></span></strong><em><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></em></p>
', 'High', '', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16', 'METASTATIC', '<p><strong>Pembrolizumab</strong> 200 mg IV given on day 1&nbsp;at least 30 minutes prior to chemotherapy<br />
<strong>Pemetrexed</strong> 500mg/m<sup>2</sup>&nbsp;given on day 1&nbsp;<br />
<strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;given on day 1</p>

<p><strong>Administer in 21 day cycles for 4 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (495, 'Ribociclib: Kisqali<br>Letrozole: Femara', 'Ribociclib/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ribociclib</strong><br />
	If Child-Pugh A, no dose reduction<br />
	If&nbsp;Child-Pugh B or C, reduce starting dose to 400 mg/day</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Ribociclib</strong><br />
	If CrCl &ge;30 mL/min, no dose reduction<br />
	If CrCl 15-30 mL/min, decrease starting dose to 200 mg/day</li>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt;10 mL/min, no dose reduction</li>
</ul>
', 'Minimal', '', 'Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.', 'METASTATIC', '<p><strong>Ribociclib</strong>&nbsp;600mg PO daily for 21 days<br />
<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (567, 'Gemcitabine: Gemzar<br>Cisplatin: CDDP', 'Gemcitabine/Cisplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9.', '', '<p><strong>Gemcitabine</strong>&nbsp;800-1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Cisplatin</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (533, 'Cisplatin: CDDP<br>Irinotecan: Camptosar', 'Cisplatin/Irinotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong><br />
	No dose reduction</li>
	<li><strong>Irinotecan</strong>:<br />
	If bilirubin 1-2 mg/dL, may need to reduce the dose<br />
	If bilurubin &gt; 2 mg/dL, may not use &nbsp;</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Irinotecan</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7.', '', '<p><strong>Cisplatin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Irinotecan</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (405, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere', 'TC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7.', 'ADJUVANT', '<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />
<strong>Cyclophosphamide</strong> 600 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (406, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'TAC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.', 'ADJUVANT', '<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />
<strong>Doxorubicin</strong> 50 mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 6 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (407, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Fluorouracil: 5-FU', 'CAF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate-High', '', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'ADJUVANT', '<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Doxorubicin</strong>&nbsp;60 mg/m<sup>2</sup> IV on day 1<br />
<strong>5-Fluorouracil</strong>&nbsp;600 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 28 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (408, 'Epirubicin: Ellence<br>Cyclophosphamide: Cytoxan<br>Methotrexate: MTX<br>5-Fluorouracil: 5-FU', 'Epirubicin/CMF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Methotrexate</strong>:<br />
	If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Methotrexate</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'ADJUVANT', '<p><strong>Epirubicin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Cyclophosphamide</strong> 600 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Methotrexate</strong> 40 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>5-Fluorouracil</strong> 600 mg/m<sup>2</sup> IV on&nbsp;day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (403, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel (q3weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 'ADJUVANT', '<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV on day 1<br />
<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.<br />
<br />
<strong>FOLLOWED BY</strong><br />
<br />
<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (412, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'A/T/C (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate, low for paclitaxel', '', 'Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY&nbsp;</strong></p>

<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (501, 'Tamoxifen: Nolvadex', 'Tamoxifen', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29.', 'METASTATIC', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (413, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'AC/Docetaxel (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (414, 'Cyclophosphamide: Cytoxan<br>Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'Docetaxel/AC (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High for AC, low for docetaxel', '', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'ADJUVANT', '<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (542, 'Gemcitabine: Gemzar, various', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7.', '', '<p><strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (543, 'Pembrolizumab: Keytruda', 'Pembrolizumab', '', 'Minimal', '', 'Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514).', '', '<p><strong>Pembrolizumab</strong>&nbsp;200mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (415, 'Carboplatin: Paraplatin
Etoposide: Vepesid', 'Carboplatin + Etoposide', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal</strong>: AUC dosing&nbsp;</p>

<p>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></p>

<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic</strong>- No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', 'High', '', 'Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed', '', '<p><em>Recommended for use with concominant RT&nbsp;if Cisplatin + Etoposide is contraindicated or not tolerated.&nbsp;</em></p>

<p><strong>Carboplatin</strong> AUC 5-6 IV over 60 minutes, day 1-&nbsp;<em>given first</em><br />
<strong>Etoposide</strong> 100mg/m<sup>2&nbsp;</sup>IV over 1-2 hours,&nbsp;days 1, 2, 3-&nbsp;<em>given second</em></p>

<p>&nbsp;</p>
', 104);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (502, 'Toremifene: Fareston', 'Toremifene', '', 'N/A', '', 'Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66.', 'METASTATIC', '<p><strong>Toremifene</strong> 60mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (503, 'Exemestane: Aromasin, various', 'Exemestane', '', 'N/A', '', 'Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4. ', 'METASTATIC', '<p><strong>Exemestane</strong>&nbsp;25mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (504, 'Anastrozole: Arimidex', 'Anastrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11.', 'METASTATIC', '<p><strong>Anastrozole</strong>&nbsp;1mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (717, '', 'Gemcitabine + Capecitabine', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (544, 'Paclitaxel: Taxol<br>Carboplatin: Paraplatin', 'Paclitaxel/Carboplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Hoskins PJ, Swenerton KD, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19(20):4048-53.', '', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />
<strong>Carboplatin</strong>&nbsp;AUC of 5-7, IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (546, 'Doxorubicin: Adriamycin<br>Cisplatin: CDDP', 'AP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6.', '', '<p><strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (566, 'Gemcitabine: Gemzar<br>Doxorubicin liposome: Doxil, various', 'Gemcitabine/Doxorubicin liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong><br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong><br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'D''Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4.', '', '<p><strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (497, 'Abemaciclib: Verzenio<br>Fulvestrant: Faslodex', 'Abemaciclib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Abemaciclib</strong><br />
	Child-Pugh C: Reduce dosing frequency to once daily</li>
	<li><strong>Fulvestrant</strong>:<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	No dose reduction</li>
</ul>
', 'Minimal', '', 'Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.', 'METASTATIC', '<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />
<strong>Fulvestrant</strong>&nbsp;500mg IM on days 1 and 15 of first cycle, then 500mg IM on day 1 for all subsequent cycles</p>

<p>Repeat cycle every 28 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (496, 'Palbociclib: Ibrance<br>Fulvestrant: Faslodex', 'Palbociclib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Palbociclib</strong><br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li>
	<li><strong>Fulvestrant</strong>:<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	No dose reduction</li>
</ul>
', 'Minimal', '', 'Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19.', 'METASTATIC', '<p><strong>Palbociclib</strong>&nbsp;125mg PO daily for 21 days<br />
<strong>Fulvestrant</strong>&nbsp;500mg IM on days 1 and 15 of first cycle, then 500mg IM on day 1 for all subsequent cycles</p>

<p>Repeat cycle every 28 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (505, 'Letrozole: Femara', 'Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61.', 'METASTATIC', '<p><strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (420, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol<br>Trastuzumab: Herceptin', 'AC/Paclitaxel/Trastuzumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for paclitaxel and trastuzumab', '', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;80mg/m<sup>2</sup>&nbsp;IV over 1 hour on day 1<br />
<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly</p>

<p>Repeat every 7 days for 12 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Trastuzumab</strong>&nbsp;2mg/kg IV weekly</p>

<p>Repeat every 7 days for 40 cycles.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (506, 'Fulvestrant: Faslodex', 'Fulvestrant', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600.', 'METASTATIC', '<p><strong>Fulvestrant</strong>&nbsp;250mg IM on day 1</p>

<p>Repeat every month.</p>

<p>OR</p>

<p><strong>Fulvestrant</strong>&nbsp;500mg IM loading dose on day 1, then 500mg IM on days 15 and 29</p>

<p>Continue treatment on a monthly basis until disease progression.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (397, 'Cisplatin: Platinol
Etoposide: Vepesid', 'Cisplatin + Etoposide', '<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Hepatic</strong></p>

<ul>
	<li>No Dosage Adjustments</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic</strong></p>

<ul>
	<li>No dose adjustments in manufacturers labeling</li>
	<li>Per Hendrayana, Wilmer, Kurth et al, 2017:
	<ul>
		<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
		<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
	</ul>
	</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', 'High', '', 'Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2

Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391

T. Marcello, Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.

Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.

Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008
', '', '<p><em>Recommended for use with concominant RT (category I)</em></p>

<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;on day 1&nbsp;<br />
<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />
21 day cycle for 4-6 cycles</p>

<p>OR</p>

<p><strong>Cisplatin</strong> 60&nbsp;mg/m<sup>2</sup>&nbsp;on day 1&nbsp;<br />
<strong>Etoposide</strong> 120&nbsp;mg/m<sup>2&nbsp;</sup>on days 1, 2, 3<br />
21 day cycle for 4-6 cycles</p>

<p>OR</p>

<p><strong>Cisplatin</strong> 25 mg/m<sup>2</sup>&nbsp;on days 1, 2, 3<br />
<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />
21 day cycle for 4-6 cycles</p>

<p>&nbsp;</p>
', 104);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (507, 'Megestrol: Megace', 'Megestrol', '', 'N/A', '', 'Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54.', 'METASTATIC', '<p><strong>Megestrol</strong> 40mg PO QID</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (417, 'Carboplatin: Paraplatin
Etoposide: Vepesid
Durvalumab: Imfinzi', 'Carboplatin + Etoposide + Durvalumab', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal</strong>: AUC dosing&nbsp;</p>

<ul>
	<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>
</ul>

<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal:</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>

<p><u><strong>Durvalumab</strong></u></p>

<p><strong>Hepatic</strong>:</p>

<p><em>Hepatic impairment prior to treatment initiation:</em></p>

<ul>
	<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>
</ul>

<p><em>Hepatotoxicity during treatment:</em></p>

<ul>
	<li>ALT or AST &gt;3 - 8 x ULN or total bilirubin &gt;1.5 -&nbsp;5 x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent&nbsp;taper. May resume when hepatitis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>
	<li>ALT or AST &gt;8 times ULN or total bilirubin &gt;5 times ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.&nbsp;</li>
	<li>Concurrent ALT or AST &gt;3 x ULN and total bilirubin &gt;2 x ULN without alternate cause: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent taper.&nbsp;</li>
</ul>

<p><strong>Renal:</strong></p>

<p><em>Renal toxicity prior to initiation of&nbsp;treatment (nephritis):</em></p>

<ul>
	<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>
</ul>

<p><em>Renal toxicity during treatment (nephritis):</em></p>

<ul>
	<li>Creatinine &gt;1.5 - 3x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 - 2 mg/kg/day or equivalent) followed by a taper. May resume durvalumab when nephritis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>
	<li>Creatinine &gt;3x&nbsp;ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.</li>
</ul>
', 'High', '', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. ', '', '<p><strong>Carboplatin</strong> AUC 5-6 day 1 OR 75-80mg/m<sup>2</sup><br />
<strong>Etoposide</strong> 80-100 mg/m2 days 1, 2, 3<br />
<strong>Durvalumab</strong> 1,500 mg day 1&nbsp;</p>

<p><strong>Every 21 days for maximum of 4 cycles</strong></p>

<p>Followed by maintenance <strong>durvalumab</strong> 1,500 mg&nbsp; on day 1, repeat cycle&nbsp;<strong>every 28 days</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (418, 'Carboplatin: Paraplatin
Etoposide: Vepesid', 'Carboplatin + Etoposide', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal</strong>:&nbsp; AUC dosing&nbsp;</p>

<ul>
	<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>
</ul>

<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal:</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', 'High', '', 'Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810', '', '<p><strong>Carboplatin</strong> AUC 5-6 on day 1&nbsp;<br />
<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp; on days 1, 2, 3</p>

<p><strong>Maximum of&nbsp;4-6 cycles</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (508, 'Trastuzumab: Herceptin', 'Trastuzumab', '', 'Low', '', 'Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly</p>

<p>Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2mg/kg.</p>

<p>OR</p>

<p><strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose, then 6mg/kg IV every 3 weeks.</p>

<p>Continue treatment until disease progression.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (421, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol<br>Trastuzumab: Herceptin', 'AC/Paclitaxel/Trastuzumab (dose-dense)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for paclitaxel and trastuzumab', '', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14&nbsp;days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 14 days for 4 cycles.</p>

<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose along with paclitaxel and&nbsp;then 2mg/kg IV weekly</p>

<p>Repeat every 7 days for 52 cycles.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (422, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'TCH', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate for TC, low for trastuzumab', '', 'Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52).', 'ADJUVANT', '<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Carboplatin</strong> AUC of 6, IV on&nbsp;day 1<br />
<strong>Trastuzumab&nbsp;</strong>4mg/kg IV loading dose and then 2mg/kg IV weekly during chemotherapy</p>

<p>Repeat every 21 days for 6 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Trastuzumab</strong>&nbsp;6mg/kg IV on day 1</p>

<p>Repeat every 21 days for 1 year.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (423, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'DH/FEC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for FEC', '', 'Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.', 'ADJUVANT', '<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose on day 1 and then 2mg/kg IV weekly</p>

<p>Repeat every 21 days for 3 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>5-Fluorouracil</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Epirubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide&nbsp;</strong>600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 3 cycles.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (424, 'Pertuzumab: Perjeta<br>Trastuzumab: Herceptin<br>Docetaxel: Taxotere', 'Pertuzumab/Trastuzumab/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.', 'ADJUVANT', '<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks<br />
<strong>Pertuzumab</strong>&nbsp;840mg IV loading dose on day 1 and then 420mg IV every 3 weeks</p>

<p>Repeat every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (425, 'Neratinib: Nerlynx', 'Neratinib', '<p><strong>Hepatic Impairment:</strong><br />
Severe (Child-Pugh C): reduce starting dose to 80mg.</p>

<p><strong>Renal Impairment:</strong><br />
No dose reduction necessary.</p>
', 'Minimal', '', 'Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.', 'ADJUVANT', '<p><strong>Neratinib</strong>&nbsp;240mg PO daily</p>

<p>Repeat daily for 1 year following trastuzumab-based adjuvant therapy.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (426, 'Ado-trastuzumab emtansine: Kadcyla', 'Ado-Trastuzumab Emtansine', '', 'Minimal', '', 'von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.', 'ADJUVANT', '<p><strong>Ado-trastuzumab emtansine</strong>: 3.6mg/kg IV on day 1</p>

<p>Repeat every 21 days for 14 cycles.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (429, '', 'Cisplatin + Irinotecan', '<p><u><strong>isplatin</strong></u></p>

<p><strong>Hepatic:</strong></p>

<ul>
	<li>No Dosage Adjustments</li>
</ul>

<p><strong>Renal:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><u><strong>Irinotecan</strong></u></p>

<p><strong>Renal</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>

<ul>
	<li><strong>Dialysis</strong>: manufacturer does not recommend use in patients with dialysis.

	<ul>
		<li><em>Janus 2010:</em>&nbsp;may consider reduction of&nbsp;weekly dose from 125 mg/m<sup>2</sup>&nbsp;to 50 mg/m<sup>2</sup>&nbsp;and administration&nbsp;after hemodialysis or on nondialysis days</li>
	</ul>
	</li>
</ul>

<p><strong>Hepatic:&nbsp;</strong>Per manufacturer&#39;s guidelines:<strong>&nbsp;</strong></p>

<ul>
	<li>Bilirubin 1 - 2 mg/dL: increased liklihood of grade 3 or 4 neutropenia. Consider reducing initial dose by one dose level</li>
	<li>Bilirubin &gt;2 mg/dL or transaminases &gt; 3 x ULN without liver metastasis or transaminases &gt; 5 x ULN with liver metastasis: Use is not recommended</li>
</ul>
', 'High', '', 'JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.
SWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6.
JCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17.', '', '<p><strong>Cisplatin</strong>&nbsp;30mg/m<sup>2&nbsp;</sup>on day 1, 8&nbsp;<br />
<strong>Irinotecan</strong> 60 mg/m<sup>2</sup>&nbsp;on days 1, 8</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>

<p>OR</p>

<p><strong>Cisplatin</strong> 60mg/m<sup>2&nbsp;</sup>on day 1&nbsp;<br />
<strong>Irinotecan</strong> 60 mg/m<sup>2</sup>&nbsp;on days 1, 8, 15</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (522, 'Talazoparib: Talzenna', 'Talazoparib', '<h4>Renal impairment</h4>

<ul>
	<li>CrCl 30-59 mL/min: Reduce dose to 0.75mg daily</li>
	<li>CrCl 15-29 mL/min: Reduce dose to 0.5mg daily</li>
</ul>
', 'Moderate', '', 'Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.', 'METASTATIC', '<p><strong>Talazoparib</strong>&nbsp;1mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (416, 'Carboplatin: Paraplatin
Etoposide: Vepesid
Atezolizumab: Tecentriq
', 'Carboplatin + Etoposide + Atezolizumab', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal</strong>: AUC dosing&nbsp;</p>

<p>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></p>

<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p>&nbsp;</p>

<p><u><strong>Atezolizumab</strong></u>:</p>

<p><strong>Renal</strong>: No dosing instructions in manufacturer&#39;s labeling</p>

<p><strong>Hepatic</strong>:&nbsp;</p>

<p><em>P</em><em>rior to initiation of treatment:</em></p>

<p>No dosing instructions in manufactureer&#39;s labeling for modifications</p>

<p><em>During treatment:</em></p>

<p>AST or ALT &gt;3 - 8 x ULN&nbsp;<strong>or</strong>&nbsp;total bilirubin &gt;1.5 - 3 x ULN: Withhold treatment and administer&nbsp;high-dose systemic corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) and subsequent&nbsp;corticosteroid taper. Resume treatment when&nbsp;grade 1 or resolved and prednisone dose is &le;10 mg/day (or equivalent).</p>

<p>AST or ALT &gt;8 x ULN&nbsp;<strong>or</strong>&nbsp;total bilirubin &gt;3 x ULN: Discontinue permanently. Administer high-dose systemic corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) and subsequent corticosteroid taper.</p>
', 'High', '', 'IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed', '', '<p><strong>Carboplatin</strong> AUC 5 IV on day 1<br />
<strong>Etoposide</strong> 100mg/m<sup>2</sup>&nbsp;IV on days 1, 2, 3<br />
<strong>Atezolizumab</strong> 1200 mg IV on day one</p>

<p><strong>21-day cycle for 4 cycles</strong></p>

<p><strong>Followed by maintenance atezolizumab: </strong>1,200 mg on day 1 <strong>every 21 days</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (511, 'Docetaxel: Taxotere', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19-24. --- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9.', 'METASTATIC', '<p><strong>Docetaxel&nbsp;</strong>100mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Docetaxel</strong>&nbsp;35-40mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks.</p>

<p>Repeat cycle every 8 weeks.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (427, 'Cisplatin: Platinol.
Etoposide: Vepesid', 'Cisplatin + Etoposide + Durvalumab ', '<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Hepatic:</strong></p>

<ul>
	<li>No Dosage Adjustments</li>
</ul>

<p><strong>Renal:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal:</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>

<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>

<ul>
	<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
	<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>

<p><u><strong>Durvalumab</strong></u></p>

<p><strong>Hepatic</strong>:</p>

<p><em>Hepatic impairment prior to treatment initiation:</em></p>

<ul>
	<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>
</ul>

<p><em>Hepatotoxicity during treatment:</em></p>

<ul>
	<li>ALT or AST &gt;3 - 8 x ULN or total bilirubin &gt;1.5 -&nbsp;5 x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent&nbsp;taper. May resume when hepatitis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>
	<li>ALT or AST &gt;8 times ULN or total bilirubin &gt;5 times ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.&nbsp;</li>
	<li>Concurrent ALT or AST &gt;3 x ULN and total bilirubin &gt;2 x ULN without alternate cause: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent taper.&nbsp;</li>
</ul>

<p><strong>Renal:</strong></p>

<p><em>Renal toxicity prior to initiation of&nbsp;treatment (nephritis):</em></p>

<ul>
	<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>
</ul>

<p><em>Renal toxicity during treatment (nephritis):</em></p>

<ul>
	<li>Creatinine &gt;1.5 - 3x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 - 2 mg/kg/day or equivalent) followed by a taper. May resume durvalumab when nephritis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>
	<li>Creatinine &gt;3x&nbsp;ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.</li>
</ul>
', 'High', '', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print] ', '', '<p><strong>Cisplatin</strong> 75-80 mg/m<sup>2</sup>&nbsp;on day 1<br />
<strong>Etoposide</strong> 80-100 mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />
<strong>Durvalumab</strong> 1,500 mg on day 1</p>

<p><strong>Repeat cycle every 21 days x 4 cycles&nbsp;</strong></p>

<p>Followed by maintenance <strong>durvalumab</strong> 1,500 mg on day one, repeat cycle every 28 days</p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (419, 'Cisplatin: Platinol
Etoposide: Vepesid
Durvalumab: Imfinzi', 'Cisplatin + Etoposide', '<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Hepatic</strong></p>

<ul>
	<li>No Dosage Adjustments</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic</strong></p>

<ul>
	<li>No dose adjustments in manufacturers labeling</li>
	<li>Per Hendrayana, Wilmer, Kurth et al, 2017:
	<ul>
		<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
		<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
	</ul>
	</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', 'High', '', 'Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.

Sundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.

Niell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.

Ihde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034.', '', '<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;day 1<br />
<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>

<p>OR</p>

<p><strong>Cisplatin</strong> 80&nbsp;mg/m<sup>2</sup>&nbsp;day 1<br />
<strong>Etoposide</strong> 80&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong>OR</p>

<p><strong>Cisplatin</strong> 25 mg/m<sup>2</sup>&nbsp;days 1, 2, 3&nbsp;<br />
<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (510, 'Capecitabine: Xeloda', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'Low', '', 'Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID for 2 weeks followed by 1-week rest period</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (552, 'Cisplatin: CDDP<br>Ifosfamide: Ifex', 'Cisplatin/Ifosfamide', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Ifosfamide</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'High', '', 'Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001. ', '', '<p><strong>Cisplatin</strong>&nbsp;20mg/m<sup>2</sup>/day IV on days 1-4<br />
<strong>Ifosfamide</strong>&nbsp;1500mg/m<sup>2</sup>/day IV on day 1<br />
<strong>Mesna</strong>&nbsp;120mg/m<sup>2</sup>&nbsp;IV loading dose followed by 1500mg/m<sup>2</sup>/day for 24 hours</p>

<p>Repeat cycle every 21 days for 3 cycles.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (553, 'Gemcitabine: Gemzar<br>Docetaxel: Taxotere', 'Gemcitabine/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34.', '', '<p><strong>Gemcitabine</strong>&nbsp;900mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 8</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (554, 'Doxorubicin: Adriamycin, various', 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13.', '', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (523, 'Cisplatin: CDDP', 'Cisplatin/Radiation', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'High', '', 'Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53.', '', '<p><strong>Radiation therapy&nbsp;</strong>1.8-2 Gy per fraction (total dose, 45 Gy)<br />
<strong>Cisplatin</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV weekly (maximal dose, 70mg per week)</p>

<p>Cisplatin is given 4 hours before radiation therapy on weeks 1-6.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (524, 'Cisplatin: CDDP<br>Paclitaxel: Taxol', 'Paclitaxel/Cisplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43.', '', '<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1<br />
<strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (525, 'Cisplatin: CDDP<br>Topotecan: Hycamtin ', 'Cisplatin/Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m2</li>
</ul>
', 'High', '', 'Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.', '', '<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>/day IV on days 1-3</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (555, 'Megestrol: Megace', 'Megestrol', '', 'N/A', '', 'Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.', '', '<p><strong>Megestrol</strong>&nbsp;160mg PO daily</p>

<p>Continue until disease progression or undue toxicity.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (556, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81.', '', '<p><strong>Paclitaxel</strong>&nbsp;200mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days. Reduce dose to 175mg/m<sup>2</sup> IV for patients with prior pelvic radiation therapy.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (438, 'Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AT', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92.', 'METASTATIC', '<p><strong>Doxorubicin&nbsp;</strong>50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;150mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p>Repeat cycle every 21 days.<br />
&nbsp;</p>

<p><strong>OR</strong></p>

<p><br />
<strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days up to a maximum of 8 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days until disease progression.</p>

<p><br />
<strong>OR</strong></p>

<p><br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days until disease progression.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days up to a maximum of 8 cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (428, 'Carboplatin: Paraplatin
Irinotecan: Camptosar', 'Carboplatin + Irinotecan', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal</strong>: AUC dosing&nbsp;</p>

<ul>
	<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>
</ul>

<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Irinotecan</strong></u></p>

<p><strong>Renal</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>

<ul>
	<li><strong>Dialysis</strong>: manufacturer does not recommend use in patients with dialysis.

	<ul>
		<li><em>Janus 2010:</em>&nbsp;may consider reduction of&nbsp;weekly dose from 125 mg/m<sup>2</sup>&nbsp;to 50 mg/m<sup>2</sup>&nbsp;and administration&nbsp;after hemodialysis or on nondialysis days</li>
	</ul>
	</li>
</ul>

<p><strong>Hepatic:&nbsp;</strong>Per manufacturer&#39;s guidelines:<strong>&nbsp;</strong></p>

<ul>
	<li>Bilirubin 1 - 2 mg/dL: increased liklihood of grade 3 or 4 neutropenia. Consider reducing initial dose by one dose level</li>
	<li>Bilirubin &gt;2 mg/dL or transaminases &gt; 3 x ULN without liver metastasis or transaminases &gt; 5 x ULN with liver metastasis: Use is not recommended</li>
</ul>
', '', '', 'Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7.', '', '<p><strong>Carboplatin</strong> AUC 5 on day 1&nbsp;<br />
<strong>Irinotecan</strong> 50mg/m<sup>2</sup>&nbsp;on days 1, 8, 15&nbsp;</p>

<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>
', 105);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (431, 'Anastrozole: Arimidex ', 'Anastrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.', 'ADJUVANT', '<p><strong>Anastrozole</strong>&nbsp;1mg PO daily</p>

<p>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (430, 'Tamoxifen: Nolvadex', 'Tamoxifen', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.', 'ADJUVANT', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily</p>

<p>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (432, 'Letrozole: Femara', 'Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76. ', 'ADJUVANT', '<p><strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>

<p>Repeat daily for 5 years in patients with ER+ or PR+ tumors.</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (433, 'Tamoxifen: Nolvadex<br>Letrozole: Femara', 'Tamoxifen/Letrozole', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong><br />
	No dose reduction</li>
	<li><strong>Letrozole</strong>:<br />
	If Child-Pugh A or B, no dose reduction<br />
	If Child-Pugh C, reduce dose by 50%</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong><br />
	No dose reduction</li>
	<li><strong>Letrozole</strong>:<br />
	If CrCl &gt; 10 mL/min, no dose reduction</li>
</ul>
', 'N/A', '', 'Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.', 'ADJUVANT', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily for 5 years</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Letrozole&nbsp;</strong>2.5mg PO daily for 5 years</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (434, 'Tamoxifen: Nolvadex<br>Exemestane: Aromasin', 'Tamoxifen/Exemestane', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Exemestane</strong>:<br />
	No dose reduction</li>
</ul>
', 'N/A', '', 'Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.', 'ADJUVANT', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily for 2-3 years</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Exemestane</strong>&nbsp;25mg PO daily for the remainder of 5 years</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (435, 'Tamoxifen: Nolvadex<br>Goserelin: Zoladex<br>Zoledronic acid: Zometa, various', 'Tamoxifen/Goserelin/Zoledronic Acid', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Tamoxifen</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	CrCl &gt;60 mL/min: 4 mg<br />
	CrCl 50-60 mL/min: 3.5 mg<br />
	CrCl 40-49 mL/min: 3.3 mg<br />
	CrCl 30-39 mL/min: 3 mg<br />
	CrCl &lt;30 mL/min: Not recommended</li>
</ul>
', 'N/A', '', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'ADJUVANT', '<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily<br />
<strong>Goserelin</strong>&nbsp;3.6mg SC every 28 days<br />
<strong>Zoledronic acid</strong>&nbsp;4mg IV every 6 months</p>

<p>Continue treatment for 3 years.</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (436, 'Anastrozole: Arimidex<br>Goserelin: Zoladex<br>Zoledronic acid: Zometa, various', 'Anastrozole/Goserelin/Zoledronic Acid', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Anastrozole</strong>:<br />
	No dose reduction</li>
	<li><strong>Goserelin</strong>:<br />
	No dose reduction</li>
	<li><strong>Zoledronic acid</strong>:<br />
	CrCl &gt;60 mL/min: 4 mg<br />
	CrCl 50-60 mL/min: 3.5 mg<br />
	CrCl 40-49 mL/min: 3.3 mg<br />
	CrCl 30-39 mL/min: 3 mg<br />
	CrCl &lt;30 mL/min: Not recommended</li>
</ul>
', 'N/A', '', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'ADJUVANT', '<p><strong>Anastrozole</strong> 1mg PO daily<br />
<strong>Goserelin</strong>&nbsp;3.6mg SC every 28 days<br />
<strong>Zoledronic acid</strong>&nbsp;4mg IV every 6 months</p>

<p>Continue treatment for 3 years.</p>
', 17);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (439, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Fluorouracil: 5-FU', 'CAF (metastatic)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate-High', '', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'METASTATIC', '<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Doxorubicin</strong>&nbsp;60 mg/m<sup>2</sup> IV on day 1<br />
<strong>5-Fluorouracil</strong>&nbsp;600 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (440, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'CEF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'METASTATIC', '<p><strong>Cyclophosphamide</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;PO on days 1-14<br />
<strong>Epirubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>5-Fluorouracil</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 28 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (441, 'Cyclophosphamide: Cytoxan<br>Methotrexate: MTX<br>5-Fluorouracil: 5-FU', 'CMF', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Methotrexate</strong>:<br />
	If bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Methotrexate</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'METASTATIC', '<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Methotrexate</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>5-Fluorouracil</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (442, 'Capecitabine: Xeloda<br>Docetaxel: Taxotere', 'XT', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low ', '', 'O''Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />
<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (629, '', 'XELIRI + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;PO on days 1-14</p>

<p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (448, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-75', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'METASTATIC', '<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />
<strong>Epirubicin</strong> 75 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (443, 'Capecitabine: Xeloda<br>Paclitaxel: Taxol', 'XP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;825mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (444, 'Capecitabine: Xeloda<br>Vinorelbine: Navelbine', 'XN', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />
<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (445, 'Capecitabine: Xeloda<br>Ixabepilone: Ixempra', 'XI', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Ixabepilone</strong>:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />
	If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Ixabepilone</strong>:<br />
	If CrCl &gt; 30 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />
<strong>Ixabepilone</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repaet cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (446, 'Docetaxel: Taxotere<br>Doxorubicin: Adriamycin, various', 'Docetaxel/Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'METASTATIC', '<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (447, 'Docetaxel: Taxotere<br>Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'METASTATIC', '<p><strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;on day 1<br />
<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (409, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-100', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'ADJUVANT', '<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />
<strong>Epirubicin</strong> 100 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat every 21 days for 6&nbsp;cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (449, 'Cyclophosphamide: Cytoxan<br>Epirubicin: Ellence, various<br>5-Fluorouracil: 5-FU', 'FEC-50', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
	<li><strong>Epirubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />
	If bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
	<li><strong>Epirubicin</strong><br />
	If serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'METASTATIC', '<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />
<strong>Epirubicin</strong> 50 mg/m<sup>2</sup> IV on&nbsp;day 1<br />
<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (401, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin, various<br>Paclitaxel: Taxol', 'AC/Paclitaxel (q3weekly)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High for AC, low for paclitaxel', '', 'Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'ADJUVANT', '<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4 cycles.</p>

<p><strong>FOLLOWED BY</strong></p>

<p><strong>Paclitaxel</strong>: 175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat every 21 days for 4&nbsp;cycles.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (450, 'Gemcitabine: Gemzar, various<br>Paclitaxel: Taxol', 'Gemcitabine/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 'METASTATIC', '<p><strong>Gemcitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (735, '', 'Capecitabine', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days. Dose may be decreased to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising clinical efficacy.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (736, '', 'CPT-11 (weekly schedule)', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 4 weeks</p>

<p>Repeat cycle every 6 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>

<p>Repeat cycle every 3 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>CPT-11:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on days 1 and 10</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (737, '', 'CPT-11 (monthly schedule)', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>CPT-11:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (473, 'Ipilimumab: Yervoy
Nivolumab: Opdivo', 'Nivolumab + Ipilimumab ', '<p><strong><u><span style="font-family:Times">Ipilimumab</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<p><em><span style="font-family:Times">Prior to treatment:</span></em><span style="font-family:Times"> No dosage adjustment necessary.</span></p>

<p><em><span style="font-family:Times">Renal toxicity (immune mediated nephritis) during treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Grade 2 or 3 creatinine elevation: Withhold treatment; administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]) followed by a corticosteroid taper. </span>

	<ul style="list-style-type:circle">
		<li><span style="font-family:Times">If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 - 2 mg/kg/day (or equivalent).</span></li>
	</ul>
	</li>
	<li><span style="font-family:Times">Grade 4 creatinine elevation: Permanently discontinue; administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by a corticosteroid taper.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<p><em><span style="font-family:Times">Prior to treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (bilirubin 1 - 1.5 x ULN or AST &gt;ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): insufficient data, there are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><em><span style="font-family:Times">Hepatic impairment during treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Grade 2: Temporarily withhold treatment.</span></li>
	<li><span style="font-family:Times">Grade 3 or 4: Permanently discontinue treatment. Administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by 1 month corticosteroid taper when LFTs show sustained improvement or return to baseline. </span></li>
</ul>

<p><strong><u>Nivolumab</u></strong></p>

<p><strong>Renal Impairment: </strong></p>

<ul>
	<li>Creatitine 1.5-6 x ULN- withhold dose</li>
	<li>Creatinine &gt; 6 x ULN- permanently discontinue<strong> </strong></li>
</ul>

<p><strong>Hepatic Impairment: </strong></p>

<ul>
	<li>Transaminases 3 - 5 x ULN or bilirubin 1.5-3 x ULN- withhold dose</li>
	<li>Transaminases &gt; 5 x ULN or bilirubin &gt; 3 x ULN - permnently discontinue</li>
</ul>
', 'Moderate', '', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf
', 'METASTATIC', '<p><strong>Ipilimumab</strong> 1 mg/kg IV on day 1<br />
<strong>Nivolumab</strong> 3 mg/kg IV on day 1, 15, 29</p>

<p><strong>42-day (6 week) cycles for up to 4 cycles </strong></p>

<p>&nbsp;</p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (631, '', 'FOLFIRI + Ramucirumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (451, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol', 'Carboplatin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31.', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;200mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (452, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (453, 'Bevacizumab: Avastin<br>Paclitaxel: Taxol', 'Paclitaxel/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.', 'METASTATIC', '<p><strong>Paclitaxel</strong>&nbsp;90mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15<br />
<strong>Bevacizumab</strong>&nbsp;10mg/kg on days 1 and 15</p>

<p>Repeat cycle every 28 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (454, 'Atezolizumab: Tecentriq<br>Nab-paclitaxel: Abraxane', 'Atezolizumab/Nab-Paclitaxel', '', 'Low', '', 'Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.', 'METASTATIC', '<p><strong>Atezolizumab</strong>&nbsp;840mg IV on days 1 and 15<br />
<strong>Nab-paclitaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 15);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (455, 'Pembrolizumab: Keytruda
Carboplatin: Paraplatin
Pemetrexed: Alimta', 'Pembrolizumab + Carboplatin + Pemetrexed', '<p><u><strong>Pembrolizumab</strong></u></p>

<p><strong>Renal Impairment:</strong></p>

<p><em>Prior&nbsp;to treatment initiation:</em>&nbsp;No dosage adjustment necessary.&nbsp;</p>

<p><em>During&nbsp;treatment:</em></p>

<ul>
	<li>
	<p>Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</p>
	</li>
	<li>
	<p>Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</p>
	</li>
</ul>

<p><strong>Hepatic Impairment:</strong></p>

<p><em>Prior to treatment initiation:</em>&nbsp;</p>

<ul>
	<li>No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</li>
	<li>No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</li>
</ul>

<p><em>During treatment:</em></p>

<ul>
	<li>
	<p>Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</p>

	<ul>
		<li>
		<p>Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</p>
		</li>
		<li>
		<p>Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</p>

		<ul>
			<li>
			<p>AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</p>
			</li>
			<li>
			<p>AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</p>
			</li>
			<li>
			<p>If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</p>
			</li>
		</ul>
		</li>
	</ul>
	</li>
</ul>

<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Pemetrexed</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span class="marker"><span style="background-color:white"><span style="color:#232323">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>
	</li>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>
	</li>
</ul>

<p><strong><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">Hepatic Impairment:</span></span></span></strong></p>

<ul>
	<li><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></li>
</ul>
', 'High', '', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16

KEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Pembrolizumab</strong>&nbsp;200 mg IV given on day 1.&nbsp;Administer at least 30 minutes prior to chemotherapy<br />
<strong>Carboplatin</strong> AUC 5 given on day 1<br />
<strong>Pemetrexed</strong> 500 mg/m<sup>2</sup>&nbsp;IV given on day 1</p>

<p><strong>21-day cycle for 4 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (608, '', 'Cetuximab + Irinotecan', '', '', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p><strong>Irinotecan:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days</p>

<p><strong>OR</strong></p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (609, '', 'Capecitabine + Oxaliplatin (XELOX)', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m<sup>2</sup>&nbsp;PO twice daily and dose of oxaliplatin to 100 mg/m<sup>2</sup>&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p>

<p><strong>OR</strong></p>

<p><strong>Capecitabine:&nbsp;</strong>1,750 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-7</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days. May decrease dose of capecitabine to 1,000-1,250 mg/m<sup>2</sup>&nbsp;PO twice daily to reduce risk of toxicity without compromising clinical efficacy.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (457, 'Carboplatin: Paraplatin
Atezolizumab: Tecentriq
Paclitaxel: Taxol
Bevacizumab: Avastin', 'Atezolizumab + Carboplatin + Paclitaxel + Bevacizumab ', '<p><u><strong>Atezolizumab</strong></u></p>

<p><strong><span style="font-family:Times">Renal </span></strong></p>

<ul>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>: no clinically significant effect on the systemic exposure of atezolizumab. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">eGFR &lt;30 mL/minute: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling (has not been studied).</span></span></span></li>
</ul>

<p><strong><u><span style="font-family:Times">Hepatic impairment</span></u></strong></p>

<p style="margin-left:0in; margin-right:0in"><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Prior to treatment:</span></span></em></span></p>

<ul>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">Mild impairment: (bilirubin &le; ULN and AST &gt; ULN <strong>or</strong> bilirubin &gt;1 - 1.5 x ULN and any AST):&nbsp;no clinically significant effect on the systemic exposure of atezolizumab and no dosage instructions provided in manufacturer&#39;s labeling.</span></span></span></li>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">Moderate to severe impairment: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>
</ul>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">During treatment:</span></span></em></span></p>

<p style="margin-left:48.0pt; margin-right:0in"><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">AST or ALT &gt;3 - 8 x ULN or bilirubin &gt;1.5 - 3 x ULN: Withhold treatment. Administer corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) followed by a corticosteroid taper. May resume when &le; grade 1 toxicity and prednisone dose is &le;10 mg/day (or equivalent).</span></span></span></p>

<p style="margin-left:48.0pt; margin-right:0in"><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">AST or ALT &gt;8 x ULN <strong>or</strong> bilirubin &gt;3 x ULN: Discontinue permanently. Administer corticosteroids (prednisone 1 - 2 mg/kg daily or equivalent) followed by a corticosteroid taper.</span></span></span></p>

<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><span style="font-family:Times"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><span style="font-family:Times"><strong>Hepatic Impairment:</strong> </span></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>

<p><strong><u><span style="font-family:Times">Bevacizumab</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal impairment:</span></strong></p>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Renal impairment prior to treatment:</span></span></em><span style="font-family:Times"><span style="color:#232323"> There are no recommended dosage adjustments.</span></span></span></p>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Renal toxicity during treatment:</span></span></em></span></p>

<ul>
	<li><span style="font-family:Times"><span style="color:#232323">If Proteinuria &ge;2 g/24 hours: Withhold bevacizumab until proteinuria &lt;2 g/24 hours. </span></span>The safety of continued Avastin treatment in patients with moderate to severe proteinuria has not been evaluated</li>
	<li><span style="font-family:Times"><span style="color:#232323">Discontinue in patients with nephrotic syndrome. &nbsp;</span></span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment: </span></strong><span style="font-family:Times"><span style="color:#232323">There are no recommended dosage adjustments.</span></span></p>

<p>&nbsp;</p>
', 'High', '', 'Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A. Papadimitrakopoulou, Mark A. Socinski & Alan Sandler (2020) Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Review of Respiratory Medicine, 14:2, 125-136, DOI: 10.1080/17476348.2020.1701439

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Atezolizumab</strong>&nbsp;1,200 mg given on day 1,&nbsp; <em>given first</em><br />
<strong>Bevacizumab</strong> 15 mg/kg&nbsp;given on day 1<br />
<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;given on day 1 OR 175 mg/m<sup>2</sup> in Asian patients<br />
<strong>Carboplatin</strong> AUC &nbsp;6 given on day 1&nbsp;</p>

<p><strong>21-day cycle for a maximum of 4 or 6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (557, 'Topotecan: Hycamtin', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'Low', '', 'Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4.', '', '<p><strong>Topotecan</strong>&nbsp;1.0mg/m<sup>2</sup>/day IV on days 1-5</p>

<p>Repeat cycle every 21 days. Reduce dose to 0.8mg/m<sup>2</sup>/day IV on days 1-3 in patients with prior pelvic radiation therapy.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (474, 'Carboplatin: Platinol
nab-Paclitaxl: Abraxane', 'Carboplatin + nab-Paclitaxel', '<p><strong><u>Carboplatin</u></strong></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p>&nbsp;</p>

<p><strong><u><span style="font-size:9.0pt"><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></span></u></strong></p>

<p><strong><span style="font-size:9.0pt"><span style="font-family:Times">Renal Impairment</span></span></strong></p>

<ul>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">CrCl 30-90 mL/min: No dosage adjustment necessary.</span></span></li>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">CrCl &lt;30 mL/min and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></li>
</ul>

<p><strong><span style="font-size:9.0pt"><span style="font-family:Times">Hepatic Impairment</span></span></strong></p>

<ul>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></span></li>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>
	<li><span style="font-size:9.0pt"><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></span></li>
</ul>
', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.

Abraxane for Injectable Suspension. (paclitaxel protein-bound
particles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf
', '', '<p><strong>Carboplatin</strong> AUC 6 IV once on day 1</p>

<p><strong>nab-Paclitaxel</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15</p>

<p><strong>21-day cycle for 4 cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (472, 'Pembrolizumab: Keytruda
nab-Paclitaxal: Abraxane
Carboplatin: Platinol', 'Carboplatin + Pembrolizumab + nab-paclitaxal', '<p><span style="font-size:12px"><strong><u><span style="font-family:&quot;Times New Roman&quot;">Pembrolizumab</span></u></strong></span></p>

<p><span style="font-size:12px"><strong><span style="font-family:&quot;Times New Roman&quot;">Renal Impairment:</span></strong></span></p>

<p><span style="font-size:12px"><em><span style="font-family:&quot;Times New Roman&quot;">Prior to treatment initiation:</span></em><span style="font-family:&quot;Times New Roman&quot;"> No dosage adjustment necessary. </span></span></p>

<p><span style="font-size:12px"><em><span style="font-family:&quot;Times New Roman&quot;">During treatment:</span></em></span></p>

<ul>
	<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</span></span></li>
</ul>

<p><span style="font-size:12px"><strong><span style="font-family:&quot;Times New Roman&quot;">Hepatic Impairment:</span></strong></span></p>

<p><span style="font-size:12px"><em><span style="font-family:&quot;Times New Roman&quot;">Prior to treatment initiation:</span></em></span></p>

<ul>
	<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</span></span></li>
</ul>

<p><span style="font-size:12px"><em><span style="font-family:&quot;Times New Roman&quot;">During treatment:</span></em></span></p>

<ul>
	<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</span></span>

	<ul style="list-style-type:circle">
		<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</span></span></li>
		<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</span></span>
		<ul style="list-style-type:square">
			<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</span></span></li>
			<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</span></span></li>
			<li><span style="font-size:12px"><span style="font-family:&quot;Times New Roman&quot;">If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</span></span></li>
		</ul>
		</li>
	</ul>
	</li>
</ul>

<p><span style="font-size:12px"><strong><u>Carboplatin</u></strong></span></p>

<p><span style="font-size:12px"><strong>Renal Impairment</strong>: AUC dosing</span></p>

<p><span style="font-size:12px"><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</span></p>

<p><span style="font-size:12px"><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</span></p>

<p><span style="font-size:12px"><strong><u><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></u></strong></span></p>

<p><span style="font-size:12px"><strong><span style="font-family:Times">Renal Impairment</span></strong></span></p>

<ul>
	<li><span style="font-size:12px"><span style="font-family:Times">CrCl 30-90 mL/min: No dosage adjustment necessary.</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:Times">CrCl &lt;30 mL/min and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></li>
</ul>

<p><span style="font-size:12px"><strong><span style="font-family:Times">Hepatic Impairment</span></strong></span></p>

<ul>
	<li><span style="font-size:12px"><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>
	<li><span style="font-size:12px"><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></span></li>
</ul>
', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />
<strong>Paclitaxal</strong>, nanoparticle albumin bound, 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15<br />
<strong>Pembrolizumab</strong>&nbsp;200 mg IV once on day 1,&nbsp;<em>administered&nbsp;first</em></p>

<p><strong>21-day cycle for 4 cycles</strong></p>

<p><strong>Followed by pembrolizumab monotherapy</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (558, 'Temsirolimus: Torisel', 'Temsirolimus', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Temsirolimus</strong>:<br />
	Unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Temsirolimus</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.', '', '<p><strong>Temsirolimus</strong>&nbsp;25mg IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (559, 'Carboplatin: Paraplatin<br>Cyclophosphamide: Cytoxan', 'CC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26.', '', '<p><strong>Carboplatin</strong>&nbsp;300mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (394, '', '5-Fluorouracil + Mitomycin-C + Radiation Therapy (RTOG/ECOG regimen)', '', '', '', '', '', '<p><strong>5 Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 and 29-32</p>

<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV (maximum of 20 mg) on days 1 and 29</p>

<p><strong>Radiation Therapy:</strong>&nbsp;180 cGy/day, 5 days/week for a total of 5 weeks (total dose, 4,500 cGy)</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (571, 'Altretamine: Hexalen', 'Altretamine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Altretamine</strong>:<br />
	No dose reduction&nbsp;</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Altretamine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate-High', '', 'Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9.', '', '<p><strong>Altretamine</strong>&nbsp;260mg/m<sup>2</sup>/day PO in 4 divided doses after meals and at bedtime</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (632, '', 'Vemurafenib + Irinotecan + Cetuximab (VIC)', '', '', '', '', 'METASTATIC', '<p><strong>Vemurafenib:&nbsp;</strong>960 mg PO twice daily</p>

<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cetuximab:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks. Use only for patients with <em>BRAF</em> V600E-mutant mCRC.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (480, 'Cisplatin: Platinol Gemcitabine: Gemzar', 'Cisplatin + Gemcitabine', '<p><strong><u>Cisplatin</u></strong></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>

<p><strong><u>Gemcitabine</u></strong></p>

<p><strong>Renal Impairment: </strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>
', 'High', '', 'SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1.', 'METASTATIC', '<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1<br />
<strong>Gemcitabine</strong>&nbsp;1250 mg/m<sup>2</sup>&nbsp;IV over 2 hours once per day on days 1 &amp; 8</p>

<p><strong>21-day cycle for up to 6 cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (460, 'Carboplatin: Paraplatin
Paclitaxel: Taxol
Bevacizumab: Avastin', 'Bevacizumab + Carboplatin + Paclitaxel', '<p><strong><u><span style="font-family:Times">Bevacizumab</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal impairment:</span></strong></p>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Renal impairment prior to treatment:</span></span></em><span style="font-family:Times"><span style="color:#232323"> There are no recommended dosage adjustments.</span></span></span></p>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Renal toxicity during treatment:</span></span></em></span></p>

<ul>
	<li><span style="font-family:Times"><span style="color:#232323">If Proteinuria &ge;2 g/24 hours: Withhold bevacizumab until proteinuria &lt;2 g/24 hours. </span></span>The safety of continued Avastin treatment in patients with moderate to severe proteinuria has not been evaluated</li>
	<li><span style="font-family:Times"><span style="color:#232323">Discontinue in patients with nephrotic syndrome. &nbsp;</span></span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment: </span></strong><span style="font-family:Times"><span style="color:#232323">There are no recommended dosage adjustments.</span></span></p>

<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><span style="font-family:Times"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><span style="font-family:Times"><strong>Hepatic Impairment:</strong> </span></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>
', '', '', 'Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC 6 IV over 15 to 30 minutes once on day <strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1,&nbsp;<strong>given first<br />
Bevacizumb</strong> 15 mg/kg IV once on day 1, given third</p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (458, 'Carboplatin: Paraplatin
Albumin-Bound Paclitaxel: Abraxane
Atezolizumab: Tecentriq', 'Atezolizumab + Carboplatin + nab-Paclitaxel ', '<p><u><strong>Atezolizumab</strong></u></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<ul>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>: no clinically significant effect on the systemic exposure of atezolizumab. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">eGFR &lt;30 mL/minute: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling (has not been studied).</span></span></span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic impairment:</span></strong></p>

<p style="margin-left:0in; margin-right:0in"><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">Prior to treatment:</span></span></em></span></p>

<ul>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">Mild impairment: (bilirubin &le; ULN and AST &gt; ULN <strong>or</strong> bilirubin &gt;1 - 1.5 x ULN and any AST):&nbsp;no clinically significant effect on the systemic exposure of atezolizumab and no dosage instructions provided in manufacturer&#39;s labeling.</span></span></span></li>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">Moderate to severe impairment: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>
</ul>

<p><span style="background-color:white"><em><span style="font-family:Times"><span style="color:#232323">During treatment:</span></span></em></span></p>

<ul>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">AST or ALT &gt;3 - 8 x ULN or bilirubin &gt;1.5 - 3 x ULN: Withhold treatment. Administer corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) followed by a corticosteroid taper. May resume when &le; grade 1 toxicity and prednisone dose is &le;10 mg/day (or equivalent).</span></span></span></li>
	<li><span style="background-color:white"><span style="font-family:Times"><span style="color:#232323">AST or ALT &gt;8 x ULN <strong>or</strong> bilirubin &gt;3 x ULN: Discontinue permanently. Administer corticosteroids (prednisone 1 - 2 mg/kg daily or equivalent) followed by a corticosteroid taper.</span></span></span></li>
</ul>

<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>
</ul>

<p>&nbsp;</p>
', 'High', '', 'Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC 6 IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;(<strong>nanoparticle albumin-bound)</strong> 100mg/m<sup>2&nbsp;</sup>IV on days 1, 8, 15<br />
<strong>Atezolizumab</strong> 1200mg IV on day 1&nbsp;</p>

<p><strong>21 day cycle for 4-6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (478, 'Cisplatin: Platinol
Docetaxel: Taxotere', 'Cisplatin + Docetaxel ', '<p><strong><u>Cisplatin</u></strong></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>

<p><strong><u>Docetaxel</u></strong></p>

<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>

<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>

<ul>
	<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>
	<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>
</ul>
', 'High', '', 'JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.

5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11.', 'METASTATIC', '<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycles</strong></p>

<p>OR</p>

<p><strong>Cisplatin</strong>&nbsp;80 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Docetaxel</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycle for 4 to 6 cycles</strong></p>

<p>&nbsp;</p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (481, 'Cisplatin: Platinol
Paclitaxel: Taxol', 'Cisplatin + Paclitaxel', '<p><strong><u>Cisplatin</u></strong></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>

<p>&nbsp;</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment:</span></strong><span style="font-family:Times"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><strong><span style="font-family:Times">Hepatic Impairment:</span></strong></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>
', 'High', '', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549

EORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.
', '', '<p><strong>Cisplatin</strong> 70 mg/m<sup>2 </sup>IV once on day 1<br />
<strong>Paclitaxel</strong> 175 mg/m<sup>2</sup> IV once on day 1</p>

<p><strong>21 day cycle for 4 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup> IV once on day 1<br />
<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup> IV over 3 hours once on day 1</p>

<p><strong>14 day cycle for up to 9 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup> IV once on day 2<br />
<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours, given on day 1</p>

<p><strong>Administered in 21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin </strong>80 mg/m2 IV once on day 1<br />
<strong>Paclitaxel </strong>200ng/m<sup>2</sup> IV over 3 hours on day 1</p>

<p><strong>Administered in 21 day cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (626, '', 'FOLFOX4 + Panitumumab', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (572, 'Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8.', '', '<p><strong>Doxorubicin liposome</strong>&nbsp;40-50mg/m<sup>2</sup>&nbsp;IV over 1 hour on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (573, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9.', '', '<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (627, '', 'FOLFIRI + Panitumumab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (463, 'Carboplatin: Paraplatin
Paclitaxel: Taxol', 'Carboplatin + Paclitaxel', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><span style="font-family:Times"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><span style="font-family:Times"><strong>Hepatic Impairment:</strong> </span></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>
', 'High', '', 'ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.

IPASS: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19.

MONET1: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.

BEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.

Paclitaxel injection. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC &nbsp;6 IV&nbsp;once on day 1<br />
<strong>Paclitaxel</strong>&nbsp;175 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>

<p><strong>21-day cycle for up to&nbsp;6 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Carboplatin</strong> AUC &nbsp;6 IV&nbsp;once on day 1<br />
<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV&nbsp;once on day 1</p>

<p><strong>21-day cycle for 3 or more cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (568, 'Gemcitabine: Gemzar<br>Carboplatin: Paraplatin', 'Gemcitabine/Carboplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32.', '', '<p><strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />
<strong>Carboplatin</strong>&nbsp;AUC of 4, IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (569, 'Paclitaxel: Taxol<br>Cisplatin: CDDP', 'Paclitaxel/IP Cisplatin/IP Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.', '', '<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1<br />
<strong>Cisplatin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IP on day 2<br />
<strong>Paclitaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IP on day 8</p>

<p>Repeat cycle every 21 days up to 6 cycles.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (570, 'Pemetrexed: Alimta<br>Carboplatin: Paraplatin', 'Pemetrexed/Carboplatin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	If CrCl &gt; 45 mL/min, no dose reduction<br />
	If CrCl &lt; 45 mL/min, do not use</li>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
</ul>
', 'High', '', 'Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6.', '', '<p><strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (630, '', 'FOLFIRI + Ziv-aflibercept', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Ziv-aflibercept:&nbsp;</strong>4 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (479, 'Cisplatin: Platinol
Etoposide: Vepesid', 'Cisplatin + Etoposide', '<p><strong><u>Cisplatin</u></strong></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li>No dose adjustments in manufacturers labeling</li>
	<li>Per Hendrayana, Wilmer, Kurth et al, 2017:
	<ul>
		<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
		<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
	</ul>
	</li>
</ul>

<p><strong>Renal&nbsp;Impairment</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', 'High', '', 'ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.

EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.
 Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.
 ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.
 Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28. ', 'METASTATIC', '<p><strong>Cisplatin</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Etoposide</strong> 120 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>

<p><strong>21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>

<p><strong>21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong>&nbsp;100 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>

<p><strong>21-day cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (482, 'Gemcitabine: Gemzar
Docetaxel: Taxotere', 'Gemcitabine + Docetaxel', '<p><strong><u>Gemcitabine</u></strong></p>

<p><strong>Renal Impairment: </strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>

<p><strong><u>Docetaxel</u></strong></p>

<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>

<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>

<ul>
	<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>
	<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>
</ul>
', 'Moderate', '', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.
', 'METASTATIC', '<p><strong>Docetaxel</strong> 85 mg/m<sup>2</sup> IV, 1 hour infusion, given on day 8<br />
<strong>Gemcitabine</strong> 1,000 mg/m<sup>2</sup> IV, 30-min infusion, given on day 1, 8</p>

<p><strong>Repeat cycle every 21 days</strong></p>

<p><strong>OR</strong></p>

<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV, 1 hour infusion, given on day 8<br />
<strong>Gemcitabine</strong> 1,100 mg/m<sup>2</sup> IV, 30-min infusion, given on day 1, 8</p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (465, 'Cisplatin: Platinol
Paclitaxel: Taxol', 'Cisplatin + Paclitaxel', '<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>

<p>&nbsp;</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><span style="font-family:Times"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><span style="font-family:Times"><strong>Hepatic Impairment:</strong> </span></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>
', 'High', '', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.

Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.

Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549', 'METASTATIC', '<p><strong>Cisplatin</strong> 70 mg/m<sup>2&nbsp;</sup>IV once on day 1<br />
<strong>Paclitaxel</strong> 175 mg/m<sup>2</sup>&nbsp;IV once on day 1&nbsp;</p>

<p><strong>21 day cycle for 4 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>

<p><strong>14 day cycle for up to 9 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 2<br />
<strong>Paclitaxel</strong>&nbsp;135 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours, given on day 1</p>

<p><strong>Administered in 21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin </strong>80 mg/m2 IV once on day 1<br />
<strong>Paclitaxel </strong>200ng/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p><strong>Administered in 21 day cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (483, 'Gemcitabine: Gemxar
Vinorelbine: Navelbine', 'Gemcitabine + Vinorelbine', '<p><strong><u>Gemcitabine</u></strong></p>

<p><strong>Renal Impairment: </strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>

<p>&nbsp;</p>

<p><strong><u>Vinorelbine</u></strong></p>

<p><strong>Renal Impairment</strong>: There are no dosage adjustments provided in the manufacturer&#39;s labeling.</p>

<ul>
	<li>Hemodialysis: Initially reduce dose to 20 mg/m<sup>2 </sup>once a week; administer either post-dialysis (on dialysis days) or on nondialysis days (Janus 2010)</li>
</ul>

<p><strong>Hepatic Impairment:</strong> Vinorelbine is metabolized substantially by the liver. There is limited data available on use in patients with baseline severe liver dysfunction. Caution is recommended with administration of vinorelbine in patients with baseline hepatic injury or impairment.</p>

<ul>
	<li>Total bilirubin &gt;2 - no dose modification</li>
	<li>Total bilirubin 2.1-3 - administer 50% of dose</li>
	<li>Total bilirubin &gt;3.0 - administer 25% of dose</li>
</ul>
', 'Moderate', '', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 'METASTATIC', '<p><strong>Gemcitibine</strong> 1000 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8<br />
<strong>Vinorelbine</strong> 25 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8</p>

<p><strong>21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Gemcitibine </strong>1000 mg/m<sup>2</sup> IV once per day on days 1, 8, and 15<br />
<strong>Vinorelbine </strong>25 mg/m<sup>2</sup> IV once per day on days 1, 8 and 15</p>

<p><strong>28-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine</strong> 1000 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8<br />
<strong>Vinorelbine</strong> 60 mg/m<sup>2</sup> PO once per day on days 1 &amp; 8</p>

<p><strong>21-day cycle for 3 cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (531, 'Cisplatin: CDDP<br>Fluorouracil: 5-FU', 'Cisplatin/5-Fluorouracil', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	If bilirubin &lt; 5 mg/dL, no dose reduction<br />
	If bilirubin &gt; 5 mg/dL, do not use<br />
	No dose reduction for infusional administration</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>5-Fluorouracil</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.', '', '<p><strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>5-Fluorouracil</strong>&nbsp;1000mg/m<sup>2</sup>/day IV continuous infusion on days 2-5</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (532, 'Cisplatin: CDDP<br>Vinorelbine: Navelbine', 'Cisplatin/Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60.', '', '<p><strong>Cisplatin</strong>&nbsp;80mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (584, 'Niraparib: Zejula', 'Niraparib', '<h4>Renal impairment</h4>

<ul>
	<li>Mild-to-moderate (CrCl &ge;30 mL/min): No dose adjustment required</li>
	<li>Severe or ESRD: Not studied</li>
</ul>

<h4>Hepatic impairment</h4>

<ul>
	<li>Mild: No dose adjustment required</li>
	<li>Moderate or severe: Not studied</li>
</ul>
', 'Moderate-High', '', 'Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164.', '', '<p><strong>Niraparib</strong>&nbsp;300mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (464, 'Carboplatin: Paraplatin
Pemetrexed: Alimta', 'Carboplatin + Pemetrexed', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Pemetrexed</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span class="marker"><span style="background-color:white"><span style="color:#232323">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>
	</li>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>
	</li>
</ul>

<p><strong><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">Hepatic Impairment:</span></span></span></strong></p>

<ul>
	<li><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></li>
</ul>
', '', '', 'Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O''Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC 5 or 6 IV on day 1<br />
<strong>Pemetrexed</strong> 500mg/m<sup>2</sup>&nbsp;on day 1</p>

<p><strong>21 day cycle for up to 6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (461, 'Carboplatin: Paraplatin
Nanoparticle albumin bound paclitaxel- Abraxane', 'Carboplatin + nab-Paclitaxel ', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>
</ul>
', '', '', 'CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30.', 'METASTATIC', '<p><strong>Carboplatin AUC&nbsp;</strong>AUC 6&nbsp;IV once on day 1</p>

<p><strong>Paclitaxel, nanoparticlealbumin-bound</strong> 100 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1, 8, 15 given first</p>

<p><strong>21-day cycle for 4 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (486, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere<br>Trastuzumab: Herceptin', 'TCH (metastatic)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate for TC, low for trastuzumab', '', 'Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008).', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose on day 1, then 2mg/kg IV on days 8 and 15, then 2mg/kg IV weekly thereafter</p>

<p>Repeat cycle every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (488, 'Trastuzumab: Herceptin<br>Vinorelbine: Navelbine', 'Trastuzumab/Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />
<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every week until disease progression.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (489, 'Trastuzumab: Herceptin<br>Gemcitabine: Gemzar', 'Trastuzumab/Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'O''Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />
<strong>Gemcitabine</strong>&nbsp;1200mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>

<p>Repeat cycles every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (664, '', 'TAS-102', '', '', '', '', 'METASTATIC', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (665, '', 'Pembrolizumab', '', '', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (739, '', 'Panitumumab', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (740, '', '5-Fluorouracil', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV over 24 hours weekly</p>

<p>Repeat cycle weekly for 4 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>

<p>Repeat cycle every 21-28 days.</p>

<p><strong>OR</strong></p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>

<p><strong>L-Leucovorin:&nbsp;</strong>5 mg/m<sup>2</sup>/day IV on days 1-14</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (718, '', 'Gemcitabine + Oxaliplatin', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 14 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (466, '', 'Cisplatin + Pemetrexed', '<p><u><strong>Cisplatin</strong></u></p>

<p><strong>Renal Impairment:</strong></p>

<ul>
	<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>
	<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>
	<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>
	<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>
	<li>Continuous renal replacement therapy: Administer 75% of dose.</li>
</ul>

<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>

<p><u><strong>Pemetrexed</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span class="marker"><span style="background-color:white"><span style="color:#232323">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>
	</li>
	<li>
	<p><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>
	</li>
</ul>

<p><strong><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">Hepatic Impairment:&nbsp;</span></span></span></strong><em><span style="font-family:Times New Roman,Times,serif"><span style="background-color:white"><span style="color:#232323">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></em></p>
', '', '', 'PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.

Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11.', 'METASTATIC', '<p><strong>Cisplatin</strong>&nbsp;70 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Pemetrexed</strong>&nbsp;500 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycle for up to 4 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cisplatin&nbsp;</strong>70 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Pemetrexed</strong>&nbsp;500 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycle for 4-6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (490, 'Trastuzumab: Herceptin<br>Capecitabine: Xeloda', 'Trastuzumab/Capecitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'Low', '', 'Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />
<strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose, then 6mg/kg IV on day 1 of all subsequent cycles<br />
<strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>

<p>Repeat cycle every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (491, 'Trastuzumab: Herceptin<br>Lapatinib: Tykerb ', 'Trastuzumab/Lapatinib', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Lapatinib</strong>:<br />
	If Child-Pugh C, reduce dose to 750 mg/d</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Lapatinib</strong>:<br />
	Not studied. Only 2% eliminated by kidneys</li>
</ul>
', 'Low', '', 'Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />
<strong>Lapatinib</strong>&nbsp;1000mg PO daily</p>

<p>Continue until disease progression.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (467, 'Gemcitabine: Gemzar
Carboplatin: Paraplatin', 'Gemcitabine + Carboplatin', '<p><u><strong>Gemcitabine</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>

<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<ul>
	<li><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</li>
</ul>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>
', 'High', '', 'Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14.

Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31.

Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR; Swedish Lung Cancer Study Group. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8.

Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O''Byrne K; British Thoracic Oncology Group. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.

Grigorescu, Alexandru C. et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, Volume 37, Issue 1, 9 - 14.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Cabroplatin</strong> AUC 4 IV once on day 1<br />
<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>

<p><strong>21 day cycle for 3 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />
<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>

<p><strong>21 day cycle for up to 4&nbsp;cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong> AUC 5&nbsp;IV once on day 1<br />
<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8, 15</p>

<p><strong>28-day cycle for 4 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />
<strong>Gemcitabine</strong> 1200mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>

<p><strong>21 day cycle for up to 6 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />
​​​​​​​<strong>Gemcitabine</strong> 1250mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>

<p><strong>21 day cycle for 4-&nbsp;6 cycles OR 28 day cycle for 4 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong> AUC 6&nbsp;IV once on day 1<br />
​​​​​​​<strong>Gemcitabine</strong> 1250mg/m<sup>2</sup>&nbsp;IV&nbsp;on days 1, 8&nbsp;</p>

<p><strong>21-day cycle for 4 to 6 cycles</strong>​​​​​​​</p>

<p><strong>OR</strong></p>

<p><strong>Cabroplatin</strong>&nbsp;300mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
​​​​​​​<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV&nbsp;on days 1, 8</p>

<p><strong>21-day cycle for 4 to 6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (492, 'Capecitabine: Xeloda<br>Lapatinib: Tykerb ', 'Capecitabine/Lapatinib', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Lapatinib</strong>:<br />
	If Child-Pugh C, reduce dose to 750 mg/d</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Lapatinib</strong>:<br />
	Not studied. Only 2% eliminated by kidneys</li>
</ul>
', 'Low', '', 'Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.', 'METASTATIC', '<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />
<strong>Lapatinib</strong>&nbsp;1250mg PO daily</p>

<p>Repeat cycle every 21 days.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (468, 'Gemcitabine: Gemzar
Docetaxel: Taxotere', 'Gemcitabine + Docetaxel', '<p><u><strong>Gemcitabine</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>

<p><u><strong>Docetaxel</strong></u></p>

<p><strong>Renal Impairment:</strong>&nbsp;No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>

<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt;&nbsp;5 x ULN)</em></p>

<ul>
	<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases&nbsp;&gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>
	<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of&nbsp;20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>
</ul>
', 'High', '', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.

Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.

Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x

Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 'METASTATIC', '<p><strong>Docetaxel</strong> 85 mg/m<sup>2</sup>&nbsp;IV, 1 hour&nbsp;infusion, given on day 8<br />
<strong>Gemcitabine</strong> 1,000 mg/m<sup>2</sup>&nbsp;IV, 30-min&nbsp;infusion, given on&nbsp;day 1, 8</p>

<p><strong>Repeat cycle every 21 days</strong></p>

<p>OR</p>

<p><strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV, 1 hour&nbsp;infusion, given on day 8<br />
<strong>Gemcitabine</strong> 1,100 mg/m<sup>2</sup>&nbsp;IV, 30-min&nbsp;infusion, given on&nbsp;day 1, 8</p>

<p><strong>Repeat cycle every 21 days</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (487, 'Gemcitabine: Gemzar<br>Carboplatin: Paraplatin<br>Trastuzumab: Herceptin', 'Gemcitabine/Carboplatin/Trastuzumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
</ul>
', 'High', '', 'Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86. ', 'METASTATIC', '<p><strong>Gemcitabine</strong>&nbsp;1500mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Carboplatin</strong>&nbsp;AUC of 2.5, IV on day 1<br />
<strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose on day 1, then 4mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (469, 'Carboplatin: Paraplatin
Docetaxel: Taxotere', 'Carboplatin + Docetaxel', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Docetaxel</strong></u></p>

<p><strong>Renal Impairment:</strong>&nbsp;No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>

<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt;&nbsp;5 x ULN)</em></p>

<ul>
	<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases&nbsp;&gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>
	<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of&nbsp;20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>
</ul>

<p>&nbsp;</p>
', 'Moderate', '', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />
<strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycle for maximum of 6 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (462, 'Carboplatin: Paraplatin
Etoposide: VP-16', 'Carboplatin + Etoposide', '<p><u><strong>Carboplatin</strong></u></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><u><strong>Etoposide:</strong></u></p>

<p><strong>Hepatic</strong></p>

<ul>
	<li>No dose adjustments in manufacturers labeling</li>
	<li>Per Hendrayana, Wilmer, Kurth et al, 2017:
	<ul>
		<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>
		<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>
	</ul>
	</li>
</ul>

<p><strong>Renal</strong></p>

<ul>
	<li>CrCl &gt;50 mL/minute: No adjustment required.</li>
	<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>
	<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>
</ul>
', '', '', 'EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong>:&nbsp;325 mg/m<sup>2</sup>&nbsp;IV over 60 minutes once on day 1<br />
<strong>Etoposide</strong>: 100 mg/m<sup>2</sup>&nbsp;once per day on days 1-3</p>

<p><strong>21 to 28 day cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (689, '', 'Irinotecan', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 3 weeks. Dose of irinotecan can be increased to 350 mg/m<sup>2</sup> based on toxicity.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (470, 'Gemcitabine: Gemxar
Vinorelbine: Navelbine', 'Gemcitabine + Vinorelbine ', '<p><u><strong>Gemcitabine</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>
	<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>
</ul>

<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>

<p>&nbsp;</p>

<p><u><strong>Vinorelbine</strong></u></p>

<p><strong>Renal Impairment</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&#39;s labeling.</p>

<ul>
	<li>Hemodialysis: Initially&nbsp;reduce dose to 20 mg/m<sup>2&nbsp;</sup>once a week; administer either post-dialysis (on dialysis days) or on nondialysis days (Janus 2010)</li>
</ul>

<p><strong>Hepatic Impairment:</strong> Vinorelbine is metabolized&nbsp;substantially by the liver. There is limited data available on use in patients with baseline severe liver dysfunction. Caution is recommended with administration of vinorelbine in patients with baseline hepatic injury or impairment.</p>

<ul>
	<li>Total bilirubin &gt;2 - no dose modification</li>
	<li>Total bilirubin 2.1-3&nbsp;&nbsp;- administer 50% of dose</li>
	<li>Total bilirubin &gt;3.0 - administer 25% of dose</li>
</ul>
', 'Moderate', '', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)

National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.

GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.

Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.

Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403. ', 'METASTATIC', '<p><strong>Gemcitibine</strong>&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8<br />
<strong>Vinorelbine</strong>&nbsp;25 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</p>

<p><strong>21-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Gemcitibine&nbsp;</strong>1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, and 15<br />
<strong>Vinorelbine&nbsp;</strong>25 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8 and 15</p>

<p><strong>28-day cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine</strong> 1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8<br />
<strong>Vinorelbine</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;PO once per day on days 1 &amp; 8</p>

<p><strong>21-day cycle for 3 cycles</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (471, 'Carboplatin: Paraplatin
Pembrolizumab: Keytruda
Paclitaxel: Taxol', 'Carboplatin + Pembrolizumab + Paclitaxal', '<p><strong><u><span style="font-family:&quot;Times New Roman&quot;">Pembrolizumab</span></u></strong></p>

<p><strong><span style="font-family:&quot;Times New Roman&quot;">Renal Impairment:</span></strong></p>

<p><em><span style="font-family:&quot;Times New Roman&quot;">Prior to treatment initiation:</span></em><span style="font-family:&quot;Times New Roman&quot;"> No dosage adjustment necessary. </span></p>

<p><em><span style="font-family:&quot;Times New Roman&quot;">During treatment:</span></em></p>

<ul>
	<li><span style="font-family:&quot;Times New Roman&quot;">Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</span></li>
	<li><span style="font-family:&quot;Times New Roman&quot;">Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</span></li>
</ul>

<p><strong><span style="font-family:&quot;Times New Roman&quot;">Hepatic Impairment:</span></strong></p>

<p><em><span style="font-family:&quot;Times New Roman&quot;">Prior to treatment initiation:</span></em></p>

<ul>
	<li><span style="font-family:&quot;Times New Roman&quot;">No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</span></li>
	<li><span style="font-family:&quot;Times New Roman&quot;">No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</span></li>
</ul>

<p><em><span style="font-family:&quot;Times New Roman&quot;">During treatment:</span></em></p>

<ul>
	<li><span style="font-family:&quot;Times New Roman&quot;">Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</span>

	<ul style="list-style-type:circle">
		<li><span style="font-family:&quot;Times New Roman&quot;">Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</span></li>
		<li><span style="font-family:&quot;Times New Roman&quot;">Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</span>
		<ul style="list-style-type:square">
			<li><span style="font-family:&quot;Times New Roman&quot;">AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</span></li>
			<li><span style="font-family:&quot;Times New Roman&quot;">AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</span></li>
			<li><span style="font-family:&quot;Times New Roman&quot;">If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</span></li>
		</ul>
		</li>
	</ul>
	</li>
</ul>

<p><strong><u>Carboplatin</u></strong></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment:</span></strong><span style="font-family:Times"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><strong><span style="font-family:Times">Hepatic Impairment:</span></strong></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>

<p><strong><u><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>
</ul>
', 'High', '', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.
', 'METASTATIC', '<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />
<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />
<strong>Pembrolizumab&nbsp;</strong>200 mg IV once on day 1,&nbsp;<strong>given first</strong></p>

<p><strong>21-day cycle for 4 cycles</strong></p>

<p>Followed by pembrolizumab maintenence&nbsp;</p>

<p>&nbsp;</p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (690, '', 'Ramucirumab', '', '', '', '', 'METASTATIC', '<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (459, 'Ipilimumab: Yervoy
Nivolumab: Opdivo', 'Ipilimumab + Nivolumab', '<p><strong><u><span style="font-family:Times">Ipilimumab</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<p><span style="font-family:Times"><em>Prior to treatment:</em> No dosage adjustment necessary.</span></p>

<p><em><span style="font-family:Times">Renal toxicity (immune mediated nephritis) during treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Grade 2 or 3 creatinine elevation: Withhold treatment; administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]) followed by a corticosteroid taper. </span>

	<ul>
		<li><span style="font-family:Times">If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 - 2 mg/kg/day (or equivalent).</span></li>
	</ul>
	</li>
	<li><span style="font-family:Times">Grade 4&nbsp;creatinine elevation: Permanently discontinue; administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by a corticosteroid taper.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<p><em><span style="font-family:Times">Prior to treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (bilirubin 1 - 1.5 x ULN or AST &gt;ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): insufficient data, there are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><em><span style="font-family:Times">Hepatic impairment during treatment:</span></em></p>

<ul>
	<li><span style="font-family:Times">Grade 2: Temporarily withhold treatment.</span></li>
	<li><span style="font-family:Times">Grade 3 or 4: Permanently discontinue treatment. Administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by&nbsp;1 month corticosteroid taper when LFTs show sustained improvement or return to baseline.&nbsp;&nbsp; </span></li>
</ul>

<p><u><strong>Nivolumab</strong></u></p>

<p><strong>Renal Impairment:&nbsp;</strong></p>

<ul>
	<li>Creatitine 1.5-6 x ULN- withhold dose</li>
	<li>Creatinine &gt; 6 x ULN- permanently discontinue<strong>&nbsp;</strong></li>
</ul>

<p><strong>Hepatic Impairment:&nbsp;</strong></p>

<ul>
	<li>Transaminases 3 - 5 x ULN or bilirubin 1.5-3 x ULN- withhold dose</li>
	<li>Transaminases &gt; 5 x ULN or bilirubin &gt; 3 x ULN - permnently discontinue</li>
</ul>
', 'Moderate', '', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.

Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf

Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf', 'METASTATIC', '<p><strong>Ipilimumab</strong> 1 mg/kg IV on day 1</p>

<p><strong>Nivolumab</strong> 3 mg/kg IV on day 1, 15, 29</p>

<p><strong>42-day (6 week) cycles for up to 4 cycles&nbsp;</strong></p>
', 106);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (691, '', 'Pembrolizumab', '', '', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (692, '', 'TAS-102', '', '', '', '', 'METASTATIC', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (693, '', 'Imatinib', '', '', '', '', 'ADJUVANT', '<p><strong>Imatinib:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;PO</p>

<p>Continue treatment for a total of 3 years.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (694, '', 'Imatinib', '', '', '', '', 'METASTATIC', '<p><strong>Imatinib:&nbsp;</strong>400 mg/day PO</p>

<p>Continue treatment until disease progression. May increase dose to 600 mg/day if no response is seen. In patients with KIT exon 9 (or exon 11) mutation, use dose of 800 mg/day (400 mg twice daily).</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (475, 'Carboplatin: Paraplatin
Docetaxel: Taxotere', 'Carboplatin + Docetaxel', '<p><strong><u>Carboplatin</u></strong></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u>Docetaxel</u></strong></p>

<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>

<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>

<ul>
	<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>
	<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity (Minami 2009)</li>
</ul>
', 'Moderate', '', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
2. Fossella F, et al. J Clin Oncol 2003; 21:3016.
3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.
4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC 6 IV once on day 1<br />
<strong>Docetaxel</strong> 75mg/m<sup>2</sup>&nbsp;IV once on day 1</p>

<p><strong>21-day cycle for up to 6 cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (476, 'Carboplatin:Paraplatin
Gemcitabine: Gemzar', 'Carboplatin + Gemcitabine', '<p><strong><u>Carboplatin</u></strong></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>
', 'High', '', 'Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. ', '', '<p><strong>Carboplatin</strong> AUC 5 IV once on day 1<br />
<strong>Gemcitabine</strong><sup>&nbsp;</sup>1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8</p>

<p><strong>21-day cycle for up to 6 cycles</strong></p>

<p><strong>OR</strong></p>

<p><strong>Carboplatin</strong> AUC 5.5 IV once on day 1<br />
<strong>Gemcitabine</strong><sup>&nbsp;</sup>1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8</p>

<p><strong>21-day cycle for up to 6 cycles</strong></p>
', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (484, 'Trastuzumab: Herceptin<br>Paclitaxel: Taxol', 'Trastuzumab/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose and then 2mg/kg weekly<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose and then 2mg/kg weekly<br />
<strong>Paclitaxel</strong>&nbsp;80mg/m<sup>2&nbsp;</sup>IV weekly</p>

<p>Repeat cycle every 4 weeks.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (485, 'Trastuzumab: Herceptin<br>Docetaxel: Taxotere', 'Trastuzumab/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.', 'METASTATIC', '<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose,&nbsp;then 2mg/kg IV on days 8 and 15<br />
<strong>Docetaxel</strong>&nbsp;35mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>First cycle is administered weekly for 3 weeks, with 1-week rest. For subsequent cycles:</p>

<p><strong>Trastuzumab&nbsp;</strong>2mg/kg IV weekly<br />
<strong>Docetaxel</strong>&nbsp;35 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 4 weeks.</p>
', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (600, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (FOLFIRI regimen)', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (695, '', 'Nilotinib', '', '', '', '', 'METASTATIC', '<p><strong>Nilotinib:&nbsp;</strong>400 mg PO twice daily</p>

<p>Continue treatment until disease progression.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (512, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389.', 'METASTATIC', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Paclitaxel</strong>&nbsp;80-100mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks</p>

<p>Repeat cycle every 4 weeks.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (513, 'Ixabepilome: Ixempra ', 'Ixabepilone', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />
	If AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m2<br />
	If AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2<br />
	If AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use<br />
	In combination with capecitabine:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />
	If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If CrCl &gt; 30 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14.', 'METASTATIC', '<p><strong>Ixabepilone</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (514, 'Vinorelbine: Navelbine', 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Fumoleau P, Delozier T, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.Semin Oncol. 1995 Apr;22(2 Suppl 5):22-8.', 'METASTATIC', '<p><strong>Vinorelbine</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 7 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (515, 'Doxorubicin: Adriamycin, various', 'Doxorubicin', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9.', 'METASTATIC', '<p><strong>Doxorubicin</strong>&nbsp;20mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 7 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (516, 'Gemcitabine: Gemzar', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81.', 'METASTATIC', '<p><strong>Gemcitabine</strong>&nbsp;725mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks.</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (517, 'Doxorubicin liposome: Doxil, various', 'Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6. ', 'METASTATIC', '<p><strong>Doxorubicin liposome</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (519, 'Eribulin: Halaven', 'Eribulin', '', 'Low', '', 'Cortes J, O''Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23. ', 'METASTATIC', '<p><strong>Eribulin</strong>&nbsp;1.4mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (518, 'Nab-paclitaxel: Abraxane', 'Nab-Paclitaxel', '', 'Low', '', 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O''Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).', 'METASTATIC', '<p><strong>Nab-paclitaxel</strong>&nbsp;260mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Nab-paclitaxel</strong>&nbsp;125mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (520, 'Abemaciclib: Verzenio', 'Abemaciclib', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Abemaciclib</strong><br />
	Child-Pugh C: Reduce dosing frequency to once daily</li>
</ul>
', 'Minimal', '', 'Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224.', 'METASTATIC', '<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (696, '', 'Sunitinib', '', '', '', '', 'METASTATIC', '<p><strong>Sunitinib:&nbsp;</strong>50 mg/day PO for 4 weeks</p>

<p>Repeat cycle every 6 weeks.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (697, '', 'Sorafenib', '', '', '', '', 'METASTATIC', '<p><strong>Sorafenib:&nbsp;</strong>400 mg/day PO twice daily</p>

<p>Continue treatment until disease progression.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (698, '', 'Regorafenib', '', '', '', '', 'METASTATIC', '<p><strong>Regorafenib:&nbsp;</strong>160 mg/day PO for 21 days</p>

<p>Repeat cycle every 28 days.</p>
', 8);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (527, 'Cisplatin: CDDP<br>Paclitaxel: Taxol<br>Bevacizumab: Avastin', 'Cisplatin/Paclitaxel/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', '', '<p><strong>Cisplatin&nbsp;</strong>50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;135-175mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (528, 'Paclitaxel: Taxol<br>Topotecan: Hycamtin', 'Paclitaxel/Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'High', '', '', '', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>&nbsp;IV on days 1-3&nbsp;</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (526, 'Paclitaxel: Taxol<br>Topotecan: Hycamtin<br>Bevacizumab: Avastin', 'Paclitaxel/Topotecan/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'High', '', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', '', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>/day IV on days 1-3<br />
<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (529, 'Bleomycin: Blenoxane<br>Ifosfamide: Ifex<br>Mesna: Mesnex<br>Cisplatin: CDDP', 'BIP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Bleomycin</strong>:<br />
	No dose reduction</li>
	<li><strong>Ifosfamide</strong>:<br />
	No dose reduction</li>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>
	<p><strong>Bleomycin</strong><br />
	CrCl &gt;50 mL/min: No dose reduction<br />
	CrCl 40-50 mL/min: 70% of normal dose<br />
	CrCl 30-40 mL/min: 60% of normal dose<br />
	CrCl 20-30 mL/min: 55% normal dose<br />
	CrCl 10-20 mL/min: 45% normal dose<br />
	CrCl 5-10 mL/min: 40% normal dose</p>
	</li>
	<li>
	<p><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</p>
	</li>
</ul>
', 'High', '', 'Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61.', '', '<p><strong>Bleomycin</strong>&nbsp;30U IV over 24 hours on day 1<br />
<strong>Ifosfamide</strong>&nbsp;5000mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 2<br />
<strong>Mesna</strong>&nbsp;6000mg/m<sup>2</sup>&nbsp;IV over 36 hours on day 2<br />
<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (530, 'Bleomycin: Blenoxane<br>Ifosfamide: Ifex<br>Mesna: Mesnex<br>Carboplatin: Paraplatin', 'BIC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Bleomycin</strong>:<br />
	No dose reduction</li>
	<li><strong>Ifosfamide</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>
	<p><strong>Bleomycin</strong><br />
	CrCl &gt;50 mL/min: No dose reduction<br />
	CrCl 40-50 mL/min: 70% of normal dose<br />
	CrCl 30-40 mL/min: 60% of normal dose<br />
	CrCl 20-30 mL/min: 55% normal dose<br />
	CrCl 10-20 mL/min: 45% normal dose<br />
	CrCl 5-10 mL/min: 40% normal dose</p>
	</li>
	<li>
	<p><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</p>
	</li>
</ul>
', 'High', '', 'Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9.', '', '<p><strong>Bleomycin</strong>&nbsp;30U IV on day 1<br />
<strong>Ifosfamide</strong>&nbsp;2000mg/m<sup>2</sup>&nbsp;IV on days 1-3<br />
<strong>Mesna</strong>&nbsp;400mg/m<sup>2</sup>&nbsp;IV, 15min before ifosfamide dose, then 400mg/m<sup>2</sup>&nbsp;IV at 4 and 8 hours following ifosfamide<br />
<strong>Carboplatin&nbsp;</strong>200mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (534, 'Cisplatin: CDDP<br>Gemcitabine: Gemzar', 'Cisplatin/Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'High', '', 'Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8.', '', '<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days for up to 6 cycles.</p>

<p>OR</p>

<p><strong>Cisplatin</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 28 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (535, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9.', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (536, 'Cisplatin: CDDP<br>Pemetrexed: Alimta', 'Cisplatin/Pemetrexed', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Pemetrexed</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Pemetrexed</strong>:<br />
	If CrCl &gt; 45 mL/min, no dose reduction<br />
	If CrCl &lt; 45 mL/min, do not use</li>
</ul>
', 'High', '', 'Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9.', '', '<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (537, 'Docetaxel: Taxotere', 'Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a.', '', '<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (538, 'Paclitaxel: Taxol', 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46.', '', '<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (539, 'Irinotecan: Camptosar', 'Irinotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Irinotecan</strong>:<br />
	If bilirubin 1-2 mg/dL, may need to reduce the dose<br />
	If bilurubin &gt; 2 mg/dL, may not use &nbsp;</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Irinotecan</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31.', '', '<p><strong>Irinotecan</strong>&nbsp;125mg/m<sup>2</sup>&nbsp;IV weekly for 4 weeks</p>

<p>Repeat cycle every 6 weeks.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (540, 'Topotecan: Hycamtin ', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'Low', '', 'Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5.', '', '<p><strong>Topotecan</strong>&nbsp;1.5mg/m<sup>2</sup>/day on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (541, 'Pemetrexed: Alimta', 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	If CrCl &gt; 45 mL/min, no dose reduction<br />
	If CrCl &lt; 45 mL/min, do not use</li>
</ul>
', 'Low', '', 'Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6.', '', '<p><strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 18);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (699, '', 'Gemcitabine + Capecitabine (GEM-CAP)', '', '', '', '', 'ADJUVANT', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Capecitabine:&nbsp;</strong>880 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (547, 'Doxorubicin: Adriamycin<br>Paclitaxel: Taxol', 'Doxorubicin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45. ', '', '<p><strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;150mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (548, 'Cisplatin: CDDP<br>Doxorubicin: Adriamycin<br>Paclitaxel: Taxol', 'Cisplatin/Doxorubicin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66.', '', '<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Doxorubicin</strong>&nbsp;45mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;160mg/m<sup>2</sup>&nbsp;over 3 hours on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (549, 'Cyclophosphamide: Cytoxan<br>Doxorubicin: Adriamycin<br>Cisplatin: CDDP', 'CAP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50.', '', '<p><strong>Cyclophosphamide</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (550, 'Carboplatin: Paraplatin<br>Doxorubicin liposome: Doxil, various', 'Carboplatin/Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
</ul>
', 'High', '', 'Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43.', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1<br />
<strong>Doxorubicin liposome</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (551, 'Paclitaxel: Taxol<br>Ifosfamide: Ifex', 'Paclitaxel/Ifosfamide', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ifosfamide</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31.', '', '<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />
<strong>Ifosfamide</strong>&nbsp;1600mg/m<sup>2</sup>/day IV on days 1-3</p>

<p>Repeat cycle every 21 days for up to 8 cycles.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (601, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4)', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (560, 'Cisplatin: CDDP<br>Cyclophosphamide: Cytoxan', 'CC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt;5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li>
	<p><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</p>
	</li>
	<li>
	<p><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</p>
	</li>
</ul>
', 'High', '', 'Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17.', '', '<p><strong>Cisplatin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (561, 'Cisplatin: CDDP<br>Paclitaxel: Taxol', 'CP', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.', '', '<p><strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 2<br />
<strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (562, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol', 'Carboplatin/Paclitaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong>:<br />
	For 3-hour infusion:<br />
	If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />
	For 24-hour infusion:<br />
	If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />
	If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />
	If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />
	If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Paclitaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36.', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6-7.5, IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day</p>

<p>Repeat cycle every 21 days.</p>

<p>OR</p>

<p><strong>Carboplatin</strong>&nbsp;AUC of 2, IV on days 1, 8, and 15<br />
<strong>Paclitaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (563, 'Carboplatin: Paraplatin<br>Paclitaxel: Taxol<br>Bevacizumab: Avastin', 'Carboplatin/Paclitaxel/Bevacizumab', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Bevacizumab</strong><br />
	No dose reduction</li>
	<li><strong>Carboplatin</strong><br />
	No dose reduction</li>
	<li><strong>Paclitaxel</strong><br />
	Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup><br />
	Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup><br />
	Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup><br />
	Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Bevacizumab</strong><br />
	If proteinuria &ge;2g/24 hours: withhold bevacizumab until proteinuria &lt;2g/24 hours. Discontinue in patients with nephrotic syndrome. &nbsp;</li>
	<li><strong>Carboplatin</strong><br />
	Dosing based on AUC</li>
	<li><strong>Paclitaxel</strong><br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />
<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days for 6 cycles, then maintenance bevacizumab for cycles 7-22.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (564, 'Carboplatin: Paraplatin<br>Docetaxel: Taxotere', 'Carboplatin/Docetaxel', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Docetaxel</strong>:<br />
	If bilirubin &gt; upper normal limit, do not use<br />
	If&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong>:<br />
	Dosing based on AUC</li>
	<li><strong>Docetaxel</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5.', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />
<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (565, 'Carboplatin: Paraplatin<br>Doxorubicin liposome: Doxil, various', 'Carboplatin/Doxorubicin Liposome', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong><br />
	No dose reduction</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Carboplatin</strong><br />
	Dosing based on AUC</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).', '', '<p><strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1<br />
<strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (575, 'Topotecan: Hycamtin ', 'Topotecan', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Topotecan</strong>:<br />
	If CrCl &gt; 40 mL/min, no dose reduction<br />
	If CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>
</ul>
', 'Low', '', 'Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7.', '', '<p><strong>Topotecan</strong>&nbsp;1.5mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (574, 'Ixabepilone: Ixempra', 'Ixabepilone', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />
	If AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m<sup>2</sup><br />
	If AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m<sup>2</sup><br />
	If AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use<br />
	In combination with capecitabine:<br />
	If AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />
	If AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Ixabepilone</strong>:<br />
	If CrCl &gt; 30 mL/min, no dose reduction</li>
</ul>
', 'Low', '', 'De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53.', '', '<p><strong>Ixabepilone</strong>&nbsp;20mg/m<sup>2</sup> IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (576, 'Gemcitabine: Gemzar', 'Gemcitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Gemcitabine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Moderate', '', 'Lund B, Hansen OP, et al. Phase II study of gemcitabine (2'',2''-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3.', '', '<p><strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks</p>

<p>Repeat cycle every 4 weeks.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (577, 'Etoposide: VP-16', 'Etoposide', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Etoposide</strong>:<br />
	If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br />
	If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Etoposide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'Low', '', 'Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58 Suppl 3:43-9.', '', '<p><strong>Etoposide</strong>&nbsp;50mg/m<sup>2</sup>/day PO on days 1-21</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (578, 'Vinorelbine: Navelbine', 'Vinorelbine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	If bilirubin 2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Vinorelbine</strong>:<br />
	No dose reduction</li>
</ul>
', 'Low', '', 'Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.', '', '<p><strong>Vinorelbine</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (579, 'Pemetrexed: Alimta', 'Pemetrexed', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Pemetrexed</strong>:<br />
	If CrCl &gt; 45 mL/min, no dose reduction<br />
	If CrCl &lt; 45 mL/min, do not use</li>
</ul>
', 'Low', '', 'Miller DS, et al. J Clin Oncol 2009;27:2686-2691.', '', '<p><strong>Pemetrexed</strong>&nbsp;900mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (580, 'Bevacizumab: Avastin', 'Bevacizumab', '', 'Low', '', 'Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.', '', '<p><strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (581, 'Capecitabine: Xeloda', 'Capecitabine', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	No dose reduction</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Capecitabine</strong>:<br />
	If CrCl 30-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
</ul>
', 'Moderate', '', 'Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74.', '', '<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (582, 'Olaparib: Lynparza', 'Olaparib', '<h4>Renal impairment</h4>

<ul>
	<li><strong>Olaparib</strong><br />
	CrCl 31-50 mL/min: Reduce dose to 200mg BID</li>
</ul>
', 'Low', '', 'Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.', '', '<p><strong>Olaparib</strong>&nbsp;400mg PO BID</p>

<p>Repeat cycle every 28 days.</p>

<p>OR&nbsp;</p>

<p><strong>Olaparib&nbsp;</strong>(maintenance after 1st-line chemo) 300mg PO BID</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (521, 'Olaparib: Lynparza ', 'Olaparib', '<h4>Renal impairment</h4>

<ul>
	<li><strong>Olaparib</strong><br />
	CrCl 31-50 mL/min: Reduce dose to 200mg BID</li>
</ul>
', 'Low', '', 'Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.', 'METASTATIC', '<p><strong>Olaparib&nbsp;</strong>300mg PO BID</p>

<p>Repeat cycle every 28 days.</p>
', 5);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (583, 'Rucaparib: Rubraca', 'Rucaparib', '<h4>Hepatic impairment</h4>

<ul>
	<li>Mild (total bilirubin &le;upper limit of normal [ULN] and AST &gt;ULN, or total bilirubin between 1-1.5x ULN and any AST): No dose adjustment required</li>
	<li>Moderate-to-severe (total bilirubin &gt;1.5x ULN): Lack of data; no recommendation available</li>
</ul>

<h4>Renal impairment</h4>

<ul>
	<li>Mild-to-moderate (CrCl 30-89): No dose adjustment required</li>
	<li>Severe (CrCl &lt;30 mL/min) or patients on dialysis: Lack of data; no recommendation available</li>
</ul>
', 'Moderate-High', '', 'Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87.', '', '<p><strong>Rucaparib</strong>&nbsp;600mg PO daily</p>

<p>Repeat cycle every 28 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (585, 'Bleomycin: Blenoxane<br>Etoposide: VP-16<br>Cisplatin: CDDP', 'BEP (germ cell)', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Bleomycin</strong>:<br />
	No dose reduction</li>
	<li><strong>Cisplatin</strong>:<br />
	No dose reduction</li>
	<li><strong>Etoposide</strong>:<br />
	If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br />
	If bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Bleomycin</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Cisplatin</strong>:<br />
	If CrCl 30-60 mL/min, reduce dose by 50%<br />
	If CrCl &lt; 30 mL/min, do not use</li>
	<li><strong>Etoposide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
</ul>
', 'High', '', 'Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700.', '', '<p><strong>Bleomycin</strong>&nbsp;30U IV on days 2, 9, and 16<br />
<strong>Etoposide</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on days 1-5<br />
<strong>Cisplatin</strong>&nbsp;20mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 99);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (595, '', 'Oxaliplatin + Capecitabine (XELOX)', '', '', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 3 weeks for a total of 8 cycles (6 months total). Dose may be decreased to 850 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising efficacy.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (596, '', 'LV5FU2 (deGramont regimen)', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>OR</strong></p>

<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (597, '', 'Capecitabine', '', '', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days for a total of 8 cycles. Does may be decreased to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising clinical efficacy.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (598, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (Modified IFL Saltz regimen)', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>

<p>Repeat cycle every 3 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (599, '', 'Irinotecan + 5-Fluorouracil + Leucovorin (Douillard regimen)', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 g/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (587, 'Erivedge', 'Vismodegib ', '<p>No Dose Adjustment is necessary in Renal or Hepatic impairment</p>
', 'Low', '', 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/', '', '<p>Vismodegib 150 mg P.O. Once&nbsp;a day</p>
', 111);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (588, 'Odomzo', 'Sonidegib', '<p>No Adjustment is needed in Renal Impairment</p>

<p>No Adjustment is needed in Mild and Moderate Hepatic Impairment</p>

<p>Use Caution in Severe Hepatic Impairment</p>
', 'Low', '', 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext', '', '<p><strong>Sondegib 200 mg P.O. Once a Day</strong></p>
', 111);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (589, '', '5-Fluorouracil + Leucovorin (Mayo Clinic schedule)', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5, administered before 5-fluorouracil</p>

<p>Repeat cycle every 4-5 weeks for a total of 6 cycles.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (590, '', '5-Fluorouracil + Leucovorin (weekly schedule, high dose)', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p>

<p>Repeat cycle every 8 weeks for a total of 4 cycles (32 weeks total)</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (591, '', '5-Fluorouracil + Leucovorin (weekly schedule, low dose)', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p>Repeat cycle every 8 weeks for a total of 4 or 6 cycles (32 or 48 weeks total)</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (592, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4)', '', '', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total)</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (593, '', 'Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7)', '', '', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total)</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (594, '', 'FLOX', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered 1 hour after LV infusion begun</p>

<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p>

<p><strong>Oxaliplatin:</strong>&nbsp;85 mg/m<sup>2</sup>&nbsp;IV administered before 5-fluorouracil and LV and on days 1, 15, and 29</p>

<p>Repeat cycle every 8 weeks for a total of 3 cycles (6 months total)</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (719, '', '5-Fluorouracil + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1, followed by 600 mg/m<sup>2</sup>&nbsp;IV infusion over 22 hours on days 1 and 2</p>

<p><strong>Cisplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (610, '', 'Capecitabine + Irinotecan (XELIRI)', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Irinotecan:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m<sup>2</sup>&nbsp;PO twice daily and dose of irinotecan to 200 mg/m<sup>2</sup>&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p>

<p><strong>OR</strong></p>

<p><strong>Capecitabine:&nbsp;</strong>1,500 mg/m<sup>2</sup>&nbsp;PO twice daily on days 2-8</p>

<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (611, '', 'Capecitabine + Mitomycin-C', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat capecitabine every 3 weeks and mitomycin-C every 6 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (612, '', 'Oxaliplatin + Irinotecan (IROX regimen)', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (613, '', '5-Fluorouracil + Leucovorin (Roswell Park schedule, high dose)', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p>Repeat cycle every 8 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (614, '', '5-Fluorouracil + Leucovorin + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 8 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (615, '', '5-Fluorouracil + Leucovorin (German schedule, low dose)', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>600 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>

<p>Repeat cycle every 8 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (616, '', '5-Fluorouracil + Leucovorin (de Gramont regimen)', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV and then 600 mg/m<sup>2</sup>&nbsp;IV for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (617, '', 'FOLFOX4 + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Bevacizumab:&nbsp;</strong>10 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (618, '', 'LV5FU2 + Mitomycin-C', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat 5-FU/LV every 2 weeks and mitomycin-C every 4 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (619, '', 'Capecitabine + Oxaliplatin (XELOX) + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>850 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg every 3 weeks</p>

<p>Repeat cycle every 21 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (620, '', 'Cetuximab + Bevacizumab + Irinotecan', '', '', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p><strong>Bevacizumab:</strong>&nbsp;5 mg/kg IV every 2 weeks</p>

<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (621, '', 'Cetuximab + Bevacizumab', '', '', '', '', 'METASTATIC', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>

<p>Repeat cycle every 2 weeks</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (622, '', 'Irinotecan + Cetuximab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:</strong>&nbsp;125 mg/m<sup>2</sup>&nbsp;IV weekly for 4 weeks</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 6 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>Irinotecan:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (623, '', 'FOLFIRI + Cetuximab', '', '', '', '', 'METASTATIC', '<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (624, '', 'FOLFOX4 + Cetuximab', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (625, '', 'FOLFOX6 + Cetuximab', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>

<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose and then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>

<p>Repeat cycle every 2 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (700, '', 'FOLFIRINOX', '', '', '', '', 'ADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p>Repeat cycle every 2 weeks for a total of 12 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (635, '', '5-Fluorouracil + Mitomycin-C + Radiation Therapy (EORTC regimen)', '', '', '', '', '', '<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-26</p>

<p><strong>Mitomycin-C:</strong>&nbsp;10 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 4 weeks (total dose, 3,600 cGy)</p>

<p>Chemotherapy is given concurrently with radiation therapy. There is a 2-week break following the completion of this first treatment, after which the second treatment is initiated with concurrent chemotherapy and radiation therapy.</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-17</p>

<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 2,340 cGy over 17 days</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (636, '', 'Capecitabine + Mitomycin-C + Radiation Therapy', '', '', '', '', '', '<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday</p>

<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV on days 1 and 29</p>

<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 5,500 cGy over 6 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (637, '', '5-Fluorouracil + Cisplatin + Radiation Therapy', '', '', '', '', '', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 of each week of radiation therapy</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on days 1, 29, 57, and 85 during radiation therapy</p>

<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 4,500 cGy over 5 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (638, '', 'XELOX + Radiation Therapy', '', '', '', '', '', '<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday for 6 weeks</p>

<p><strong>Oxaliplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 22, 29</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 6 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (641, '', 'mFOLFOX6', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, then 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycles every 2 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (640, '', 'Carboplatin + Paclitaxel', '', '', '', '', 'METASTATIC', '<p><strong>Carboplatin:&nbsp;</strong>AUC of 5, IV on day 1</p>

<p><strong>Paclitaxel:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycles every 3 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (639, '', '5-Fluorouracil + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycles every 4 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (644, '', 'Capecitabine', '', '', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycles every 21 days for a total of 8 cycles.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (645, '', 'Gemcitabine + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Cisplatin:&nbsp;</strong>25 mg/m<sup>2</sup>&nbsp;on days 1 and 8</p>

<p>Repeat cycle every 21 days for 8 cycles.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (642, '', 'Pembrolizumab', '', '', '', '', 'METASTATIC', '<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1 or 200 mg IV on day 1</p>

<p>Repeat cycles every 2 weeks if using 10 mg/kg, or every 3 weeks if using 200 mg dosing.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (643, '', 'Nivolumab', '', '', '', '', 'METASTATIC', '<p><strong>Nivolumab:&nbsp;</strong>480 mg IV on day 1</p>

<p>Repeat cycles every 4 weeks.</p>
', 91);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (646, '', 'Paclitaxel + Carboplatin + Radiation Therapy (CROSS regimen)', '', '', '', '', 'NEOADJUVANT', '<p><strong>Paclitaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 15, 22 and 29</p>

<p><strong>Carboplatin:&nbsp;</strong>AUC of 2, IV on days 1, 8, 15, 22 and 29</p>

<p>Chemotherapy concurrently with radiation therapy of 1.8 Gy in 23 fractions for total dose of 41.4 Gy over 5 weeks.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (647, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (PRODIGE5/ACCORD17)', '', '', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 28 days for a total of 2 cycles given concurrently with radiation therapy. Two additional cycles are given every 21 days after completion of the combined modality therapy.</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (648, '', 'FOLFOX + Radiation Therapy (PRODIGE5/ACCORD17)', '', '', '', '', 'NEOADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 1,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before the bolus 5-fluorouracil dose</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p>

<p>Repeat cycle every 2 weeks for a total of 6 cycles with the first 3 cycles given concurrently with radiation therapy.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (649, '', 'CAPOX + Radiation Therapy', '', '', '', '', 'NEOADJUVANT', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on days 1, 15, and 29</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 for 5 weeks</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week to a total dose of 5,400 cGy</p>

<p>Chemotherapy is given concurrently with radiation therapy, followed by surgical resection</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (650, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (FFD French regimen)', '', '', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>15 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 6,600 cGy over 6.5 weeks</p>

<p>Chemotherapy is given concurrently with radiation therapy for 2 cycles starting on days 1 and 22, followed by surgical resection.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (709, '', 'Gemcitabine + Oxaliplatin', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 2</p>

<p>Repeat cycle every 2 weeks.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (651, '', '5-Fluorouracil + Cisplatin + Radiation Therapy (Hopkins/Yale regimen)', '', '', '', '', '', '<p><strong>5-Fluorouracil:</strong>&nbsp;225 mg/m<sup>2</sup>/day IV continuous infusion on days 1-30</p>

<p><strong>Cisplatin:&nbsp;</strong>20 mg/m<sup>2</sup>/day IV on days 1-5 and 26-30</p>

<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day to a total dose of 4,400 cGy</p>

<p>Chemotherapy is given concurrently with radiation therapy. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>

<p><strong>Adjuvant Chemotherapy:</strong></p>

<p><strong>Paclitaxel:&nbsp;</strong>135 mg/m<sup>2</sup>&nbsp;IV for 24 hours on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Adjuvant chemotherapy is given 8-12 weeks after esophagectomy, and each cycle is given every 21 days for a total of 3 cycles.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (652, '', 'MAGIC Trial', '', '', '', '', '', '<p><strong>Preoperative ECF Chemotherapy:</strong></p>

<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-21</p>

<p>Repeat cycle every 21 days for 3 cycles.</p>

<p>Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>

<p><strong>Adjuvant Chemotherapy:</strong></p>

<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-21</p>

<p>Repeat cycle every 21 days for 3 cycles.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (653, '', 'FLOT4 Trial', '', '', '', '', '', '<p><strong>Preoperative FLOT chemotherapy:</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>

<p>Repeat cycle every 2 weeks for 4 cycles. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>

<p><strong>Adjuvant Chemotherapy:</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>

<p>Repeat cycle every 2 weeks for 4 cycles. Note that only patients with resectable gastric or GE junction tumors were included in this trial.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (654, '', '5-Fluorouracil + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle on weeks 1, 5, 8, and 11.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (655, '', 'FOLFOX', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>

<p><strong>Leucovorin:</strong>&nbsp;400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (656, '', 'Paclitaxel + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>

<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (657, '', 'Capecitabine + Oxaliplatin', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (658, '', 'ECF', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (659, '', 'EOF', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (660, '', 'ECX', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (661, '', 'EOX', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (662, '', 'Paclitaxel', '', '', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>

<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (663, '', 'Docetaxel', '', '', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 94);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (666, '', 'FLOT4 Trial', '', '', '', '', '', '<p><strong>Preoperative FLOT chemotherapy:</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>

<p>Repeat cycle every 2 weeks for 4 cycles. Followed by gastrectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>

<p><strong>Adjuvant Chemotherapy:</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>

<p>Repeat cycle every 2 weeks for 4 cycles. Note that only patients with resectable gastric and GE junction tumors were included in this trial.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (710, '', 'Gemcitabine + Erlotinib', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>

<p><strong>Erlotinib:&nbsp;</strong>100 mg PO daily</p>

<p>Repeat 3-week cycles every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (667, '', '5-Fluorouracil + Leucovorin', '', '', '', '', 'ADJUVANT', '<p>One cycle of chemotherapy is administered as follows:</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>&nbsp;425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Chemoradiotherapy is then started 28 days after the start of the initial cycle of chemotherapy as follows:</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 4,500 cGy, starting on day 28</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p>

<p>Chemoradiotherapy is followed by 2 cycles of chemotherapy that are given 1 month apart and include:</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup> IV on days 1-5</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (668, '', 'Capecitabine + Oxaliplatin', '', '', '', '', 'ADJUVANT', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days for 6 months.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (669, '', 'DCF', '', '', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>750 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (706, '', '5-Fluorouracil + Leucovorin', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (670, 'Temodar', 'Glioblastoma - Temozolamide + RT ', '', '', '', '', 'ADJUVANT', '<h4 style="margin-left:0px; margin-right:0px; text-align:left">Chemotherapy</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li><a href="https://hemonc.org/wiki/Temozolomide_(Temodar)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Temozolomide (Temodar)">Temozolomide (Temodar)</a> 75 mg/m<sup>2</sup> PO or IV once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days</li>
</ul>

<h4 style="margin-left:0px; margin-right:0px; text-align:left">Supportive medications</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li>PCP prophylaxis with ONE of the following:
	<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
		<li><a href="https://hemonc.org/wiki/Trimethoprim-Sulfamethoxazole_(Bactrim_DS)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Trimethoprim-Sulfamethoxazole (Bactrim DS)">Trimethoprim/Sulfamethoxazole (Bactrim)</a></li>
		<li><a href="https://hemonc.org/wiki/Pentamidine_(Nebupent)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Pentamidine (Nebupent)">Pentamidine (Nebupent)</a> 300 mg nebulized inhaled</li>
	</ul>
	</li>
	<li><a href="https://hemonc.org/wiki/Metoclopramide_(Reglan)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Metoclopramide (Reglan)">Metoclopramide (Reglan)</a> or <a href="https://hemonc.org/wiki/Category:Serotonin_5-HT3_antagonists" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Category:Serotonin 5-HT3 antagonists">5-HT3 antagonist</a> recommended before the initial doses of radiation therapy &amp; temozolomide</li>
</ul>

<h4 style="margin-left:0px; margin-right:0px; text-align:left">Radiotherapy</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li>Concurrent <a href="https://hemonc.org/wiki/External_beam_radiotherapy" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="External beam radiotherapy">radiation therapy</a>, 2 Gy fractions x 30 fractions, for a total dose of 60 Gy</li>
</ul>
', 1);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (701, '', '5-Fluorouracil + Leucovorin', '', '', '', '', 'ADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (702, '', 'Gemcitabine', '', '', '', '', 'ADJUVANT', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days for a total of 6 cycles.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (704, '', 'Gemcitabine + Radiation Therapy (ECOG regimen)', '', '', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>600 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy. Chemotherapy and radiation therapy started on the same day and given concurrently.</p>

<p><strong>Four weeks after the completion of chemoradiation:</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 4 weeks for a total of 5 cycles. For patients&nbsp;with locally advanced unresectable pancreatic adenocarcinoma.&nbsp;</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (703, '', 'RTOG Chemoradiation Regimen', '', '', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Followed by concurrent chemoradiation:</strong></p>

<p><strong>5-Fluorouracil:&nbsp;</strong>250 mg/m<sup>2</sup>/day IV continuous infusion during radiation therapy</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p>

<p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p>

<p><strong>After chemoradiation:</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 4 weeks for a total of 3 cycles. Adjuvant chemotherapy is given to patients with complete gross total resection of pancreatic adenocarcinoma.</p>

<p>&nbsp;</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (705, '', 'Capecitabine-based Chemoradiotherapy (SCALOP Regimen)', '', '', '', '', 'LOCALLY ADVANCED', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>

<p>Repeat cycle every 28 days for 3 cycles. Patients with stable or responding disease receive one additional cycle, followed by concurrent chemoradiation.</p>

<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily Monday-Friday for 6 weeks</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p>

<p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (707, '', 'Gemcitabine + Capecitabine (GEM-CAP)', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>

<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (711, '', 'FOLFIRINOX', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (712, '', 'Nab-Paclitaxel + Gemcitabine', '', '', '', '', 'METASTATIC', '<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (713, '', 'Liposomal Irinotecan + 5-Fluorouracil + Leucovorin', '', '', '', '', 'METASTATIC', '<p><strong>Liposomal Irinotecan:&nbsp;</strong>70 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (671, '', 'AML FLT3 positive ', '', '', '', '', 'INDUCTION', '<h4 style="margin-left:0px; margin-right:0px; text-align:left">Chemotherapy</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li><a href="https://hemonc.org/wiki/Cytarabine_(Ara-C)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Cytarabine (Ara-C)">Cytarabine (Ara-C)</a> 200 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m<sup>2</sup>)</li>
	<li><a href="https://hemonc.org/wiki/Daunorubicin_(Cerubidine)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Daunorubicin (Cerubidine)">Daunorubicin (Cerubidine)</a> 60 mg/m<sup>2</sup> IV once per day on days 1 to 3</li>
	<li><a href="https://hemonc.org/wiki/Midostaurin_(Rydapt)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Midostaurin (Rydapt)">Midostaurin (Rydapt)</a> 50 mg PO twice per day on days 8 to 21</li>
</ul>
', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (679, '', 'Docetaxel + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (672, '', 'AML IDH1 mutated  First line therapy ', '', '', '', '', 'FIRST LINE ', '<h4 style="margin-left:0px; margin-right:0px; text-align:left">Chemotherapy</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li><a href="https://hemonc.org/wiki/Ivosidenib_(Tibsovo)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Ivosidenib (Tibsovo)">Ivosidenib (Tibsovo)</a> 500 mg PO once per day</li>
</ul>
', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (673, '', 'AML IDH2 mutated First line therapy ', '', '', '', '', 'FIRST LINE ', '<h4 style="margin-left:0px; margin-right:0px; text-align:left">Chemotherapy</h4>

<ul style="list-style-type:disc; margin-left:1.6em; margin-right:0px">
	<li><a href="https://hemonc.org/wiki/Enasidenib_(Idhifa)" style="background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;" title="Enasidenib (Idhifa)">Enasidenib (Idhifa)</a> 100 mg PO once per day</li>
</ul>
', 33);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (674, '', 'CF', '', '', '', '', 'METASTATIC', '<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (675, '', 'ECF', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (676, '', 'EOF', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (677, '', 'ECX', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (678, '', 'EOX', '', '', '', '', 'METASTATIC', '<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (680, '', 'Capecitabine + Cisplatin', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (681, '', 'XP + Trastuzumab', '', '', '', '', 'METASTATIC', '<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (682, '', 'FP + Trastuzumab', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1-5</p>

<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks.</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (683, '', 'FLO', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV on day 1 as a continuous infusion over 24 hours</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion</p>

<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 14 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (684, '', 'FOLFOX', '', '', '', '', 'METASTATIC', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1-3</p>

<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 2 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (685, '', 'Paclitaxel + Ramucirumab', '', '', '', '', 'METASTATIC', '<p><strong>Paclitaxel:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>

<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on days 1 and 15</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (686, '', '5-Fluorouracil', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 28 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (687, '', '5-Fluorouracil + Leucovorin', '', '', '', '', 'METASTATIC', '<p><strong>5-Fluorouracil:&nbsp;</strong>370 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>

<p>Repeat cycle every 21 days.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (688, '', 'Docetaxel', '', '', '', '', 'METASTATIC', '<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>

<p><strong>OR</strong></p>

<p><strong>Docetaxel:&nbsp;</strong>36 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks.</p>

<p>Repeat cycle every 8 weeks.</p>
', 92);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (726, '', 'Floxuridine', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Floxuridine (FUDR):&nbsp;</strong>0.3 mg/kg/day HAI on days 1-14</p>

<p><strong>Dexamethasone:&nbsp;</strong>20 mg HAI on days 1-14</p>

<p><strong>Heparin:&nbsp;</strong>50,000 U HAI on days 1-14</p>

<p>Repeat cycle every 14 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (727, '', 'FOLFOX4', '', '', '', '', '', '<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>

<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>

<p>Repeat cycle every 2 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (728, '', 'Sorafenib', '', '', '', '', '', '<p><strong>Sorafenib:&nbsp;</strong>400 mg PO twice daily</p>

<p>Continue until disease progression. Dose may be reduced to 400 mg once daily or 400 mg every 2 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (729, '', 'Lenvatinib', '', '', '', '', '', '<p><strong>Lenvatinib:&nbsp;</strong>12 mg PO daily if body weight &gt; 60 kg, or 8 mg PO daily if body weight &lt; 60 kg</p>

<p>Continue until disease progression. Dose may be reduced to 4 mg daily or 4 mg every other day depending on toxicity.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (730, '', 'Cabozantinib', '', '', '', '', '', '<p><strong>Cabozantinib:</strong>&nbsp;60 mg PO daily</p>

<p>Continue until disease progression. Dose may be reduced to 40 mg daily and 20 mg daily depending on toxicity.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (731, '', 'Regorafenib', '', '', '', '', '', '<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily for 21 days.</p>

<p>Repeat cycle every 28 days.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (732, '', 'Nivolumab', '', '', '', '', '', '<p><strong>Nivolumab:&nbsp;</strong>240 mg IV on day 1</p>

<p>Repeat cycle every 2 weeks. May also give 480 mg IV on day 1 every 4 weeks.</p>
', 95);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (741, '', 'Regorafenib', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily on days 1-21</p>

<p>Repeat cycle every 28 days.</p>

<p><strong>OR</strong></p>

<p><strong>Regorafenib:&nbsp;</strong>80 mg PO daily on days 1-7. Increase by 40 mg PO daily every week until target dosing of 160 mg is reached depending on tolerability.</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (742, '', 'TAS-102', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>

<p>Repeat cycle every 28 days.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (743, '', 'Pembrolizumab', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>

<p>Repeat cycle every 3 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (744, '', 'Nivolumab', '', '', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p>

<p>Repeat cycle every 2 weeks. May also administer using a fixed dose of 240 mg IV on day 1 every 2 weeks or 480 mg IV on day 1 every 4 weeks.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (745, '', '5-Fluorouracil + Radiation Therapy (German AIO regimen)', '', '', '', '', 'NEOADJUVANT', '<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>

<p>Repeat infusional 5-FU on weeks 1 and 5.</p>

<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week (total dose, 5,040 cGy)</p>

<p>Followed by surgical resection and then adjuvant chemotherapy with 5-FU at 500 mg/m<sup>2</sup> IV for 5 days every 28 days for a total of 4 cycles.</p>
', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (715, '', 'Gemcitabine', '', '', '', '', 'METASTATIC', '<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>

<p>Repeat 3-week cycle every 28 days.</p>

<p><strong>OR</strong></p>

<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 min at 10 mg/m<sup>2</sup>/min on days 1, 8, and 15</p>

<p>Repeat cycle every 28 days.</p>
', 96);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (498, 'Alpelisib: Piqray<br>Fulvestrant: Faslodex', 'Alpelisib/Fulvestrant', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />
	If SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Fulvestrant</strong>:<br />
	No dose reduction</li>
</ul>
', 'Mild', '', 'Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940.', 'METASTATIC', '<p><strong>Alpelisib</strong>&nbsp;300mg PO daily<br><strong>Fulvestrant</strong>&nbsp;500mg IM on days 1, 15, and 29 and then once per month</p><p>Repeat cycle every 28 days.</p>', 16);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (746, null, 'Afatinib', '<p><strong>RENAL DOSE ADJUSTMENT</strong></p><p>eGFR &gt;30 mL/minute/1.73 m2: No dosage adjustment is necessary.</p><p>eGFR 15 to-29 mL/minute/1.73 m2: Starting dose reduced to 30 mg once daily.</p><p>eGFR &lt;15 mL/minute/1.73 m2 and hemodialysis: has not been studied</p><p><strong>HEPATIC</strong> <strong>DOSE ADJUSTMENT</strong></p><p><strong>Preexisting mild to moderate impairment (Child-Pugh class A/B): </strong>No dosage adjustment is necessary.</p><p><strong>Preexisting severe impairment (Child-Pugh class C): </strong>has not been studied; closely monitor and adjust dose if necessary.</p><p><strong>Hepatotoxicity during treatment:</strong>&nbsp;</p><ul><li>Withhold therapy for ≥ grade 3 hepatic dysfunction.&nbsp;<ul><li>If improvement to baseline or ≤ grade 1, resume therapy at 10 mg per day less than previous dose.&nbsp;</li><li>Permanently discontinue for severe hepatic impairment.</li></ul></li></ul>', 'Low', null, null, null, '<p>40 mg once daily&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (747, null, 'Afatinib', '<p><strong>Renal</strong>:&nbsp;</p><ul><li>Severe renal impairment (eGFR 15 to-29 mL/min /1.73 m2: Reduce starting dose to 30 mg once daily. (i.e., 10 mg per day less than the dose at which the adverse reaction occurred.)</li><li>eGFR &lt;15 mL/minute/1.73 m2 and hemodialysis: Has not been studied</li></ul><p><strong>Hepatic</strong>:</p><ul><li><strong>Preexisting mild to moderate impairment (Child-Pugh class A/B): </strong>No dosage adjustment is necessary.</li><li><strong>Preexisting severe impairment (Child-Pugh class C): </strong>Has not been studied. Close monitoring</li><li><strong>Hepatotoxicity during treatment:</strong> Withhold treatment</li></ul>', 'Low', null, null, null, '<p>30 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (757, null, 'Ceritinib', '<p><strong>Renal Impairment</strong></p><p>Mild-moderate renal impairment: no dosage adjustment necessary (renal excretion is low)</p><p>Severe renal impairment: has not been studied</p><p><strong>Hepatic Impairment</strong></p><p>Mild hepatic impairment (total bilirubin &lt;ULN and AST &gt; ULN, or total bilirubin &gt; 1.0-1.5x ULN and any AST):</p><p>Severe hepatic impairment: not yet been determined&nbsp;</p>', 'Moderate-High', null, null, null, '<p>450mg once per day by mouth (with food) for indefinite duration</p><p>OR</p><p>750mg once per day by mouth (without food)&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (758, null, 'Crizotinib', '<p>&nbsp;Renal Impairment</p><p>Hepatic Impairment</p>', 'Moderate-High', null, null, null, '<p>250 mg daily by mouth for indefinite duration</p><p><i>(for severe hepatic or renal impairment, see below)</i></p><p>OR</p><p>200 mg twice per day by mouth for indefinite duration</p><p><i>(for moderate hepatic impairment, see below)</i></p><p><i>OR</i></p><p>250 mg twice per day by mouth for indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (750, null, 'Gefitinib', '<p><strong>Renal</strong>:</p><ul><li>CrCl&gt;20mL/min: No dosage adjustments provided in the manufacturer’s labeling ( &lt;4% renal excretion)&nbsp;</li><li>CrCl &nbsp;≤20 mL/minute: Has not been studied</li></ul><p><strong>Hepatic</strong></p><ul><li>Grade 2 or higher hepatic impairment: Withhold treatment for up to 14 days; may resume treatment when fully resolved or improved to grade 1 hepatic impairment.</li><li>Severe hepatic impairment: Permanently discontinue.</li></ul>', 'Low', null, null, null, '<p>250mg PO daily, &nbsp;24 month duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (751, null, 'Osimertinib', '<p><strong>Renal</strong></p><ul><li>CrCl 15 to 89 mL/minute: No dosage adjustment necessary.</li><li>CrCl ≤15 mL/minute and ESRD: Has not been studied</li></ul><p><strong>Hepatic</strong></p><ul><li>Mild to moderate impairment : No dosage adjustment necessary<ul><li>Child-Pugh class A /B, OR</li><li>Total bilirubin ≤ ULN and AST &gt; ULN, OR&nbsp;</li><li>Total bilirubin 1 - 3 x ULN and any AST</li></ul></li><li>Severe impairment: Has not been studied<ul><li>Total bilirubin 3 - 10 x ULN and any AST</li></ul></li></ul>', 'Low', null, null, null, '<p><strong>Osimertinib: 80 mg PO daily, indefinite duration</strong></p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (258, 'Cytarabine : Ara-C', '7 + 3 with hi-dose daunorubicin (<60 years)', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Moderate', '<b>7 + 3 with hi-dose daunorubicin <br>(<60 years)</b>', 'Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia. $N Engl J Med. 2009;361(13):1249-1259.$', null, '<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 90 mg/m<sup>2</sup>/d IV, days 1-3', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (749, null, 'Dacomitinib', '<p>Renal:</p><ul><li>Mild-moderate renal impairment (CrCl 30 to 89 mL/minute): No dosage adjustment is necessary.</li><li>Severe renal impairment (CrCl &lt;30 mL/minute): Has not been studied.</li></ul><p>Hepatic:</p><ul><li>Mild: No dosage adjustment is necessary.<ul><li>AST &gt; ULN and total bilirubin within normal limits, OR</li><li>Total bilirubin 1 - 1.5 x ULN</li></ul></li><li>Moderate: No dosage adjustment is necessary.<ul><li>Total bilirubin 1.5 -3x ULN</li></ul></li><li>Severe: has not been studied<ul><li>Total bilirubin 3 -10 x ULN</li></ul></li></ul>', 'Low', null, null, null, '<p>40 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (748, null, 'Erlotinib', '<p><strong>Renal</strong></p><p><i>Renal impairment at treatment initiation:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although &lt;9% of a single dose is excreted in the urine.</p><p><i>Renal toxicity during treatment:</i></p><ul><li>Renal toxicity, hepatorenal syndrome, dehydration: Withhold treatment</li></ul><p><strong>Hepatic</strong></p><p><i>Hepatic impairment at treatment initiation:</i></p><ul><li>Total bilirubin &gt; ULN or Child-Pugh classes A, B, and C: &nbsp;No dosage adjustments provided; use with caution and monitor closely during treatment.</li><li>Total bilirubin &gt;3 times ULN: Use with extra caution.</li></ul><p><br><i>Hepatic impairment during treatment:</i></p><ul><li>Withhold treatment if severe changes in bilirubin or transaminases</li></ul>', 'Low', null, null, null, '<p>Erlotinib 150 mg daily, indefinite duration</p><p>Erlotinib 25 mg daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (752, null, 'Erlotinib & Ramucirumab', '<p><strong>Renal</strong></p><p><i>Renal impairment at treatment initiation:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although &lt;9% of a single dose is excreted in the urine.</p><p><i>Renal toxicity during treatment:</i></p><ul><li>Renal toxicity, hepatorenal syndrome, dehydration: Withhold treatment</li></ul><p><strong>Hepatic</strong></p><p><i>Hepatic impairment at treatment initiation:</i></p><ul><li>Total bilirubin &gt; ULN or Child-Pugh classes A, B, and C: &nbsp;No dosage adjustments provided; use with caution and monitor closely during treatment.</li><li>Total bilirubin &gt;3 times ULN: Use with extra caution.</li></ul><p><br><i>Hepatic impairment during treatment:</i></p><ul><li>Withhold treatment if severe changes in bilirubin or transaminases</li></ul><p><i><strong>Ramucirumab</strong></i></p><p><strong>Renal</strong></p><ul><li>No dose adjustments provided by manufacturer per studies</li></ul><p><strong>Hepatic</strong></p><ul><li>Use with caution in Child-Pugh class B or C cirrhosis. Monitor for &nbsp;encephalopathy, ascites, or hepatorenal syndrome.<br>&nbsp;</li></ul>', 'Low', null, null, null, '<ul><li>Erlotinib: 150 mg PO daily</li><li>Ramucirumab: 10 mg/kg IV on day 1<ul><li>14 day cycles</li></ul></li></ul>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (753, null, 'Nelarabine', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', null, null, null, '<b>Nelarabine</b> 1,500 mg/m<sup>2</sup>/d IV, days 1, 3 and 5', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (755, null, 'Alecitinib', '<p><strong>Renal Impairment</strong></p><ul><li>Prior to initiation:<ul><li>Mild-moderate renal impairment: No dose adjustment provided</li><li>Severe renal impairment (CrCl&lt;30) or ESRD: Not yet studied</li></ul></li><li>During treatment:<ul><li>Grade 3 renal impairment: temporarily withhold until sCr &lt; 1.5, then resume at reduced dose</li><li>Grade 4 renal impairment: permanently discontinue</li></ul></li></ul><p><strong>Hepatic Impairment</strong></p><ul><li>Prior to initiation:<ul><li>Mild Hepatic Impairment(Total bilirubin &lt; ULN and AST &gt; ULN, or total bilirubin &gt; 1.0-1.5x ULN): No dose adjustment recommended&nbsp;</li><li>Moderate to severe hepatic impairment: Not yet studied</li></ul></li></ul>', 'Low', null, null, null, '<p>300mg twice a day by mouth, indefinite duration<br>OR</p><p>600mg twice a day by mouth, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (586, 'Calquence', 'Acalabrutinib', '<p>Hepatic Impairment:</p><p>Mild and Moderate impairment- No dose modification is necessary</p><p>Avoid in severe hepatic impairment</p><p>Renal Impairment:</p><p>No dose adjustment in mild to moderate impairment</p><p>Not studied in severe or end stage renal disease&nbsp;</p>', 'Low', '', 'Sharman et al. 2020 https://doi.org/10.1016/s0140-6736(20)30262-2', '', '<p><strong>Acalabrutinib 100 mg P.O. Twice Daily</strong></p>
', 34);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (754, null, 'R - CVP', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Moderate', null, null, null, '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> up to a maximum dose of 2 mg IV, day 1<br> <b>Prednisone</b> 40 mg PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for a maximum off 8 cycles ', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (756, null, 'Brigatinib', '<p><strong>Renal Impairment</strong></p><p>Mild-moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment is recommended&nbsp;</p><p>Severe renal impairment (CrCl 15-29 mL/min): Reduce daily dose by approximately 50%&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Mild-moderate hepatic impairment (Child Pugh A/B): No dose adjustment is recommended</p><p>Severe hepatic impairment (Child-Pugh C): Reduce daily dose by approximately 40%&nbsp;</p>', 'Low', null, null, null, '<p>90mg once per day by mouth for 1 week duration</p><p>Followed by</p><p>180mg once per day for indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (270, 'Bendamustine : Treanda', 'BR', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>
<ul><li>Rituximab:<br>No dose reduction</li></ul>', 'Moderate', '<b>Bendamustine</b>', 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lyphocytic leukemia. $J Clin Oncol. 2009;27(26):4378-4348.$', null, '<p><strong>Bendamustine</strong> 100 mg/m2 IV over 30 min, days 1, 2<br>Repeat every 28 days</p><p><strong>Rituximab:&nbsp;375</strong>mg/m2&nbsp;IV on day 1, Cycle 1&nbsp;</p><p>500 mg/m2 IV on day 1, Cycle 2-6</p><p>Repeat cycle every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (761, null, 'Bosutinib', '<ul><li>Bosutinib:<br>No dose reduction is needed in mild renal dysfunction. Dose reduction is indicated in moderate to severe dysfunction. Not been studied in ESRD</li></ul>', 'Low', null, null, null, '<p><strong>Bosutinib:&nbsp;500 mg po daily</strong></p><p>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (762, null, 'Ponatinib', '<ul><li>Ponatinib:<br>No dose reduction in mild renal dysfuntion. Dose reduction may be needed in moderate to severe renal dysfunction.</li></ul>', 'Low', null, null, null, '<p><strong>Ponatinib:&nbsp;45 mg po bid</strong></p><p>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (763, null, 'Omacetaxine', '<ul><li>Omacetaxine:<br>Not known</li></ul>', 'Low', null, null, null, '<p><strong>Omacetaxine:&nbsp;1.25 </strong>mg/m2&nbsp;subcutaneous bid on days 1-14, cycle 1 (induction) followed by 1.25 mg/m2 subcutaneous bid on days 1-7 as maintenance</p><p>Repeat cycles every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (279, '', 'Interferon alfa-2a', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Low', '<b>Interferon alfa-2a</b>', 'Ratain MJ, et al. $Blood 1985;65:644-648.$', null, '<p><strong>Interferon alfa-2a:</strong> 3 million IU SC or IM, 3 times per week<br>Continue treatment for up to 1.5 years.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (760, null, 'Lorlatinib', '<p><strong>Renal Impairment</strong></p><p>Mild/moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment is recommended.&nbsp;</p><p>Severe renal impairment: The recommended dose has not been established&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>Mild hepatic impairment (Total bilirubin &lt; ULN with AST &gt; ULN or total bilirubin 1-1.5 x ULN with any AST) No dose adjustment is recommended&nbsp;</p><p>Moderate/severe hepatic impairment: The recommended dose has not been established&nbsp;</p>', 'Low', null, null, null, '<p>100mg once daily, indefinite duration</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (765, null, 'Cladribine/Rituximab', '<ul><li>Cladribine:<br>Dose reduction by 25% if creatinine clearence is 10-50 mL/min. Dose reduction by 50% if creatinine clearence is &lt;10 mL/min</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:&nbsp;0.15 mg/kg/day Day1-5</strong></p><p><strong>Rituximab &nbsp;375 mg/m2 weekly x 8</strong></p><p>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (764, null, 'Cladribine', '<ul><li>Cladribine:<br>Dose reduction by 25% if creatinine clearence is 10-50 mL/min. Dose reduction by 50% if creatinine clearence is &lt;10 mL/min</li></ul>', 'Low', null, null, null, '<p><strong>Cladribine:&nbsp;0.1 mg/kg/day IV as continuous infusion on days 1-7 x 1 cycle</strong></p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (766, null, 'Azacitidine', '
<ul><li>Azacitidine:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Azacitidine:&nbsp;75 mg/m2 subcutaneous daily x 7 days</strong></p><p>Repeat cycles every 28 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (767, null, 'Decitabine', '
<ul><li>Decitabine:<br>No dose reduction</li></ul>', 'Low', null, null, null, '<p><strong>Decitabine:&nbsp;15 mg/m2 IV over 3 hrs every 8 years 3 days&nbsp;</strong></p><p><strong>OR</strong></p><p><strong>20 mg/m2 IV over 1 hour daily x 5</strong></p><p>Repeat cycles every 4 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (285, 'Dexamethasone : various<br>Lenalidomide : Revlimid', 'Lenalidomide', '<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>', 'Low', '<b>Lenalidomide/Dexamethasone</b>', 'Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. $N Engl J Med. 2007;357(21):2123-2132.$', null, '<p><strong>Lenalidomide</strong> 10 mg/d PO, daily or days 1-21<br><br>Repeat every 28 days until disease progression</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (204, 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various', 'AD', '<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>AD</b>', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', null, '<p><strong>Doxorubicin</strong> 15 mg/m2/d Continuous IV, days 1-4<br>Dacarbazine 250 mg/m2/d Continues IV, days 1-4<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (207, 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various', 'MAID', '<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'High', '<b>MAID</b>', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', null, '<p><strong>Mesna</strong> 2,500 mg/m2/d Continuous IV, days 1-4<br><strong>Doxorubicin</strong> 20 mg/m2/d Continuous IV, days 1-3<br><strong>Ifosfamide</strong> 2,500 mg/m2/d Continuous IV, days 1-3<br><strong>Dacarbazine</strong> 300 mg/m2/d CIVI, days 1-3<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (206, 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR', 'CAV-IE', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'CAV-High: IE-Moderate', '<b>VAC-IE</b>', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', null, '<p><strong>Cyclophosphamide</strong> 1,200 mg/m2 IV, day 1<br><strong>FOLLOWED BY</strong> mesna<br><strong>Vincristine</strong> 2 mg/m2 IV, day 1<br><strong>Doxorubicin</strong> 75 mg/m2 IV bolus, day 1<br><strong>Dactinomycin</strong> 1.25 mg/m2 IV, day 1 substitued for doxorubicin when cumulative doxorubicin dose reaches 375 mg/m2<br>Alternating with each cycle<br><strong>Ifosfamide</strong> 1,800 mg/m2/d IV, days 1-5 (given with mesna)<br><strong>Etoposide</strong> 100 mg/m2/d IV, days 1-5<br>Repeat cycle every 21 days for 17 total cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (768, null, 'AI', '
<ul><li>Doxorubicin:<br>No dose reduction</li></ul>
<ul><li>Ifosfamide:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Doxorubicin:&nbsp;20 mg/m2&nbsp; continuous IV on day 1-3</strong></p><p><strong>Ifosfamide:&nbsp;1,500 mg/m2&nbsp;Continuous IV on day 1-4</strong></p><p><strong>Mesna: 225 mg/m2 IV over 1 hour before ifosfamide and at 4 and 8 hours after ifosfamide</strong></p><p>Repeat cycles every 3 weeks.</p><p>Consider G-CSF support</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (8, 'Cisplatin : CDDP', 'CF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>
<ul><li>Fluorouracil:<br>No dose reduction</li></ul>', 'High', '<b>CF</b>', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', null, '<p><strong>Cisplatin</strong> 100 mg/m2 IV, day 1<br><strong>5-Fluorouracil</strong> 1000 mg/m2/day CIVI, days 1-4<br>Repeat every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (545, 'Doxorubicin: Adriamycin<br>Cyclophosphamide: Cytoxan', 'AC', '<p><strong>Hepatic Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
	<li><strong>Doxorubicin</strong>:<br />
	If bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />
	If bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />
	If bilirubin &gt; 5 mg/dL, do not use</li>
</ul>

<p><strong>Renal Impairment</strong></p>

<ul>
	<li><strong>Cyclophosphamide</strong>:<br />
	If CrCl 10-50 mL/min, reduce dose by 25%<br />
	If CrCl &lt; 10 mL/min, reduce dose by 50%</li>
	<li><strong>Doxorubicin</strong>:<br />
	No dose reduction</li>
</ul>
', 'High', '', 'Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14.', '', '<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />
<strong>Cyclophosphamide</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>

<p>Repeat cycle every 21 days.</p>
', 98);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (13, 'Cetuximab : Erbitux', 'Cetuximab', '<p><strong>Hepatic Impairment</strong></p><p>No dose adjustment necessary</p><p><strong>Renal Impairment</strong></p><p>No dose adjustment necessary</p>', 'Low', '<b>Cetuximab</b>', 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival. $Lancet Oncol.2010;11(1):21-28.$', null, '<b>Cetuximab</b> 400 mg/m<sup>2</sup> loading dose over 120 minutes, <b>THEN</b> 250 mg/m<sup>2</sup> over 60 minutes, every 7 days', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (12, 'Cisplatin : CDDP<br>Docetaxel : Taxotere', 'TPF', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'High', '<b>TPF</b>', 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. $N Engl J Med. 2007;357(17):1695-1704.$<br> Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. $N Engl J Med. 2007;357(17):1705-1715.$', null, '<p><strong>Docetaxelb</strong> 75mg/m2 IV over 1 hour, day1<br><strong>Cisplatin</strong> 75mg/m2 IV over 1 hour, day 1<br><strong>5-Fluorouracil</strong> 750 mg/m2/d, days 1-5<br>Repeat every 21 days<br><strong>OR</strong><br><strong>Docetaxel</strong> 75 mg/m2 IV, day 1<br><strong>Cisplatin</strong> 100 mg/m2 IV, day 1<br><strong>5-Fluorouracil</strong> 1,000 mg/m2/d CIVI, days 1-4<br>Repeat every 21 days for 3 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (769, null, 'TPF Induction- followed by RT and Carbo', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Moderate to High', null, null, null, '<p><strong>Docetaxel</strong> 75 mg/m2 IV, day 1<br><strong>Cisplatin</strong> 75-100 mg/m2 IV, day 1<br><strong>5-Fluorouracil</strong> 1,000 mg/m2/d CIVI, days 1-4<br>Repeat every 21 days for 3 cycles followed by</p><p>Carboplatin AUC 1.5 IV, every week x 7 along with radiation therapy</p><p>Evaluate for surgical resection</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (477, 'Carboplatin; Paralatin
Paclitaxal: Taxol ', 'Carboplatin + Paclitaxel', '<p><strong><u>Carboplatin</u></strong></p>

<p><strong>Renal Impairment</strong>: AUC dosing</p>

<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>

<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>

<p><strong><u><span style="font-family:Times">Paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment:</span></strong><span style="font-family:Times"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>

<p><strong><span style="font-family:Times">Hepatic Impairment:</span></strong></p>

<ul>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>
	<li><span style="font-family:Times">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>
</ul>

<p><strong><u><span style="font-family:Times">Nanoparticle albumin bound paclitaxel</span></u></strong></p>

<p><strong><span style="font-family:Times">Renal Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>
</ul>

<p><strong><span style="font-family:Times">Hepatic Impairment</span></strong></p>

<ul>
	<li><span style="font-family:Times">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>
	<li><span style="font-family:Times">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>
	<li><span style="font-family:Times">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>
</ul>
', 'High', '', 'CA184-104: Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O''Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30.

EYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.

KEYNOTE-042: Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4.', 'METASTATIC', '<p><strong>Carboplatin</strong> AUC 6&nbsp;IV over 15 to 60 minutes once on day 1<br><strong>Paclitaxel</strong>&nbsp;175 mg/m2&nbsp;IV over 3 hours onc<strong>e o</strong>n day 1</p><p><strong>21-day cycle for up to 6 cycles</strong></p><p>&nbsp;</p>', 107);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (738, '', 'Cetuximab', '
<ul><li>Cetuximab:<br>No dose reduction</li></ul>', 'Low', '', '', 'HEPATIC ARTERY INFUSION', '<p><strong>Cetuximab:&nbsp;</strong>400 mg/m2&nbsp;IV loading dose, then 250 mg/m2&nbsp;IV weekly</p><p>Repeat cycle on a weekly basis.</p><p><strong>OR</strong></p><p><strong>Cetuximab:&nbsp;</strong>500 mg/m2&nbsp;IV every 2 weeks (no loading dose is necessary)</p><p>Repeat cycle every 2 weeks.</p><p>&nbsp;</p>', 93);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (772, null, 'Cisplatin + radiation (Nasopharyngeal)', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin</strong> 100 mg/m2 IV, days 1,22, 43 concomitantly with radiation&nbsp;</p><p>Followed by&nbsp;</p><p>Cisplatin 80 mg/m2 IV on day 1</p><p>5-Fluorouracil 1000 mg/m2/day as IV continuous infusion Day 1-4</p><p>Repeat every 28 days x 3 cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (773, null, 'Carboplatin/Fluorouracil', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Moderate', null, null, null, '<b>Carboplatin</b> AUC of 5, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1 <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week.', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (774, null, 'Cisplatin and Cetuximab', '<p><strong>Hepatic Impairment</strong></p><ul><li>Cisplatin:<br>No dose reduction</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li>Cetuximab:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin</strong> 75 mg/m2, day 1 and</p><p><strong>Cetuximab:&nbsp;400</strong> mg/m2&nbsp;IV on day loading dose followed by 250 mg/m2 IV every week</p><p>Repeat cycles every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (770, null, 'TIP', '<p><strong>Hepatic Impairment</strong></p><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li>Ifosfamide: No dose reduction needed</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li><li>Ifosfamide:</li><li>If CrCl 46-59 mL/min, reduce dose by 20%</li><li>If CrCl 31-45 mL/min, reduce dose by 25%</li><li>If CrCl &lt;30mL/min, reduce dose by 30%</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin</strong> 60 mg/m2, day 1 and<br><strong>Paclitaxel</strong> 175 mg/m2 over 3 hours on day 1</p><p>Ifosfamide 1000 mg/m2 on day 1-3</p><p>Mesna 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV 4 hrs after Ifosfamide</p><p><br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (771, null, 'TIC', '<p><strong>Hepatic Impairment</strong></p><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li><li>Ifosfamide: No dose reduction needed</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li><li>Ifosfamide:</li><li>If CrCl 46-59 mL/min, reduce dose by 20%</li><li>If CrCl 31-45 mL/min, reduce dose by 25%</li><li>If CrCl &lt;30mL/min, reduce dose by 30%</li></ul>
<ul><li>Ifosfamide:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Carboplatin AUC of 6 on Day 1&nbsp;</strong><br><strong>Paclitaxel</strong> 175 mg/m2 over 3 hours on day 1</p><p>Ifosfamide 1000 mg/m2 on day 1-3</p><p>Mesna 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV 4 hrs after Ifosfamide</p><p><br>Repeat cycle every 21 days</p><p>&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (778, null, 'Paclitaxel', '<p><strong>Hepatic Impairment</strong></p><p>&nbsp;</p><ul><li>Paclitaxel:<br>For 3-hour infusion:&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use&nbsp;<br>For 24-hour infusion:&nbsp;<br>If transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)&nbsp;<br>If transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2&nbsp;<br>If transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2&nbsp;<br>If transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Moderate', null, null, null, '<p><strong>Paclitaxel</strong> 175 mg/m2 over 3 hours on day 1<br>Repeat cycle every 21 days</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (779, null, 'Vinorelbine', '<p>Hepatic Impairment</p><p>If bilirubin is &lt;2.0 mg/dL, no dose reduction</p><p>If bilirubin is 2.0-3.0 mg/dL, dose reduce by 50%</p><p>If bilirubin is 3.1-5.0 mg mg/dL, dose reduce by 75%</p><p>If bilirubin is &gt;5, omit the drug</p><p>Renal Impairment<br>No dose reduction needed</p>', 'Low', null, null, null, '<p><strong>Vinorelbine:&nbsp;30 </strong>mg/m2&nbsp;IV every week</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (780, null, 'VP', '<p>Am J Clin Oncol. 1995 Aug;18(4):293-6. doi: 10.1097/00000421-199508000-00004.<strong>Hepatic Impairment</strong></p><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine</li><li>If bilirubin is &lt;2.0 mg/dL, no dose reduction needed</li><li>If bilirubin is 2.0-3.0 mg/dL, reduce dose by 50%</li><li>If bilirubin is 3.1-5 mg/dL, reduce dose by 75%</li><li>If bilirubin &gt;5 mg/dL, Omit</li></ul><p><strong>Renal Impairment</strong></p><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%&nbsp;<br>If CrCl &lt; 30 mL/min, do not use</li><li>Cetuximab:<br>No dose reduction</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'High', null, null, null, '<p><strong>Cisplatin</strong> 80 mg/m2, day 1 and</p><p><strong>Vinorelbine:&nbsp;25 </strong>mg/m2&nbsp;IV on day 1 and 8</p><p>Repeat cycles every 3 weeks.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (781, null, 'Afatinib', '<p><strong>Renal impairment&nbsp;</strong></p><p>eGFR 15 - 29 mL/min /1.73 m2 : reduce dose to 30 mg PO, once daily</p><p>&nbsp;</p><p><strong>Hepatic toxicity</strong></p><p>Monitor with periodic liver testing. Withhold or discontinue for severe or worsening liver tests.</p><p>&nbsp;</p><p>&nbsp;</p>', 'Low', null, null, null, '<p>40 mg PO once daily per FDA approval</p><p>OR</p><p>50 mg PO once daily&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (786, null, 'Erlotinib & Bevacizumab', '<p><strong>Erlotinib:</strong></p><p><strong>Renal Toxicity:</strong></p><p>For grade 3- 4 renal toxicity: Withhold Erlotinib until resolved and reinitiate with 50 mg dose reduction. Consider discontinuation.</p><p><strong>Hepatic toxicity:</strong></p><p>Total bilirubin &gt;3 times ULN: Use extreme caution.</p><p>&nbsp;</p><p><strong>Bevacizumab</strong></p><p><strong>Renal impairment:</strong></p><p><i>Renal impairment prior to treatment:</i> There are no recommended dosage adjustments.</p><p><i>Renal toxicity during treatment:</i></p><ul><li>Moderate Proteinuria: temporarily withhold bevacizumab</li><li>Discontinue in patients with nephrotic syndrome. &nbsp;</li></ul><p><strong>Hepatic Impairment: </strong>There are no recommended dosage adjustments.</p>', 'Low', null, null, null, '<p>Erlotinib 150 mg PO once daily</p><p>Bevacizimab 15 mg/kg IV once on day 1</p><p>21 day cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (783, null, 'Dacomitinib', '<p>&nbsp;<strong>Renal Impairment:</strong></p><p>Mild/Moderate Impairment: No dosing adjustment recommended.</p><p>Severe Impairment (CrCl &lt; 30 mL/min): No dosing adjustment established</p><p><strong>Hepatic Impairment:</strong></p><p>Mild/Moderate Impairment: No dosing adjustment recommended.</p><p>Severe Impairment (total bilirubin &gt; 3 -10 × ULN and any AST): No dosing adjustment established</p>', 'Low', null, null, null, '<p>45 mg PO once daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (784, null, 'Gefitinib', '<p>Renal Impairment:</p><p>&lt; 4% renally excreted. Has not been studied in severe renal impairment.</p><p>Hepatic Impairment:</p><p><i>Note: Obtain periodic liver function testing.&nbsp;</i></p><p>Grade 2 or higher for ALT and/or AST elevations: Withhold gefitinib&nbsp;</p><p>Severe hepatic impairment: Discontinue</p>', 'Low', null, null, null, '<p>250 mg PO daily</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (785, null, 'Osimertinib', '<p>Renal impairment:</p><p>No dosage adjustment recommended in mild, moderate, or severe renal disease. No recommendations available for end stage renal disease.</p><p>Hepatic Impairment:</p><p>No dosage adjustment recommended in mild, moderate hepatic disease. No recommendations available for severe hepatic impairment.</p>', 'Low', null, null, null, '<p>80 mg PO daily continue indefinitely&nbsp;</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (782, null, 'Erlotinib', '<p>For 150 mg dosing schedule:</p><p><strong>Renal Toxicity:</strong></p><p>For grade 3- 4 renal toxicity: Withhold Erlotinib until resolved and reinitiate with 50 mg dose reduction. Consider discontinuation.</p><p><strong>Hepatic toxicity:</strong></p><p>Total bilirubin &gt;3 times ULN: Use extreme caution.</p>', 'Low', null, null, null, '<p>150mg PO once a day continued indefinitely (FDA approved)</p><p>OR</p><p>25mg PO once a day continued indefinitely</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (787, null, 'Erlotinib & Ramucirumab', '<p><strong>Ramucirumab</strong></p><p><strong>Renal Toxicity:</strong></p><p>No dosage adjustment recommended</p><p><strong>Hepatic Toxicity:</strong></p><p>Child-Pugh B or C cirrhosis who received single-agent ramucirumab were noted to have clinical deterioration. Use only if risks outweight benefits.&nbsp;</p><p>&nbsp;</p><p><strong>Erlotinib:</strong></p><p><strong>Renal Toxicity:</strong></p><p>For grade 3- 4 renal toxicity: Withhold Erlotinib until resolved and reinitiate with 50 mg dose reduction. Consider discontinuation.</p><p><strong>Hepatic toxicity:</strong></p><p>Total bilirubin &gt;3 times ULN: Use extreme caution.</p>', 'Low', null, null, null, '<p>Erlotinib 150mg PO daily</p><p>Ramucirumab 10 mg/kg IV once on day 1</p><p>14 day cycles</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (788, null, 'Etoposide + Doxorubicin + Cisplatin + Mitotane', '<p><strong>Renal Impairment &nbsp; &nbsp;</strong></p><ul><li><strong>Etoposide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>CrCl &gt;50 mL/min: No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;CrCl &nbsp;15-50 mL/min: 75% of normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;CrCl &lt;15 mL/min: 50% of normal dose&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></li><li><strong>Cisplatin : &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> CrCl &gt;60 mL/min: No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CrCl &nbsp;45-59 mL/min: 75% of normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CrCl &lt;45 mL/min: Consider switching to Carboplatin &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Doxorubicin:</strong><br>CrCl &lt; 20 mL/min: Avoid doxorubicin. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Mitotane:</strong><br>CrCl &lt;60 mL/min: Consider dose reduction.</li></ul><p><strong>Hepatic Impairment</strong></p><ul><li><strong>Etoposide: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>AST/ALT: 60-180 unit/L: 50% of normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;AST/ALT: &gt;180 unit/L: dosing based on clinical decision &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li><li><strong>Doxorubicin: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>AST/ALT: 60-180 unit/L: 50% of normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;AST/ALT: &gt;180 unit/L: 25% of normal dose</li></ul>', 'Medium', null, null, null, '<p><strong>Etoposide:&nbsp;100</strong> mg/m2&nbsp;IV on days 5-7</p><p><strong>Doxorubicin:&nbsp;20</strong> mg/m2&nbsp;IV on day 1 and 8</p><p><strong>Cisplatin:&nbsp;40</strong> mg/m2&nbsp;IV on days 1 and 9</p><p><strong>Mitotane: 4</strong> g PO daily</p><p>Repeat cycle every 21 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (789, null, 'Streptozocin + Mitotane', '<p><strong>Renal Impairment &nbsp; &nbsp;</strong></p><ul><li><strong>Mitotane:</strong><br>CrCl &lt;60 mL/min: Consider dose reduction. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li><li><strong>Streptozosin:</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CrCl &gt;50 mL/min: No dose reduction &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CrCl 10-50 mL/min: 75% of normal dose &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CrCl &lt;10 mL/min: Avoid Streptozosin.</li></ul>', 'Medium', null, null, null, '<p><strong>Streptozocin:&nbsp; 1,000</strong> mg IV on days 1-5 for cycle 1 and &nbsp;2,000 mg IV on days 1-5 on subsequent cycles</p><p><strong>Mitotane:&nbsp; 4 </strong>g PO daily</p><p>Repeat cycle every 28 days.</p>', null);
insert into public.regimen_detail (id, brand_names, disp_name, dosage_modifications, emetogenic_potential, name, reference, regimen_type, schedule, subcancer_type3_id) values (790, null, 'Carboplatin+Paclitaxel', '<p>No dosage modifications.</p>', 'Medium', null, null, null, '<p><strong>Carboplatin:&nbsp;</strong>AUC of 5<strong>,</strong>&nbsp;IV on day 1</p><p><strong>Paclitaxel:&nbsp;</strong>175 mg/m2&nbsp;IV on day 1</p><p>Repeat cycles every 3 weeks.</p>', null);

insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (1, 'J Clin Oncol. 2007;25(30):4722-4279.', 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.', 1);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (2, 'Clin Cancer Res.2000;6(10):3878-3884.', 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.', 2);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (3, 'N Engl J Med 2005; 352:987-996', 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.', 3);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (4, 'Neurosurgery.2002;51(2):343-355; discussion 355-357.', 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine.', 4);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (5, 'J Clin Oncol. 2009;27(5):740-745.', 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma.', 5);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (6, 'Cancer.2010;116(22):597-5305.', 'Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas.', 5);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (7, 'J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27', 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.', 6);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (8, 'N Engl J Med. 2008;359(11):1116-1127.', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.', 7);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (9, 'J Clin Oncol. 2005;23(15):3562-3567.', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.', 8);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (10, 'N Engl J Med. 2008;359(11):1116-1127.', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.', 9);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (11, 'Cancer. 2009;115(11):2464-2471.', 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma.', 10);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (12, 'J Clin Oncol. 2005;23(15):3562-3567.', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.', 11);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (13, 'N Engl J Med. 2007;357(17):1695-1704.', 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.', 12);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (14, 'N Engl J Med. 2007;357(17):1705-1715.', 'Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.', 12);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (15, 'Lancet Oncol.2010;11(1):21-28.', 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival.', 13);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (25, 'J Clin Oncol. 2006;24(31):4991-4997', 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.', 23);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (26, 'Ann Oncol. 2000;11(3):301-306', 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma.', 24);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (27, 'Br J Cancer. 1999;80(1-2):269-272.', 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.', 25);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (28, 'J Clin Oncol. 2000;18(41):2648-2657', 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group.', 26);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (29, 'N Engl J Med. 2001;345(10):725-730.', 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.', 27);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (30, 'Lancet. 2010;376(99742):687-697.', 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial.', 28);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (48, 'N Engl J Med. 2011;364(19):1817-1825.', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.', 48);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (21, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 19);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (49, 'J Clin Oncol. 2007;25(16):221-2217.', 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.', 49);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (50, 'J Clin Oncol. 2007;25(15):1960-1966.', 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group.', 50);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (51, 'J Clin Oncol. 2005;23(15):3509-3516.', 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.', 51);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (52, 'J Clin Oncol. 1997;15(6):2403-2413.', 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.', 52);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (53, 'N Engl J Med. 2004;351(4):337-345.', 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.', 53);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (54, 'J Clin Oncol. 1989;7(10):1407-1418', 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma.', 54);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (55, 'J Clin Oncol. 1989;7(10):1419-1426', 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial.', 55);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (56, 'J Clin Oncol. 1987;5(10):1559-1565.', '<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma.', 55);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (57, 'J Clin Oncol. 2005;23(16):3706-3712.', 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer.', 56);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (58, 'J Clin Oncol. 2005;23(15):3502-3508', '<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer.', 56);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (59, 'J Clin Oncol. 2007;25(16):2198-2204.', 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.', 57);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (60, 'J Clin Oncol. 2004;22(2):229-237', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.', 58);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (61, 'J Clin Oncol. 2007;25(30):4779-4786.', 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.', 59);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (62, 'J Clin Oncol. 2007;25:4000 (abstract).', 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial.', 60);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (63, 'http://jco.ascopubs.org/content/24/25/4085.abstract', 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.', 61);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (64, 'J Clin Oncol. 2008;26(18)2013-2019.', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.', 62);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (65, 'J Clin Oncol. 2010;28(31):4697-4705.', 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.', 63);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (66, 'Am J Clin Oncol. 2007;30(4):350-357', 'Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer.', 66);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (67, 'J Clin Oncol. 2004;22(11):2084-2091', 'Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer.', 67);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (68, 'J Clin Oncol. 2008;26(18)2013-2019.', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.', 68);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (69, 'J Clin Oncol. 2001;19(21):4097-4106', 'Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study.', 69);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (70, 'Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011.', 'Erbitux [package insert].', 70);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (71, 'J Clin Oncol. 1990;8(2):313-318.', 'Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.', 71);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (72, 'lEur J Cancer. 1996;32A(suppl 5):S18-S22.', '<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.', 71);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (73, 'J Clin Oncol. 1997;15(1):251-260', 'Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy.', 72);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (74, 'J Clin Oncol. 1996;14(3):709-715.', '<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.', 72);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (75, 'Lancet. 1998;352(9138):1413-1418.', '<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.', 72);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (76, 'J Clin Oncol. 2008;26(4):626-632', 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033.', 77);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (77, 'Eur J Cancer. 2009;45:2293-2297.', 'Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.', 78);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (286, 'Blood. 2006;107(9):3469-3473.', 'Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.', 254);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (78, 'Lancet. 2006;368(9544):1329-1338.', 'Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial.', 79);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (79, 'N Engl J Med. 2002;346(2):92-98.', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 80);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (80, 'J Clin Oncol. 2008;26(21):3543-3551.', 'Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer.', 81);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (81, 'Lancet. 2009;373(9674):1525-1531.', 'Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.', 82);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (82, 'N Engl J Med. 2002;346(2):92-98.', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 83);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (83, 'N Engl J Med. 2002;346(2):92-98.', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.', 84);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (84, 'J Clin Oncol. 1999;17(1):12-18.', '<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.', 84);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (85, 'Lancet. 2001;357(9267):1478-1484.', 'Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial.', 85);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (86, 'J Clin Oncol. 2002;20(17):3578-3585.', 'Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.', 86);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (87, 'J Clin Oncol. 2000;18(13):2529-2536.', 'Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.', 87);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (88, 'Chest. 2000;117(6):1583-1589.', '<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer.', 87);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (89, 'Cancer. 2000;88(6):1353-1358.', '<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial.', 87);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (90, 'N Eng/J Med.2002;346(2);92-98.', 'Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer.', 88);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (91, 'J Clin Oncol.2003;21(21):3909-3917.', '<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975.', 88);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (92, 'N Engl J Med. 2006;355(24):2542-2550.', 'Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer.', 89);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (93, 'Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial.', 'Lancet Oncol.2006:7(9):719-727.', 90);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (94, 'N engl J Med.2010;363(18):1693-1703.', 'Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer.', 91);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (95, 'New York, NY: Pfizer labs;2011.', '<br> Xalkori [packages insert].', 91);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (96, 'J Clin Oncol. 2000;18(10):2095-2103.', 'Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.', 92);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (97, 'J Clin Oncol. 2000;18(12):2354-2362.', '<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens.', 92);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (98, 'J Clin Oncol. 2008;26(14):2350-2357.', 'Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21.', 93);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (99, 'Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010.', '<br> Tarceva [packaga insert].', 93);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (100, 'J Clin Oncol. 1999;17(7):2081-2085.', 'Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial.', 94);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (101, 'Lung Cancer.2000;27(2):75-80.', '<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study.', 94);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (102, 'J Clin Oncol. 2004;22(9):1589-1597.', 'Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy.', 95);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (103, 'J Clin Oncol.1994;12(2):360-367.', 'Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.', 96);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (104, 'J Clin Oncol. 2008:26(26):4261-4267.', 'Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.', 97);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (105, 'N Engl J Med. 2002;346(2):85-91.', 'Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.', 98);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (108, 'Acta Oncal. 1994;33(8):921-924.', 'Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer.', 101);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (109, 'J Clin Oncol.1994; 12(10):2022-2034.', 'Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.', 102);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (110, 'Semin Oncol. 1993;20(4):315-325.', 'Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer.', 103);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (111, 'J Clin Oncol. 1995;13(6):1430-1435.', 'Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.', 104);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (322, 'Palumbo A, et al. Lancet 2006;28:367-835.', 'Palumbo A, et al. Lancet 2006;28:367-835.', 287);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (112, 'Am J Clin Oncol. 1999;22(5):517-522', '<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.', 104);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (114, 'J Clin Oncol.1997;15(5):2090-2096.', 'Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease.', 105);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (115, 'J Clin Oncol. 1999;17(2):658-667.', '<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.', 105);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (116, 'J Clin Oncol. 2007;25(15):2086-2092.', 'Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.', 106);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (118, 'J Clin Oncol 1994;12:1164-1168.', 'Loehrer PJ, et al.', 107);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (119, 'J Clin Oncol 1996;14:814-820.', 'Giaccone G, et al.', 108);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (120, 'Cancer 1991;68:30-33.', 'Fornasiero A, et al.', 109);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (121, 'Cancer 2001;91:2010-2015.', 'Loehrer PJ, et al.', 110);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (122, 'Am J Clin Oncol 2009;32:15-19.', 'William WN, et al.', 111);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (123, 'J Clin Oncol 2011;29:2060-2065.', 'Lemma GL, et al.', 112);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (124, 'J Clin Oncol. 1990;8(9):1483-1496', 'Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15.', 113);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (126, 'N Engl J Med. 2005;353(16):1673-1684.', 'Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.', 115);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (127, 'J Clin Oncol. 2003;21(8): 1431-1439', 'Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741.', 116);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (128, 'Ann Oncol. 2006; 17(3):381-390', 'Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial.', 117);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (129, 'J Clin Oncol. 2003;21(6):968-975.', 'Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial.', 118);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (130, 'J Clin Oncol. 2001;19(6):1707-1715', 'Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.', 119);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (131, 'J Clin Oncol. 2003;21(8):1431-1439', 'Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741.', 120);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (132, 'J Clin Oncol. 2003;3(6):421-422', 'Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.', 121);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (133, 'J Clin Oncol. 2005;23(33):8313-8321.', 'Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102.', 122);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (134, 'J Clin Oncol. 1998;16(8):2651:2658.', 'Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer.', 123);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (135, 'J Clin Oncol. 2000;18(7):3115-3124.', '<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment.', 123);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (136, 'J Clin Oncol. 2000:18(17):3125-3134.', 'Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study.', 124);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (137, 'JAMA. 1995:273(7):542-547.', '<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results.', 124);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (138, 'J Clin Oncol. 2008;26(24):3950-3957.', 'Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.', 125);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (139, 'J Clin Oncol. 2001;19(12):3103-3110.', 'Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.', 126);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (140, 'J Clin Oncol. 2007;25(33):5210-5217.', 'Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.', 127);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (141, 'N Engl J Med. 2006;355(26):2733-2743.', 'Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.', 128);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (142, 'J Clin Oncol. 200927(33):5538-5546.', 'Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.', 129);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (143, 'N Engl J Med. 2008;238(16):1663-1671.', 'Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer.', 130);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (144, 'N Engl J Med. 2005;352(22):2303-2313.', 'Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer.', 131);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (145, 'J Clin Oncol. 2006:24(34):5381-5387.', 'Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.', 132);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (146, 'J Clin Oncol. 2002;20(12):2812-2823.', 'O''Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results.', 133);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (147, 'J Clin Oncol. 2007;25:LBA 1008 (abstract).', 'Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC).', 134);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (148, 'J Clin Oncol. 2006;24(18):2786-2792.', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.', 135);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (149, 'J Clin Oncol. 2006;24(18):2786-2792.', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.', 136);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (150, 'J Clin Oncol. 2005;23(31):7794-7803.', 'Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.', 137);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (151, 'Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.', 'Arimidex [package insert].', 138);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (152, 'San Francisco, CA: Genentech; 2011.', 'Xeloda [package insert].', 139);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (153, 'J Clin Oncol. 1999;17(8):2341-2354.', 'Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.', 140);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (154, 'J Clin Oncol. 1999;17(5):1413-1424.', '<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.', 140);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (155, 'New York, NY: Sanofi-Aventis; 2010.', '<br> Taxotere [package insert].', 140);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (156, 'Lancet. 2011;377(9769):914-923.', 'Cortes J, O''Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.', 141);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (157, 'J Clin Oncol. 2000;18(11):2234-2244.', 'Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial.', 142);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (158, 'J Clin Oncol. 2000;18(7):1399-1411.', '<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.', 142);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (159, 'N Engl J Med. 2004;350(11):1081-1092.', '<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.', 142);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (160, 'J Clin Oncol. 2010 Oct 20;28(30):4594-600', 'Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.', 143);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (161, 'J Clin Oncol. 1995;13(11):2731-2736.', 'Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine.', 144);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (162, 'N Engl J Med. 2003;349(19): 1793-1802.', '<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.', 145);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (163, 'J Clin Oncol. 1998;16(2):453-461.', 'Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate.', 145);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (164, 'Cancer. 1997;80(2):218-224.', '<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.', 145);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (165, 'J Clin Oncol. 2001;19(14):3357-3366.', 'Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate.', 146);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (166, 'J Clin Oncol. 1995;13(10):2575-2581.', 'Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.', 147);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (167, 'J Clin Oncol. 1999;17(11):3403-3411.', '<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.', 147);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (168, 'J Clin Oncol. 2011;29(13):1657-1663.', 'Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.', 148);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (169, 'J Clin Oncol. 1995;13(10):2556-2566.', 'Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.', 149);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (170, 'Memphis, TN: GTx, Inc,:2011.', '<br> Fareston [package insert].', 149);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (171, 'South San Francisco, CA: Genentech, Inc: 2010.', 'Herception [package insert].', 150);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (172, 'N Engl J Med. 2005;353(16):1659-1672.', 'Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.', 151);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (173, 'J Clin Oncol. 1995;13(11):2722-2730.', 'Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer.', 152);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (174, 'J Natl Cancer Inst. 2004;96(22):1682-1691.', 'Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.', 153);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (175, 'J Clin Oncol. 2000;18(17):3084-3092.', 'Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.', 154);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (176, 'J Clin Oncol. 2010;28:3323-3329.', 'Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase.', 155);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (177, 'N Engl J Med. 1996;334(1):1-6.', 'McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.', 156);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (178, 'J Clin Oncol. 2000;18(17):3084-3092.', '<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.', 156);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (179, 'J Clin Oncol. 2006;24(29):4699-4707.', 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.', 157);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (180, 'N Engl J Med. 2006;354(1):34-43.', 'Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.', 158);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (181, 'Gynecol Oncol. 1998;69(3):226-229.', 'Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.', 159);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (182, 'J Clin Oncol. 2007;25(33):5165-5171.', 'Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.', 160);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (183, 'J Natl Cancer Inst. 1994;86(20):1530-1533.', 'Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'', 2'' difluorodeoxycytidine) in previously treated ovarian cancer patients.', 161);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (184, 'J Clin Oncol. 1997;15(6):2183-2193.', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.', 162);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (185, 'Raritan, NJ: Centocor Ortho Biotech Products, LP;2010.', '<br> Doxil [package insert].', 163);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (186, 'J Clin Oncol. 2000;18(17):3093-3100.', 'Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.', 163);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (187, 'J Clin Oncol. 1997;15(6):2183-2193.', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.', 164);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (188, 'J Clin Oncol. 2006;24(1):36-44.', 'Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.', 165);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (189, 'J Clin Oncol. 2004;22(11):2159-2166.', 'Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study.', 166);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (190, 'J Clin Oncol. 2004;22(19):3902-3908.', 'Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study.', 167);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (191, 'J Clin Oncol. 1999;17(6):1736-1744.', 'Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group.', 168);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (192, 'N Engl J Med. 1999;340(15):1137-1143.', 'Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.', 169);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (193, 'J Clin Oncol. 1999;17(5):1339-1348.', '<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study.', 169);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (194, 'J Clin Oncol. 2009;27(28):4649-4655.', 'Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study.', 170);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (195, 'J Clin Oncol. 2005;23(21):4626-4633.', 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.', 171);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (196, 'N Engl J Med. 1999;340(15):1154-1161.', 'Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.', 172);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (197, 'N Engl J Med. 2007;356(2):125-134.', 'Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma.', 177);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (198, 'N Engl J Med. 2007;356(2):115-124', 'Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.', 178);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (199, 'N Engl J Med. 2007;356(22):2271-2281.', 'Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma.', 179);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (200, 'Cancer. 2006;106(2):297-303.', 'Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma.', 180);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (201, 'J Clin Oncol. 2000;18(17):3068-3077.', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study.', 181);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (202, 'J Clin Oncol. 2000;18(17):3068-3077.', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study.', 182);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (203, 'J Clin Oncol. 1998;16(4):1287-1293.', 'Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study.', 183);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (204, 'J Clin Oncol. 1995;13(11):2700-2704.', 'Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.', 184);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (205, 'J Oncol. 2005;23(27):6549-6555.', 'Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.', 185);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (206, 'Ann Intern Med. 1988;109(7):540-546.', 'Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.', 186);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (207, 'Lancet. 2010;376(9747):1147-1154.', 'de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.', 187);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (208, 'N Engl J Med. 2004;351(15):1513-1520.', 'Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.', 188);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (209, 'N Engl J Med. 2004;351(15):1502-1512.', 'Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.', 189);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (210, 'Urology. 2000;55(3):391-396.', 'Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?', 190);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (211, 'J Clin Oncol. 2009;26(4):585-591.', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610.', 191);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (439, null, 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 403);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (212, 'J Clin Oncol. 1996;14(6)1756-1764.', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints.', 192);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (213, 'Urology. 1995;45(5):745:752.', 'Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.', 193);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (214, 'BJU Int. 2008;102(11):1531-1538.', 'Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.', 194);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (215, null, 'N. Engl. J. Med. 368 (2): 138–48.', 195);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (216, 'Wilmington, DE: AstraZeneca; 2010.', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts].', 198);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (217, 'North Chicago, IL: Abbot Laboratories; 2011.', 'Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers].', 199);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (218, 'J Urol. 1997;158(1):160-163.', 'Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group.', 200);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (219, 'J Clin Oncol. 1996;14(6)1756-1764.', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints.', 201);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (220, 'Parsippany, NJ: Watson Pharma, Inc.; 2011.', 'Provenge [package insert].', 202);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (221, 'Parsippany, NJ: Watson Pharma, Inc.; 2011.', 'Trelstar [package insert].', 203);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (222, 'J Clin Oncol. 1993;11(7):1276-1285.', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.', 204);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (223, 'J Clin Oncol. 1995;13(7):1537-1545.', 'Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.', 205);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (224, 'N Engl J Med. 2003;348(8):694-701.', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone.', 206);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (225, 'J Clin Oncol. 1993;11(7):1276-1285.', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.', 207);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (226, 'J Clin Oncol. 2005;23(34):8845-8852.', 'Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.', 208);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (227, 'Br J Cancer. 1998;78(12):1634-1639.', 'Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group.', 209);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (228, 'Ann Intern Med. 1984 May;100(5):671-6', 'Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome.', 210);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (229, 'AM J Clin Oncol.2002;25(1): 57-59', 'Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.', 211);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (230, 'http://jco.ascopubs.org/content/17/6/1876.full', 'Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi''s Sarcoma.', 212);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (231, 'Int J Nanomedicine. 2007 September; 2(3): 345–352.', 'Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.', 213);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (232, 'J Clin Oncol. 2000; 18(17):3101-3107.', 'Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study.', 214);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (233, 'Acta Oncol. 2008;47(6): 1148-1155.', 'Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study.', 215);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (235, 'JClin Oncol. 2003;21(18):3479-3482.', 'Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01).', 217);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (236, 'Cancer. 2004; 100(6): 1257-1261.', 'Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.', 218);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (237, 'Cancer. 2010; 116(10):2448-2454.', 'Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium.', 219);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (238, 'J Clin Oncol. 2006;24(22):3548-3554.', 'Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study.', 220);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (239, 'Ann Intern Med. 1984;  101(4):440-446', 'Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin''s disease after failure of MOPP: ABVD and B-CAVe.', 221);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (240, 'J Clin Oncol. 1997; 15(11): 3338-3346', '.<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin''s disease.', 221);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (242, 'N Engl J Med. 2003;348(24):2386-2395', 'Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin''s disease.', 222);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (244, 'J Clin Oncol. 1995; 13(5):1080-1088', 'Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin''s disease: a Preliminary report.', 223);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (246, 'Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405.', 'Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany).', 224);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (247, 'Eur J Cancer. 1995;31A(6):903-911', 'Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin''s lymphomas.', 225);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (249, 'N Engl J Med. 2002;346(4):235-242.', 'Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.', 226);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (250, 'J Clin Oncol. 1999; 17(1):268-276', '<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.', 226);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (252, 'Ann Oncol. 2002, 13(8): 1254-1274.', 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study.', 227);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (253, 'Blood, 105(4): 1417-1423.', 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.', 228);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (254, 'J Clin Oncol. 2008;26(28):4578-4589.', '<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma.', 228);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (255, 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).', 'Blood. 1988;71(1):117-122.', 229);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (256, 'J Clin Oncol. 1994; 12(6): 1169-1176.', 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.', 230);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (257, 'J Clin Oncol. 1995; 13(7): 1734-1741.', '<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.', 230);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (258, 'J Clin Oncol. 1998; 16(12): 3803-3809', 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma.', 231);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (260, 'Ann Oncol. 2004; 15(3):511-516', 'Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.', 232);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (262, 'Blood. 2004; 103(10):3684-3688.', 'Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.', 233);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (263, 'Cancer. 2010,116(1):106-114', 'Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study.', 234);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (265, 'Woodcliff Lake, NJ: Eisai Inc.; 2011.', 'Targretin [package insert].', 235);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (266, 'Ann Oncol. 2009;20(3):520-525.', 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study.', 236);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (267, 'Blood (ASH Annula Meeting Abstracts). 2011; 118:443.', 'Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update.', 237);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (268, 'Bothell, WA: Seattle Genetics; 2011.', '<br> Adcetris [package insert].', 237);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (269, 'J Clin Oncol. 2001; 19(2):376-388.', 'Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.', 238);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (270, 'J Clin Oncol. 2002;20(24):4649-4654.', 'Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin''s lymphoma previously treated with an alkylating agent or alkylatic containing regimen.', 239);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (271, 'San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010.', 'Zevalin [package insert].', 240);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (272, 'Crit Rev Oncol Hematol. 2001;39(1-2):181-194.', '<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin''s lymphoma.', 240);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (273, 'Westminster, CO: Allos Therapeutics Inc.; 2012.', 'Folotyn [package insert].', 241);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (274, 'JClin Oncol. 2010;28(17):2853-2858.', 'van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin''s lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study.', 242);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (275, 'Summit , NJ: Celgene Corporation; 2011.', 'Istodax [package insert].', 243);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (276, 'J Clin Oncol.2009; 27(23):3822-3829.', 'Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator''s choice therapy for the treatment or relapsed or refractory mantle cell lymphoma.', 244);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (277, 'Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011.', 'Bexxar [package insert].', 245);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (278, null, 'Zolinza [package insert].', 246);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (279, 'J Clin Oncol. 2004; 22(8): 1491-1500.', 'Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491).', 247);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (280, 'Cancer. 2006; 106(7): 1560-1568.', 'Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.', 248);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (281, 'Cancer. 2003;98(6): 1196-1205.', 'Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma.', 249);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (282, 'BLOOD.2003;101(12):4653-4659.', 'Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.', 250);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (283, 'Blood. 1995;85(8):2025-2037.', 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811.', 251);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (284, 'J Clin Oncol. 2000;18(3):547-561.', 'Kantarjian HM, O''Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.', 252);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (285, 'Research Triangle Park, NC: GlaxoSmithKline;2011.', 'Arranon [package insert].', 253);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (287, 'Blood. 2008;112(8):3130-3134.', 'Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group.', 255);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (288, 'J Clin Oncol. 2009;32(10):5397-5403.', 'Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10.', 256);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (289, 'Blood. 1987;69(5):1441-1449.', 'Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study.', 257);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (290, 'Blood. 1992;79(2):313-319.', '<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia.', 257);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (291, 'Cancer Chemother Pharmacol. 1991;28(6):480-483.', '<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.', 257);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (292, 'N Engl J Med. 2009;361(13):1249-1259.', 'Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia.', 258);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (293, 'Frazer, PA: Cephalon; 2010.', 'Trisenox [package insert].', 259);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (294, 'Blood. 1995;85(10):2643-2653.', 'Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.', 260);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (295, 'Frazer, PA: Cephalon; 2010.', 'Trisenox [package insert].', 261);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (296, 'N Engl J Med. 1994;331(14):896-903.', 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B.', 262);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (297, 'Blood. 2001;98(3):548-553.', 'Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.', 263);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (298, 'J Clin Oncol. 2011;29(26)3559-3566.', 'Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG).', 264);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (299, 'Lancet. 2007; 370(9583):230-239.', 'Catovsky D, Richards S, Oscier D, et al. Assesmentof fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial.', 265);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (300, 'J Clin Oncol. 2010;28(10):1756-1765.', 'Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.', 266);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (301, 'Blood. 2003;101(1):6-14', 'Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).', 267);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (302, 'Blood. 2007;109(2):405-411.', 'Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.', 268);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (303, 'Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009.', 'Campath [package insert].', 269);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (304, 'J Clin Oncol. 2009;27(26):4378-4348.', 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lyphocytic leukemia.', 270);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (305, 'Blood. 2009;114:3382-3391.', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.', 271);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (306, 'Blood. 2009;114:3382-3391.', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.', 272);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (307, 'J Clin Oncol. 2010;28:1749-1755.', 'Arzerra [package insert]. <br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fluda-rabine-refractory chronic lymphocytic leukemia.', 273);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (308, 'N Engl J Med. 2010;362(24):2260-2270.', 'Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia.', 274);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (309, 'N Engl J Med. 2001 Apr 5;344(14):1031-7.', 'Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.', 275);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (310, 'Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17', 'Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.', 276);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (311, 'Blood 1992;79:1111-1120.', 'Saven A, et al.', 277);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (312, 'J Clin Oncol. 1991;9:243-246.', 'Cassileth PA, et al.', 278);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (313, 'Blood 1985;65:644-648.', 'Ratain MJ, et al.', 279);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (314, 'Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010.', 'Doxil [package insert].', 280);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (315, 'J clin Oncol. 2007;25(25):3892.', '<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.', 280);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (316, 'Blood. 2008;112(11):Abstract 653.', 'Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM).', 281);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (317, 'Lancet. 2010;18;376(9758):2075-2085.', 'Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.', 282);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (318, 'Br J Haematol. 2011 [Epub ahead of print].', 'Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma.', 283);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (319, 'J Clin Oncol. 2003;21(14):2732-2739.', 'Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.', 284);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (320, null, 'DOI: 10.1056/NEJMoa061292', 285);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (323, 'Blood. 2010;116(5):679-686.', 'Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.', 288);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (324, 'Br J Haematol. 1999;105(1):127-130.', 'Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.', 289);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (325, 'Blood. 2007;110(11 pt 1): Abstract 78.', 'San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma.', 290);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (326, 'N Engl J Med. 2008;359(9):906-917.', '<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.', 290);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (327, 'N Engl J Med. 2003;348(26):2609-2617.', 'Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma.', 291);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (328, 'Blood. 1992;80(4):887-890.', 'Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma.', 292);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (329, 'N Engl J Med. 1999;341(21):1565-1571.', 'Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma.', 293);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (331, 'Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25', 'Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.', 294);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (332, 'Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14', 'Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.', 295);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (333, 'J Clin Oncol. 1990;8(2):330-336.', 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study.', 296);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (334, 'N Engl J Med. 1993;328(24):1725-1731.', 'Duffner id, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors.', 297);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (335, 'Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.', 'Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164.', 298);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (336, 'http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012.', '<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma.', 298);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (337, 'J Clin Oncol. 2003;21(8):1581-1591.', 'Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children''s Cancer Study Group PNET-3 study.', 299);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (338, 'J Clin Oncol. 1995;13(1):112-123.', 'Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen.', 300);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (339, 'J Clin Oncol. 2000;18(22):3819-3828.', 'Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.', 301);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (340, 'J Pediatr Hematol Oncol. 2002;24(8):613-621.', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.', 302);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (341, 'J Pediatr Hematol Oncol. 2002;24(8):613-621.', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.', 303);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (342, 'J Clin Oncol. 1994;12(12):2607-2613.', 'Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.', 304);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (343, 'N Engl J Med. 1999;341(16):1165-1173.', 'Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid.', 305);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (344, 'Arch Ophthalmol. 2003;121(7):979-984.', 'Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy.', 306);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (345, 'J Clin Oncol. 2000;18(22):3819-3828.', 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology.', 307);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (346, 'J Clin Oncol. 1995; 13(1):124-133.', 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study.', 308);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (347, 'Cancer. 1994;73(12):3081-3086.', '<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor.', 308);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (348, 'J Clin Oncol. 1987;5(8):1191-1198.', 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.', 309);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (349, 'Cancer Treat Rep. 1986;70(12):1431-1432.', 'Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.', 310);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (350, 'J Clin Oncol. 2002;20(2):426-433.', 'Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.', 311);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (351, 'Semin Oncol. 1995;22(3 suppl 7):23-27.', 'Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.', 312);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (352, 'N Engl J Med. 2003;348(8):694-701.', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone.', 313);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (353, 'J Clin Oncol. 2003;21(18):3423-3430.', 'Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing''s family of tumors in children and young adults.', 314);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (354, 'J Clin Oncol. 1998;16(3):945-952.', 'Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncolgy Group study.', 315);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (355, 'J Clin Oncol. 2001;19(12):3091-3102.', 'Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.', 316);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (356, 'J Clin Oncol. 1990;8(12):1971-1980.', 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group.', 317);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (357, 'Ann Oncol. 2002;13(suppl 1):107-111.', 'Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin''s lymphoma: preliminary results from the Children''s Cancer Group Study Ccg-59704.', 318);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (358, 'N Engl J Med. 1990;322(17):1169-1174.', 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy.', 319);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (359, 'J Clin Oncol. 1996;14(4):1252-1261.', 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study.', 320);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (360, 'Blood 2003;101(10):3809-3817.', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group.', 321);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (361, 'Blood. 2002;99(6):1986-1994.', 'Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children''s Cancer Group Study.', 322);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (363, 'Research Triangle Park, NC: GlaxoSmithKline; 2011.', 'Arranon [package insert].', 323);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (364, 'Blood 2003;101(10):3809-3817.', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group.', 324);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (365, 'Cancer. 1993;71(9):2854-2861.', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study.', 325);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (366, 'Cancer. 1993;71(9):2854-2861.', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study.', 326);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (367, 'J Clin Oncol. 2000;18(6):1285-1294.', 'Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study.', 327);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (368, 'Blood. 2000;95(11):3310-3322.', 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.', 328);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (369, 'J Clin Oncol. 1989;7(10):1539-1544.', 'Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study.', 329);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (370, 'Cancer. 2006;66(6):1106-1113.', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.', 330);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (371, 'Cancer. 2006;66(6):1106-1113.', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.', 331);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (372, 'J Clin Oncol. 1991;9(4):572-580.', 'Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.', 332);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (373, 'Blood. 1996;87(12):4979-4989.', 'Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children''s Cancer Group.', 333);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (374, 'J Pediatr Hematol Oncol. 1995;17(3):185-197.', 'Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade.', 334);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (375, 'Br J Haematol. 1998;101(1):130-140.', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial.', 335);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (376, 'Br J Haematol. 1998;101(1):130-140.', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial.', 336);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (377, 'Lancet Oncol. 2015 Mar;16(3):257-65.', 'Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.', 337);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (378, 'Lancet. 2014 Aug 23;384(9944):665-73.', 'Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.', 338);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (379, 'J Clin Oncol. 2015 Nov 23. pii: JCO639443.', 'Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study.', 339);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (380, 'N Engl J Med. 2014 Mar 27;370(13):1189-97.', 'Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer.', 340);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (381, 'Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.', 'Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial.', 341);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (383, 'N Engl J Med 2015; 372:2018-2028.', 'Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer.', 343);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (384, 'N Engl J Med. 2013 Aug 8;369(6):507-16.', 'Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.', 344);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (385, 'J Clin Oncol. 2013 Sep 20;31(27):3327-34.', 'Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.', 345);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (386, 'N Engl J Med. 2010 Jun 24;362(25):2380-8.', 'Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR.', 346);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (387, 'Br J Haematol. 2015 Mar;168(6):811-9.', 'Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.', 347);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (388, 'Lancet. 2015 May 9;385(9980):1853-62.', 'Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin''s lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial.', 348);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (389, 'N Engl J Med. 2014 Mar 13;370(11):997-1007.', 'Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.', 349);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (390, 'N Engl J Med. 2014 Jul 17;371(3):213-23.', 'Byrd JC, Brown JR, O''Brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.', 350);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (391, 'Lancet. 2015 May 9;385(9980):1873-83.', 'Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial.', 351);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (392, 'Lancet Oncol. 2014 Dec;15(13):1503-12.', 'Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma .', 353);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (393, 'N Engl J Med. 2015 Sep 24;373(13):1207-19.', 'Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.', 354);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (394, 'Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma.', 'N Engl J Med. 2015 Nov 5;373(19):1803-13.', 355);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (395, 'Lancet Oncol. 2013 May;14(6):552-62.', 'Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial.', 356);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (396, 'N Engl J Med. 2012 Feb 23; 366(8): 707–714 .', 'Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib.', 357);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (397, 'N Engl J Med 2010; 363:711-723.', 'Hodi FS, O''Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma.', 358);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (398, 'N Engl J Med. 2015 May 21;372(21):2006-17.', 'Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma.', 359);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (399, 'N Engl J Med. 2015 Jan 1;372(1):30-9.', 'Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib.', 360);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (400, 'N Engl J Med. 2014 Nov 13;371(20):1867-76.', 'Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma.', 361);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (401, 'N Engl J Med 2015; 372:2521-2532.', 'Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma.', 362);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (402, 'N Engl J Med. 2015 Aug 13;373(7):621-31.', 'Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma .', 363);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (403, 'N Engl J Med. 2015 May 14;372(20):1909-19..', 'Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.', 364);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (440, 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 'Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03.', 404);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (405, 'Lancet Oncol. 2015 May;16(5):499-508.', 'Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.', 365);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (406, 'Lancet Oncol. 2014 Oct;15(11):1224-35.', 'Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial.', 366);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (407, 'Lancet. 2014 Jan 4;383(9911):31-9.', 'Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.', 367);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (408, 'Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1.', 'Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial.', 368);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (409, 'N Engl J Med. 2013 Oct 31;369(18):1691-703.', 'Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.', 369);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (410, 'Lancet Oncol. 2015 Jan;16(1):25-35.', 'Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study.', 370);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (411, 'Breast Cancer Res Treat. 2014 Feb;143(3):459-67.', 'Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2.', 371);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (412, 'N Engl J Med. 2012 Jan 12;366(2):109-19. S', 'Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.', 372);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (413, 'N Engl J Med. 2012 Nov 8;367(19):1783-91.', 'Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.', 373);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (414, 'J Clin Oncol.2012  October 30;(28):3486-3492.', 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.', 374);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (415, 'N Engl J Med.2013 Nov 7;369(19):1783-96.', 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.', 375);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (416, 'Blood.2012 Sep;120(13):2573-2580.', 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.', 376);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (417, 'N Engl J Med. 2014 Mar 20;370(12):1101-10.', 'Goede V, et. al. Obinutuzumab plus chlorambulcil in patients with CLL and coexisting conditions.', 377);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (455, 'Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.  Sundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.  Niell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.  Ihde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034.', 'Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.  Sundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.  Niell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.  Ihde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034.', 419);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (473, 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 437);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (493, null, 'Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A. Papadimitrakopoulou, Mark A. Socinski & Alan Sandler (2020) Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Review of Respiratory Medicine, 14:2, 125-136, DOI: 10.1080/17476348.2020.1701439  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 457);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (598, 'Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).', 'Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1).', 563);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (578, null, 'Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514).', 543);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (587, 'Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001.', 'Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001.', 552);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (623, 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext', 'https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext', 588);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (622, 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/', 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/', 587);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (621, 'Sharman et al. 2020 https://doi.org/10.1016/s0140-6736(20)30262-2', 'Sharman et al. 2020 https://doi.org/10.1016/s0140-6736(20)30262-2', 586);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (624, 'LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22.', 'https://hemonc.org/wiki/Afatinib_(Gilotrif)', 746);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (625, 'LUX-Lung 7: Park K, Tan EH, O''Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12.', 'LUX-Lung 2: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26.', 746);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (627, 'UX-Lung 2: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26.', 'Uptodate.com ', 747);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (628, 'LUX-Lung 6: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. ', 'LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O''Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1.', 747);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (629, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 'LUX-Lung 7: Park K, Tan EH, O''Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Epub 2016 Apr 12.', 747);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (630, 'Rosell R, Carcereny E, Gervais R,  et al; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. ', 'Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23.', 748);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (631, 'O''Bryant CL, Haluska P, Rosen L, et al, “An Open-Label Study to Describe Pharmacokinetic Parameters of Erlotinib in Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function,” Cancer Chemother Pharmacol, 2012, 69(3):605-12.', 'Yeo WL, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. ', 748);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (633, null, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 748);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (635, 'UPDATE: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4.', 'Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Onol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25..', 749);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (636, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 'Uptodate.com', 749);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (638, null, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.', 750);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (639, 'National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020 – April 23, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. ', 'Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. ', 751);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (640, null, 'Uptodate.com', 751);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (632, 'Miller AA, Murry DJ, Owzar K, et al, “Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101,” J Clin Oncol, 2007, 25(21):3055-60.', 'Miller AA, Murry DJ, Owzar K, et al, “Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101,” J Clin Oncol, 2007, 25(21):3055-60.', 748);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (642, 'Research Triangle Park, NC: GlaxoSmithKline;2011.', 'Arranon [package insert].', 753);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (643, 'Blood, 105(4): 1417-1423.', 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.', 754);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (644, 'J Clin Oncol. 2008;26(28):4578-4589.', '<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma.', 754);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (645, 'Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39. Epub 2017 May 10.', 'Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013 Jun;14(7):590-8. Epub 2013 Apr 30.', 755);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (646, 'Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. Epub 2019 Apr 10.', 'Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017 Aug 31;377(9):829-838. Epub 2017 Jun 6.', 755);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (637, 'Zhong WZ, Wang Q, Mao WM, et al; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21.', 'Zhong WZ, Wang Q, Mao WM, et al; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21.', 750);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (675, 'Am J Clin Oncol. 1995 Aug;18(4):293-6. doi: 10.1097/00000421-199508000-00004.', 'Am J Clin Oncol. 1995 Aug;18(4):293-6. doi: 10.1097/00000421-199508000-00004.', 780);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (648, 'Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929. Epub 2017 Jan 24.', 'Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97.', 757);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (655, 'Wei, G., Rafiyath, S. & Liu, D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 3, 47 (2010). https://doi.org/10.1186/1756-8722-3-47', 'Wei, G., Rafiyath, S. & Liu, D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 3, 47 (2010). https://doi.org/10.1186/1756-8722-3-47', 759);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (650, 'Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct;12(11):1004-12. Epub 2011 Sep 18.', 'Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703.', 758);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (651, 'Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.', 'Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O''Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. Epub 2013 Jun 1.', 758);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (652, 'Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017 Aug 31;377(9):829-838. Epub 2017 Jun 6. ', 'Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39. Epub 2017 May 10.', 758);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (653, 'Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018 Oct;13(10):1539-1548. Epub 2018 Aug 14.', 'Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017 Aug 17;2(3):e000219. eCollection 2017.', 758);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (654, 'hou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. Epub 2019 Apr 10.', 'Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. Epub 2018 Sep 25. ', 758);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (662, 'https://doi.org/10.1182/blood.V110.11.817.817', 'https://doi.org/10.1182/blood.V110.11.817.817', 766);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (663, 'https://doi.org/10.1002/cncr.21792', 'https://doi.org/10.1002/cncr.21792', 767);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (660, 'DOI: 10.1200/JCO.2003.05.093', 'Hematol Oncol Clin North Am 2006 Oct;20(5):1109-23.  doi: 10.1016/j.hoc.2006.06.008.', 764);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (661, null, 'DOI: 10.12000/JCO.19.02250', 765);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (671, null, 'DOI: 10.1016/S1470-2045(17)30421-7', 776);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (676, 'GILOTRIF (afatinib) [package insert]: Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.  2018. ', 'Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1. PMID: 23816963.', 781);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (677, 'Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O''Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12. PMID: 25589191.', 'Afatinib: Drug Information. UpToDate, Copyright 1978-2020 Lexicomp, Inc: Accessed Nov 29, 2020. ', 781);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (678, 'OPTIMAL: Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23.', 'Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53. ', 782);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (679, 'JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.', 'EURTAC: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group; Groupe Français de Pneumo-Cancérologie; Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26', 782);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (680, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC, 2016. Northbrook, IL', 'Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul;5(7):1048-53.', 782);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (681, 'ARCHER 1050: Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25.', 'ARCHER 1009: Ramalingam SS, Jänne PA, Mok T, O''Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O''Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.', 783);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (682, 'A7471028: Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O''Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2.', 'ARCHER 1050 UPDATE: Update: Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. Epub 2018 Jun 4.', 783);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (683, null, 'VIZIMPRO (Dacomitinib) [package insert]: Pfizer Inc. NY, NY.', 783);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (684, 'WJTOG3405 Update: Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019 Dec 1;30(12):1978-1984.', 'WJTOG3405: Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Thoracic Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. ', 784);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (685, 'NEJ002, HRQoL analysis: Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11.', 'NEJ002: Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. ', 784);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (582, 'Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45.', 'Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45.', 547);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (686, 'IRESSA (gefitinib) [product label]: AstraZeneca Pharmaceuticals LP Wilmington, DE ', 'NEJ002 Update: Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. ', 784);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (687, 'FLAURA Subgroup analysis: Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Nov 20;36(33):3290-7. Epub 2018 Aug 28.', 'FLAURA: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18.', 785);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (688, 'Osimertinib (TAGRISSO) [product label]: AstraZeneca Pharmaceuticals LP, Wilmington, DE ', 'FLAURA Update: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. Epub 2019 Nov 21.', 785);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (689, 'NEJ026: Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. Epub 2019 Apr 8. ', 'JO25567: Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.', 786);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (690, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC. 2016. Northbrook, IL', 'AVASTIN (Bevacizumab) [package insert]: Genitech Inc. 2013. San Francisco, CA.', 786);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (691, 'Tarceva (erlotinib) [package insert]: OSI Pharmaceuticals, LLC, 2016. Northbrook, IL', 'RELAY: Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4.', 787);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (692, null, 'CYRAMZA (ramucirumab) [package insert]: Eli Lilly and Company, 2014. Indianapolis, IN', 787);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (20, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 18);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (23, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 21);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (22, 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 'Cunningham D, et al. N Engl J Med 2008;358:36-46.', 20);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (41, 'Andre T, et al. Ann Oncol 2004;15:1339-1343.', 'Andre T, et al. Ann Oncol 2004;15:1339-1343.', 41);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (35, 'Venook AP. J Clin Oncol 1994;12:1323-1334.', 'Venook AP. J Clin Oncol 1994;12:1323-1334.', 35);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (32, 'Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).', 'Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).', 32);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (42, 'Taieb J, et al. Ann Oncol 2002;13:1192-1196.', 'Taieb J, et al. Ann Oncol 2002;13:1192-1196.', 42);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (44, 'Nehis O, et al. Br J Cancer 2008;98:309-315.', 'Nehis O, et al. Br J Cancer 2008;98:309-315.', 44);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (17, 'Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.', 'Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.', 15);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (47, 'Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.', 'Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.', 47);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (40, 'Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.', 'Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.', 40);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (19, 'Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.', 'Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.', 17);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (16, 'Kies MS, et al. Cancer 1987;60:2156-2160.', 'Kies MS, et al. Cancer 1987;60:2156-2160.', 14);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (45, 'Patt YZ, et al. Cancer 2004;101:578-586.', 'Patt YZ, et al. Cancer 2004;101:578-586.', 45);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (18, 'Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.', 'Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.', 16);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (33, 'Thomas MB, et al. J Clin Oncol 2009;27:843-850.', 'Thomas MB, et al. J Clin Oncol 2009;27:843-850.', 33);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (38, 'Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.', 'Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.', 38);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (43, 'Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.', 'Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.', 43);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (34, 'Llovet J, et al. N Engl J Med 2008;359:378-390.', 'Llovet J, et al. N Engl J Med 2008;359:378-390.', 34);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (31, 'Taieb J, et al. Cancer 2003;98:2664-2670.', 'Taieb J, et al. Cancer 2003;98:2664-2670.', 31);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (24, 'Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.', 'Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.', 22);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (39, 'Thongprasert S, et al. Ann Oncol 2005;16:279-281', 'Thongprasert S, et al. Ann Oncol 2005;16:279-281', 39);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (46, 'Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.', 'Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.', 46);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (37, 'Patt YZ, et al. Cancer 2004;101:578-586.', 'Patt YZ, et al. Cancer 2004;101:578-586.', 37);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (36, 'Okada S, et al. Oncology 1993;50:22-26.', 'Okada S, et al. Oncology 1993;50:22-26.', 36);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (457, 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 421);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (456, 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 'Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.', 420);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (615, 'Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.', 'Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.', 580);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (567, 'Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60.', 'Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60.', 532);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (657, 'Isfort S, Brümmendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. J Blood Med. 2018;9:43-50. Published 2018 Apr 10. doi:10.2147/JBM.S129821', 'Isfort S, Brümmendorf TH. Bosutinib in chronic myeloid leukemia: patient selection and perspectives. J Blood Med. 2018;9:43-50. Published 2018 Apr 10. doi:10.2147/JBM.S129821', 761);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (626, 'LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O''Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1.', 'LUX-Lung 3: Sequist LV, Yang JC, Yamamoto N, O''Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1.', 746);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (603, 'Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32.', 'Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32.', 568);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (546, 'Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.', 'Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.', 510);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (668, 'J Clin Oncol 1998 Apr;16(4):1310-7 doi: 10.1200/JCO.1998.16.4.1310.', 'J Clin Oncol 1998 Apr;16(4):1310-7 doi: 10.1200/JCO.1998.16.4.1310.', 772);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (492, 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16', 456);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (430, 'BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O''Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348.', 'BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O''Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348.', 390);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (604, 'Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.', 'Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.', 569);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (491, 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16  KEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16  KEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 455);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (550, 'Fumoleau P, Delozier T, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.Semin Oncol. 1995 Apr;22(2 Suppl 5):22-8.', 'Fumoleau P, Delozier T, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.Semin Oncol. 1995 Apr;22(2 Suppl 5):22-8.', 514);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (476, 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 440);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (421, 'Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8.', 'Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8.', 381);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (573, 'Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46.', 'Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46.', 538);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (610, 'Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7.', 'Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7.', 575);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (549, 'Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14.', 'Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14.', 513);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (586, 'Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31.', 'Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31.', 551);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (581, 'Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6.', 'Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6.', 546);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (693, 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 788);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (563, 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 527);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (447, 'Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7.', 'Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7.', 411);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (444, 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 408);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (577, 'Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7.', 'Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7.', 542);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (541, 'Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61.', 'Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61.', 505);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (451, 'Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed', 'Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed', 415);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (672, 'J Clin Oncol 1996 May;14(5):1672-8. doi: 10.1200/JCO.1996.14.5.1672.', 'J Clin Oncol 1996 May;14(5):1672-8. doi: 10.1200/JCO.1996.14.5.1672.', 777);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (525, 'O''Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7.', 'O''Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7.', 489);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (595, 'Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17.', 'Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17.', 560);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (613, 'Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.', 'Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62.', 578);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (619, 'Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164.', 'Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164.', 584);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (486, 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 'O''Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21.', 450);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (612, 'Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58 Suppl 3:43-9.', 'Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58 Suppl 3:43-9.', 577);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (611, 'Lund B, Hansen OP, et al. Phase II study of gemcitabine (2'',2''-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3.', 'Lund B, Hansen OP, et al. Phase II study of gemcitabine (2'',2''-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3.', 576);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (535, 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 499);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (452, 'IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed', 'IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed', 416);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (117, 'Erratum in: J Clin Oncol. 2007;25(22):3387.', 'Erratum in: J Clin Oncol. 2007;25(22):3387.', 106);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (488, 'Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).', 'Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90).', 452);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (424, 'Meluch AA, Greco FA, Burris HA 3rd, O''Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24.', 'Meluch AA, Greco FA, Burris HA 3rd, O''Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24.', 384);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (537, 'Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29.', 'Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29.', 501);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (478, 'O''Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23.', 'O''Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23.', 442);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (438, 'Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71.', 'Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71.', 402);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (571, 'Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9.', 'Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9.', 536);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (470, 'Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.', 'Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92.', 434);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (453, 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4.', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4.', 417);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (506, 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)  National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)  Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.  Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.  GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.  Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.  Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.  Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)  National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)  Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.  Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.  GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.  Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.  Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.  Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 470);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (560, 'Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43.', 'Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43.', 524);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (443, 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 407);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (665, 'Posner M, et al. N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956.', 'Posner M, et al. N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956.', 769);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (499, 'ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.  IPASS: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19.  MONET1: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.  BEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.  Paclitaxel injection. United States Prescribing Information. US National Library of Medicine.', 'ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.  IPASS: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19.  MONET1: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.  BEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.  Paclitaxel injection. United States Prescribing Information. US National Library of Medicine.', 463);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (533, 'Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.', 'Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.', 497);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (448, 'Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 412);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (552, 'Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81.', 'Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81.', 516);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (618, 'Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87.', 'Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87.', 583);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (523, 'Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86.', 'Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86.', 487);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (555, 'Cortes J, O''Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23.', 'Cortes J, O''Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23.', 519);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (474, 'Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92.', 'Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92.', 438);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (659, 'Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20(7):1735-1740. doi:10.1158/1078-0432.CCR-13-1283', 'Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20(7):1735-1740. doi:10.1158/1078-0432.CCR-13-1283', 763);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (667, ' DOI: 10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0', ' DOI: 10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0', 771);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (580, 'Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14.', 'Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14.', 545);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (431, 'Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26', 'Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26', 392);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (574, 'Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31.', 'Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31.', 539);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (607, 'Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8.', 'Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8.', 572);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (551, 'Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9.', 'Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9.', 515);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (540, 'Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11.', 'Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11.', 504);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (558, 'Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.', 'Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.', 522);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (584, 'Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50.', 'Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50.', 549);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (435, 'Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84.', 'Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84.', 399);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (545, 'Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.', 'Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.', 509);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (585, 'Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43.', 'Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43.', 550);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (234, 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.', 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.', 216);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (543, 'Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54.', 'Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54.', 507);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (428, 'Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O''Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6.', 'Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O''Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6.', 388);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (459, 'Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.', 'Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.', 423);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (498, 'EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 462);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (516, 'SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1.', 'SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1.', 480);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (594, 'Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26.', 'Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26.', 559);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (522, 'Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008).', 'Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008).', 486);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (445, 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 'Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.', 409);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (569, 'Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8.', 'Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8.', 534);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (485, 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 449);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (666, 'Semin Oncol 1998 Apr;25(2 Suppl 4):40-4; discussion 45-8.', 'Semin Oncol 1998 Apr;25(2 Suppl 4):40-4; discussion 45-8.', 770);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (509, 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.  Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf  Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.  Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf  Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf', 473);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (572, 'Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a.', 'Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a.', 537);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (450, 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 414);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (593, 'Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.', 'Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85.', 558);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (501, 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.  Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.  Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549', 465);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (472, 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 436);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (561, 'Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.', 'Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.', 525);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (524, 'Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.', 'Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.', 488);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (579, 'J Clin Oncol. 2001;19(20):4048-53.', 'Hoskins PJ, Swenerton KD, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19(20):4048-53.', 544);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (461, 'Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.', 'Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.', 425);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (462, 'von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.', 'von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.', 426);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (673, 'Forastiere AA, Urba SG. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol. 1995;22(3 Suppl 6):24-27.', 'Forastiere AA, Urba SG. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol. 1995;22(3 Suppl 6):24-27.', 778);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (454, 'Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810', 'Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810', 418);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (464, 'Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.  Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7.', 'Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.  Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7.', 428);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (471, 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 'Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.', 435);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (641, 'Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4.', 'Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4.', 752);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (433, 'Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2  Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391  T. Marcello, Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.  Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.  Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008', 'Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2  Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391  T. Marcello, Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.  Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.  Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008', 397);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (568, 'Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7.', 'Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7.', 533);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (494, 'Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 458);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (434, 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 398);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (503, 'Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14.  Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31.  Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR; Swedish Lung Cancer Study Group. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8.  Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O''Byrne K; British Thoracic Oncology Group. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.  Grigorescu, Alexandru C. et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, Volume 37, Issue 1, 9 - 14.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14.  Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31.  Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR; Swedish Lung Cancer Study Group. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8.  Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O''Byrne K; British Thoracic Oncology Group. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.  Grigorescu, Alexandru C. et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, Volume 37, Issue 1, 9 - 14.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 467);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (437, 'Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 'Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.', 401);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (423, 'Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9', 'Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9', 383);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (495, 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.  Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf  Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf', 'Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O''Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.  Opdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf  Yervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf', 459);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (508, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 472);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (592, 'Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4.', 'Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4.', 557);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (565, 'Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9.', 'Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9.', 530);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (658, 'N Engl J Med 2013; 369:1783-1796DOI: 10.1056/NEJMoa1306494', 'N Engl J Med 2013; 369:1783-1796DOI: 10.1056/NEJMoa1306494', 762);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (519, 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)  National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)  Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.  Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.  GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.  Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.  Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.  Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 'National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)  National Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)  Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.  Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.  GLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.  Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.  Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.  Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403.', 483);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (596, 'McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.', 'McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.', 561);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (436, 'Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.', 'Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96.', 400);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (521, 'Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.', 'Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.', 485);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (484, 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 'A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12.', 448);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (542, 'Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600.', 'Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600.', 506);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (536, 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 'Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646.', 500);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (601, 'D''Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4.', 'D''Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4.', 566);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (694, 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 'Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. doi:10.1056/NEJMoa1200966', 789);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (553, 'Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6.', 'Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6.', 517);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (465, 'JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. SWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6. JCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17.', 'JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. SWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6. JCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17.', 429);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (487, 'Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31.', 'Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31.', 451);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (420, 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7', 380);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (500, 'Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O''Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O''Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 464);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (529, 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 'Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9.', 493);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (526, 'Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.', 'Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.', 490);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (505, '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11. 2. Fossella F, et al. J Clin Oncol 2003; 21:3016. 3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11. 2. Fossella F, et al. J Clin Oncol 2003; 21:3016. 3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 469);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (125, 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 'Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.', 114);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (589, 'Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13.', 'Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13.', 554);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (404, 'Lancet Oncol. 2014 Oct;15(11):1195-206.', 'Lancet Oncol. 2014 Oct;15(11):1195-206.', 364);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (507, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 471);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (489, 'Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.', 'Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.', 453);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (463, 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print]', 'CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print]', 427);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (539, 'Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4.', 'Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4.', 503);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (511, '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11. 2. Fossella F, et al. J Clin Oncol 2003; 21:3016. 3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', '1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11. 2. Fossella F, et al. J Clin Oncol 2003; 21:3016. 3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine. 4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 475);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (458, 'Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52).', 'Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52).', 422);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (528, 'Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.', 'Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.', 492);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (469, 'Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.', 'Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.', 433);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (600, 'Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).', 'Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509).', 565);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (432, 'Rosenberg JE, O''Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29.', 'Rosenberg JE, O''Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29.', 393);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (620, 'Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700.', 'Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700.', 585);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (427, 'McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7', 'McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7', 387);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (562, 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 'Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3).', 526);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (617, 'Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.', 'Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.', 582);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (468, 'BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76.', 'BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76.', 432);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (419, 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7.', 'Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7.', 379);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (564, 'Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61.', 'Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61.', 529);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (609, 'De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53.', 'De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53.', 574);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (590, 'Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.', 'Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.', 555);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (515, 'ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.  EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.  Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11. Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.  Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.  ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28.', 'ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.  EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.  Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11. Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.  Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.  ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28.', 479);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (477, 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 'Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62.', 441);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (616, 'Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74.', 'Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74.', 581);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (512, 'Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.', 'Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.  Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.', 476);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (330, 'Erratum in N Engl J Med. 2000;342(5):364.', 'Erratum in N Engl J Med. 2000;342(5):364.', 293);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (446, 'Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71.', 'Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71.', 410);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (588, 'Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34.', 'Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34.', 553);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (656, 'Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. Epub 2017 Oct 23.', 'Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. Epub 2017 Oct 23.', 760);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (647, 'Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. Epub 2018 Sep 25.', 'Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. Epub 2018 Sep 25.', 756);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (599, 'Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5.', 'Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5.', 564);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (570, 'Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9.', 'Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9.', 535);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (531, 'Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.', 'Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.', 495);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (520, 'Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18.', 'Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18.', 484);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (576, 'Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6.', 'Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6.', 541);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (429, 'Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.', 'Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.', 389);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (597, 'Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36.', 'Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36.', 562);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (460, 'Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.', 'Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.', 424);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (467, 'Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.', 'Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.', 431);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (481, 'Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.', 'Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.', 445);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (547, 'Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19-24. --- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9.', 'Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19-24. --- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9.', 511);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (527, 'Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.', 'Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.', 491);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (518, 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.  Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.  Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x  Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.  Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.  Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.  Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x  Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.  Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 482);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (530, 'Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.', 'Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.', 494);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (504, 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.  Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.  Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x  Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.  Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 'Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.  Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.  Minami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x  Floyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.  Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.', 468);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (422, 'KEYNOTE-052: Balar AV, Castellano D, O''Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26.', 'KEYNOTE-052: Balar AV, Castellano D, O''Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26.', 382);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (591, 'Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81.', 'Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81.', 556);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (497, 'CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30.', 'CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30.', 461);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (426, 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17', 'Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17', 386);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (614, 'Miller DS, et al. J Clin Oncol 2009;27:2686-2691.', 'Miller DS, et al. J Clin Oncol 2009;27:2686-2691.', 579);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (514, 'JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.  5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11.', 'JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.  5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11.', 478);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (548, 'Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389.', 'Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389.', 512);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (664, 'Worden FP, et al. J clin Oncol 2005;23:105-112', 'Worden FP, et al. J clin Oncol 2005;23:105-112', 768);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (534, 'Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940.', 'Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940.', 498);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (449, 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 'Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7.', 413);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (510, 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.  Abraxane for Injectable Suspension. (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf', 'KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.  Abraxane for Injectable Suspension. (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf', 474);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (106, 'Roth  BJ, et al. J Clin Oncol 1992;10:282-291.', 'Roth  BJ, et al. J Clin Oncol 1992;10:282-291.', 99);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (606, 'Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9.', 'Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9.', 571);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (321, 'Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152', 'Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152', 286);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (583, 'Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66.', 'Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66.', 548);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (107, 'Neubauer M, et al. J Clin Oncol2004;22:1872-1877', 'Neubauer M, et al. J Clin Oncol2004;22:1872-1877', 100);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (674, 'Ann Oncol  1998 Oct;9(10):1103-7. doi: 10.1023/a:1008446706578.', 'Ann Oncol  1998 Oct;9(10):1103-7. doi: 10.1023/a:1008446706578.', 779);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (554, 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O''Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).', 'O''Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O''Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070).', 518);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (442, 'Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.', 'Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.', 406);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (490, 'Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.', 'Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59.', 454);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (466, 'Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.', 'Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82.', 430);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (649, ' Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017 Sep;12(9):1357-1367. Epub 2017 Jul 17.', ' Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017 Sep;12(9):1357-1367. Epub 2017 Jul 17.', 757);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (566, 'Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.', 'Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.', 531);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (483, 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 447);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (480, 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 444);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (532, 'Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19.', 'Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19.', 496);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (425, 'CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25.', 'CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25.', 385);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (670, 'Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.', 'Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.', 775);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (556, 'Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224.', 'Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224.', 520);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (475, 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 'Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.', 439);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (513, 'Semin Oncol 1997 Feb;24(1 Suppl 2):S2-65-S2-67.', 'Semin Oncol 1997 Feb;24(1 Suppl 2):S2-65-S2-67.', 477);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (538, 'Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66.', 'Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66.', 502);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (605, 'Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6.', 'Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6.', 570);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (575, 'Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5.', 'Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5.', 540);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (418, 'Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12.', 'Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12.', 378);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (479, 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 'Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35.', 443);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (544, 'Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71.', 'Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71.', 508);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (382, 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406.', 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406.', 342);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (608, 'McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9.', 'McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9.', 573);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (669, 'J Clin Oncol. 2005 Dec 1;23(34):8646-54. doi: 10.1200/JCO.2005.02.4646.', 'J Clin Oncol. 2005 Dec 1;23(34):8646-54. doi: 10.1200/JCO.2005.02.4646.', 774);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (496, 'Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 'Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.', 460);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (362, 'Erratum in: Blood. 2002; 100(6):1531.', 'Erratum in: Blood. 2002; 100(6):1531.', 322);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (559, 'Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53.', 'Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53.', 523);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (441, 'Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7.', 'Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7.', 405);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (602, 'Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9.', 'Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9.', 567);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (557, 'Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.', 'Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.', 521);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (517, 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.  Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549  EORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.', 'COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.  Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.  Rosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549  EORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17.', 481);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (482, 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 'Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3.', 446);
insert into public.regimen_reference (id, link, reference, regimen_detail_id) values (502, 'PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.  Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11.', 'PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.  Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11.', 466);

insert into public.level_type (id, level) values (1, 'ADJUVANT');
insert into public.level_type (id, level) values (2, 'NEOADJUVANT');
insert into public.level_type (id, level) values (3, 'METASTATIC');
insert into public.level_type (id, level) values (6, 'LOCALLY ADVANCED');
insert into public.level_type (id, level) values (7, 'HEPATIC ARTERY INFUSION');
insert into public.level_type (id, level) values (8, 'First Line');
insert into public.level_type (id, level) values (9, 'Second Line');
insert into public.level_type (id, level) values (10, 'Third Line');
insert into public.level_type (id, level) values (11, '5 q Deletion Syndrome');
insert into public.level_type (id, level) values (12, 'First Line');
insert into public.level_type (id, level) values (13, 'First Line');
insert into public.level_type (id, level) values (14, 'First Line');
insert into public.level_type (id, level) values (15, 'Definitive');
insert into public.level_type (id, level) values (16, 'Nasopharyngeal');
insert into public.level_type (id, level) values (17, 'ADVANCED');


insert into public.drug (id, generic_name) values (78, 'Necitumumab');
insert into public.drug (id, generic_name) values (3, 'Ribociclib');
insert into public.drug (id, generic_name) values (81, 'Megestrol');
insert into public.drug (id, generic_name) values (28, 'Methylprednisolone');
insert into public.drug (id, generic_name) values (41, 'Thioguanine');
insert into public.drug (id, generic_name) values (4, 'Enfortumab vedotin (Padcev) ');
insert into public.drug (id, generic_name) values (5, 'Synribo');
insert into public.drug (id, generic_name) values (84, 'Iclusig');
insert into public.drug (id, generic_name) values (156, 'Dacarbazine');
insert into public.drug (id, generic_name) values (66, 'Sunitinib');
insert into public.drug (id, generic_name) values (85, 'Pembrolizumab');
insert into public.drug (id, generic_name) values (7, 'Docetaxel (Taxotere)');
insert into public.drug (id, generic_name) values (2, 'Lomustine');
insert into public.drug (id, generic_name) values (10, 'Altretamine');
insert into public.drug (id, generic_name) values (11, 'Zykadia');
insert into public.drug (id, generic_name) values (86, 'Methotrexate');
insert into public.drug (id, generic_name) values (133, 'Sipuleucel-T');
insert into public.drug (id, generic_name) values (154, 'Thalidomide');
insert into public.drug (id, generic_name) values (65, 'Vinblastine');
insert into public.drug (id, generic_name) values (82, 'Obinutuzumab');
insert into public.drug (id, generic_name) values (13, 'Lenalidomide');
insert into public.drug (id, generic_name) values (87, 'Nivolumab (Opdivo)');
insert into public.drug (id, generic_name) values (71, 'Prednisone');
insert into public.drug (id, generic_name) values (90, 'Zelboraf');
insert into public.drug (id, generic_name) values (37, 'Trametinib');
insert into public.drug (id, generic_name) values (61, 'Pentostatin');
insert into public.drug (id, generic_name) values (93, 'Ipilumimab');
insert into public.drug (id, generic_name) values (50, 'Nivolumab');
insert into public.drug (id, generic_name) values (95, 'Pembrolizumab (Keytruda)');
insert into public.drug (id, generic_name) values (97, 'Toremifene');
insert into public.drug (id, generic_name) values (99, 'Darzalex');
insert into public.drug (id, generic_name) values (100, 'Atezolizumab (Tecentriq)');
insert into public.drug (id, generic_name) values (101, 'Alpelisib');
insert into public.drug (id, generic_name) values (91, 'Ramicurimab');
insert into public.drug (id, generic_name) values (102, 'Iressa');
insert into public.drug (id, generic_name) values (40, 'Capecitabine');
insert into public.drug (id, generic_name) values (104, 'Durvalumab (Imfinzi)');
insert into public.drug (id, generic_name) values (18, 'Ofatumumab');
insert into public.drug (id, generic_name) values (120, 'Cabazitaxel');
insert into public.drug (id, generic_name) values (63, 'Oxaliplatin');
insert into public.drug (id, generic_name) values (19, 'Paclitaxel');
insert into public.drug (id, generic_name) values (20, 'Opdivo');
insert into public.drug (id, generic_name) values (21, 'Zoledronic acid');
insert into public.drug (id, generic_name) values (74, 'Ixabepilone');
insert into public.drug (id, generic_name) values (23, 'Idelalisib');
insert into public.drug (id, generic_name) values (34, 'Prednisolone');
insert into public.drug (id, generic_name) values (22, 'paclitaxel');
insert into public.drug (id, generic_name) values (108, 'Cotellic');
insert into public.drug (id, generic_name) values (59, 'Dexamethasone');
insert into public.drug (id, generic_name) values (25, 'Tagrisso');
insert into public.drug (id, generic_name) values (26, 'Anastrozole');
insert into public.drug (id, generic_name) values (109, 'Erivedge');
insert into public.drug (id, generic_name) values (27, 'Dabrafenib');
insert into public.drug (id, generic_name) values (16, 'Gemcitabine (Gemzar), Cisplatin (Platinum)');
insert into public.drug (id, generic_name) values (29, 'Pablociclib');
insert into public.drug (id, generic_name) values (119, 'Alemtuzumab');
insert into public.drug (id, generic_name) values (125, 'Estramustine');
insert into public.drug (id, generic_name) values (30, 'Tamoxifen');
insert into public.drug (id, generic_name) values (31, 'Cisplatin');
insert into public.drug (id, generic_name) values (112, 'Nab-paclitaxel');
insert into public.drug (id, generic_name) values (143, 'Flutamide');
insert into public.drug (id, generic_name) values (113, 'Keytruda');
insert into public.drug (id, generic_name) values (35, 'Doxorubicin liposome');
insert into public.drug (id, generic_name) values (98, 'Vorinostat');
insert into public.drug (id, generic_name) values (38, 'Methotrexate');
insert into public.drug (id, generic_name) values (114, 'Ixabepilome');
insert into public.drug (id, generic_name) values (161, 'Bicalutamide');
insert into public.drug (id, generic_name) values (57, 'Procarbazine');
insert into public.drug (id, generic_name) values (132, 'Abaraterone');
insert into public.drug (id, generic_name) values (42, 'Liposomal Irinotecan');
insert into public.drug (id, generic_name) values (117, 'Imbruvica');
insert into public.drug (id, generic_name) values (118, '5-Fluorouracil');
insert into public.drug (id, generic_name) values (157, 'Carboplatin; Paralatin Paclitaxal');
insert into public.drug (id, generic_name) values (126, 'Nilutamide');
insert into public.drug (id, generic_name) values (43, 'Temsirolimus');
insert into public.drug (id, generic_name) values (44, 'Olaparib');
insert into public.drug (id, generic_name) values (121, 'Odomzo');
insert into public.drug (id, generic_name) values (45, 'Doxorubicin');
insert into public.drug (id, generic_name) values (24, 'Pralatrexate');
insert into public.drug (id, generic_name) values (94, 'Degarelix');
insert into public.drug (id, generic_name) values (96, 'Fulvestrant');
insert into public.drug (id, generic_name) values (123, 'Bevacizumab');
insert into public.drug (id, generic_name) values (46, 'Bleomycin');
insert into public.drug (id, generic_name) values (127, 'Pertuzumab');
insert into public.drug (id, generic_name) values (159, 'Azacitidine');
insert into public.drug (id, generic_name) values (128, 'Blincyto');
insert into public.drug (id, generic_name) values (130, 'Lapatinib');
insert into public.drug (id, generic_name) values (115, 'Cetuximab');
insert into public.drug (id, generic_name) values (162, 'Mitoxantrone');
insert into public.drug (id, generic_name) values (131, 'Everolimus');
insert into public.drug (id, generic_name) values (48, 'Various');
insert into public.drug (id, generic_name) values (136, 'Crizotinib');
insert into public.drug (id, generic_name) values (47, 'Dasatinib');
insert into public.drug (id, generic_name) values (49, 'Eribulin');
insert into public.drug (id, generic_name) values (103, 'Imatinib');
insert into public.drug (id, generic_name) values (150, 'Bexarotene');
insert into public.drug (id, generic_name) values (79, 'Bortezomib');
insert into public.drug (id, generic_name) values (1, 'Ifosfamide');
insert into public.drug (id, generic_name) values (51, 'Rucaparib');
insert into public.drug (id, generic_name) values (32, 'Carmustine');
insert into public.drug (id, generic_name) values (56, 'Docetaxel');
insert into public.drug (id, generic_name) values (134, 'Palbociclib');
insert into public.drug (id, generic_name) values (116, 'Rituximab');
insert into public.drug (id, generic_name) values (53, 'Paclitaxel (Taxol)');
insert into public.drug (id, generic_name) values (8, 'Exemestane');
insert into public.drug (id, generic_name) values (137, 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)');
insert into public.drug (id, generic_name) values (54, 'Ixazomib');
insert into public.drug (id, generic_name) values (55, 'Pemetrexed');
insert into public.drug (id, generic_name) values (138, 'Inlyta');
insert into public.drug (id, generic_name) values (139, 'Kadcyla');
insert into public.drug (id, generic_name) values (140, 'Abemaciclib');
insert into public.drug (id, generic_name) values (12, 'Cyclophosphamide');
insert into public.drug (id, generic_name) values (72, 'Erlotinib');
insert into public.drug (id, generic_name) values (110, 'Sorafenib');
insert into public.drug (id, generic_name) values (129, 'Pomalidamide');
insert into public.drug (id, generic_name) values (151, 'Cladribine');
insert into public.drug (id, generic_name) values (39, 'Carfilzomib');
insert into public.drug (id, generic_name) values (135, 'Carboplatin');
insert into public.drug (id, generic_name) values (92, 'Idarubicin');
insert into public.drug (id, generic_name) values (141, 'Ramucirumab');
insert into public.drug (id, generic_name) values (58, 'Ado-trastuzumab emtansine');
insert into public.drug (id, generic_name) values (62, 'Temozolomide');
insert into public.drug (id, generic_name) values (111, 'Goserelin');
insert into public.drug (id, generic_name) values (142, 'Neratinib');
insert into public.drug (id, generic_name) values (6, 'Trastuzumab');
insert into public.drug (id, generic_name) values (17, 'Letrozole');
insert into public.drug (id, generic_name) values (15, 'Nilotinib');
insert into public.drug (id, generic_name) values (9, 'Mesna');
insert into public.drug (id, generic_name) values (68, 'Gemcitabine');
insert into public.drug (id, generic_name) values (145, 'Lonsurf');
insert into public.drug (id, generic_name) values (146, 'Ipilimumab');
insert into public.drug (id, generic_name) values (60, 'nab-paclitaxel');
insert into public.drug (id, generic_name) values (163, 'Hydrocortisone');
insert into public.drug (id, generic_name) values (124, 'Chlorambucil');
insert into public.drug (id, generic_name) values (64, 'Calquence');
insert into public.drug (id, generic_name) values (36, 'Cytarabine');
insert into public.drug (id, generic_name) values (106, 'Bendamustine');
insert into public.drug (id, generic_name) values (122, 'Melphalan');
insert into public.drug (id, generic_name) values (67, 'Temodar');
insert into public.drug (id, generic_name) values (52, 'Epirubicin');
insert into public.drug (id, generic_name) values (88, 'Fluorouracil');
insert into public.drug (id, generic_name) values (152, 'Gilotrif');
insert into public.drug (id, generic_name) values (153, 'Cyramza');
insert into public.drug (id, generic_name) values (69, 'Etoposide');
insert into public.drug (id, generic_name) values (70, 'Niraparib');
insert into public.drug (id, generic_name) values (105, 'Topotecan');
insert into public.drug (id, generic_name) values (158, 'Talazoparib');
insert into public.drug (id, generic_name) values (14, 'Dactinomycin');
insert into public.drug (id, generic_name) values (155, 'Vincristine');
insert into public.drug (id, generic_name) values (160, 'Irinotecan');
insert into public.drug (id, generic_name) values (33, 'Lenalidamide');
insert into public.drug (id, generic_name) values (80, 'Fludarabine');
insert into public.drug (id, generic_name) values (144, 'Gemcitabine (Gemzar), CIsplatin (Platinum)');
insert into public.drug (id, generic_name) values (73, 'Gemcitabine (Gemzar), Paclitaxel (Taxol)');
insert into public.drug (id, generic_name) values (75, 'Elotuzumab');
insert into public.drug (id, generic_name) values (76, 'Erdafitinib (Balversa)');
insert into public.drug (id, generic_name) values (148, 'Vinorelbine');
insert into public.drug (id, generic_name) values (164, 'Yervoy');
insert into public.drug (id, generic_name) values (77, 'Atezolizumab');
insert into public.drug (id, generic_name) values (107, 'Brentuximab');
insert into public.drug (id, generic_name) values (89, 'Alectinib');
insert into public.drug (id, generic_name) values (149, 'Avelumab');
insert into public.drug (id, generic_name) values (83, 'Belenostat');
insert into public.drug (id, generic_name) values (147, 'Bosutinib');
insert into public.drug (id, generic_name) values (165, 'Ponatinib');
insert into public.drug (id, generic_name) values (166, 'Omacetaxine');
insert into public.drug (id, generic_name) values (167, 'Cladribine');
insert into public.drug (id, generic_name) values (168, 'Cladribine');
insert into public.drug (id, generic_name) values (169, 'Azacitidine');
insert into public.drug (id, generic_name) values (170, 'Decitabine');
insert into public.drug (id, generic_name) values (171, 'Mitotane');
insert into public.drug (id, generic_name) values (172, 'Streptozocin');

insert into public.brand (id, brand_name, generic_name, manufacturer) values (2, 'Ifex', 'Ifosfamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (3, 'CCNU', 'Lomustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (4, 'Kisqali', 'Ribociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (5, '', 'Enfortumab vedotin (Padcev) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (6, '', 'Synribo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (7, 'Herceptin', ' Trastuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (8, '', 'Docetaxel (Taxotere)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (9, 'Aromasin', ' Exemestane', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (10, 'Mesnex, various', 'Mesna ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (11, 'Hexalen', 'Altretamine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (12, '', 'Zykadia', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (13, 'Cytoxan', 'Cyclophosphamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (14, 'Revlimid', ' Lenalidomide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (15, 'Actinomycin', 'Dactinomycin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (16, 'Tasigna', 'Nilotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (17, '', 'Gemcitabine (Gemzar), Cisplatin (Platinum) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (18, 'Femara', ' Letrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (19, 'Arzerra', 'Ofatumumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (20, 'Femara', 'Letrozole ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (21, 'Taxol', 'Paclitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (22, '', 'Opdivo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (23, 'Taxol', 'Paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (24, 'Zometa, various', 'Zoledronic acid', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (25, 'Taxol', 'paclitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (26, 'Zydelig', 'Idelalisib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (27, 'Folotyn', 'Pralatrexate ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (28, '', 'Tagrisso', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (29, 'Arimidex', 'Anastrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (30, 'Tafilnar', 'Dabrafenib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (31, 'Depo-Medrol, Solu-Medrol, various', 'Methylprednisolone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (32, 'Ibrance', 'Pablociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (33, 'Nolvadex', 'Tamoxifen', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (34, 'CDDP', 'Cisplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (35, 'BCNU', 'Carmustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (36, 'Revlimid', ' Lenalidamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (37, 'Arimidex', 'Anastrozole ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (38, 'Flo-pred, various', 'Prednisolone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (39, 'Doxil, various', 'Doxorubicin liposome', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (40, 'Ara-C', 'Cytarabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (41, 'Mekinist', ' Trametinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (42, '', 'Methotrexate (Otrexup; Rasuvo; Rheumatrex [DSC]; Trexall; Xatmep). Vinblastine (Vinblastine), Doxorubicin (Adriamycin), (Cisplatin (Platinum)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (43, '', ' Cisplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (44, 'Kyprolis', 'Carfilzomib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (45, 'Xeloda', 'Capecitabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (46, '6-TG', 'Thioguanine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (47, 'Onivyde', 'Liposomal Irinotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (48, 'Torisel', 'Temsirolimus', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (49, 'Lynparza', 'Olaparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (50, 'Adriamycin', 'Doxorubicin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (51, 'Blenoxane', 'Bleomycin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (52, 'Revlimid', 'Lenalidomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (53, 'Sprycel', 'Dasatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (54, '', 'Various', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (55, 'Halaven', 'Eribulin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (56, 'Opdivo', ' Nivolumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (57, 'Ifex', 'Ifosfamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (58, 'Rubraca', 'Rucaparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (59, 'Ellence, various', 'Epirubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (60, '', 'Paclitaxel (Taxol)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (61, 'Ninlaro', 'Ixazomib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (62, 'Alimta', 'Pemetrexed', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (63, 'Cytoxan', 'Cyclophosphamide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (64, 'Taxotere', ' Docetaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (65, 'Matulane', 'Procarbazine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (66, 'Kadcyla', 'Ado-trastuzumab emtansine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (67, 'CDDP', 'Cisplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (68, 'Taxotere', 'Docetaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (69, 'Mesnex', 'Mesna', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (70, 'Decadron, various', ' Dexamethasone', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (71, 'Abraxane', 'nab-paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (72, 'Nipent', 'Pentostatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (73, 'Temodar', 'Temozolomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (74, 'Eloxatin, Oxaliplatin, various', 'Oxaliplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (75, '', 'Calquence', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (76, 'Velban', 'Vinblastine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (77, 'Sutent', 'Sunitinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (78, '', 'Temodar', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (79, 'Ellence, various', 'Epirubicin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (80, 'Hexalen', 'Altretamine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (81, 'Gemzar, various', 'Gemcitabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (82, 'VP-16', 'Etoposide', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (83, 'Zejula', 'Niraparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (84, 'Arzerra', 'Ofatumumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (85, 'various', 'Prednisone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (86, 'Tarceva', 'Erlotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (87, '', 'Gemcitabine (Gemzar), Paclitaxel (Taxol)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (88, 'Ixempra', 'Ixabepilone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (89, 'Empliciti', 'Elotuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (90, '', 'Erdafitinib (Balversa)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (91, 'Tecentriq', 'Atezolizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (92, 'Portrazza', 'Necitumumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (93, 'Velcade', 'Bortezomib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (94, 'Fludara', 'Fludarabine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (95, 'Megace', 'Megestrol', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (96, 'Gazyva', 'Obinutuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (97, 'Alimta', 'Pemetrexed ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (98, '', 'Beleodaq', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (99, '', 'Iclusig', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (100, 'Keytruda
nab-Paclitaxal', 'Pembrolizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (101, 'MTX', 'Methotrexate', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (102, '', 'Nivolumab (Opdivo)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (103, 'Adriamycin, various', 'Doxorubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (104, '5-FU', 'Fluorouracil ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (105, 'Aromasin, various', 'Exemestane ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (106, '', 'Alecensa', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (107, '', 'Zelboraf', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (108, 'Cyramza', ' Ramicurimab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (109, 'Idamycin', 'Idarubicin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (110, 'Yeroy', 'Ipilumimab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (111, 'Firmagon', 'Degarelix ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (112, '', 'Pembrolizumab (Keytruda)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (113, 'Faslodex', 'Fulvestrant ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (114, 'Fareston', 'Toremifene', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (115, 'Zolinza', 'Vorinostat ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (116, '', 'Darzalex', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (117, '', 'Atezolizumab (Tecentriq)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (118, 'Piqray', 'Alpelisib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (119, '', 'Iressa', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (120, 'Xeloda', 'Capecitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (121, 'Gleevec', 'Imatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (122, '', 'Durvalumab (Imfinzi)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (123, 'Hycamtin', 'Topotecan ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (124, 'Treanda', 'Bendamustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (125, 'Ixempra', 'Ixabepilone', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (126, '', 'Adcetris', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (127, '', 'Cotellic', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (128, '', 'Erivedge', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (129, 'Nexavar', 'Sorafenib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (130, 'Zoladex', 'Goserelin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (131, 'Abraxane', 'Nab-paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (132, '', 'Keytruda', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (133, 'Ixempra', 'Ixabepilome', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (134, 'Erbitux', 'Cetuximab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (135, 'Rituxan', 'Rituximab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (136, '', 'Imbruvica', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (137, '5-FU', '5-Fluorouracil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (138, 'Campath', 'Alemtuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (139, 'Jevtana', 'Cabazitaxel ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (140, '', 'Odomzo', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (141, 'Alkeran', 'Melphalan ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (142, 'Faslodex', 'Fulvestrant', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (143, 'Avastin', 'Bevacizumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (144, 'Various', ' Chlorambucil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (145, 'Estracyte', 'Estramustine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (146, 'Nilandron', 'Nilutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (147, 'VP-16', 'Etoposide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (148, 'Perjeta', 'Pertuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (149, '', 'Blincyto', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (150, 'Herceptin', 'Trastuzumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (151, 'Gemzar', ' Gemcitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (152, 'Pomalyst', 'Pomalidamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (153, 'Tykerb', 'Lapatinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (154, 'Afinitor', 'Everolimus', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (155, 'Zytiga', 'Abaraterone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (156, 'Avastin', 'Bevacizumab ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (157, 'Provenge', 'Sipuleucel-T ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (158, 'Taxotere', 'Docetaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (159, 'Ibrance', 'Palbociclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (160, 'Paraplatin', 'Carboplatin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (161, 'Aromasin', 'Exemestane', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (162, 'Xalkori', 'Crizotinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (163, '', 'Carboplatin (Paraplatin), Gemcitabine (Gemzar)', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (164, '', 'Inlyta', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (165, '', 'Kadcyla', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (166, 'Verzenio', 'Abemaciclib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (167, 'Leukeran', 'Chlorambucil ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (168, 'Paraplatin', 'Carboplatin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (169, 'Halaven', 'Eribulin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (170, 'Cyramza', 'Ramucirumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (171, 'Nerlynx', 'Neratinib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (172, 'Zoladex', 'Goserelin', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (173, 'Rituxan', ' Rituximab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (174, 'Herceptin', 'Trastuzumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (175, 'Femara', 'Letrozole', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (176, 'various', 'Flutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (177, '', 'Gemcitabine (Gemzar), CIsplatin (Platinum) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (178, 'Gemzar', 'Gemcitabine', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (179, '', 'Lonsurf', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (180, 'Yervoy
Nivolumab', 'Ipilimumab', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (181, 'Blenoxane', 'Bleomycin ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (182, 'Taxol', ' Paclitaxel', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (183, '', 'Bosulif', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (184, 'Navelbine', 'Vinorelbine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (185, '', 'Avelumab (Bavencio) ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (186, 'Targretin', 'Bexarotene ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (187, '2-CdA', 'Cladribine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (188, 'Tykerb', 'Lapatinib ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (189, '', 'Gilotrif', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (190, '', 'Cyramza', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (191, '5-FU', 'Fluorouracil', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (192, 'Thalomid', 'Thalidomide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (193, 'Oncovin, VCR', 'Vincristine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (194, 'DTIC', 'Dacarbazine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (195, 'Nolvadex', 'Tamoxifen ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (196, 'Hycamtin', 'Topotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (197, 'Taxol', 'Carboplatin; Paralatin
Paclitaxal', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (198, 'Talzenna', 'Talazoparib', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (199, 'various', 'Dexamethasone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (200, 'Vidaza', 'Azacitidine ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (201, 'Camptosar', 'Irinotecan', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (202, 'Casodex', 'Bicalutamide ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (203, 'Novantrone', 'Mitoxantrone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (204, 'various', 'Hydrocortisone ', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (205, '', 'Yervoy', '');
insert into public.brand (id, brand_name, generic_name, manufacturer) values (206, 'Navelbine', 'Vinorelbine', '');

insert into public.drug_brand (id, brand_name, manufacturer) values (115, 'Vidaza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (10, 'Actinomycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (37, 'Sprycel', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (93, 'Estracyte', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (25, 'Flo-pred, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (87, 'Rituxan', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (5, 'Aromasin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (72, 'Aromasin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (32, 'Onivyde', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (110, '2-CdA', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (59, 'Tarceva', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (12, 'Femara', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (98, 'Tykerb', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (36, 'Blenoxane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (30, 'Xeloda', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (75, 'Yeroy', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (8, 'Cytoxan', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (60, 'Ixempra', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (114, 'Talzenna', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (26, 'Doxil, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (47, 'Mesnex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (99, 'Afinitor', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (45, 'Matulane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (117, 'Casodex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (27, 'Ara-C', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (54, 'Sutent', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (80, 'Piqray', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (62, 'Tecentriq', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (74, 'Idamycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (102, 'Paraplatin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (85, 'Zoladex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (2, 'CCNU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (20, 'Depo-Medrol, Solu-Medrol, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (79, 'Zolinza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (11, 'Tasigna', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (89, 'Jevtana', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (61, 'Empliciti', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (66, 'Megace', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (103, 'Xalkori', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (43, 'Alimta', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (78, 'Fareston', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (112, 'Oncovin, VCR', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (28, 'Mekinist', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (76, 'Firmagon', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (39, 'Opdivo', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (17, 'Folotyn', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (105, 'Leukeran', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (63, 'Portrazza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (19, 'Tafilnar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (14, 'Taxol', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (33, 'Torisel', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (7, 'Hexalen', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (84, 'Nexavar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (16, 'Zydelig', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (31, '6-TG', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (42, 'Ninlaro', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (96, 'Gemzar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (82, 'Hycamtin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (9, 'Revlimid', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (21, 'Ibrance', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (68, 'Keytruda nab-Paclitaxal', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (34, 'Lynparza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (71, '5-FU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (116, 'Camptosar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (13, 'Arzerra', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (113, 'DTIC', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (64, 'Velcade', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (77, 'Faslodex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (104, 'Verzenio', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (4, 'Herceptin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (69, 'MTX', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (1, 'Ifex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (52, 'Eloxatin, Oxaliplatin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (97, 'Pomalyst', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (67, 'Gazyva', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (100, 'Zytiga', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (57, 'Zejula', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (92, 'Various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (44, 'Taxotere', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (83, 'Treanda', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (95, 'Perjeta', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (22, 'Nolvadex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (118, 'Novantrone', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (40, 'Rubraca', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (101, 'Provenge', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (111, 'Thalomid', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (88, 'Campath', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (91, 'Avastin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (46, 'Kadcyla', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (23, 'CDDP', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (29, 'Kyprolis', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (107, 'Yervoy Nivolumab', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (50, 'Nipent', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (109, 'Targretin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (35, 'Adriamycin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (90, 'Alkeran', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (41, 'Ellence, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (70, 'Adriamycin, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (94, 'Nilandron', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (18, 'Arimidex', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (24, 'BCNU', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (51, 'Temodar', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (48, 'Decadron, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (73, 'Cyramza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (65, 'Fludara', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (106, 'Nerlynx', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (3, 'Kisqali', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (81, 'Gleevec', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (6, 'Mesnex, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (108, 'Navelbine', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (86, 'Erbitux', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (53, 'Velban', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (55, 'Gemzar, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (15, 'Zometa, various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (49, 'Abraxane', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (58, 'various', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (38, 'Halaven', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (56, 'VP-16', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (119, 'Adcetris', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (120, 'Alecensa', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (121, 'Bavencio', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (122, 'Beleodaq', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (123, 'Bosulif', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (124, 'Bendeka', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (125, 'Mvasi', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (126, 'Iclusig', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (127, 'Synribo', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (128, 'Leustatin', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (129, 'Vidaza', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (130, 'Dacogen', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (131, '', '');
insert into public.drug_brand (id, brand_name, manufacturer) values (132, '', '');

insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (102, 102, 135);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (90, 90, 122);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (17, 17, 24);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (43, 43, 55);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (22, 22, 30);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (13, 13, 18);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (59, 59, 72);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (70, 70, 45);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (78, 78, 97);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (39, 39, 50);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (54, 54, 66);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (88, 88, 119);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (38, 38, 49);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (31, 31, 41);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (85, 85, 111);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (99, 99, 131);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (21, 21, 29);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (69, 69, 86);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (50, 50, 61);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (95, 95, 127);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (62, 62, 77);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (26, 26, 35);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (71, 71, 88);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (82, 82, 105);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (76, 76, 94);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (46, 46, 58);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (19, 19, 27);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (2, 2, 2);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (9, 9, 13);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (36, 36, 46);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (110, 110, 151);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (56, 56, 69);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (87, 87, 116);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (4, 4, 6);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (92, 92, 124);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (57, 57, 70);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (24, 24, 32);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (63, 63, 78);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (114, 114, 158);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (96, 96, 68);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (18, 18, 26);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (61, 61, 75);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (33, 33, 43);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (11, 11, 15);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (116, 116, 160);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (15, 15, 21);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (28, 28, 37);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (74, 74, 92);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (97, 97, 129);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (44, 44, 56);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (1, 1, 1);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (113, 113, 156);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (8, 8, 12);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (30, 30, 40);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (84, 84, 110);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (66, 66, 81);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (10, 10, 14);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (6, 6, 9);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (94, 94, 126);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (111, 111, 154);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (25, 25, 34);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (48, 48, 59);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (75, 75, 93);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (40, 40, 51);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (118, 118, 162);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (35, 35, 45);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (106, 106, 142);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (51, 51, 62);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (86, 86, 115);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (67, 67, 82);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (29, 29, 39);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (16, 16, 23);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (42, 42, 54);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (58, 58, 71);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (105, 105, 124);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (23, 23, 31);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (12, 12, 17);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (104, 104, 140);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (79, 79, 98);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (108, 108, 148);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (49, 49, 60);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (32, 32, 42);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (53, 53, 65);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (103, 103, 136);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (20, 20, 28);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (98, 98, 130);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (5, 5, 8);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (27, 27, 36);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (73, 73, 91);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (47, 47, 9);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (45, 45, 57);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (72, 72, 8);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (65, 65, 80);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (55, 55, 68);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (37, 37, 47);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (109, 109, 150);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (93, 93, 125);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (107, 107, 146);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (81, 81, 103);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (64, 64, 79);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (117, 117, 161);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (14, 14, 19);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (89, 89, 120);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (101, 101, 133);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (41, 41, 52);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (77, 77, 96);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (60, 60, 74);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (112, 112, 155);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (34, 34, 44);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (3, 3, 3);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (7, 7, 10);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (52, 52, 63);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (68, 68, 85);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (120, 119, 107);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (121, 100, 132);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (122, 120, 89);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (123, 80, 101);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (124, 121, 149);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (125, 122, 83);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (126, 123, 147);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (127, 83, 106);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (128, 124, 106);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (129, 91, 123);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (130, 125, 123);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (131, 126, 165);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (132, 127, 166);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (133, 128, 168);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (134, 129, 169);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (135, 115, 159);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (136, 130, 170);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (137, 131, 170);
insert into public.drug_brand_link (id, drug_brand_id, drug_id) values (138, 132, 171);

insert into public.brand_regimen_link (id, brand_id, regimen_id) values (0, 114, 502);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1, 98, 347);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (2, 161, 503);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (3, 156, 1);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (4, 3, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (5, 65, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (6, 193, 2);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (7, 73, 3);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (8, 35, 4);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (9, 156, 5);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (10, 73, 6);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (11, 168, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (12, 134, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (13, 191, 7);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (14, 67, 8);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (15, 134, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (16, 67, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (17, 191, 9);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (18, 37, 138);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (19, 67, 10);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (20, 67, 11);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (21, 182, 11);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (22, 67, 12);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (23, 158, 12);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (24, 134, 13);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (25, 67, 14);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (26, 191, 14);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (27, 67, 15);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (28, 67, 16);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (29, 182, 16);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (30, 120, 17);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (31, 74, 17);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (32, 67, 18);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (33, 79, 18);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (34, 79, 19);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (35, 74, 19);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (36, 120, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (37, 67, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (38, 79, 20);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (39, 120, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (40, 79, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (41, 74, 21);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (42, 182, 22);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (43, 178, 31);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (44, 74, 31);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (45, 126, 348);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (46, 67, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (47, 158, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (48, 191, 23);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (49, 67, 24);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (50, 158, 24);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (51, 67, 25);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (52, 79, 25);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (53, 147, 26);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (54, 191, 26);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (55, 191, 27);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (56, 120, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (57, 67, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (58, 191, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (59, 174, 28);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (60, 74, 32);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (61, 156, 33);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (62, 86, 33);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (63, 129, 34);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (64, 103, 35);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (65, 67, 36);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (66, 120, 37);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (67, 156, 38);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (68, 67, 39);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (69, 178, 39);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (70, 120, 40);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (71, 178, 40);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (72, 178, 41);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (73, 74, 41);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (74, 67, 42);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (75, 120, 43);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (76, 67, 43);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (77, 26, 349);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (78, 173, 349);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (79, 120, 44);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (80, 74, 44);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (81, 120, 45);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (82, 158, 46);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (83, 178, 47);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (84, 120, 139);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (85, 191, 48);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (86, 74, 48);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (87, 120, 49);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (88, 178, 49);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (89, 86, 50);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (90, 178, 50);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (91, 178, 51);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (92, 74, 51);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (93, 178, 52);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (94, 134, 53);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (95, 191, 55);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (96, 156, 56);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (97, 191, 56);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (98, 191, 57);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (99, 74, 57);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (100, 191, 58);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (101, 74, 67);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (102, 136, 350);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (103, 156, 59);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (104, 191, 59);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (105, 134, 60);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (106, 191, 60);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (107, 191, 61);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (108, 74, 61);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (109, 156, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (110, 191, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (111, 74, 62);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (112, 191, 63);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (113, 74, 63);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (114, 156, 68);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (115, 74, 68);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (116, 120, 69);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (117, 134, 70);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (118, 191, 71);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (119, 174, 151);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (120, 121, 77);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (121, 16, 78);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (122, 77, 79);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (123, 168, 80);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (124, 182, 80);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (125, 66, 426);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (126, 67, 81);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (127, 97, 81);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (128, 134, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (129, 67, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (130, 206, 82);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (131, 67, 83);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (132, 158, 83);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (133, 206, 152);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (134, 67, 84);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (135, 178, 84);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (136, 158, 85);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (137, 178, 85);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (138, 178, 86);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (139, 182, 86);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (140, 86, 93);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (141, 178, 87);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (142, 206, 87);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (143, 67, 88);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (144, 182, 88);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (145, 156, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (146, 168, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (147, 182, 89);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (148, 158, 189);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (149, 85, 189);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (150, 67, 90);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (151, 206, 90);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (152, 162, 91);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (153, 158, 92);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (154, 84, 351);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (155, 167, 351);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (156, 178, 94);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (157, 97, 95);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (158, 206, 96);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (159, 168, 97);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (160, 67, 98);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (161, 176, 190);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (162, 63, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (163, 103, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (164, 193, 99);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (165, 168, 100);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (166, 182, 100);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (167, 168, 101);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (168, 147, 101);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (169, 149, 352);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (170, 67, 102);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (171, 147, 102);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (172, 147, 103);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (173, 182, 104);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (174, 196, 105);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (175, 196, 106);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (176, 67, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (177, 63, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (178, 103, 107);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (179, 67, 108);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (180, 147, 108);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (181, 161, 142);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (182, 67, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (183, 63, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (184, 103, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (185, 193, 109);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (186, 67, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (187, 147, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (188, 57, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (189, 69, 110);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (190, 178, 111);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (191, 196, 111);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (192, 168, 112);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (193, 182, 112);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (194, 63, 113);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (195, 103, 113);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (196, 142, 143);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (197, 63, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (198, 103, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (199, 182, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (200, 174, 115);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (201, 63, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (202, 103, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (203, 182, 116);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (204, 63, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (205, 103, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (206, 191, 122);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (207, 63, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (208, 158, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (209, 103, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (210, 174, 117);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (211, 178, 144);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (212, 61, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (213, 36, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (214, 199, 353);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (215, 158, 118);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (216, 103, 118);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (217, 103, 119);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (218, 182, 119);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (219, 63, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (220, 103, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (221, 182, 120);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (222, 156, 121);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (223, 182, 121);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (224, 63, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (225, 103, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (226, 182, 130);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (227, 63, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (228, 79, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (229, 191, 123);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (230, 116, 354);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (231, 63, 124);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (232, 191, 124);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (233, 178, 125);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (234, 182, 125);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (235, 63, 126);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (236, 79, 126);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (237, 120, 127);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (238, 125, 127);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (239, 120, 128);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (240, 188, 128);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (241, 188, 129);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (242, 175, 129);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (243, 63, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (244, 158, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (245, 103, 131);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (246, 63, 132);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (247, 158, 132);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (248, 120, 133);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (249, 158, 133);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (250, 168, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (251, 158, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (252, 174, 134);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (253, 182, 135);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (254, 174, 135);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (255, 168, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (256, 182, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (257, 174, 136);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (258, 158, 140);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (259, 169, 141);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (260, 175, 145);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (261, 182, 147);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (262, 195, 148);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (263, 174, 150);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (264, 168, 153);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (265, 158, 153);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (266, 168, 154);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (267, 182, 154);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (268, 168, 155);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (269, 67, 156);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (270, 182, 156);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (271, 22, 355);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (272, 168, 157);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (273, 178, 157);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (274, 67, 158);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (275, 182, 158);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (276, 80, 159);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (277, 156, 160);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (278, 178, 161);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (279, 176, 191);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (280, 172, 191);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (281, 182, 162);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (282, 196, 164);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (283, 164, 356);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (284, 107, 357);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (285, 67, 165);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (286, 103, 165);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (287, 67, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (288, 103, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (289, 182, 166);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (290, 103, 167);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (291, 158, 188);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (292, 145, 188);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (293, 67, 169);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (294, 191, 169);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (295, 67, 170);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (296, 182, 170);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (297, 205, 358);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (298, 67, 171);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (299, 196, 171);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (300, 67, 172);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (301, 129, 177);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (302, 77, 178);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (303, 168, 180);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (304, 178, 180);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (305, 67, 181);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (306, 178, 181);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (307, 67, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (308, 103, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (309, 76, 182);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (310, 202, 193);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (311, 172, 193);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (312, 111, 194);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (313, 181, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (314, 67, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (315, 147, 183);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (316, 67, 184);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (317, 147, 184);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (318, 67, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (319, 57, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (320, 69, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (321, 182, 185);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (322, 67, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (323, 147, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (324, 69, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (325, 76, 186);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (326, 139, 187);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (327, 85, 187);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (328, 203, 192);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (329, 85, 192);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (330, 40, 262);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (331, 155, 195);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (332, 172, 198);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (333, 146, 200);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (334, 85, 201);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (335, 157, 202);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (336, 194, 204);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (337, 103, 204);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (338, 103, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (339, 57, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (340, 69, 205);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (341, 63, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (342, 15, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (343, 103, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (344, 147, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (345, 57, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (346, 69, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (347, 193, 206);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (348, 110, 359);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (349, 56, 359);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (350, 194, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (351, 103, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (352, 57, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (353, 69, 207);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (354, 67, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (355, 103, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (356, 57, 208);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (357, 103, 209);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (358, 182, 212);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (359, 173, 242);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (360, 168, 214);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (361, 182, 214);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (362, 30, 360);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (363, 41, 360);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (364, 168, 215);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (365, 158, 215);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (366, 168, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (367, 178, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (368, 182, 216);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (369, 67, 217);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (370, 178, 217);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (371, 158, 218);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (372, 178, 218);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (373, 120, 219);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (374, 74, 219);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (375, 168, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (376, 147, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (377, 182, 220);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (378, 40, 263);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (379, 127, 361);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (380, 181, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (381, 194, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (382, 103, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (383, 76, 221);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (384, 181, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (385, 63, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (386, 103, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (387, 147, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (388, 85, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (389, 65, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (390, 193, 222);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (391, 181, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (392, 103, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (393, 147, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (394, 85, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (395, 76, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (396, 193, 223);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (397, 124, 224);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (398, 173, 224);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (399, 63, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (400, 103, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (401, 38, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (402, 193, 225);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (403, 63, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (404, 103, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (405, 85, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (406, 173, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (407, 193, 226);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (408, 63, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (409, 40, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (410, 147, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (411, 57, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (412, 69, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (413, 193, 227);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (414, 85, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (415, 173, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (416, 193, 228);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (417, 67, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (418, 40, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (419, 199, 229);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (420, 67, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (421, 40, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (422, 147, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (423, 31, 230);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (424, 27, 241);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (425, 115, 246);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (426, 63, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (427, 40, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (428, 199, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (429, 193, 231);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (430, 63, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (431, 103, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (432, 147, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (433, 85, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (434, 173, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (435, 193, 232);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (436, 168, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (437, 147, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (438, 57, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (439, 69, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (440, 173, 233);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (441, 124, 234);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (442, 186, 235);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (443, 93, 236);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (444, 94, 239);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (445, 63, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (446, 103, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (447, 147, 247);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (448, 63, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (449, 103, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (450, 193, 248);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (451, 63, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (452, 40, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (453, 147, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (454, 57, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (455, 69, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (456, 193, 249);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (457, 63, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (458, 147, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (459, 85, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (460, 193, 250);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (461, 40, 258);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (462, 63, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (463, 40, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (464, 199, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (465, 103, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (466, 85, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (467, 46, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (468, 193, 251);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (469, 63, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (470, 40, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (471, 199, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (472, 103, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (473, 69, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (474, 31, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (475, 193, 252);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (476, 109, 255);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (477, 40, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (478, 147, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (479, 109, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (480, 203, 256);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (481, 40, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (482, 109, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (483, 203, 257);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (484, 124, 264);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (485, 173, 264);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (486, 63, 265);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (487, 94, 265);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (488, 63, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (489, 94, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (490, 173, 266);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (491, 94, 267);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (492, 173, 267);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (493, 63, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (494, 72, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (495, 173, 268);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (496, 138, 269);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (497, 124, 270);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (498, 167, 271);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (499, 94, 272);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (500, 132, 362);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (501, 84, 273);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (502, 53, 274);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (503, 121, 275);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (504, 16, 276);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (505, 187, 277);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (506, 72, 278);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (507, 93, 280);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (508, 93, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (509, 199, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (510, 103, 281);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (511, 93, 282);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (512, 192, 282);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (513, 93, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (514, 63, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (515, 199, 283);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (516, 28, 342);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (517, 67, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (518, 199, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (519, 103, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (520, 147, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (521, 192, 284);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (522, 199, 285);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (523, 52, 285);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (524, 141, 286);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (525, 85, 286);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (526, 141, 287);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (527, 85, 287);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (528, 93, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (529, 199, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (530, 52, 288);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (531, 199, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (532, 103, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (533, 193, 289);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (534, 93, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (535, 141, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (536, 85, 290);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (537, 93, 291);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (538, 199, 292);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (539, 192, 293);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (540, 44, 294);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (541, 152, 295);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (542, 67, 296);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (543, 147, 296);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (544, 67, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (545, 63, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (546, 147, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (547, 193, 297);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (548, 67, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (549, 63, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (550, 193, 298);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (551, 132, 343);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (552, 136, 344);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (553, 189, 345);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (554, 168, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (555, 63, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (556, 147, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (557, 69, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (558, 193, 299);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (559, 3, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (560, 85, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (561, 193, 300);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (562, 168, 301);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (563, 67, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (564, 63, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (565, 103, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (566, 147, 302);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (567, 67, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (568, 63, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (569, 103, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (570, 147, 303);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (571, 67, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (572, 63, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (573, 103, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (574, 147, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (575, 193, 304);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (576, 67, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (577, 63, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (578, 103, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (579, 147, 305);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (580, 168, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (581, 147, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (582, 193, 306);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (583, 67, 307);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (584, 103, 307);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (585, 15, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (586, 103, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (587, 193, 308);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (588, 147, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (589, 57, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (590, 69, 309);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (591, 119, 346);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (592, 67, 310);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (593, 103, 310);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (594, 147, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (595, 57, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (596, 69, 311);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (597, 168, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (598, 147, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (599, 57, 312);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (600, 63, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (601, 103, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (602, 193, 313);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (603, 63, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (604, 103, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (605, 147, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (606, 57, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (607, 193, 314);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (608, 40, 330);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (609, 63, 315);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (610, 196, 315);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (611, 63, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (612, 15, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (613, 193, 316);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (614, 181, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (615, 194, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (616, 103, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (617, 76, 317);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (618, 181, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (619, 63, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (620, 103, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (621, 147, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (622, 85, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (623, 65, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (624, 193, 318);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (625, 63, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (626, 103, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (627, 85, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (628, 193, 319);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (629, 40, 331);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (630, 63, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (631, 40, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (632, 103, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (633, 193, 320);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (634, 199, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (635, 85, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (636, 193, 321);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (637, 40, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (638, 85, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (639, 193, 322);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (640, 199, 324);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (641, 193, 324);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (642, 40, 326);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (643, 204, 326);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (644, 40, 332);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (645, 46, 332);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (646, 40, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (647, 199, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (648, 147, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (649, 46, 333);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (650, 200, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (651, 40, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (652, 147, 334);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (653, 22, 337);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (654, 158, 338);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (655, 108, 338);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (656, 106, 339);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (657, 12, 340);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (658, 92, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (659, 178, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (660, 67, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (661, 54, 341);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (662, 89, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (663, 52, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (664, 199, 363);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (665, 179, 364);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (666, 170, 365);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (667, 170, 366);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (668, 182, 366);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (669, 190, 367);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (670, 47, 368);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (671, 131, 369);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (672, 178, 369);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (673, 32, 370);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (674, 175, 370);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (675, 154, 371);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (676, 161, 371);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (677, 148, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (678, 174, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (679, 158, 372);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (680, 165, 373);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (681, 183, 374);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (682, 99, 375);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (683, 6, 376);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (684, 96, 377);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (685, 177, 379);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (686, 117, 381);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (687, 42, 378);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (688, 17, 380);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (689, 112, 382);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (690, 87, 383);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (691, 87, 384);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (692, 102, 385);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (693, 154, 493);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (694, 161, 493);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (695, 60, 386);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (696, 8, 387);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (697, 122, 388);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (698, 185, 389);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (699, 90, 390);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (700, 163, 391);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (701, 5, 393);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (702, 163, 392);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (703, 63, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (704, 158, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (705, 103, 114);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (706, 63, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (707, 158, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (708, 103, 398);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (709, 168, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (710, 158, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (711, 148, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (712, 174, 399);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (713, 63, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (714, 79, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (715, 137, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (716, 158, 410);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (717, 154, 437);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (718, 161, 437);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (719, 63, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (720, 103, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (721, 182, 411);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (722, 159, 494);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (723, 175, 494);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (724, 166, 500);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (725, 175, 500);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (726, 63, 400);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (727, 103, 400);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (728, 63, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (729, 103, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (730, 182, 402);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (731, 63, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (732, 158, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (733, 103, 404);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (734, 100, 456);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (735, 4, 495);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (736, 175, 495);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (737, 178, 567);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (738, 67, 567);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (739, 118, 498);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (740, 142, 498);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (741, 67, 533);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (742, 201, 533);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (743, 63, 405);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (744, 158, 405);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (745, 63, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (746, 158, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (747, 103, 406);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (748, 63, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (749, 103, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (750, 191, 407);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (751, 79, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (752, 63, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (753, 101, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (754, 137, 408);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (755, 168, 415);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (756, 63, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (757, 158, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (758, 103, 403);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (759, 63, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (760, 103, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (761, 182, 412);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (762, 63, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (763, 158, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (764, 103, 413);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (765, 63, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (766, 158, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (767, 103, 414);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (768, 178, 542);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (769, 100, 543);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (770, 195, 501);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (771, 182, 544);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (772, 168, 544);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (773, 103, 545);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (774, 63, 545);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (775, 103, 546);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (776, 67, 546);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (777, 178, 566);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (778, 39, 566);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (779, 166, 497);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (780, 142, 497);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (781, 159, 496);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (782, 142, 496);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (783, 166, 499);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (784, 37, 499);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (785, 37, 504);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (786, 175, 505);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (787, 63, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (788, 103, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (789, 182, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (790, 174, 420);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (791, 142, 506);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (792, 67, 397);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (793, 95, 507);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (794, 168, 417);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (795, 168, 418);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (796, 174, 508);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (797, 66, 509);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (798, 63, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (799, 103, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (800, 182, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (801, 174, 421);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (802, 168, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (803, 158, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (804, 174, 422);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (805, 63, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (806, 79, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (807, 137, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (808, 158, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (809, 174, 423);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (810, 148, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (811, 174, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (812, 158, 424);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (813, 171, 425);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (814, 168, 416);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (815, 158, 511);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (816, 67, 427);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (817, 67, 419);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (818, 120, 510);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (819, 67, 552);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (820, 57, 552);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (821, 196, 557);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (822, 178, 553);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (823, 158, 553);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (824, 198, 522);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (825, 103, 554);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (826, 67, 523);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (827, 67, 524);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (828, 182, 524);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (829, 67, 525);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (830, 196, 525);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (831, 95, 555);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (832, 182, 556);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (833, 168, 428);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (834, 37, 431);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (835, 195, 430);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (836, 175, 432);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (837, 195, 433);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (838, 175, 433);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (839, 195, 434);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (840, 161, 434);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (841, 195, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (842, 172, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (843, 24, 435);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (844, 37, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (845, 172, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (846, 24, 436);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (847, 103, 438);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (848, 182, 438);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (849, 63, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (850, 103, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (851, 191, 439);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (852, 63, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (853, 79, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (854, 137, 440);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (855, 63, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (856, 101, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (857, 137, 441);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (858, 120, 442);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (859, 158, 442);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (860, 120, 443);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (861, 182, 443);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (862, 120, 444);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (863, 206, 444);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (864, 120, 445);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (865, 125, 445);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (866, 174, 491);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (867, 188, 491);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (868, 158, 446);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (869, 103, 446);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (870, 158, 447);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (871, 39, 447);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (872, 63, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (873, 79, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (874, 137, 409);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (875, 63, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (876, 79, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (877, 137, 448);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (878, 63, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (879, 79, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (880, 137, 449);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (881, 63, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (882, 103, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (883, 182, 401);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (884, 178, 450);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (885, 182, 450);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (886, 168, 451);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (887, 182, 451);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (888, 168, 452);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (889, 158, 452);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (890, 156, 453);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (891, 182, 453);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (892, 91, 454);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (893, 131, 454);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (894, 100, 455);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (895, 180, 473);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (896, 168, 457);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (897, 168, 474);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (898, 100, 472);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (899, 48, 558);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (900, 168, 559);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (901, 63, 559);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (902, 67, 480);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (903, 178, 482);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (904, 168, 460);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (905, 168, 458);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (906, 67, 478);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (907, 67, 481);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (908, 80, 571);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (909, 39, 572);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (910, 182, 573);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (911, 168, 463);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (912, 178, 568);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (913, 168, 568);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (914, 182, 569);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (915, 67, 569);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (916, 97, 570);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (917, 168, 570);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (918, 67, 479);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (919, 67, 465);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (920, 178, 483);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (921, 67, 531);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (922, 191, 531);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (923, 67, 532);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (924, 206, 532);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (925, 83, 584);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (926, 168, 464);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (927, 168, 461);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (928, 168, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (929, 158, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (930, 174, 486);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (931, 174, 488);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (932, 206, 488);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (933, 174, 489);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (934, 178, 489);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (935, 174, 490);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (936, 120, 490);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (937, 178, 467);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (938, 120, 492);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (939, 188, 492);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (940, 178, 468);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (941, 178, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (942, 168, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (943, 174, 487);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (944, 168, 469);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (945, 168, 462);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (946, 178, 470);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (947, 168, 471);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (948, 180, 459);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (949, 168, 475);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (950, 168, 476);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (951, 174, 484);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (952, 182, 484);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (953, 197, 477);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (954, 174, 485);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (955, 158, 485);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (956, 182, 512);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (957, 133, 513);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (958, 206, 514);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (959, 103, 515);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (960, 178, 516);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (961, 39, 517);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (962, 169, 519);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (963, 131, 518);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (964, 166, 520);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (965, 67, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (966, 182, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (967, 156, 527);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (968, 168, 535);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (969, 158, 535);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (970, 182, 528);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (971, 196, 528);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (972, 182, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (973, 196, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (974, 156, 526);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (975, 181, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (976, 57, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (977, 69, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (978, 67, 529);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (979, 181, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (980, 57, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (981, 69, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (982, 168, 530);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (983, 67, 534);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (984, 178, 534);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (985, 67, 536);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (986, 97, 536);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (987, 158, 537);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (988, 182, 538);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (989, 201, 539);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (990, 196, 540);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (991, 97, 541);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (992, 103, 547);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (993, 182, 547);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (994, 67, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (995, 103, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (996, 182, 548);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (997, 63, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (998, 103, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (999, 67, 549);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1000, 168, 550);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1001, 39, 550);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1002, 182, 551);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1003, 57, 551);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1004, 67, 560);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1005, 63, 560);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1006, 67, 561);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1007, 182, 561);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1008, 168, 562);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1009, 182, 562);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1010, 168, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1011, 182, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1012, 156, 563);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1013, 168, 564);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1014, 158, 564);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1015, 168, 565);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1016, 39, 565);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1017, 196, 575);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1018, 125, 574);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1019, 178, 576);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1020, 147, 577);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1021, 206, 578);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1022, 97, 579);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1023, 156, 580);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1024, 120, 581);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1025, 49, 582);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1026, 49, 521);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1027, 58, 583);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1028, 181, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1029, 147, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1030, 67, 585);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1031, 75, 586);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1032, 128, 587);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1033, 140, 588);
insert into public.brand_regimen_link (id, brand_id, regimen_id) values (1034, 78, 670);


insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (1, 1, 1);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (2, 1, 2);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (3, 1, 3);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (4, 1, 4);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (5, 1, 5);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (6, 2, 7);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (7, 2, 8);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (8, 2, 9);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (9, 2, 10);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (10, 2, 11);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (11, 2, 12);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (54, 8, 77);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (55, 8, 78);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (56, 8, 79);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (57, 9, 39);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (58, 9, 40);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (59, 9, 41);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (60, 9, 42);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (61, 9, 43);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (62, 9, 44);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (63, 9, 45);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (64, 9, 46);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (65, 9, 47);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (66, 10, 31);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (67, 10, 32);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (68, 10, 33);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (69, 10, 34);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (70, 10, 35);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (71, 10, 36);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (72, 10, 37);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (73, 10, 38);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (74, 11, 48);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (75, 11, 49);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (76, 11, 50);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (77, 11, 51);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (78, 11, 52);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (79, 12, 80);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (80, 12, 81);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (81, 12, 82);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (82, 12, 83);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (83, 12, 84);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (84, 12, 85);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (85, 12, 86);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (86, 12, 87);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (87, 12, 88);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (88, 12, 89);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (89, 12, 90);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (90, 12, 91);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (91, 12, 92);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (92, 12, 93);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (93, 12, 94);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (94, 12, 95);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (95, 12, 96);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (97, 13, 98);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (98, 13, 99);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (99, 13, 100);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (100, 13, 101);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (101, 13, 102);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (102, 13, 103);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (103, 13, 104);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (106, 14, 107);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (107, 14, 108);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (108, 14, 109);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (109, 14, 110);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (110, 14, 111);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (111, 14, 112);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (112, 15, 152);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (113, 15, 113);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (114, 15, 114);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (115, 15, 116);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (116, 15, 130);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (117, 15, 118);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (118, 15, 119);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (119, 15, 120);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (120, 15, 121);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (121, 15, 122);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (122, 15, 131);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (123, 15, 123);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (124, 15, 124);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (125, 15, 125);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (126, 15, 126);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (127, 15, 127);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (128, 15, 132);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (129, 15, 133);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (130, 15, 137);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (131, 15, 139);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (132, 15, 140);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (133, 15, 141);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (134, 15, 144);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (135, 15, 147);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (136, 16, 115);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (137, 16, 117);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (138, 16, 128);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (139, 16, 129);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (140, 16, 134);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (141, 16, 135);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (142, 16, 136);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (143, 16, 151);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (144, 16, 150);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (145, 17, 138);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (146, 17, 142);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (147, 17, 143);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (148, 17, 145);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (149, 17, 146);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (150, 17, 148);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (151, 17, 149);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (152, 18, 169);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (153, 18, 170);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (154, 18, 171);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (155, 18, 172);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (156, 19, 165);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (157, 19, 166);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (158, 19, 167);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (159, 19, 168);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (160, 20, 153);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (161, 20, 154);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (162, 20, 155);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (163, 20, 156);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (164, 20, 157);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (165, 20, 158);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (166, 20, 159);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (167, 20, 160);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (168, 20, 161);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (169, 20, 162);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (170, 20, 163);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (171, 20, 164);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (172, 21, 180);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (173, 21, 181);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (174, 21, 182);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (179, 22, 177);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (180, 22, 178);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (181, 22, 179);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (182, 23, 193);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (183, 23, 187);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (184, 23, 188);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (185, 23, 189);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (186, 23, 190);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (187, 23, 191);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (188, 23, 192);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (189, 23, 195);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (192, 23, 201);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (193, 23, 202);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (194, 24, 194);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (195, 24, 198);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (196, 24, 199);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (197, 24, 200);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (198, 24, 203);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (199, 26, 204);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (200, 26, 205);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (201, 26, 206);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (202, 26, 207);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (203, 26, 208);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (204, 26, 209);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (205, 27, 210);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (206, 27, 211);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (207, 27, 212);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (208, 27, 213);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (209, 28, 214);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (210, 28, 215);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (211, 28, 216);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (212, 28, 217);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (213, 28, 218);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (214, 28, 219);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (215, 28, 220);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (216, 29, 248);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (217, 29, 249);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (218, 29, 250);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (219, 29, 251);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (220, 30, 221);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (221, 30, 222);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (222, 30, 223);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (223, 31, 225);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (224, 31, 226);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (225, 31, 227);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (226, 31, 228);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (227, 31, 229);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (228, 31, 230);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (229, 31, 231);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (230, 31, 232);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (231, 31, 233);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (232, 31, 234);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (233, 31, 235);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (234, 31, 236);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (235, 31, 237);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (236, 31, 238);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (237, 31, 239);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (238, 31, 240);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (239, 31, 241);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (240, 31, 242);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (241, 31, 243);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (242, 31, 244);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (243, 31, 245);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (244, 31, 246);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (245, 31, 247);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (246, 32, 252);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (247, 32, 253);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (249, 33, 256);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (250, 33, 255);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (251, 33, 257);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (252, 33, 258);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (253, 33, 259);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (254, 33, 260);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (255, 33, 261);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (256, 33, 262);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (257, 33, 263);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (259, 34, 266);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (260, 34, 265);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (261, 34, 267);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (262, 34, 268);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (263, 34, 269);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (264, 34, 270);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (265, 34, 271);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (266, 34, 272);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (267, 34, 273);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (271, 35, 276);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (272, 35, 275);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (273, 36, 278);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (274, 36, 279);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (276, 37, 281);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (277, 37, 282);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (278, 37, 283);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (279, 37, 284);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (280, 37, 285);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (281, 37, 286);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (282, 37, 287);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (283, 37, 288);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (284, 37, 289);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (285, 37, 290);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (286, 37, 291);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (287, 37, 292);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (288, 37, 293);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (289, 37, 294);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (290, 37, 295);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (291, 37, 296);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (292, 38, 297);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (293, 38, 298);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (294, 38, 299);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (295, 38, 300);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (296, 38, 301);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (297, 38, 302);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (298, 39, 303);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (299, 39, 304);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (300, 39, 305);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (301, 39, 306);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (302, 40, 307);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (303, 41, 308);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (304, 42, 309);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (305, 43, 310);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (306, 43, 311);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (307, 43, 312);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (308, 44, 313);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (309, 44, 314);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (310, 44, 315);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (311, 44, 316);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (312, 44, 317);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (313, 45, 318);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (314, 45, 319);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (315, 45, 320);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (316, 46, 321);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (317, 47, 322);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (318, 47, 323);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (319, 47, 324);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (320, 47, 325);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (321, 47, 326);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (322, 47, 327);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (323, 47, 329);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (324, 47, 330);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (325, 47, 331);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (326, 48, 332);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (327, 48, 333);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (328, 48, 334);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (329, 48, 335);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (330, 48, 336);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (331, 48, 337);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (332, 96, 714);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (333, 95, 720);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (334, 95, 721);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (335, 5, 509);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (336, 95, 722);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (337, 95, 723);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (338, 95, 724);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (339, 95, 725);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (340, 96, 716);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (341, 93, 602);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (342, 100, 379);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (343, 100, 381);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (344, 93, 633);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (345, 100, 378);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (346, 100, 380);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (347, 100, 382);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (348, 100, 383);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (349, 100, 384);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (350, 100, 385);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (351, 100, 386);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (352, 100, 392);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (353, 93, 634);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (354, 100, 387);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (355, 100, 388);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (356, 100, 389);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (357, 100, 390);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (358, 100, 391);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (359, 96, 708);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (360, 100, 393);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (361, 93, 628);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (362, 5, 398);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (363, 16, 399);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (364, 93, 603);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (365, 16, 493);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (366, 15, 410);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (367, 16, 499);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (368, 17, 437);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (369, 15, 411);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (370, 16, 494);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (371, 93, 604);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (372, 93, 605);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (373, 93, 606);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (374, 93, 607);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (375, 95, 733);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (376, 95, 734);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (377, 15, 400);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (378, 16, 500);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (379, 15, 402);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (380, 15, 404);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (381, 106, 456);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (382, 16, 495);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (383, 99, 567);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (384, 18, 533);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (385, 15, 405);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (386, 15, 406);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (387, 15, 407);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (388, 15, 408);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (389, 15, 403);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (390, 15, 412);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (391, 5, 501);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (392, 15, 413);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (393, 15, 414);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (394, 18, 542);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (395, 18, 543);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (396, 104, 415);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (397, 5, 502);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (398, 5, 503);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (399, 5, 504);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (400, 95, 717);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (401, 98, 544);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (402, 98, 545);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (403, 98, 546);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (404, 99, 566);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (405, 16, 497);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (406, 16, 496);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (407, 16, 498);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (408, 5, 505);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (409, 16, 420);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (410, 5, 506);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (411, 104, 397);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (412, 5, 507);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (413, 105, 417);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (414, 105, 418);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (415, 5, 508);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (416, 16, 421);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (417, 16, 422);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (418, 16, 423);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (419, 16, 424);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (420, 16, 425);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (421, 16, 426);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (422, 105, 429);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (423, 5, 522);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (424, 105, 416);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (425, 5, 511);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (426, 105, 427);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (427, 105, 419);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (428, 5, 510);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (429, 98, 552);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (430, 98, 553);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (431, 98, 554);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (432, 18, 523);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (433, 18, 524);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (434, 18, 525);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (435, 98, 555);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (436, 98, 556);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (437, 15, 438);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (438, 105, 428);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (439, 17, 431);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (440, 17, 430);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (441, 17, 432);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (442, 17, 433);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (443, 17, 434);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (444, 17, 435);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (445, 17, 436);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (446, 15, 439);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (447, 15, 440);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (448, 15, 441);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (449, 15, 442);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (450, 93, 629);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (451, 15, 448);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (452, 15, 443);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (453, 15, 444);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (454, 15, 445);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (455, 15, 446);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (456, 15, 447);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (457, 15, 409);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (458, 15, 449);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (459, 15, 401);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (460, 15, 450);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (461, 93, 735);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (462, 93, 736);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (463, 93, 737);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (464, 93, 738);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (465, 107, 473);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (466, 93, 631);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (467, 15, 451);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (468, 15, 452);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (469, 15, 453);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (470, 15, 454);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (471, 106, 455);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (472, 93, 608);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (473, 93, 609);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (474, 106, 457);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (475, 98, 557);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (476, 107, 474);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (477, 107, 472);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (478, 98, 558);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (479, 99, 559);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (480, 91, 394);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (481, 99, 571);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (482, 93, 632);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (483, 107, 480);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (484, 106, 460);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (485, 106, 458);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (486, 107, 478);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (487, 107, 481);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (488, 93, 626);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (489, 99, 572);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (490, 99, 573);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (491, 93, 627);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (492, 106, 463);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (493, 99, 568);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (494, 99, 569);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (495, 99, 570);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (496, 93, 630);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (497, 107, 479);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (498, 107, 482);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (499, 106, 465);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (500, 107, 483);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (501, 18, 531);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (502, 18, 532);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (503, 99, 584);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (504, 106, 464);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (505, 106, 461);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (506, 16, 486);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (507, 16, 488);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (508, 16, 489);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (509, 94, 664);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (510, 94, 665);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (511, 93, 739);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (512, 93, 740);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (513, 95, 718);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (514, 106, 466);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (515, 16, 490);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (516, 16, 491);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (517, 106, 467);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (518, 16, 492);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (519, 106, 468);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (520, 16, 487);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (521, 106, 469);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (522, 106, 462);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (523, 92, 689);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (524, 106, 470);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (525, 107, 471);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (526, 92, 690);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (527, 106, 459);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (528, 92, 691);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (529, 92, 692);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (530, 8, 693);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (531, 8, 694);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (532, 107, 475);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (533, 107, 476);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (534, 16, 484);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (535, 107, 477);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (536, 16, 485);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (537, 93, 600);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (538, 8, 695);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (539, 5, 512);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (540, 5, 513);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (541, 5, 514);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (542, 5, 515);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (543, 5, 516);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (544, 5, 517);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (545, 5, 519);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (546, 5, 518);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (547, 5, 520);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (548, 8, 696);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (549, 8, 697);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (550, 8, 698);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (551, 18, 527);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (552, 18, 528);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (553, 18, 526);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (554, 18, 529);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (555, 18, 530);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (556, 18, 534);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (557, 18, 535);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (558, 18, 536);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (559, 18, 537);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (560, 18, 538);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (561, 18, 539);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (562, 18, 540);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (563, 18, 541);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (564, 96, 699);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (565, 98, 547);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (566, 98, 548);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (567, 98, 549);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (568, 98, 550);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (569, 98, 551);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (570, 93, 601);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (571, 99, 560);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (572, 99, 561);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (573, 99, 562);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (574, 99, 563);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (575, 99, 564);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (576, 99, 565);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (577, 99, 575);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (578, 99, 574);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (579, 99, 576);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (580, 99, 577);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (581, 99, 578);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (582, 99, 579);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (583, 99, 580);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (584, 99, 581);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (585, 99, 582);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (586, 5, 521);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (587, 99, 583);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (588, 99, 585);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (589, 93, 595);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (590, 93, 596);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (591, 93, 597);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (592, 93, 598);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (593, 34, 586);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (594, 93, 599);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (595, 111, 587);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (596, 111, 588);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (597, 93, 589);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (598, 93, 590);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (599, 93, 591);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (600, 93, 592);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (601, 93, 593);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (602, 93, 594);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (603, 95, 719);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (604, 93, 610);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (605, 93, 611);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (606, 93, 612);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (607, 93, 613);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (608, 93, 614);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (609, 93, 615);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (610, 93, 616);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (611, 93, 617);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (612, 93, 618);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (613, 93, 619);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (614, 93, 620);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (615, 93, 621);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (616, 93, 622);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (617, 93, 623);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (618, 93, 624);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (619, 93, 625);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (620, 96, 700);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (621, 91, 635);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (622, 91, 636);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (623, 91, 637);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (624, 91, 638);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (627, 91, 639);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (628, 95, 644);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (629, 95, 645);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (632, 94, 646);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (633, 94, 647);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (634, 94, 648);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (635, 94, 649);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (636, 94, 650);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (637, 96, 709);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (638, 94, 651);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (639, 94, 652);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (640, 94, 653);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (641, 94, 654);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (642, 94, 655);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (643, 94, 656);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (644, 94, 657);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (645, 94, 658);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (646, 94, 659);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (647, 94, 660);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (648, 94, 661);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (649, 94, 662);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (650, 94, 663);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (651, 92, 666);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (652, 96, 710);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (653, 92, 667);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (654, 92, 668);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (655, 92, 669);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (656, 96, 706);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (657, 1, 670);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (658, 96, 701);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (659, 96, 702);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (660, 96, 704);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (661, 96, 703);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (662, 96, 705);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (663, 96, 707);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (664, 96, 711);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (665, 96, 712);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (666, 96, 713);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (667, 33, 671);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (668, 92, 679);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (669, 33, 672);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (670, 33, 673);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (671, 92, 674);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (672, 92, 675);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (673, 92, 676);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (674, 92, 677);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (675, 92, 678);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (676, 92, 680);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (677, 92, 681);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (678, 92, 682);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (679, 92, 683);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (680, 92, 684);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (681, 92, 685);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (682, 92, 686);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (683, 92, 687);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (684, 92, 688);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (685, 93, 726);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (686, 95, 727);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (687, 95, 728);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (688, 95, 729);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (689, 95, 730);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (690, 95, 731);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (691, 95, 732);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (692, 93, 741);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (693, 93, 742);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (694, 93, 743);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (695, 93, 744);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (696, 93, 745);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (697, 96, 715);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (704, 32, 753);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (705, 31, 754);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (712, 35, 759);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (713, 35, 761);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (714, 35, 762);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (715, 35, 763);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (716, 36, 764);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (717, 36, 765);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (718, 117, 766);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (719, 117, 767);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (720, 117, 285);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (721, 26, 768);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (722, 2, 769);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (723, 2, 770);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (724, 2, 477);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (737, 2, 738);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (739, 2, 771);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (740, 2, 772);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (741, 2, 773);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (742, 2, 774);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (743, 2, 775);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (744, 2, 776);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (745, 2, 777);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (746, 2, 778);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (747, 2, 779);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (748, 2, 780);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (749, 115, 781);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (750, 115, 782);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (751, 115, 783);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (752, 115, 784);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (753, 115, 785);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (754, 115, 786);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (755, 115, 787);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (756, 119, 788);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (757, 119, 789);
insert into public.cancer_regimen_link (id, cancer_id, regimen_id) values (758, 91, 790);

insert into public.regimen_level_link (id, level_id, regimen_id) values (1, 3, 502);
insert into public.regimen_level_link (id, level_id, regimen_id) values (2, 3, 503);
insert into public.regimen_level_link (id, level_id, regimen_id) values (3, 1, 426);
insert into public.regimen_level_link (id, level_id, regimen_id) values (4, 3, 602);
insert into public.regimen_level_link (id, level_id, regimen_id) values (5, 2, 379);
insert into public.regimen_level_link (id, level_id, regimen_id) values (6, 3, 381);
insert into public.regimen_level_link (id, level_id, regimen_id) values (7, 2, 378);
insert into public.regimen_level_link (id, level_id, regimen_id) values (8, 2, 380);
insert into public.regimen_level_link (id, level_id, regimen_id) values (9, 3, 382);
insert into public.regimen_level_link (id, level_id, regimen_id) values (10, 3, 383);
insert into public.regimen_level_link (id, level_id, regimen_id) values (11, 3, 384);
insert into public.regimen_level_link (id, level_id, regimen_id) values (12, 3, 385);
insert into public.regimen_level_link (id, level_id, regimen_id) values (13, 3, 493);
insert into public.regimen_level_link (id, level_id, regimen_id) values (14, 3, 632);
insert into public.regimen_level_link (id, level_id, regimen_id) values (15, 3, 386);
insert into public.regimen_level_link (id, level_id, regimen_id) values (16, 3, 387);
insert into public.regimen_level_link (id, level_id, regimen_id) values (17, 3, 388);
insert into public.regimen_level_link (id, level_id, regimen_id) values (18, 3, 389);
insert into public.regimen_level_link (id, level_id, regimen_id) values (19, 3, 390);
insert into public.regimen_level_link (id, level_id, regimen_id) values (20, 3, 391);
insert into public.regimen_level_link (id, level_id, regimen_id) values (21, 3, 708);
insert into public.regimen_level_link (id, level_id, regimen_id) values (22, 3, 633);
insert into public.regimen_level_link (id, level_id, regimen_id) values (23, 3, 393);
insert into public.regimen_level_link (id, level_id, regimen_id) values (24, 3, 392);
insert into public.regimen_level_link (id, level_id, regimen_id) values (25, 2, 398);
insert into public.regimen_level_link (id, level_id, regimen_id) values (26, 2, 399);
insert into public.regimen_level_link (id, level_id, regimen_id) values (27, 3, 603);
insert into public.regimen_level_link (id, level_id, regimen_id) values (28, 1, 410);
insert into public.regimen_level_link (id, level_id, regimen_id) values (29, 1, 437);
insert into public.regimen_level_link (id, level_id, regimen_id) values (30, 1, 411);
insert into public.regimen_level_link (id, level_id, regimen_id) values (31, 3, 494);
insert into public.regimen_level_link (id, level_id, regimen_id) values (32, 3, 604);
insert into public.regimen_level_link (id, level_id, regimen_id) values (33, 3, 605);
insert into public.regimen_level_link (id, level_id, regimen_id) values (34, 3, 606);
insert into public.regimen_level_link (id, level_id, regimen_id) values (35, 3, 607);
insert into public.regimen_level_link (id, level_id, regimen_id) values (36, 3, 500);
insert into public.regimen_level_link (id, level_id, regimen_id) values (37, 1, 400);
insert into public.regimen_level_link (id, level_id, regimen_id) values (38, 1, 402);
insert into public.regimen_level_link (id, level_id, regimen_id) values (39, 1, 404);
insert into public.regimen_level_link (id, level_id, regimen_id) values (40, 3, 456);
insert into public.regimen_level_link (id, level_id, regimen_id) values (41, 3, 495);
insert into public.regimen_level_link (id, level_id, regimen_id) values (42, 3, 498);
insert into public.regimen_level_link (id, level_id, regimen_id) values (43, 1, 405);
insert into public.regimen_level_link (id, level_id, regimen_id) values (44, 1, 406);
insert into public.regimen_level_link (id, level_id, regimen_id) values (45, 1, 407);
insert into public.regimen_level_link (id, level_id, regimen_id) values (46, 1, 408);
insert into public.regimen_level_link (id, level_id, regimen_id) values (47, 3, 634);
insert into public.regimen_level_link (id, level_id, regimen_id) values (48, 1, 403);
insert into public.regimen_level_link (id, level_id, regimen_id) values (49, 1, 412);
insert into public.regimen_level_link (id, level_id, regimen_id) values (50, 1, 413);
insert into public.regimen_level_link (id, level_id, regimen_id) values (51, 1, 414);
insert into public.regimen_level_link (id, level_id, regimen_id) values (52, 3, 501);
insert into public.regimen_level_link (id, level_id, regimen_id) values (53, 3, 497);
insert into public.regimen_level_link (id, level_id, regimen_id) values (54, 3, 496);
insert into public.regimen_level_link (id, level_id, regimen_id) values (55, 3, 499);
insert into public.regimen_level_link (id, level_id, regimen_id) values (56, 3, 504);
insert into public.regimen_level_link (id, level_id, regimen_id) values (57, 3, 505);
insert into public.regimen_level_link (id, level_id, regimen_id) values (58, 1, 420);
insert into public.regimen_level_link (id, level_id, regimen_id) values (59, 3, 506);
insert into public.regimen_level_link (id, level_id, regimen_id) values (60, 3, 507);
insert into public.regimen_level_link (id, level_id, regimen_id) values (61, 3, 508);
insert into public.regimen_level_link (id, level_id, regimen_id) values (62, 3, 509);
insert into public.regimen_level_link (id, level_id, regimen_id) values (63, 3, 628);
insert into public.regimen_level_link (id, level_id, regimen_id) values (64, 1, 421);
insert into public.regimen_level_link (id, level_id, regimen_id) values (65, 1, 422);
insert into public.regimen_level_link (id, level_id, regimen_id) values (66, 1, 423);
insert into public.regimen_level_link (id, level_id, regimen_id) values (67, 1, 424);
insert into public.regimen_level_link (id, level_id, regimen_id) values (68, 1, 425);
insert into public.regimen_level_link (id, level_id, regimen_id) values (69, 3, 511);
insert into public.regimen_level_link (id, level_id, regimen_id) values (70, 3, 510);
insert into public.regimen_level_link (id, level_id, regimen_id) values (71, 3, 522);
insert into public.regimen_level_link (id, level_id, regimen_id) values (72, 3, 688);
insert into public.regimen_level_link (id, level_id, regimen_id) values (73, 1, 431);
insert into public.regimen_level_link (id, level_id, regimen_id) values (74, 1, 430);
insert into public.regimen_level_link (id, level_id, regimen_id) values (75, 1, 432);
insert into public.regimen_level_link (id, level_id, regimen_id) values (76, 1, 433);
insert into public.regimen_level_link (id, level_id, regimen_id) values (77, 1, 434);
insert into public.regimen_level_link (id, level_id, regimen_id) values (78, 3, 709);
insert into public.regimen_level_link (id, level_id, regimen_id) values (79, 1, 435);
insert into public.regimen_level_link (id, level_id, regimen_id) values (80, 1, 436);
insert into public.regimen_level_link (id, level_id, regimen_id) values (81, 3, 438);
insert into public.regimen_level_link (id, level_id, regimen_id) values (82, 3, 439);
insert into public.regimen_level_link (id, level_id, regimen_id) values (83, 3, 440);
insert into public.regimen_level_link (id, level_id, regimen_id) values (84, 3, 710);
insert into public.regimen_level_link (id, level_id, regimen_id) values (85, 3, 441);
insert into public.regimen_level_link (id, level_id, regimen_id) values (86, 3, 442);
insert into public.regimen_level_link (id, level_id, regimen_id) values (87, 3, 629);
insert into public.regimen_level_link (id, level_id, regimen_id) values (88, 3, 443);
insert into public.regimen_level_link (id, level_id, regimen_id) values (89, 3, 444);
insert into public.regimen_level_link (id, level_id, regimen_id) values (90, 3, 445);
insert into public.regimen_level_link (id, level_id, regimen_id) values (91, 3, 491);
insert into public.regimen_level_link (id, level_id, regimen_id) values (92, 3, 446);
insert into public.regimen_level_link (id, level_id, regimen_id) values (93, 3, 447);
insert into public.regimen_level_link (id, level_id, regimen_id) values (94, 1, 409);
insert into public.regimen_level_link (id, level_id, regimen_id) values (95, 3, 448);
insert into public.regimen_level_link (id, level_id, regimen_id) values (96, 3, 449);
insert into public.regimen_level_link (id, level_id, regimen_id) values (97, 3, 711);
insert into public.regimen_level_link (id, level_id, regimen_id) values (98, 1, 401);
insert into public.regimen_level_link (id, level_id, regimen_id) values (99, 3, 450);
insert into public.regimen_level_link (id, level_id, regimen_id) values (100, 7, 735);
insert into public.regimen_level_link (id, level_id, regimen_id) values (101, 7, 736);
insert into public.regimen_level_link (id, level_id, regimen_id) values (102, 7, 737);
insert into public.regimen_level_link (id, level_id, regimen_id) values (104, 3, 451);
insert into public.regimen_level_link (id, level_id, regimen_id) values (105, 3, 452);
insert into public.regimen_level_link (id, level_id, regimen_id) values (106, 3, 712);
insert into public.regimen_level_link (id, level_id, regimen_id) values (107, 3, 453);
insert into public.regimen_level_link (id, level_id, regimen_id) values (108, 3, 454);
insert into public.regimen_level_link (id, level_id, regimen_id) values (109, 3, 455);
insert into public.regimen_level_link (id, level_id, regimen_id) values (110, 3, 608);
insert into public.regimen_level_link (id, level_id, regimen_id) values (111, 3, 609);
insert into public.regimen_level_link (id, level_id, regimen_id) values (112, 3, 473);
insert into public.regimen_level_link (id, level_id, regimen_id) values (113, 3, 457);
insert into public.regimen_level_link (id, level_id, regimen_id) values (114, 3, 713);
insert into public.regimen_level_link (id, level_id, regimen_id) values (115, 3, 472);
insert into public.regimen_level_link (id, level_id, regimen_id) values (116, 3, 480);
insert into public.regimen_level_link (id, level_id, regimen_id) values (117, 3, 482);
insert into public.regimen_level_link (id, level_id, regimen_id) values (118, 3, 460);
insert into public.regimen_level_link (id, level_id, regimen_id) values (119, 3, 458);
insert into public.regimen_level_link (id, level_id, regimen_id) values (120, 3, 478);
insert into public.regimen_level_link (id, level_id, regimen_id) values (121, 3, 626);
insert into public.regimen_level_link (id, level_id, regimen_id) values (122, 3, 627);
insert into public.regimen_level_link (id, level_id, regimen_id) values (123, 3, 463);
insert into public.regimen_level_link (id, level_id, regimen_id) values (124, 3, 479);
insert into public.regimen_level_link (id, level_id, regimen_id) values (125, 3, 714);
insert into public.regimen_level_link (id, level_id, regimen_id) values (126, 3, 465);
insert into public.regimen_level_link (id, level_id, regimen_id) values (127, 3, 483);
insert into public.regimen_level_link (id, level_id, regimen_id) values (128, 3, 464);
insert into public.regimen_level_link (id, level_id, regimen_id) values (129, 3, 461);
insert into public.regimen_level_link (id, level_id, regimen_id) values (130, 3, 486);
insert into public.regimen_level_link (id, level_id, regimen_id) values (131, 3, 488);
insert into public.regimen_level_link (id, level_id, regimen_id) values (132, 3, 489);
insert into public.regimen_level_link (id, level_id, regimen_id) values (133, 3, 664);
insert into public.regimen_level_link (id, level_id, regimen_id) values (134, 3, 665);
insert into public.regimen_level_link (id, level_id, regimen_id) values (135, 7, 739);
insert into public.regimen_level_link (id, level_id, regimen_id) values (136, 7, 740);
insert into public.regimen_level_link (id, level_id, regimen_id) values (137, 3, 466);
insert into public.regimen_level_link (id, level_id, regimen_id) values (138, 3, 490);
insert into public.regimen_level_link (id, level_id, regimen_id) values (139, 3, 716);
insert into public.regimen_level_link (id, level_id, regimen_id) values (140, 3, 467);
insert into public.regimen_level_link (id, level_id, regimen_id) values (141, 3, 492);
insert into public.regimen_level_link (id, level_id, regimen_id) values (142, 3, 468);
insert into public.regimen_level_link (id, level_id, regimen_id) values (143, 3, 487);
insert into public.regimen_level_link (id, level_id, regimen_id) values (144, 3, 469);
insert into public.regimen_level_link (id, level_id, regimen_id) values (145, 3, 462);
insert into public.regimen_level_link (id, level_id, regimen_id) values (146, 3, 689);
insert into public.regimen_level_link (id, level_id, regimen_id) values (147, 3, 717);
insert into public.regimen_level_link (id, level_id, regimen_id) values (148, 3, 470);
insert into public.regimen_level_link (id, level_id, regimen_id) values (149, 3, 471);
insert into public.regimen_level_link (id, level_id, regimen_id) values (150, 3, 690);
insert into public.regimen_level_link (id, level_id, regimen_id) values (151, 3, 459);
insert into public.regimen_level_link (id, level_id, regimen_id) values (152, 3, 691);
insert into public.regimen_level_link (id, level_id, regimen_id) values (153, 3, 692);
insert into public.regimen_level_link (id, level_id, regimen_id) values (154, 1, 693);
insert into public.regimen_level_link (id, level_id, regimen_id) values (155, 3, 694);
insert into public.regimen_level_link (id, level_id, regimen_id) values (156, 3, 475);
insert into public.regimen_level_link (id, level_id, regimen_id) values (157, 3, 484);
insert into public.regimen_level_link (id, level_id, regimen_id) values (159, 3, 485);
insert into public.regimen_level_link (id, level_id, regimen_id) values (160, 3, 600);
insert into public.regimen_level_link (id, level_id, regimen_id) values (161, 3, 695);
insert into public.regimen_level_link (id, level_id, regimen_id) values (162, 3, 512);
insert into public.regimen_level_link (id, level_id, regimen_id) values (163, 3, 513);
insert into public.regimen_level_link (id, level_id, regimen_id) values (164, 3, 718);
insert into public.regimen_level_link (id, level_id, regimen_id) values (165, 3, 514);
insert into public.regimen_level_link (id, level_id, regimen_id) values (166, 3, 515);
insert into public.regimen_level_link (id, level_id, regimen_id) values (167, 3, 516);
insert into public.regimen_level_link (id, level_id, regimen_id) values (168, 3, 517);
insert into public.regimen_level_link (id, level_id, regimen_id) values (169, 3, 519);
insert into public.regimen_level_link (id, level_id, regimen_id) values (170, 3, 518);
insert into public.regimen_level_link (id, level_id, regimen_id) values (171, 3, 520);
insert into public.regimen_level_link (id, level_id, regimen_id) values (172, 3, 696);
insert into public.regimen_level_link (id, level_id, regimen_id) values (173, 3, 697);
insert into public.regimen_level_link (id, level_id, regimen_id) values (174, 3, 698);
insert into public.regimen_level_link (id, level_id, regimen_id) values (175, 1, 700);
insert into public.regimen_level_link (id, level_id, regimen_id) values (176, 1, 699);
insert into public.regimen_level_link (id, level_id, regimen_id) values (177, 3, 601);
insert into public.regimen_level_link (id, level_id, regimen_id) values (178, 3, 719);
insert into public.regimen_level_link (id, level_id, regimen_id) values (179, 3, 630);
insert into public.regimen_level_link (id, level_id, regimen_id) values (180, 3, 521);
insert into public.regimen_level_link (id, level_id, regimen_id) values (181, 3, 631);
insert into public.regimen_level_link (id, level_id, regimen_id) values (182, 1, 595);
insert into public.regimen_level_link (id, level_id, regimen_id) values (183, 1, 596);
insert into public.regimen_level_link (id, level_id, regimen_id) values (184, 1, 597);
insert into public.regimen_level_link (id, level_id, regimen_id) values (185, 3, 598);
insert into public.regimen_level_link (id, level_id, regimen_id) values (186, 3, 599);
insert into public.regimen_level_link (id, level_id, regimen_id) values (187, 1, 589);
insert into public.regimen_level_link (id, level_id, regimen_id) values (188, 1, 590);
insert into public.regimen_level_link (id, level_id, regimen_id) values (189, 1, 591);
insert into public.regimen_level_link (id, level_id, regimen_id) values (190, 1, 592);
insert into public.regimen_level_link (id, level_id, regimen_id) values (191, 1, 593);
insert into public.regimen_level_link (id, level_id, regimen_id) values (192, 1, 594);
insert into public.regimen_level_link (id, level_id, regimen_id) values (193, 3, 720);
insert into public.regimen_level_link (id, level_id, regimen_id) values (194, 3, 610);
insert into public.regimen_level_link (id, level_id, regimen_id) values (195, 3, 611);
insert into public.regimen_level_link (id, level_id, regimen_id) values (196, 3, 612);
insert into public.regimen_level_link (id, level_id, regimen_id) values (197, 3, 613);
insert into public.regimen_level_link (id, level_id, regimen_id) values (198, 3, 614);
insert into public.regimen_level_link (id, level_id, regimen_id) values (199, 3, 615);
insert into public.regimen_level_link (id, level_id, regimen_id) values (200, 3, 616);
insert into public.regimen_level_link (id, level_id, regimen_id) values (201, 3, 617);
insert into public.regimen_level_link (id, level_id, regimen_id) values (202, 3, 618);
insert into public.regimen_level_link (id, level_id, regimen_id) values (203, 3, 619);
insert into public.regimen_level_link (id, level_id, regimen_id) values (204, 3, 620);
insert into public.regimen_level_link (id, level_id, regimen_id) values (205, 3, 621);
insert into public.regimen_level_link (id, level_id, regimen_id) values (206, 3, 622);
insert into public.regimen_level_link (id, level_id, regimen_id) values (207, 3, 623);
insert into public.regimen_level_link (id, level_id, regimen_id) values (208, 3, 624);
insert into public.regimen_level_link (id, level_id, regimen_id) values (209, 3, 625);
insert into public.regimen_level_link (id, level_id, regimen_id) values (210, 3, 721);
insert into public.regimen_level_link (id, level_id, regimen_id) values (211, 3, 641);
insert into public.regimen_level_link (id, level_id, regimen_id) values (212, 3, 640);
insert into public.regimen_level_link (id, level_id, regimen_id) values (213, 3, 639);
insert into public.regimen_level_link (id, level_id, regimen_id) values (214, 1, 644);
insert into public.regimen_level_link (id, level_id, regimen_id) values (215, 3, 645);
insert into public.regimen_level_link (id, level_id, regimen_id) values (216, 3, 642);
insert into public.regimen_level_link (id, level_id, regimen_id) values (217, 3, 643);
insert into public.regimen_level_link (id, level_id, regimen_id) values (218, 2, 646);
insert into public.regimen_level_link (id, level_id, regimen_id) values (219, 2, 647);
insert into public.regimen_level_link (id, level_id, regimen_id) values (220, 2, 648);
insert into public.regimen_level_link (id, level_id, regimen_id) values (221, 2, 649);
insert into public.regimen_level_link (id, level_id, regimen_id) values (222, 2, 650);
insert into public.regimen_level_link (id, level_id, regimen_id) values (223, 3, 722);
insert into public.regimen_level_link (id, level_id, regimen_id) values (224, 3, 723);
insert into public.regimen_level_link (id, level_id, regimen_id) values (225, 3, 654);
insert into public.regimen_level_link (id, level_id, regimen_id) values (226, 3, 655);
insert into public.regimen_level_link (id, level_id, regimen_id) values (227, 3, 656);
insert into public.regimen_level_link (id, level_id, regimen_id) values (228, 3, 657);
insert into public.regimen_level_link (id, level_id, regimen_id) values (229, 3, 658);
insert into public.regimen_level_link (id, level_id, regimen_id) values (230, 3, 659);
insert into public.regimen_level_link (id, level_id, regimen_id) values (231, 3, 660);
insert into public.regimen_level_link (id, level_id, regimen_id) values (232, 3, 661);
insert into public.regimen_level_link (id, level_id, regimen_id) values (233, 3, 662);
insert into public.regimen_level_link (id, level_id, regimen_id) values (234, 3, 663);
insert into public.regimen_level_link (id, level_id, regimen_id) values (235, 3, 724);
insert into public.regimen_level_link (id, level_id, regimen_id) values (236, 3, 725);
insert into public.regimen_level_link (id, level_id, regimen_id) values (237, 1, 667);
insert into public.regimen_level_link (id, level_id, regimen_id) values (238, 1, 668);
insert into public.regimen_level_link (id, level_id, regimen_id) values (239, 3, 669);
insert into public.regimen_level_link (id, level_id, regimen_id) values (240, 3, 706);
insert into public.regimen_level_link (id, level_id, regimen_id) values (241, 1, 670);
insert into public.regimen_level_link (id, level_id, regimen_id) values (242, 1, 701);
insert into public.regimen_level_link (id, level_id, regimen_id) values (243, 1, 702);
insert into public.regimen_level_link (id, level_id, regimen_id) values (244, 6, 704);
insert into public.regimen_level_link (id, level_id, regimen_id) values (245, 6, 703);
insert into public.regimen_level_link (id, level_id, regimen_id) values (246, 6, 705);
insert into public.regimen_level_link (id, level_id, regimen_id) values (247, 3, 707);
insert into public.regimen_level_link (id, level_id, regimen_id) values (248, 7, 726);
insert into public.regimen_level_link (id, level_id, regimen_id) values (249, 3, 679);
insert into public.regimen_level_link (id, level_id, regimen_id) values (250, 3, 674);
insert into public.regimen_level_link (id, level_id, regimen_id) values (251, 3, 675);
insert into public.regimen_level_link (id, level_id, regimen_id) values (252, 3, 676);
insert into public.regimen_level_link (id, level_id, regimen_id) values (253, 3, 677);
insert into public.regimen_level_link (id, level_id, regimen_id) values (254, 3, 678);
insert into public.regimen_level_link (id, level_id, regimen_id) values (255, 3, 680);
insert into public.regimen_level_link (id, level_id, regimen_id) values (256, 3, 681);
insert into public.regimen_level_link (id, level_id, regimen_id) values (257, 3, 682);
insert into public.regimen_level_link (id, level_id, regimen_id) values (258, 3, 683);
insert into public.regimen_level_link (id, level_id, regimen_id) values (259, 3, 684);
insert into public.regimen_level_link (id, level_id, regimen_id) values (260, 3, 685);
insert into public.regimen_level_link (id, level_id, regimen_id) values (261, 3, 686);
insert into public.regimen_level_link (id, level_id, regimen_id) values (262, 3, 687);
insert into public.regimen_level_link (id, level_id, regimen_id) values (263, 7, 741);
insert into public.regimen_level_link (id, level_id, regimen_id) values (264, 7, 742);
insert into public.regimen_level_link (id, level_id, regimen_id) values (265, 7, 743);
insert into public.regimen_level_link (id, level_id, regimen_id) values (266, 7, 744);
insert into public.regimen_level_link (id, level_id, regimen_id) values (267, 2, 745);
insert into public.regimen_level_link (id, level_id, regimen_id) values (268, 3, 715);
insert into public.regimen_level_link (id, level_id, regimen_id) values (269, 3, 437);
insert into public.regimen_level_link (id, level_id, regimen_id) values (270, 3, 145);
insert into public.regimen_level_link (id, level_id, regimen_id) values (271, 1, 746);
insert into public.regimen_level_link (id, level_id, regimen_id) values (272, 3, 747);
insert into public.regimen_level_link (id, level_id, regimen_id) values (273, 6, 747);
insert into public.regimen_level_link (id, level_id, regimen_id) values (274, 3, 749);
insert into public.regimen_level_link (id, level_id, regimen_id) values (275, 6, 749);
insert into public.regimen_level_link (id, level_id, regimen_id) values (276, 3, 748);
insert into public.regimen_level_link (id, level_id, regimen_id) values (277, 6, 748);
insert into public.regimen_level_link (id, level_id, regimen_id) values (278, 1, 750);
insert into public.regimen_level_link (id, level_id, regimen_id) values (279, 3, 751);
insert into public.regimen_level_link (id, level_id, regimen_id) values (280, 6, 751);
insert into public.regimen_level_link (id, level_id, regimen_id) values (281, 3, 752);
insert into public.regimen_level_link (id, level_id, regimen_id) values (282, 6, 752);
insert into public.regimen_level_link (id, level_id, regimen_id) values (283, 3, 755);
insert into public.regimen_level_link (id, level_id, regimen_id) values (284, 6, 755);
insert into public.regimen_level_link (id, level_id, regimen_id) values (285, 3, 756);
insert into public.regimen_level_link (id, level_id, regimen_id) values (286, 6, 756);
insert into public.regimen_level_link (id, level_id, regimen_id) values (287, 6, 757);
insert into public.regimen_level_link (id, level_id, regimen_id) values (288, 3, 757);
insert into public.regimen_level_link (id, level_id, regimen_id) values (289, 3, 758);
insert into public.regimen_level_link (id, level_id, regimen_id) values (290, 6, 758);
insert into public.regimen_level_link (id, level_id, regimen_id) values (291, 8, 275);
insert into public.regimen_level_link (id, level_id, regimen_id) values (292, 8, 276);
insert into public.regimen_level_link (id, level_id, regimen_id) values (293, 8, 759);
insert into public.regimen_level_link (id, level_id, regimen_id) values (294, 9, 586);
insert into public.regimen_level_link (id, level_id, regimen_id) values (295, 8, 270);
insert into public.regimen_level_link (id, level_id, regimen_id) values (296, 3, 760);
insert into public.regimen_level_link (id, level_id, regimen_id) values (297, 6, 760);
insert into public.regimen_level_link (id, level_id, regimen_id) values (298, 8, 761);
insert into public.regimen_level_link (id, level_id, regimen_id) values (299, 9, 762);
insert into public.regimen_level_link (id, level_id, regimen_id) values (300, 8, 764);
insert into public.regimen_level_link (id, level_id, regimen_id) values (301, 8, 765);
insert into public.regimen_level_link (id, level_id, regimen_id) values (302, 8, 766);
insert into public.regimen_level_link (id, level_id, regimen_id) values (303, 8, 767);
insert into public.regimen_level_link (id, level_id, regimen_id) values (304, 11, 285);
insert into public.regimen_level_link (id, level_id, regimen_id) values (305, 3, 13);
insert into public.regimen_level_link (id, level_id, regimen_id) values (306, 12, 13);
insert into public.regimen_level_link (id, level_id, regimen_id) values (307, 3, 11);
insert into public.regimen_level_link (id, level_id, regimen_id) values (308, 13, 11);
insert into public.regimen_level_link (id, level_id, regimen_id) values (309, 2, 769);
insert into public.regimen_level_link (id, level_id, regimen_id) values (310, 3, 770);
insert into public.regimen_level_link (id, level_id, regimen_id) values (311, 13, 770);
insert into public.regimen_level_link (id, level_id, regimen_id) values (312, 3, 477);
insert into public.regimen_level_link (id, level_id, regimen_id) values (313, 14, 477);
insert into public.regimen_level_link (id, level_id, regimen_id) values (314, 3, 771);
insert into public.regimen_level_link (id, level_id, regimen_id) values (315, 13, 771);
insert into public.regimen_level_link (id, level_id, regimen_id) values (316, 3, 7);
insert into public.regimen_level_link (id, level_id, regimen_id) values (317, 12, 7);
insert into public.regimen_level_link (id, level_id, regimen_id) values (318, 3, 738);
insert into public.regimen_level_link (id, level_id, regimen_id) values (319, 12, 738);
insert into public.regimen_level_link (id, level_id, regimen_id) values (322, 3, 9);
insert into public.regimen_level_link (id, level_id, regimen_id) values (323, 8, 9);
insert into public.regimen_level_link (id, level_id, regimen_id) values (325, 15, 772);
insert into public.regimen_level_link (id, level_id, regimen_id) values (326, 16, 772);
insert into public.regimen_level_link (id, level_id, regimen_id) values (327, 15, 10);
insert into public.regimen_level_link (id, level_id, regimen_id) values (328, 3, 773);
insert into public.regimen_level_link (id, level_id, regimen_id) values (329, 12, 773);
insert into public.regimen_level_link (id, level_id, regimen_id) values (330, 3, 8);
insert into public.regimen_level_link (id, level_id, regimen_id) values (331, 12, 8);
insert into public.regimen_level_link (id, level_id, regimen_id) values (332, 3, 774);
insert into public.regimen_level_link (id, level_id, regimen_id) values (333, 13, 774);
insert into public.regimen_level_link (id, level_id, regimen_id) values (334, 3, 775);
insert into public.regimen_level_link (id, level_id, regimen_id) values (335, 9, 775);
insert into public.regimen_level_link (id, level_id, regimen_id) values (336, 10, 775);
insert into public.regimen_level_link (id, level_id, regimen_id) values (337, 3, 776);
insert into public.regimen_level_link (id, level_id, regimen_id) values (338, 9, 776);
insert into public.regimen_level_link (id, level_id, regimen_id) values (339, 10, 776);
insert into public.regimen_level_link (id, level_id, regimen_id) values (340, 3, 777);
insert into public.regimen_level_link (id, level_id, regimen_id) values (341, 3, 778);
insert into public.regimen_level_link (id, level_id, regimen_id) values (342, 3, 779);
insert into public.regimen_level_link (id, level_id, regimen_id) values (343, 10, 779);
insert into public.regimen_level_link (id, level_id, regimen_id) values (344, 3, 780);
insert into public.regimen_level_link (id, level_id, regimen_id) values (345, 13, 780);
insert into public.regimen_level_link (id, level_id, regimen_id) values (346, 9, 780);
insert into public.regimen_level_link (id, level_id, regimen_id) values (347, 8, 781);
insert into public.regimen_level_link (id, level_id, regimen_id) values (349, 8, 783);
insert into public.regimen_level_link (id, level_id, regimen_id) values (350, 8, 784);
insert into public.regimen_level_link (id, level_id, regimen_id) values (351, 8, 785);
insert into public.regimen_level_link (id, level_id, regimen_id) values (356, 8, 786);
insert into public.regimen_level_link (id, level_id, regimen_id) values (360, 8, 782);
insert into public.regimen_level_link (id, level_id, regimen_id) values (361, 8, 787);
insert into public.regimen_level_link (id, level_id, regimen_id) values (362, 17, 788);
insert into public.regimen_level_link (id, level_id, regimen_id) values (363, 17, 789);
insert into public.regimen_level_link (id, level_id, regimen_id) values (364, 3, 790);



insert into public.drug_regimen_link (id, drug_id, regimen_id) values (0, 97, 502);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1, 83, 347);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (2, 8, 503);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (3, 123, 1);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (4, 2, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (5, 57, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (6, 155, 2);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (7, 62, 3);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (8, 32, 4);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (9, 123, 5);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (10, 62, 6);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (18, 26, 138);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (25, 31, 14);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (26, 88, 14);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (27, 31, 15);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (28, 31, 16);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (29, 19, 16);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (30, 40, 17);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (31, 63, 17);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (32, 31, 18);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (33, 52, 18);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (34, 52, 19);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (35, 63, 19);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (36, 40, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (37, 31, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (38, 52, 20);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (39, 40, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (40, 52, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (41, 63, 21);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (42, 19, 22);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (43, 68, 31);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (44, 63, 31);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (45, 107, 348);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (46, 31, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (47, 56, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (48, 88, 23);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (49, 31, 24);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (50, 56, 24);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (51, 31, 25);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (52, 52, 25);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (53, 69, 26);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (54, 88, 26);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (55, 88, 27);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (56, 40, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (57, 31, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (58, 88, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (59, 6, 28);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (60, 63, 32);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (61, 123, 33);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (62, 72, 33);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (63, 110, 34);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (64, 45, 35);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (65, 31, 36);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (66, 40, 37);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (67, 123, 38);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (68, 31, 39);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (69, 68, 39);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (70, 40, 40);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (71, 68, 40);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (72, 68, 41);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (73, 63, 41);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (74, 31, 42);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (75, 40, 43);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (76, 31, 43);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (77, 23, 349);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (78, 116, 349);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (79, 40, 44);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (80, 63, 44);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (81, 40, 45);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (82, 56, 46);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (83, 68, 47);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (84, 40, 139);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (85, 88, 48);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (86, 63, 48);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (87, 40, 49);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (88, 68, 49);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (89, 72, 50);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (90, 68, 50);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (91, 68, 51);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (92, 63, 51);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (93, 68, 52);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (94, 115, 53);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (95, 88, 55);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (96, 123, 56);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (97, 88, 56);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (98, 88, 57);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (99, 63, 57);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (100, 88, 58);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (101, 63, 67);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (102, 117, 350);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (103, 123, 59);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (104, 88, 59);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (105, 115, 60);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (106, 88, 60);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (107, 88, 61);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (108, 63, 61);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (109, 123, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (110, 88, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (111, 63, 62);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (112, 88, 63);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (113, 63, 63);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (114, 123, 68);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (115, 63, 68);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (116, 40, 69);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (117, 115, 70);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (118, 88, 71);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (119, 6, 151);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (120, 103, 77);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (121, 15, 78);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (122, 66, 79);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (123, 135, 80);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (124, 19, 80);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (125, 58, 426);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (126, 31, 81);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (127, 55, 81);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (128, 115, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (129, 31, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (130, 148, 82);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (131, 31, 83);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (132, 56, 83);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (133, 148, 152);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (134, 31, 84);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (135, 68, 84);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (136, 56, 85);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (137, 68, 85);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (138, 68, 86);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (139, 19, 86);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (140, 72, 93);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (141, 68, 87);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (142, 148, 87);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (143, 31, 88);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (144, 19, 88);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (145, 123, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (146, 135, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (147, 19, 89);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (148, 56, 189);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (149, 71, 189);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (150, 31, 90);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (151, 148, 90);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (152, 136, 91);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (153, 56, 92);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (154, 18, 351);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (155, 124, 351);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (156, 68, 94);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (157, 55, 95);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (158, 148, 96);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (159, 135, 97);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (160, 31, 98);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (161, 143, 190);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (162, 12, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (163, 45, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (164, 155, 99);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (165, 135, 100);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (166, 19, 100);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (167, 135, 101);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (168, 69, 101);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (169, 128, 352);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (170, 31, 102);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (171, 69, 102);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (172, 69, 103);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (173, 19, 104);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (174, 105, 105);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (175, 105, 106);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (176, 31, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (177, 12, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (178, 45, 107);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (179, 31, 108);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (180, 69, 108);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (181, 8, 142);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (182, 31, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (183, 12, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (184, 45, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (185, 155, 109);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (186, 31, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (187, 69, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (188, 1, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (189, 9, 110);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (190, 68, 111);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (191, 105, 111);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (192, 135, 112);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (193, 19, 112);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (194, 12, 113);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (195, 45, 113);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (196, 96, 143);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (197, 12, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (198, 45, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (199, 19, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (200, 6, 115);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (201, 12, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (202, 45, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (203, 19, 116);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (204, 12, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (205, 45, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (206, 88, 122);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (207, 12, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (208, 56, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (209, 45, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (210, 6, 117);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (211, 68, 144);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (212, 54, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (213, 33, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (214, 59, 353);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (215, 56, 118);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (216, 45, 118);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (217, 45, 119);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (218, 19, 119);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (219, 12, 120);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (220, 45, 120);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (221, 19, 120);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (222, 123, 121);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (223, 19, 121);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (224, 12, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (225, 45, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (226, 19, 130);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (227, 12, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (228, 52, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (229, 88, 123);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (230, 99, 354);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (231, 12, 124);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (232, 88, 124);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (233, 68, 125);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (234, 19, 125);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (235, 12, 126);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (236, 52, 126);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (237, 40, 127);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (238, 74, 127);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (239, 40, 128);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (240, 130, 128);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (241, 130, 129);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (242, 17, 129);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (243, 12, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (244, 56, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (245, 45, 131);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (246, 12, 132);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (247, 56, 132);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (248, 40, 133);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (249, 56, 133);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (250, 135, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (251, 56, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (252, 6, 134);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (253, 19, 135);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (254, 6, 135);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (255, 135, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (256, 19, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (257, 6, 136);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (258, 56, 140);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (259, 49, 141);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (260, 17, 145);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (261, 19, 147);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (262, 30, 148);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (263, 6, 150);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (264, 135, 153);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (265, 56, 153);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (266, 135, 154);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (267, 19, 154);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (268, 135, 155);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (269, 31, 156);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (270, 19, 156);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (271, 20, 355);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (272, 135, 157);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (273, 68, 157);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (274, 31, 158);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (275, 19, 158);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (276, 10, 159);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (277, 123, 160);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (278, 68, 161);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (279, 143, 191);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (280, 111, 191);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (281, 19, 162);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (282, 105, 164);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (283, 138, 356);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (284, 90, 357);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (285, 31, 165);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (286, 45, 165);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (287, 31, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (288, 45, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (289, 19, 166);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (290, 45, 167);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (291, 56, 188);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (292, 125, 188);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (293, 31, 169);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (294, 88, 169);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (295, 31, 170);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (296, 19, 170);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (297, 164, 358);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (298, 31, 171);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (299, 105, 171);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (300, 31, 172);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (301, 110, 177);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (302, 66, 178);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (303, 135, 180);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (304, 68, 180);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (305, 31, 181);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (306, 68, 181);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (307, 31, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (308, 45, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (309, 65, 182);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (310, 161, 193);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (311, 111, 193);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (312, 94, 194);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (313, 46, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (314, 31, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (315, 69, 183);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (316, 31, 184);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (317, 69, 184);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (318, 31, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (319, 1, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (320, 9, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (321, 19, 185);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (322, 31, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (323, 69, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (324, 9, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (325, 65, 186);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (326, 120, 187);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (327, 71, 187);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (328, 162, 192);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (329, 71, 192);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (330, 36, 262);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (331, 132, 195);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (332, 111, 198);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (333, 126, 200);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (334, 71, 201);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (335, 133, 202);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (336, 156, 204);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (337, 45, 204);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (338, 45, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (339, 1, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (340, 9, 205);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (341, 12, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (342, 14, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (343, 45, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (344, 69, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (345, 1, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (346, 9, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (347, 155, 206);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (348, 93, 359);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (349, 50, 359);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (350, 156, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (351, 45, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (352, 1, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (353, 9, 207);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (354, 31, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (355, 45, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (356, 1, 208);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (357, 45, 209);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (358, 19, 212);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (359, 116, 242);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (360, 135, 214);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (361, 19, 214);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (362, 27, 360);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (363, 37, 360);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (364, 135, 215);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (365, 56, 215);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (366, 135, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (367, 68, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (368, 19, 216);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (369, 31, 217);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (370, 68, 217);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (371, 56, 218);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (372, 68, 218);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (373, 40, 219);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (374, 63, 219);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (375, 135, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (376, 69, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (377, 19, 220);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (378, 36, 263);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (379, 108, 361);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (380, 46, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (381, 156, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (382, 45, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (383, 65, 221);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (384, 46, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (385, 12, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (386, 45, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (387, 69, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (388, 71, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (389, 57, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (390, 155, 222);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (391, 46, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (392, 45, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (393, 69, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (394, 71, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (395, 65, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (396, 155, 223);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (397, 106, 224);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (398, 116, 224);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (399, 12, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (400, 45, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (401, 34, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (402, 155, 225);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (403, 12, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (404, 45, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (405, 71, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (406, 116, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (407, 155, 226);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (408, 12, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (409, 36, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (410, 69, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (411, 1, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (412, 9, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (413, 155, 227);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (414, 71, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (415, 116, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (416, 155, 228);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (417, 31, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (418, 36, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (419, 59, 229);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (420, 31, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (421, 36, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (422, 69, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (423, 28, 230);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (424, 24, 241);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (425, 98, 246);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (426, 12, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (427, 36, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (428, 59, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (429, 155, 231);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (430, 12, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (431, 45, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (432, 69, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (433, 71, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (434, 116, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (435, 155, 232);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (436, 135, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (437, 69, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (438, 1, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (439, 9, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (440, 116, 233);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (441, 106, 234);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (442, 150, 235);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (443, 79, 236);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (444, 80, 239);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (445, 12, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (446, 45, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (447, 69, 247);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (448, 12, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (449, 45, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (450, 155, 248);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (451, 12, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (452, 36, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (453, 69, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (454, 1, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (455, 9, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (456, 155, 249);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (457, 12, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (458, 69, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (459, 71, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (460, 155, 250);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (461, 36, 258);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (462, 12, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (463, 36, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (464, 59, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (465, 45, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (466, 71, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (467, 41, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (468, 155, 251);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (469, 12, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (470, 36, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (471, 59, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (472, 45, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (473, 9, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (474, 28, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (475, 155, 252);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (476, 92, 255);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (477, 36, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (478, 69, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (479, 92, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (480, 162, 256);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (481, 36, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (482, 92, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (483, 162, 257);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (484, 106, 264);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (485, 116, 264);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (486, 12, 265);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (487, 80, 265);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (488, 12, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (489, 80, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (490, 116, 266);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (491, 80, 267);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (492, 116, 267);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (493, 12, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (494, 61, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (495, 116, 268);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (496, 119, 269);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (497, 106, 270);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (498, 124, 271);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (499, 80, 272);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (500, 113, 362);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (501, 18, 273);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (502, 47, 274);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (503, 103, 275);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (504, 15, 276);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (505, 151, 277);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (506, 61, 278);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (507, 79, 280);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (508, 79, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (509, 59, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (510, 45, 281);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (511, 79, 282);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (512, 154, 282);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (513, 79, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (514, 12, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (515, 59, 283);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (516, 25, 342);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (517, 31, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (518, 59, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (519, 45, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (520, 69, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (521, 154, 284);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (522, 59, 285);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (523, 13, 285);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (524, 122, 286);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (525, 71, 286);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (526, 122, 287);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (527, 71, 287);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (528, 79, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (529, 59, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (530, 13, 288);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (531, 59, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (532, 45, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (533, 155, 289);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (534, 79, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (535, 122, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (536, 71, 290);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (537, 79, 291);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (538, 59, 292);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (539, 154, 293);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (540, 39, 294);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (541, 129, 295);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (542, 31, 296);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (543, 69, 296);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (544, 31, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (545, 12, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (546, 69, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (547, 155, 297);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (548, 31, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (549, 12, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (550, 155, 298);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (551, 113, 343);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (552, 117, 344);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (553, 152, 345);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (554, 135, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (555, 12, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (556, 69, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (557, 9, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (558, 155, 299);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (559, 2, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (560, 71, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (561, 155, 300);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (562, 135, 301);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (563, 31, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (564, 12, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (565, 45, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (566, 69, 302);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (567, 31, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (568, 12, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (569, 45, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (570, 69, 303);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (571, 31, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (572, 12, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (573, 45, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (574, 69, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (575, 155, 304);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (576, 31, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (577, 12, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (578, 45, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (579, 69, 305);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (580, 135, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (581, 69, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (582, 155, 306);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (583, 31, 307);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (584, 45, 307);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (585, 14, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (586, 45, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (587, 155, 308);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (588, 69, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (589, 1, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (590, 9, 309);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (591, 102, 346);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (592, 31, 310);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (593, 45, 310);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (594, 69, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (595, 1, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (596, 9, 311);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (597, 135, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (598, 69, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (599, 1, 312);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (600, 12, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (601, 45, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (602, 155, 313);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (603, 12, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (604, 45, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (605, 69, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (606, 1, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (607, 155, 314);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (608, 36, 330);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (609, 12, 315);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (610, 105, 315);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (611, 12, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (612, 14, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (613, 155, 316);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (614, 46, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (615, 156, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (616, 45, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (617, 65, 317);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (618, 46, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (619, 12, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (620, 45, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (621, 69, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (622, 71, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (623, 57, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (624, 155, 318);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (625, 12, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (626, 45, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (627, 71, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (628, 155, 319);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (629, 36, 331);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (630, 12, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (631, 36, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (632, 45, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (633, 155, 320);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (634, 59, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (635, 71, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (636, 155, 321);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (637, 36, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (638, 71, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (639, 155, 322);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (640, 59, 324);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (641, 155, 324);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (642, 36, 326);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (643, 163, 326);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (644, 36, 332);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (645, 41, 332);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (646, 36, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (647, 59, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (648, 69, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (649, 41, 333);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (650, 159, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (651, 36, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (652, 69, 334);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (653, 20, 337);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (654, 56, 338);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (655, 91, 338);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (656, 89, 339);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (657, 11, 340);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (658, 78, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (659, 68, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (660, 31, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (661, 48, 341);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (662, 75, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (663, 13, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (664, 59, 363);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (665, 145, 364);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (666, 141, 365);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (667, 141, 366);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (668, 19, 366);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (669, 153, 367);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (670, 42, 368);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (671, 112, 369);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (672, 68, 369);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (673, 29, 370);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (674, 17, 370);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (675, 131, 371);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (676, 8, 371);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (677, 127, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (678, 6, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (679, 56, 372);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (680, 139, 373);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (681, 147, 374);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (682, 84, 375);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (683, 5, 376);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (684, 82, 377);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (685, 144, 379);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (686, 100, 381);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (687, 38, 378);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (688, 16, 380);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (689, 95, 382);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (690, 73, 383);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (691, 73, 384);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (692, 87, 385);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (693, 131, 493);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (694, 8, 493);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (695, 53, 386);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (696, 7, 387);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (697, 104, 388);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (698, 149, 389);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (699, 76, 390);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (700, 137, 391);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (701, 4, 393);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (702, 137, 392);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (703, 12, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (704, 56, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (705, 45, 114);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (706, 12, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (707, 56, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (708, 45, 398);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (709, 135, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (710, 56, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (711, 127, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (712, 6, 399);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (713, 12, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (714, 52, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (715, 118, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (716, 56, 410);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (717, 131, 437);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (718, 8, 437);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (719, 12, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (720, 45, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (721, 19, 411);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (722, 134, 494);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (723, 17, 494);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (724, 140, 500);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (725, 17, 500);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (726, 12, 400);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (727, 45, 400);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (728, 12, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (729, 45, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (730, 19, 402);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (731, 12, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (732, 56, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (733, 45, 404);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (734, 85, 456);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (735, 3, 495);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (736, 17, 495);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (737, 68, 567);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (738, 31, 567);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (739, 101, 498);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (740, 96, 498);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (741, 31, 533);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (742, 160, 533);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (743, 12, 405);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (744, 56, 405);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (745, 12, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (746, 56, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (747, 45, 406);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (748, 12, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (749, 45, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (750, 88, 407);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (751, 52, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (752, 12, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (753, 86, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (754, 118, 408);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (755, 135, 415);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (756, 12, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (757, 56, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (758, 45, 403);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (759, 12, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (760, 45, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (761, 19, 412);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (762, 12, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (763, 56, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (764, 45, 413);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (765, 12, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (766, 56, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (767, 45, 414);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (768, 68, 542);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (769, 85, 543);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (770, 30, 501);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (771, 19, 544);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (772, 135, 544);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (775, 45, 546);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (776, 31, 546);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (777, 68, 566);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (778, 35, 566);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (779, 140, 497);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (780, 96, 497);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (781, 134, 496);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (782, 96, 496);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (783, 140, 499);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (784, 26, 499);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (785, 26, 504);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (786, 17, 505);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (787, 12, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (788, 45, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (789, 19, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (790, 6, 420);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (791, 96, 506);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (792, 31, 397);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (793, 81, 507);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (794, 135, 417);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (795, 135, 418);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (796, 6, 508);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (797, 58, 509);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (798, 12, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (799, 45, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (800, 19, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (801, 6, 421);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (802, 135, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (803, 56, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (804, 6, 422);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (805, 12, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (806, 52, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (807, 118, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (808, 56, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (809, 6, 423);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (810, 127, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (811, 6, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (812, 56, 424);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (813, 142, 425);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (814, 135, 416);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (815, 56, 511);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (816, 31, 427);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (817, 31, 419);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (818, 40, 510);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (819, 31, 552);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (820, 1, 552);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (821, 105, 557);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (822, 68, 553);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (823, 56, 553);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (824, 158, 522);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (825, 45, 554);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (826, 31, 523);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (827, 31, 524);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (828, 19, 524);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (829, 31, 525);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (830, 105, 525);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (831, 81, 555);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (832, 19, 556);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (833, 135, 428);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (834, 26, 431);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (835, 30, 430);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (836, 17, 432);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (837, 30, 433);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (838, 17, 433);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (839, 30, 434);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (840, 8, 434);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (841, 30, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (842, 111, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (843, 21, 435);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (844, 26, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (845, 111, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (846, 21, 436);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (847, 45, 438);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (848, 19, 438);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (849, 12, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (850, 45, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (851, 88, 439);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (852, 12, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (853, 52, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (854, 118, 440);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (855, 12, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (856, 86, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (857, 118, 441);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (858, 40, 442);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (859, 56, 442);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (860, 40, 443);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (861, 19, 443);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (862, 40, 444);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (863, 148, 444);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (864, 40, 445);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (865, 74, 445);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (866, 6, 491);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (867, 130, 491);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (868, 56, 446);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (869, 45, 446);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (870, 56, 447);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (871, 35, 447);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (872, 12, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (873, 52, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (874, 118, 409);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (875, 12, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (876, 52, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (877, 118, 448);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (878, 12, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (879, 52, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (880, 118, 449);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (881, 12, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (882, 45, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (883, 19, 401);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (884, 68, 450);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (885, 19, 450);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (886, 135, 451);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (887, 19, 451);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (888, 135, 452);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (889, 56, 452);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (890, 123, 453);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (891, 19, 453);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (892, 77, 454);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (893, 112, 454);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (894, 85, 455);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (895, 146, 473);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (896, 135, 457);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (897, 135, 474);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (898, 85, 472);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (899, 43, 558);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (900, 135, 559);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (901, 12, 559);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (902, 31, 480);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (903, 68, 482);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (904, 135, 460);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (905, 135, 458);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (906, 31, 478);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (907, 31, 481);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (908, 10, 571);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (909, 35, 572);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (910, 19, 573);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (911, 135, 463);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (912, 68, 568);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (913, 135, 568);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (914, 19, 569);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (915, 31, 569);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (916, 55, 570);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (917, 135, 570);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (918, 31, 479);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (919, 31, 465);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (920, 68, 483);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (921, 31, 531);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (922, 88, 531);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (923, 31, 532);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (924, 148, 532);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (925, 70, 584);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (926, 135, 464);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (927, 135, 461);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (928, 135, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (929, 56, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (930, 6, 486);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (931, 6, 488);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (932, 148, 488);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (933, 6, 489);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (934, 68, 489);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (935, 6, 490);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (936, 40, 490);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (937, 68, 467);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (938, 40, 492);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (939, 130, 492);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (940, 68, 468);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (941, 68, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (942, 135, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (943, 6, 487);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (944, 135, 469);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (945, 135, 462);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (946, 68, 470);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (947, 135, 471);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (948, 146, 459);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (949, 135, 475);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (950, 135, 476);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (951, 6, 484);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (952, 19, 484);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (954, 6, 485);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (955, 56, 485);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (956, 19, 512);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (957, 114, 513);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (958, 148, 514);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (959, 45, 515);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (960, 68, 516);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (961, 35, 517);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (962, 49, 519);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (963, 112, 518);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (964, 140, 520);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (965, 31, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (966, 19, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (967, 123, 527);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (968, 135, 535);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (969, 56, 535);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (970, 19, 528);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (971, 105, 528);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (972, 19, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (973, 105, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (974, 123, 526);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (975, 46, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (976, 1, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (977, 9, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (978, 31, 529);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (979, 46, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (980, 1, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (981, 9, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (982, 135, 530);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (983, 31, 534);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (984, 68, 534);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (985, 31, 536);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (986, 55, 536);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (987, 56, 537);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (988, 19, 538);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (989, 160, 539);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (990, 105, 540);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (991, 55, 541);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (992, 45, 547);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (993, 19, 547);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (994, 31, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (995, 45, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (996, 19, 548);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (997, 12, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (998, 45, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (999, 31, 549);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1000, 135, 550);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1001, 35, 550);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1002, 19, 551);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1003, 1, 551);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1004, 31, 560);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1005, 12, 560);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1006, 31, 561);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1007, 19, 561);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1008, 135, 562);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1009, 19, 562);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1010, 135, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1011, 19, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1012, 123, 563);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1013, 135, 564);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1014, 56, 564);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1015, 135, 565);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1016, 35, 565);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1017, 105, 575);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1018, 74, 574);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1019, 68, 576);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1020, 69, 577);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1021, 148, 578);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1022, 55, 579);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1023, 123, 580);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1024, 40, 581);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1025, 44, 582);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1026, 44, 521);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1027, 51, 583);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1028, 46, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1029, 69, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1030, 31, 585);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1031, 64, 586);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1032, 109, 587);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1033, 121, 588);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1034, 67, 670);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1035, 72, 752);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1036, 71, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1037, 116, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1038, 155, 754);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1039, 116, 270);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1040, 147, 761);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1041, 165, 762);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1042, 166, 763);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1043, 151, 764);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1044, 151, 765);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1045, 159, 766);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1046, 170, 767);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1047, 45, 768);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1048, 1, 768);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1049, 45, 545);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1050, 12, 545);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1051, 115, 13);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1052, 31, 12);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1053, 56, 12);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1054, 19, 11);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1055, 31, 11);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1056, 31, 769);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1057, 56, 769);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1058, 19, 770);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1059, 31, 770);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1060, 19, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1061, 31, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1062, 1, 771);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1063, 115, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1064, 135, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1065, 88, 7);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1066, 115, 738);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1068, 31, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1069, 115, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1070, 88, 9);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1072, 31, 772);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1073, 31, 10);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1074, 135, 773);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1075, 88, 773);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1076, 31, 8);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1077, 88, 8);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1078, 31, 774);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1079, 115, 774);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1080, 85, 775);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1081, 50, 776);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1082, 56, 777);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1083, 19, 778);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1084, 148, 779);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1085, 31, 780);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1086, 148, 780);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1087, 72, 787);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1094, 31, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1095, 45, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1096, 69, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1097, 171, 788);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1098, 171, 789);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1099, 172, 789);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1100, 135, 790);
insert into public.drug_regimen_link (id, drug_id, regimen_id) values (1101, 22, 790);
